UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 2022
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission file number: 001-37381
Medigus Ltd.
(Exact name of Registrant as specified in its charter)
Israel
(Jurisdiction of incorporation or organization)
10 Hanechoshet, 4th Floor, Tel-Aviv 6971072, Israel
(Address of principal executive offices)
Tali Dinar
10 Hanechoshet, 4th Floor, Tel-Aviv 6971072, Israel Tel:
Fax: +972 72 260-2249
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of class | Trading Symbol(s) | Name of each exchange on which registered | ||
American Depositary Shares, each representing fifteen (15) Ordinary Shares(1) | MDGS | Nasdaq Capital Market | ||
Ordinary Shares, no-par value (2) | ||||
Series C Warrants | MDGSW | Nasdaq Capital Market |
(1) | Evidenced by American Depositary Receipts. |
(2) | Not for trading, but only in connection with the registration of the American Depositary Shares. |
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of December 31, 2022: 24,661,470 Ordinary Shares, no par value per share
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act:
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act:
Yes ☐ No ☒
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934:
Yes ☐ No ☒
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of “accelerated filer and large accelerated filer” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large Accelerated filer | ☐ | Accelerated filer | ☐ | Non-accelerated filer | ☒ | |
Emerging growth company | ☐ |
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark the basis of accounting the registrant has used to prepare the financial statements included in this filing:
☐ | U.S. GAAP |
☒ | as issued by the International Accounting Standards Board |
☐ | Other |
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.
Item 17 ☐ Item 18 ☐
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):
Yes ☐ No ☒
TABLE OF CONTENTS
i
ii
INTRODUCTION
Certain Definitions
In this annual report, unless the context otherwise requires:
● | references to “ADS” refer to American Depositary Shares, each representing fifteen (15) Ordinary Shares. | |
● | references to the “Companies Law” refer to the Israeli Companies Law, 5759-1999, as amended. | |
● | references to “endoscopy” refer to a medical procedure which is used to diagnose or treat various diseases using an endoscope (a flexible tube which contains lighting features, imaging features and a system used to direct the endoscope within bodily systems). | |
● | references to “Eventer” refer to Eventer Technologies Ltd., a company incorporated under the laws of the State of Israel, a majority subsidiary of the Company. | |
● | references to “GERD IP” refer to GERD IP, Inc., a corporation incorporated under the laws of the State of Delaware, a majority owned subsidiary of the Company | |
● | references to “Gix Internet” refer to Gix Internet Ltd. (formerly known as Algomizer Ltd.), a public company incorporated under the laws of the State of Israel, a subsidiary of the Company. | |
● | references to “Group” refer to the Company and its consolidated subsidiaries, which are Jeffs’ Brands, Charging Robotics Ltd., GERD IP, Gix Internet and Eventer. | |
● | references to “Jeffs’ Brands” refer to Jeffs’ Brands Ltd., a company incorporated under the laws of the State of Israel, a majority owned subsidiary of the Company. | |
● | references to “Medigus,” the “Company,” the “Registrant,” “us,” “we” and “our” refer to Medigus Ltd., an Israeli company. | |
● | references to “MUSE™” refer to the Medigus Ultrasonic Surgical Endostapler, the trade name of an endoscopy system developed by the Company which is intended as a minimally invasive treatment for Gastroesophageal Reflux Disease, or GERD. | |
● | references to “NIS” refer to New Israeli Shekels, the Israeli currency. | |
● | references to “Ordinary Shares,” “our shares” and similar expressions refer to the Company’s Ordinary Shares, of no par value per share. | |
● | references to “Polyrizon” refer to Polyrizon Ltd., a company incorporated under the laws of the State of Israel, a minority owned entity of the Company. | |
● | references to “Pro” refer to Smart Repair Pro, Inc., a corporation incorporated under the laws of the State of California, a majority owned subsidiary of the Company. | |
● | references to “Purex” refer to Purex, Corp., a corporation incorporated under the laws of the State of California, a majority owned subsidiary of the Company. | |
● | references to the “SEC” refer to the United States Securities and Exchange Commission. | |
● | references to “ScoutCam” refer to ScoutCam Inc., a company incorporated under the laws of State of Nevada, minority owned subsidiary of the Company. |
All share data information in this annual report on Form 20-F reflects a 20-for-1 reverse share split of our ordinary shares effected on July 7, 2022, together with a ratio change of 1:15 ADSs per of ordinary shares effected on November 14, 2022, such that after the reverse share split was implemented each ADS represents 15 post- reverse share split ordinary shares, instead of 20 pre-reverse share split ordinary shares.
iii
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND A SUMMARY OF RISK FACTORS
Certain information included or incorporated by reference in this annual report on Form 20-F may be deemed to be “forward-looking statements”. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified.
These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition, statements relating to the research, development and use of our products, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.
Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things:
● | recent material changes in our strategy; | |
● | we have a history of operating losses, we may incur additional losses in the future and our ability to grow sales and achieve profitability are unpredictable; |
● | we will need additional funding. If we are unable to raise capital, we will be forced to reduce or eliminate our operations; |
● | the overall global economic and macroeconomic environment; |
● | our ability to freely operate our business; |
● | certain of our subsidiaries’ dependencies on key employees; |
● | changing laws, regulations, standards and contractual obligations related to privacy, data protection and data security and our and our subsidiaries’ ability to comply with them; |
● | Gix Internet’s performance; |
● | Eventer’s commercial success; |
● | Jeffs’ Brands commercial success; | |
● | our ability to sell or license our MUSE™ technology; |
● | our ability to secure and maintain intellectual property protections; | |
● | patent and other intellectual property litigation that could be costly, result in the diversion of management’s attention, require us to pay damages and force us to discontinue selling our products; | |
● | disruptions to the Group’s information technology systems due to cyber-attacks or the Group’s failure to upgrade and adjust our information technology systems, may materially impair the Group’s operations, hinder our growth and materially and adversely affect our business and results of operations; | |
● | regulatory reforms may adversely affect our ability to sell our products profitably; | |
● | if we fail to comply with the extensive government regulations relating to our business, we may be subject to fines, injunctions and other penalties that could harm our business; | |
● | raising additional capital by issuing securities may cause dilution to existing shareholders; |
● | increased attention to, and evolving expectations for, environmental, social, and governance (ESG) initiatives could adversely impact our business; |
● | those factors referred to in “Item 3. Key Information – D. Risk Factors,” “Item 4. Information on the Company,” and “Item 5. Operating and Financial Review and Prospects”, as well as in this annual report on Form 20-F generally. |
Readers are urged to carefully review and consider the various disclosures made throughout this annual report on Form 20-F, which are designed to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.
In addition, the section of this Annual Report on Form 20-F entitled “Item 4. Information on the Company” contains information obtained from independent industry and other sources that we have not independently verified. You should not put undue reliance on any forward-looking statements. Any forward-looking statements in this annual report are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
iv
PART I
ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISORS
Not applicable.
ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE
Not applicable.
ITEM 3. KEY INFORMATION
A. [Reserved]
B. Capitalization and Indebtedness
Not applicable.
C. Reasons for the Offer and Use of Proceeds
Not applicable.
D. Risk Factors
You should carefully consider the risks described below, together with all of the other information in this annual report on Form 20-F. The risks described below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business operations. If any of these risks actually occurs, our business and financial condition could suffer, and the price of our shares could decline.
You should carefully consider the risks described below, together with all of the other information in this annual report on Form 20-F. The risks described below are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect our business operations. If any of these risks actually occurs, our business and financial condition could suffer, and the price of our shares could decline.
1
Risks Related to Our Business
Starting 2019, we made material changes to our business strategy. We cannot guarantee that any of these changes will result in any value to our shareholders.
Since 2019, we have materially changed our business model, adjusted our exclusive focus on the medical device industry to include other industries, abandoned our strategy to commercialize the MUSE™ system, and consummated a securities exchange agreement in relation to ScoutCam Ltd. and diversified our investments into new markets and industries. In addition to the medical field, we have entered the electric vehicle field. We have also invested into different internet-related markets, specifically e-commerce and online advertising. As a result of these changes, we have acquired substantial stakes in a number of ventures, including but not limited to online business activities such as ad-tech, e-commerce, drone technology and online event management. We cannot guarantee that these strategic decisions will derive the anticipated value to our shareholders, or any value at all.
We have a history of operating losses, we may incur additional losses in the future and our ability to grow sales and achieve profitability are unpredictable.
As of December 31, 2022, we had an accumulated deficit of $85.6 million and incurred total operating loss of approximately $13.8 million in the year ended on December 31, 2022, and total operating losses of approximately $9.8 million in the year ended December 31, 2021. Our losses have had, and will continue to have, an adverse effect on our shareholders’ equity and working capital. Any failure to achieve and maintain profitability would continue to have an adverse effect on our shareholders’ equity and working capital and could result in a decline in our share price or cause us to cease operations.
Our ability to reach profitability depends on many factors, which include:
● | successfully implementing our business strategy; |
● | increasing revenues; and |
● | controlling costs. |
There can be no assurance that we will be able to successfully implement our business plan, meet our challenges and become profitable in the future.
We will need additional funding. If we are unable to raise capital, we will be forced to reduce or eliminate our operations.
During the year ended December 31, 2022, the Group incurred loss of $10.2 million mainly due to operating loss from our consolidated financial reports of approximately $13.8 million and a negative cash flow from operating activities of approximately $5.6 million. Furthermore, in the recent years, the Group has suffered recurring losses from operations, negative cash flows from operating activities and has an accumulated deficit of $85.6 million as of December 31, 2022.
As of December 31, 2022, we had a total cash and cash equivalents balance and short term deposits of approximately $21 million. Our management expects that we will continue to generate operating losses. Our management plans to continue to fund its operations primarily through utilization of its financial resources. In addition, we may raise additional capital or realize some of our investments in other entities in order to fund our operating needs. Our management is of the opinion that based on our current operating plan it will be able to carry out its plan for more than a year after the issuance date of this Annual Report on Form 20-F. However, we anticipate that we are likely to continue to incur significant losses for at least the next year. There is no assurance however, that we will be successful in obtaining the level of financing needed for our operations. If we are unable to obtain additional sufficient financing our business and results of operations will be materially harmed.
Even if we are able to continue to finance our business, the sale of additional equity or debt securities could result in dilution to our current shareholders and could require us to grant a security interest in our assets. If we raise additional funds through the issuance of debt securities, these securities may have rights senior to those of our Ordinary Shares and could contain covenants that could restrict our operations. In addition, we may require additional capital beyond our currently forecasted amounts to achieve profitability. Any such required additional capital may not be available on reasonable terms, or at all.
2
Global economic and macroeconomic conditions may adversely affect our operating results in a material manner.
Our operating businesses are subject to normal economic cycles affecting the general economy or the specific industries in which they operate. Negative conditions in the general economy, including significant inflation, rising interest rates, financial and credit market fluctuations, international trade relations, political turmoil, geopolitical conflicts such as the military conflict between Russia and Ukraine, natural catastrophes, regional or global outbreaks of contagious diseases, such as the COVID-19 pandemic, warfare and terrorist attacks, could cause a decrease in business investments and could produce a material adverse effect on one or more of our subsidiaries. Extreme volatility in financial markets, has adversely impacted and may continue to adversely impact our share price and our ability to access capital markets. To the extent that access to the capital markets is restricted or the cost of funding increases, our operations could be adversely affected.
Our ability to freely operate our business is limited as a result of certain covenants included in our Series C Warrants.
The Series C Warrant Agreement, or the Series C Warrant, contains a number of covenants that limit our operating activities, and may prevent our acquisition by a third party, including a provision setting forth that in the event of a fundamental transaction (other than a fundamental transaction not approved by the our board of directors), we or any successor entity may at the Series C Warrant holder’s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the fundamental transaction, purchase the Series C Warrants from the holder by paying to the Series C Warrant holder an amount of cash equal to the Black Scholes value of the remaining unexercised portion of the Series C Warrants on the date of the consummation of such fundamental transaction. These and other similar provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.
Certain of our subsidiaries rely on key employees and highly skilled personnel, and, if they are unable to attract, retain or motivate qualified personnel, they may not be able to operate its business effectively.
The success of certain of our subsidiaries depends largely on the continued employment of their senior management and key personnel who can effectively operate its business and its ability to attract and retain skilled employees. Competition for highly skilled management, technical, research and development, and other employees is intense, and our subsidiaries may not be able to attract or retain highly qualified personnel in the future. If any of the key employees of these subsidiaries leave or are terminated, and such companies fail to manage a transition to new personnel effectively, or if they fail to attract and retain qualified and experienced professionals on acceptable terms, the business, financial condition and results of operations of these subsidiaries could be adversely affected.
We, and our subsidiaries, are subject to stringent and changing laws, regulations, standards, and contractual obligations related to privacy, data protection, and data security. The actual or perceived failure to comply with such obligations could harm our business.
Our subsidiaries and we receive, collect, store, process, transfer, and use personal information and other data relating to users of our products, our employees and contractors, and other persons. We have legal and contractual obligations regarding the protection of confidentiality and appropriate use of certain data, including personal information. We are subject to numerous federal, state, local, and international laws, directives, and regulations regarding privacy, data protection, and data security and the collection, storing, sharing, use, processing, transfer, disclosure, and protection of personal information and other data, the scope of which are changing, subject to differing interpretations, and may be inconsistent among jurisdictions or conflict with other legal and regulatory requirements. We are also subject to certain contractual obligations to third parties related to privacy, data protection and data security. We strive to comply with our applicable policies and applicable laws, regulations, contractual obligations, and other legal obligations relating to privacy, data protection, and data security to the extent possible. However, the regulatory framework for privacy, data protection and data security worldwide is, and is likely to remain for the foreseeable future, uncertain and complex, and it is possible that these or other actual or alleged obligations may be interpreted and applied in a manner that we do not anticipate or that is inconsistent from one jurisdiction to another and may conflict with other legal obligations or our practices. Further, any significant change to applicable laws, regulations or industry practices regarding the collection, use, retention, security or disclosure of data, or their interpretation, or any changes regarding the manner in which the consent of users or other data subjects for the collection, use, retention or disclosure of such data must be obtained, could increase our costs and require us to modify our services and features, possibly in a material manner, which we may be unable to complete, and may limit our ability to store and process user data or develop new services and features.
3
If our subsidiaries or we were found in violation of any applicable laws or regulations relating to privacy, data protection, or security, our business may be materially and adversely affected, and we would likely have to change our business practices and potentially the services and features available through our platform. In addition, these laws and regulations could impose significant costs on us and could constrain our ability to use and process data in manners that may be commercially desirable. In addition, if a breach of data security were to occur or to be alleged to have occurred, if any violation of laws and regulations relating to privacy, data protection or data security were to be alleged, or if we had any actual or alleged defect in our safeguards or practices relating to privacy, data protection, or data security, our solutions may be perceived as less desirable, and our business, prospects, financial condition, and results of operations could be materially and adversely affected.
We also expect that there will continue to be new laws, regulations, and industry standards concerning privacy, data protection, and information security proposed and enacted in various jurisdictions. For example, the data protection landscape in the European Union (“EU”) is currently evolving, resulting in possible significant operational costs for internal compliance and risks to our business. The EU adopted the General Data Protection Regulation or GDPR, which became effective in May 2018, and contains numerous requirements and changes from previously existing EU laws, including more robust obligations on data processors and heavier documentation requirements for data protection compliance programs by companies. Among other requirements, the GDPR regulates the transfer of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States. Failure to comply with the GDPR could result in penalties for noncompliance (including possible fines of up to the greater of €20 million and 4% of our global annual turnover for the preceding financial year for the most serious violations, as well as the right to compensation for financial or non-financial damages claimed by individuals under Article 82 of the GDPR).
In addition to the GDPR, the European Commission has another draft regulation in the approval process that focuses on a person’s right to conduct a private life. The proposed legislation, known as the Regulation of Privacy and Electronic Communications, or ePrivacy Regulation, would replace the current ePrivacy Directive. Originally planned to be adopted and implemented at the same time as the GDPR, the ePrivacy Regulation is still being negotiated.
Additionally, in June 2018, California passed the California Consumer Privacy Act, or CCPA, which provides new data privacy rights for California consumers and new operational requirements for covered companies. Specifically, the CCPA provides that covered companies must provide new disclosures to California consumers and afford such consumers new data privacy rights that include the right to request a copy from a covered company of the personal information collected about them, the right to request deletion of such personal information, and the right to request to opt-out of certain sales of such personal information. The CCPA became operative on January 1, 2020. The California Attorney General can enforce the CCPA, including seeking an injunction and civil penalties for violations. The CCPA also provides a private right of action for certain data breaches expected to increase data breach litigation. The CCPA may require us to modify our data practices and policies and to incur substantial costs and expenses in order to comply. On November 3, 2020, California voters passed the California Privacy Rights Act (“CPRA”) into law, which took effect in January 2023 and significantly expands the CCPA, including by introducing additional obligations such as data minimization and storage limitations, granting additional rights to consumers. The CCPA and CPRA may increase our compliance costs and potential liability. More generally, some observers have noted the CCPA and CPRA could mark the beginning of a trend toward more stringent United States state and federal privacy legislations, which could increase our potential liability and adversely affect our business.
In addition, failure to comply with the Israeli Privacy Protection Law 5741-1981, and its regulations as well as the guidelines of the Israeli Privacy Protection Authority, may expose us to administrative fines, civil claims (including class actions), and in certain cases, criminal liability. Current pending amendment to the Israeli Privacy Protection Law, 1981 is expected to enhance fines and sanctions for breaching the Israeli Privacy Law and to strengthen the enforcement capacity of the Israeli Privacy Protection Authority. There have also been privacy bills enacted in other countries around the world, such as Brazil, which have introduced new or expanded privacy requirements and we expect that privacy legislation will continue to evolve in the coming years. Therefore, it is difficult to determine whether and how such existing laws and regulations will apply to and impact the internet and our business.
Any failure or perceived failure by our subsidiaries or by us to comply with our posted privacy policies, our privacy-related obligations to users or other third parties, or any other legal obligations or regulatory requirements relating to privacy, data protection, or data security may result in governmental investigations or enforcement actions, litigation, claims, or public statements against us by consumer advocacy groups or others and could result in significant liability, cause our users to lose trust in us, and otherwise materially and adversely affect our reputation and business. Furthermore, the costs of compliance with, and other burdens imposed by, the laws, regulations, other obligations, and policies that are applicable to the businesses of our users may limit the adoption and use of, and reduce the overall demand for, our platform. Additionally, if third parties we work with violate applicable laws, regulations, or contractual obligations, such violations may put our users’ data at risk, could result in governmental investigations or enforcement actions, fines, litigation, claims, or public statements against us by consumer advocacy groups or others and could result in significant liability, cause our users to lose trust in us, and otherwise materially and adversely affect our reputation and business. Further, public scrutiny of, or complaints about, technology companies or their data handling or data protection practices, even if unrelated to our business, industry, or operations, may lead to increased scrutiny of technology companies, including us, and may cause government agencies to enact additional regulatory requirements, or to modify their enforcement or investigation activities, which may increase our costs and risks.
4
Risks Related to Gix Internet’s Business and Industry
Gix Internet’s success depends, in part, upon the continued demand of digital advertising as an integral part of corporate marketing and internal communications plans and the continued growth and acceptance of digital content as effective alternatives to traditional offline marketing products and services.
Gix Internet provides digital advertising platforms. Its revenues are derived from the sale of its platforms. If the demand for digital advertising does not continue to grow or customers do not embrace its platforms, this could have a material adverse effect on its business and financial condition.
Gix Internet’s success also depends, in part, on its ability to compete for a share of available advertising/marketing expenditures as more traditional offline and emerging media companies continue to enter the digital advertising market, as well as on the continued growth and acceptance of digital advertising generally. If for any reason digital advertising is not perceived as effective (relative to traditional advertising), web browsers, software programs and/or other applications that limit or prevent advertising from being displayed become commonplace and/or the industry fails to effectively manage click fraud, the market for digital advertising will be negatively impacted. Any lack of growth in the market for digital advertising could adversely affect its business, financial condition and results of operations.
Online platform updates, including operating systems, search engines, browsers and social media might affect Gix Internet’s ability to generate revenues, temporarily or permanently.
Gix Internet complies with certain guidelines promulgated by online platforms for the use of the respective brands and services. Online platforms may unilaterally update their policies and guidelines, which could, in turn, require modifications to, or prohibit and/or render obsolete certain of its advertising solutions, products, services and practices, which could be costly to address or otherwise have an adverse effect on its business, its financial condition and results of operations. Noncompliance with platforms’ guidelines, whether by it or by third parties it works with, if not cured, could result in such online platforms’ suspension of some or all of their services to it, or to the websites of third parties it works with, or the reimbursement of funds paid to it, or the imposition of additional restrictions on our advertising abilities or the termination of certain advertising agreements with its customers.
Should the providers of internet browsers, advertisement platforms and Search Engines further regulate, constrain or limit Gix Internet’s ability to offer advertising services, or materially change their guidelines, technology or the way they operate, its ability to generate revenue from advertising could be significantly reduced.
As Gix Internet provides its services through the internet, it’s reliant on its ability to work with the different internet browsers, search engines and advertisement platforms. If Microsoft, Google, Apple, Meta or other companies that provide internet browsers, advertisement platforms and search engines, effectively further restrict, discourage or otherwise hamper companies, like Gix Internet, from offering or advertising services, this would continue to cause a material adverse effect on its revenue and its financial results.
5
Large and established internet and technology companies, such as Google and Meta, play a substantial role in the digital advertising market and may significantly impair Gix Internet’s ability to operate in this industry.
Google and Meta are substantial players in the digital advertising market and account for a large portion of the digital advertising budgets, along with other smaller players. Such high concentration subjects Gix Internet to unilateral changes with respect to advertising on their respective platforms, which may be more lucrative than alternative methods of advertising or partnerships with other publishers that are not subject to such changes. Furthermore, Gix Internet could have limited ability to respond to, and adjust for, changes implemented by such players.
These companies, along with other large and established Internet and technology companies, may also leverage their power to make changes to their web browsers, operating systems, platforms, networks or other products or services in a way that impacts the entire digital advertising marketplace.
The use of third-party software solutions for the purpose of blocking ads and / or alerts may cause Gix Internet’s business to suffer.
Digital advertising may be blocked by third-party providers. As a result, Gix Internet may lose both existing and potential new customers and its ability to generate revenue will be negatively impacted.
Gix Internet depends on supply sources to provide it with advertising inventory in order for it to deliver advertising campaigns in a cost-effective manner.
Gix Internet relies on a diverse set of publishers including direct publishers, advertising exchange platforms, social networks and other platforms, that aggregate advertising inventory, to provide it with high-quality digital advertising inventory on which it delivers ads, collectively referred to as “supply sources”. The future growth of Gix Internet’s advertising business will depend, in part, on its ability to maintain, expand and further develop successful business relationships in order to increase the network of its supply sources.
Gix Internet’s supply sources typically make their advertising inventory available to it on a non-exclusive basis and are not required to provide any minimum amounts of advertising inventory to it or to provide it with a consistent supply of advertising inventory, at any predetermined price or through real time bidding. Supply sources often maintain relationships with various sources of demand that compete with Gix Internet, and it is easy for supply sources to quickly shift their advertising inventory among these demand sources, or to shift inventory to new demand sources, without notice or accountability. Supply sources may also seek to change the terms at which they offer inventory to Gix Internet, or they may allocate their advertising inventory to its competitors who offer more favorable economic terms, better solutions and advanced technology. Supply sources may also elect to sell all, or a portion, of their advertising inventory directly to advertisers and agencies, or they may develop their own competitive offerings, which could diminish the demand for Gix Internet’s solutions. In addition, significant supply sources within the industry may enter into exclusivity arrangements with Gix Internet’s competitors, which could limit its access to a meaningful supply of inventory. As a result of all of these factors, Gix Internet’s supply sources may not supply it with sufficient amounts of high-quality digital advertising inventory in order for it to fulfill the demands of its advertising customers.
Because of these factors, Gix Internet seeks to expand and diversify its supply sources; nonetheless, if its supply sources terminate or reduce its access to their advertising inventory, increase the price of inventory or place significant restrictions on the sale of their advertising inventory, or if platforms or exchanges terminate its access to them and it is unsuccessful in establishing or maintaining its relationships with supply sources on commercially reasonable terms, it may not be able to replace this with inventory from other supply sources that satisfy its requirements in a timely and cost-effective manner. If any of these happens, Gix Internet’s revenue could decline or its cost of acquiring inventory could increase, which, in turn, could lower its operating margins and materially adversely affect its advertising business.
6
Reliance upon Gix Internet’s top customers may adversely affect its revenue and operating results.
Gix Internet’s top ten customers represented approximately 68% and 88% of its consolidated revenue for the years ended December 31, 2022, and 2021, respectively on a pro forma basis. It is likely that Gix Internet will depend on a relatively small number of customers for a significant portion of its revenue in the future. If a top customer fails to pay Gix Internet, cash flow from operations would be impacted and its operating results and financial condition could be harmed. Additionally, if Gix Internet were to lose a material customer, it may not be able to offer its services at similar utilization or pricing levels and such loss could have an adverse effect on its business until the services are offered at similar utilization or pricing levels.
Gix Internet’s search platform depends heavily upon revenue generated from a material agreement with one Major Customer (the “Major Customer”), and any adverse change in that agreement could adversely affect its business, financial condition and results of operations.
Gix Internet is highly dependent on the material agreement with its Major Customer. If this material agreement is terminated or substantially amended (not on favorable terms), Gix Internet would experience a material decrease in its revenue or the profits it generates and would be forced to seek alternative customers, at less competitive terms or accelerate the business it has with the other customers. There are few companies in the market that provide internet search and search advertising services with whom Gix Internet can directly engage with in the same manner which we are engaged with its Major Customer. Such companies are substantially the only participants in western markets, and competitors do not offer as much coverage through sponsored links or searches. Gix Internet may divert its operations and user traffic to other third-party partners which provide search feed to search engines, however Gix Internet cannot guarantee that it will be successful. If Gix Internet fails to quickly locate, negotiate and finalize alternative arrangements or otherwise expedite current operations it has with such alternative search providers, or if it does, but the alternatives do not provide for terms that are as favorable as those currently provided and utilized, it would experience a material reduction in its revenue and, in turn, its business, financial condition and results of operations would be adversely affected.
Reliance upon material suppliers may adversely affect Gix Internet’s revenue and operating results.
Gix Internet is dependent on certain material suppliers and service providers for some of the services it renders. In certain cases, Gix Internet relies on single supplier and/or service provider for the services it offers its customers. In most cases Gix Internet does not have long term contracts with these suppliers, and even in the cases where it does, the contracts include significant qualifications that would make it extremely difficult for it to force the supplier or service provider to provide it with their services, should they choose not to do so. Gix Internet is therefore subject to the risk that these third-parties it works with will not be able or willing to continue to provide it with services that meet its specifications, quality standards and delivery schedules. Factors that could impact these third parties’ willingness and ability to continue to provide Gix Internet with the required services include disruption at or affecting their facilities, such as work stoppages or natural disasters, adverse weather or other conditions that affect their supply, their financial conditions and / or deterioration in its relationships with these third parties. In addition, Gix Internet cannot be sure that it will be able procure1 the services its needs on satisfactory terms. Any increase in costs could reduce Gix Internet’s revenues and harm its gross margins. In addition, any loss of a material supplier and / or service provider may permanently cause a change in one or more of Gix Internet’s services that may not be accepted by its customers or cause it to eliminate that product altogether.
Gix Internet may not be able to generate enough cash flow to meet its debt obligations or fund its other liquidity needs.
Gix Internet’s ability to satisfy its liabilities will depend upon future performance and its ability to repay or refinance its debt as it becomes due. Gix Internet’s future operating performance and ability to refinance will be affected by economic and capital market conditions, results of operations and other factors, many of which are beyond its control. Its ability to meet its debt obligations also may be impacted by changes in prevailing interest rates, as borrowings under our loans bear interest at floating rates.
7
Risks Related to Eventer’s Business
If Eventer fails to maintain and improve the quality of its platform, it may not be able to attract clients seeking to manage their online and offline events or facilitate ticket sales for events.
To satisfy both clients seeking to manage online and offline events through Eventer’s platform, Eventer needs to continue to improve the user experience and innovate and introduce features and services that both event managers and ticket purchasers find useful cause them to use Eventer’s platform more frequently. In addition, Eventer needs to adapt, expand and improve its platform and user interfaces to keep up with changing user preferences. Eventer invests substantial resources in researching and developing new features and enhancing its platform by incorporating these new features, improving the functionality, and adding other improvements to meet users’ evolving demands. The success of any enhancements or improvements to Eventer’s platform or any new features depends on several factors, including timely completion, adequate quality testing, integration with technologies on the platform and overall market acceptance. Because further development of Eventer’s platform is complex, challenging, and dependent upon an array of factors, the timetable for the release of new features and enhancements to Eventer’s platform is difficult to predict, and it may not offer new features as rapidly as users of its platform require or expect.
It is difficult to predict the problems Eventer may encounter in introducing new features to its platform. Eventer may need to devote significant resources to creating, supporting, and maintaining these features. Eventer provides no assurance that its initiatives to improve the user experience will be successful. Eventer also cannot predict whether users will well receive any new features or whether improving its platform will be successful or sufficient to offset the costs incurred to offer these new features. If Eventer is unable to improve or maintain its platform’s quality, its business, prospects, financial condition, and results of operations could be materially and adversely affected.
Eventer’s business is highly sensitive to public tastes. It is dependent on its ability to secure popular artists and other live music events. Eventer’s ticketing clients may be unable to anticipate or respond to consumer preferences changes, which may result in decreased demand for its services.
Eventer’s business is highly sensitive to rapidly changing public tastes and is dependent on the availability of popular artists and events. Eventer’s live entertainment business depends on its ability to anticipate the tastes of consumers and offer events that appeal to them. Since Eventer relies on unrelated parties to create and perform at live music events as well as online events, any lack of availability of popular artists could limit its ability to generate revenue. If artists do not choose to perform, or if Eventer cannot secure performances and events to be managed and ticketed through its platform, Eventer’s business would be adversely affected. Furthermore, Eventer’s business could be adversely affected if artists utilizing its platform do not tour or perform as frequently as anticipated, or if such tours or performances are not as widely attended by fans as anticipated due to changing tastes, general economic conditions or otherwise.
Eventer faces intense competition in the online and offline event and ticketing industries. It may not be able to maintain or increase its current revenue, which could adversely affect its business, financial condition, and operations results.
Eventer is active in highly competitive industries, and it may not be able to maintain or increase its current revenue due to such competition. Online and offline leisure events compete with other entertainment forms for consumers’ discretionary spending and within this industry, Eventer faces competition from other promoters and venue operators. Eventer’s competitors compete for relationships with popular music artists and other service providers who have a history of being able to book artists for concerts and events. These competitors may engage in more extensive development efforts, undertake more far-reaching marketing campaigns, adopt more aggressive pricing policies and make more attractive offers to existing and potential artists. Due to increasing artist influence and competition to attract and maintain artist clients for events managed on Eventer’s platform, it may enter into agreements on terms that are less favorable to it, which could negatively impact the number of commissions collected from ticket sales which may adversely affect its financial results. Eventer’s competitors may develop services and advertising options equivalent to or superior to those they provide or achieve greater market acceptance and brand recognition than it achieves. Across the live music and entertainment industry, it is possible that new competitors may emerge and rapidly acquire significant market share.
Eventer’s business faces significant competition from other ticketing service providers to continuously secure new and retain existing clients. Additionally, it faces significant and increasing challenges from companies that sell self-ticketing systems and clients who choose to self-ticket by integrating such systems into their existing operations or the acquisition of primary ticket services providers. The advent of new technology, particularly as it relates to online ticketing, has amplified this competition. The intense competition that Eventer faces in the ticketing industry could cause the volume of ticketing services to decline.
If our Eventer subsidiary fails to offer high-quality customer service, their brand and reputation could suffer.
Eventer’s clients rely on the platform to plan and manage online and offline events and expect a high level of user experience and customer service relating to both the event management functions of the platform as well as ticket sales. Providing such quality service is imperative for ensuring customer success, sustaining sales growth, and developing Eventer’s business. To the extent that Eventer cannot provide real-time support for users of its platforms, the platform may become less attractive to potential users, and its results of operations may be harmed.
8
The success of Eventer’s event management and ticketing solutions and other operations depends, in part, on the integrity of its systems and infrastructure, as well as affiliate and third-party computer systems, Wi-Fi, and other communication systems. System interruption and the lack of integration and redundancy in these systems and infrastructure may have an adverse impact on its business, financial condition, and operations results.
System interruption and the lack of integration and redundancy in the information systems and infrastructure, utilized for Eventer’s platform as well as other computer systems and third-party software, Wi-Fi and other communications systems service providers on which Eventer relies, may adversely affect its ability to operate the platform, process and fulfill transactions, respond to customer inquiries and generally maintain cost-efficient operations. Such interruptions could occur by virtue of natural disasters, malicious actions such as hacking or acts of terrorism or war, or human error. In addition, the loss of some or all of certain key personnel could require Eventer to expend additional resources to continue to maintain its software and systems and could subject it to systems interruptions. The infrastructure required to operate Eventer’s platform requires an ongoing investment of time, money, and effort to maintain or refresh hardware and software and ensure it remains at a level capable of servicing the demand and volume of business it receives. Failure to do so may result in system instability, degradation in performance, or unfixable security vulnerabilities that could adversely impact both the business and the consumers utilizing Eventer’s services.
While Eventer has backup systems for certain aspects of its operations, disaster recovery planning by its nature cannot be sufficient for all eventualities. In addition, Eventer may not have adequate insurance coverage to compensate for losses from a major interruption. If any of these adverse events were to occur, it could adversely affect Eventer’s business, financial condition, and operations results.
Eventer’s success depends, in significant part, on entertainment and leisure events and economic and other factors adversely affecting such events could have a material adverse effect on its business, financial condition and results of operations.
A decline in attendance at or reduction in the number of entertainment and leisure events may have an adverse effect on Eventer’s revenue and operating income. In addition, during periods of economic slowdown and recession, many consumers have historically reduced their discretionary spending and advertisers have reduced their advertising expenditures. The impact of economic slowdowns on Eventer’s business is difficult to predict, but they may result in reductions in ticket sales and the ability to generate revenue. The risks associated with Eventer’s businesses may become more acute in periods of a slowing economy or recession, which may be accompanied by a decrease in attendance at entertainment and leisure events. Many of the factors affecting the number and availability of entertainment and leisure events are beyond Eventer’s control. For example, COVID-19 has led to lockdowns and governmental restrictions on live entertainment and leisure events as well as restrictions regarding the attendance of such events. Although Eventer’s platform supports the management and ticketing of online events, there is no assurance that online events will generate demand on par with live events, which could adversely affect Eventer’s operations results.
Eventer’s business depends on discretionary consumer and enterprise spending. Many factors related to corporate spending and discretionary consumer spending, including economic conditions affecting disposable consumer income such as unemployment levels, fuel prices, interest rates, changes in tax rates and tax laws that impact companies or individuals, and inflation can significantly impact Eventer’s operating results. Business conditions, as well as various industry conditions, including corporate marketing and promotional spending and interest levels, can also significantly impact Eventer’s operating results. These factors can affect attendance at online and offline events, advertising, and spending, as well as the financial results of venues, events, and the industry. Negative factors such as challenging economic conditions and public concerns over terrorism and security incidents, particularly when combined, can impact corporate and consumer spending and one negative factor can result in more than another. There can be no assurance that consumer and corporate spending will not be adversely impacted by current economic conditions or by any future deterioration in economic conditions, thereby possibly impacting Eventer’s operating results and growth.
9
Errors, defects, or disruptions in Eventer’s platform could diminish its brand, subject it to liability, and materially and adversely affect its business, prospects, financial condition, and operations results.
Any errors, defects, or disruptions in Eventer’s platform or other performance problems with its platform could harm its brand and may damage the businesses of artists and clients that manage events on its platform. Eventer’s online systems, including its website and mobile apps, could contain undetected errors, or “bugs,” that could adversely affect their performance. Additionally, Eventer regularly updates and enhances its website, platform, and other online systems and introduces new versions of its software products and apps. These updates may contain undetected errors when first introduced or released, which may cause disruptions in its services and may, as a result, cause Eventer to lose market share, and its brand, business, prospects, financial condition and results of operations could be materially and adversely affected.
Eventer is subject to escrow, payment services, and money transmitter regulations that may materially and adversely affect its business.
Eventer relies on third-party to collect funds from ticket purchasers, remit payments to clients that manage events on its platform, and hold funds in connection with ticket purchases. Although Eventer believes that by working with third parties, its operations comply with existing applicable laws and regulatory requirements related to escrow, money transmission, handling or moving of money, existing laws or regulations may change, and interpretations of existing laws regulations may also change.
As a result, Eventer could be required to be licensed as an escrow agent or a money transmitter (or other similar licensees) in jurisdictions in which it is active or may choose to obtain such a license even if not required. As a result, Eventer may be required to register as a money services business under applicable laws and regulations. It is also possible that Eventer could become subject to regulatory enforcement or other proceedings in those jurisdictions with escrow, money transmission, or other similar statutes or regulatory requirements related to the handling or moving of money, which could, in turn, have a significant impact on its business, even if we were to ultimately prevail in such proceedings. Any developments in the laws or regulations related to escrow, money transmission, or the handling or moving of money or increased scrutiny of its business may lead to additional compliance costs and administrative overhead.
Eventer faces payment and fraud risks that could materially and adversely affect its business.
Requirements applicable to Eventer’s platform relating to user authentication and fraud detection are complex. If Eventer’s security measures do not succeed, Eventer’s business may be adversely affected. In addition, bad actors worldwide use increasingly sophisticated methods to engage in illegal activities involving personal data, such as unauthorized use of another’s identity or payment information, unauthorized acquisition or use of credit or debit card details, and other fraudulent use of another’s identity or information. This could result in any of the following, each of which could adversely affect Eventer’s business:
● | Eventer may be held liable for the unauthorized use of a credit card or bank account number by ticket purchasers and be required by card issuers or banks to pay a chargeback or return fee, and if chargeback or return rate becomes excessive, credit card networks may also require Eventer to pay fines or other fees; |
● | Eventer may be subject to additional risk and liability exposure, including negligence, fraud or other claims, if employees or third-party service providers misappropriate user information for their own gain or facilitate the fraudulent use of such information; and |
● | Eventer may suffer reputational damage as a result of the occurrence of any of the above. |
10
Despite measures taken by Eventer to detect and reduce the risk of this kind of conduct, it cannot ensure that any of its measures will stop illegal or improper uses of its platform. Eventer may receive complaints from users and other third parties concerning misuse of its platform in the future. Even if these claims do not result in litigation or are resolved in Eventer’s favor, these claims, and the time and resources necessary to resolve them, could divert the resources of Eventer’s management and materially and adversely affect its business, prospects, financial condition and results of operations.
Eventer uses open source software, which could negatively affect its ability to offer its platform and subject it to litigation or other actions.
Eventer uses substantial amounts of open source software in its platform and may use more open source software in the future. From time to time, there have been claims challenging both the ownership of open source software against companies that incorporate open source software into their products and whether such incorporation is permissible under various open source licenses. U.S. and Israeli courts have not interpreted the terms of many open source licenses, and there is a risk that these licenses could be construed in a way that could impose unanticipated conditions or restrictions on its ability to commercialize its platform. As a result, Eventer could be subject to lawsuits by parties claiming ownership of what we believe to be open source software, or breach of open source licenses. Litigation could be costly for Eventer to defend, have a negative effect on its results of operations and financial condition, or require it to devote additional research and development resources to change its platform. In addition, if Eventer were to combine its proprietary source code or software with open source software in a certain manner, it could, under certain of the open source licenses, be required to release the source code of its proprietary software to the public. This would allow its competitors to create similar products with less development effort and time. If Eventer inappropriately uses open source software or the license terms for open source software that its uses change, Eventer may be required to re-engineer its platform, or certain aspects of it, incur additional costs, discontinue the availability of certain features, or take other remedial actions.
In addition to risks related to license requirements, open source software usage can lead to greater risks than use of third-party commercial software, as open source licensors generally do not provide warranties or assurance of title or controls on origin of the software. In addition, many of the risks associated with usage of open source software, such as the lack of warranties or assurances of title, cannot be eliminated and could, if not properly addressed, negatively affect Eventer’s business. Eventer has established processes to help alleviate these risks, but it cannot be sure that all of its use of open source software is in a manner that is consistent with its current policies and procedures or will not subject Eventer to liability.
To the extent Eventer’s security measures are compromised, its platform may be perceived as not being secure. This may result in customers curtailing or ceasing their use of Eventer’s platform, its reputation being harmed, Eventer incurring significant liabilities, and adverse effects on its results of operations and growth prospects.
Eventer’s operations involve the storage and transmission of artist and ticket purchaser data or information. Cyberattacks and other malicious internet-based activity continue to increase, and cloud-based platform providers of services are expected to continue to be targeted. Threats include traditional computer “hackers,” malicious code (such as viruses and worms), employee theft or misuse and denial-of-service attacks. Sophisticated nation-states and nation-state supported actors now engage in such attacks, including advanced persistent threat intrusions. The ticket sales solution included in Eventer’s platform stores credit card data and other customer personal information. Hackers and malicious actors may target Eventer in order to obtain credit card information. Despite significant efforts to create security barriers to such threats, it is virtually impossible for Eventer to entirely mitigate these risks. If Eventer’s security measures are compromised as a result of third-party action, employee or customer error, malfeasance, stolen or fraudulently obtained log-in credentials, or otherwise, Eventer’s reputation could be damaged, its business may be harmed, and it could incur significant liability. Eventer may be unable to anticipate or prevent techniques used to obtain unauthorized access or to compromise its systems because they change frequently and are generally not detected until after an incident has occurred. As Eventer relies on third-party and public-cloud infrastructure, it will depend in part on third-party security measures to protect against unauthorized access, cyberattacks, and the mishandling of customer data. A cybersecurity event could have significant costs, including regulatory enforcement actions, litigation, litigation indemnity obligations, remediation costs, network downtime, increases in insurance premiums, and reputational damage. Many companies that provide cloud-based services have reported a significant increase in cyberattack activity since the beginning of the COVID-19 pandemic.
11
Risks Related to Jeffs’ Brands Business
Jeffs’ Brands have a short operating history in an evolving industry and, as a result, Jeffs’ Brands past results may not be indicative of future operating performance.
Jeffs’ Brands has a short operating history in a rapidly evolving industry that may not develop in a manner favorable to our business. Jeffs’ Brands relatively short operating history makes it difficult to assess future performance.
Jeffs’ Brands future success depends in large part upon the ability to, among other things:
● | manage inventory effectively; |
● | successfully develop, retain and expand our consumer product offerings and geographic reach; |
● | compete effectively; |
● | anticipate and respond to macroeconomic changes; |
● | effectively manage growth; |
● | hire, integrate and retain talented people at all levels of organization; |
● | avoid interruptions in Jeffs’ Brands business from information technology downtime, cybersecurity breaches or labor stoppages; |
● | maintain the quality of technology infrastructure; and |
● | develop new features to enhance functionality. |
Jeffs’ Brands may not be able to manage growth effectively, and such rapid growth may adversely affect Jeffs’ Brands corporate culture.
Jeffs’ Brands expect to rapidly and significantly expand their operations and anticipate expanding further as Jeffs’ Brands pursue growth strategies. Such expansion increases the complexity of Jeffs’ Brands business and places a significant strain on Jeffs’ Brands management, operations, technical systems, financial resources and internal control over financial reporting functions. Jeffs’ Brands current and planned personnel, systems, procedures and controls may not be adequate to support and effectively manage Jeffs’ Brands future operations, especially as Jeffs’ Brands employ personnel in several geographic locations.
Jeffs’ Brands is currently in the process of transitioning certain of Jeffs’ Brands business and financial systems to systems on a scale reflecting the increased size, scope and complexity of their operations, and the process of migrating the legacy systems could disrupt our ability to timely and accurately process information, which could adversely affect results of operations and cause harm to Jeffs’ Brands reputation. As a result, Jeffs’ Brands may not be able to manage Jeffs’ Brands expansion effectively.
We believe that Jeffs’ Brands entrepreneurial and collaborative culture has been a major contributor to its success. Jeffs’ Brands may have difficulties maintaining such culture or adapting it sufficiently to meet the needs of Jeffs’ Brands future and evolving operations as it’s continue to grow, in particular as Jeffs’ Brands grows internationally.
In addition, Jeffs’ Brands expect to experience some challenges in developing and maintaining Jeffs’ Brands culture as a public company, with the attendant changes in policies, practices, and corporate governance and management requirements. Failure to successfully develop or maintain such a culture could have a material adverse effect on Jeffs’ Brands business, results of operations, financial condition and prospects.
12
Jeffs’ Brands e-commerce operations are reliant on the Amazon marketplace and fulfillment by Amazon and changes to the marketplace, Amazon services and their terms of use may harm Jeffs’ Brands business.
Jeffs’ Brands products are sold predominantly on the Amazon marketplace and orders are fulfilled entirely by Amazon utilizing the fulfilled by Amazon, or FBA, model. In order to continue to utilize the Amazon marketplace and FBA, Jeffs’ Brands must comply with the applicable policies and terms of use relating to these services. Such policies and terms of use may be altered or amended at Amazon’s sole discretion, including changes regarding the cost of securing these services, and changes that increase the burden of compliance with its requirements, may cause Jeffs Brands to significantly alter Jeffs’ Brands business model or incur additional costs in order to comply, which could negatively impact Jeffs’ Brands results of operations. Non-compliance with applicable terms of use and policies can result in the removal of one or more products from the marketplace and suspension of fulfillment services either of which could have a material adverse effect on Jeffs’ Brands business and results of Jeffs’ Brands operations. Although Jeffs’ Brands exert efforts in order to ensure ongoing compliance and no notices of non-compliance have been received to date, we cannot assure you that events of this kind will not occur in the future.
Jeffs’ Brands relies on data provided by third parties, the loss of which could limit the functionality of its platforms, cause it to invest in the wrong product or disrupt its business.
Jeffs’ Brands uses third party software to determine market trends and what markets to enter into. Its ability to successfully use this software depends on its ability to analyze and utilize data, including search engine results, provided by unaffiliated third parties, primarily, Google and Amazon. Some of this data is provided to it pursuant to third-party data sharing policies and terms of use, under data sharing agreements by third-party providers or by customer consent. The majority of this data is sourced for free or for de minimis amounts. These sources of data allow Jeffs’ Brands, along with AI tools, to determine trends, performance and consumer sentiment on products and searches within e-commerce platforms. This functionality allows it to help determine which products to market, in some cases manufacture through contract manufacturers, import and sell on e-commerce marketplaces. The connection to multiple e-commerce platforms through application programming interfaces, or APIs, allows Jeffs’ Brands to develop the automation of the purchase of marketing and automate the change of pricing of product listings on those e-commerce platforms.
In the future, any of these third parties could change its data sharing policies, including making them more restrictive, charging fees or altering its algorithms that determine the placement, display and accessibility of search results and social media updates, any of which could result in the loss of, or significant impairment to, Jeffs’ Brands ability to collect useful data. These third parties could also interpret its, or its service providers’, data collection policies or practices as being inconsistent with their policies, which could result in the loss of its ability to collect this data. Privacy concerns may cause end users to resist providing the personal data necessary to allow Jeffs’ Brands to determine market trends as well as our ability to effectively retain existing customers. Privacy advocacy groups and the technology and other industries are considering various new, additional or different self-regulatory standards that may place additional burdens on Jeffs’ Brands. Any such changes could impair its ability to use data and could adversely impact select functionality of our proprietary software, impairing our ability to use this data to anticipate customer demand and market trends, as well as adversely affecting Jeffs’ Brands business and its ability to generate revenue.
Jeffs’ Brands business depends on its ability to build and maintain strong product listings on e-commerce platforms. It may not be able to maintain and enhance its product listings if it receives a substantial number of customer complaints, negative publicity or otherwise fails to live up to customers’ expectations, any of which could materially adversely affect its business, results of operations and growth prospects.
Maintaining and enhancing Jeffs’ Brands product listings is critical in expanding and growing its business. However, a significant portion of its perceived performance to the customer depends on third parties outside of its control, including suppliers and logistics providers such as FedEx, UPS, postal services and other third-party delivery agents and online retailers, mainly Amazon. Because Jeffs’ Brands agreements with its online retail partners are generally terminable at will, it may be unable to maintain these relationships, and its results of operations could fluctuate significantly from period to period. Because it relies on third party logistics companies, like FedEx, to deliver its products, it is subject to shipping delays or disruptions caused by inclement weather, natural disasters, labor activism, health epidemics or bioterrorism. In addition, because Jeffs’ Brands relies on national, regional and local transportation companies for the delivery of some of its other products, it is also subject to risks of breakage or other damage during delivery by any of these third parties. If these third parties do not meet its or its customers’ expectations, its brands may suffer irreparable damage. In addition, maintaining and enhancing Jeffs’ Brands current and future brands may require it to make substantial investments, and these investments may not be yield sufficient returns. If it fails to promote and maintain its brands, or if it incurs excessive expenses in this effort, its business, operating results and financial condition may be materially adversely affected. We anticipate that, as its market becomes increasingly competitive, maintaining and enhancing its brands may become increasingly difficult and expensive. Maintaining and enhancing its brands will depend largely on its ability to anticipate market trends and customer demand and to provide high quality products to its customers and a reliable, trustworthy and profitable sales channel to its suppliers, which it may not be able to do successfully.
A substantial number of customer complaints or negative publicity about Jeffs’ Brands sites, products, delivery times, customer data handling and security practices or customer support, especially on blogs, social media websites or its sites, could rapidly and severely diminish consumer views of its products and result in harm to its brands. Customers may also make safety-related claims regarding products sold through its online retail partners, such as Amazon, which may result in an online retail partner removing the product from its marketplace. Such removal may materially impact its financial results depending on the product that is removed and length of time that it is removed. Jeffs’ Brands also uses and relies on other services from third parties, such as its telecommunications services, and those services may be subject to outages and interruptions that are not within its control.
13
Risks related to our MUSE™ Technology Business
We are currently proposing our MUSE™ system business for sale or grant of license. If we are unable to sell or license our MUSE™ business or unable to sell or license it in terms acceptable to us, we will have to write off our investment in the MUSE™ system, which will adversely affect our business.
We are currently proposing our MUSE™ system business for sale or license. If we are unable to sell or license our MUSE™ business or unable to sell or license it in terms acceptable to us, we could not derive any value from the sale and will lose significant cash flow, which, in turn, will adversely affect our financial results.
Several factors may delay or prevent us from selling or granting license to our MUSE™ system business:
● | potential purchasers’ or licensee perception on the cost, safety, efficacy, and convenience of the MUSE™ system in relation to alternative treatments and products; |
● | publicity concerning our products, including MUSE™, or competing products and treatments; |
● | patients suffering from adverse events while using the MUSE™ system; and |
● | competition from the pharmaceutical sector, which could harm the ability to market and commercialize the MUSE™ system and, as a result, impact the attractiveness of the MUSE™ system in the eyes of potential purchasers. |
Further, we have only limited clinical data to support the value of the MUSE™ system, which may make patients, physicians and hospitals reluctant to accept or purchase our products, and as such a potential purchaser may be reluctant to purchase our MUSE™ business or such lack of data will be reflected in the purchase price.
Moreover, various modifications to our MUSE™ system regulator-cleared products may require new regulatory clearances or approvals or require a recall or cease marketing of the MUSE™ system until clearances or approvals are obtained. Clearances and approvals by the applicable regulator are subject to continual review, and the later discovery of previously unknown problems can result in product labeling restrictions or withdrawal of the product from the market. The potential loss of previously received approvals or clearances, or the failure to comply with existing or future regulatory requirements could reduce the potential sales, profitability and future growth prospects of the MUSE™.
We have entered into a Licensing and Sale Agreement with Shanghai Golden Grand-Medical Instruments Ltd. (“Golden Grand”) for the know-how licensing and sale of goods relating to the Medigus Ultrasonic Surgical Endostapler (MUSE™) system in China with a substantial amount of the consideration subject to milestone achievements.
We entered into a Licensing and Sale Agreement with Shanghai Golden Grand, or Golden Grand Agreement, for the know-how licensing and sale of goods relating to the Medigus Ultrasonic Surgical Endostapler (MUSE™) system in China, Hong Kong, Taiwan and Macao. The payment of a substantial amount of the consideration is contingent on achievement of certain milestones such as establishing a MUSE™ assembly line in China. In the event that we are not able to meet such milestones, due to various factors including natural disasters, public health crises, political crises and trade wars which are not under our control, our entitlement to the aggregate consideration under the agreement may be impaired. Until December 31, 2022, we recognized revenues of $2.4 million due to completion of 80% of the milestones.
14
Risks Related to Our Intellectual Property
If we are unable to secure and maintain patent or other intellectual property protection for the intellectual property used in our products, our ability to compete will be harmed.
Our commercial success depends, in part, on obtaining and maintaining patent and other intellectual property protection for the technologies used in our products. If we, or the other parties from whom we may license intellectual property, fail to obtain and maintain adequate patent or other intellectual property protection for intellectual property used in our products, or if any protection is reduced or eliminated, others could use the intellectual property used in our products, resulting in harm to our competitive business position. In addition, patent and other intellectual property protection may not provide us with a competitive advantage against competitors that devise ways of making competitive products without infringing any patents that we own or have rights to.
U.S. patents and patent applications may be subject to interference proceedings, and U.S. patents may be subject to re-examination proceedings in the U.S. Patent and Trademark Office. Foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent offices. Any of these proceedings could result in loss of the patent or denial of the patent application, or loss or reduction in the scope of one or more of the claims of the patent or patent application. Changes in either patent laws or in interpretations of patent laws may also diminish the value of our intellectual property or narrow the scope of our protection. Interference, re-examination and opposition proceedings may be costly and time consuming, and we, or the other parties from whom we might potentially license intellectual property, may be unsuccessful in defending against such proceedings. Thus, any patents that we own or might license may provide limited or no protection against competitors. In addition, our pending patent applications and those we may file in the future may have claims narrowed during prosecution or may not result in patents being issued. Even if any of our pending or future applications are issued, they may not provide us with adequate protection or any competitive advantages. Our ability to develop additional patentable technology is also uncertain.
Non-payment or delay in payment of patent fees or annuities, whether intentional or unintentional, may also result in the loss of patents or patent rights important to our business. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. In addition, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States, particularly in the field of medical products and procedures.
If we are unable to prevent unauthorized use or disclosure of our proprietary trade secrets and unpatented know-how, our ability to compete will be harmed.
Proprietary trade secrets, copyrights, trademarks and unpatented know-how are also very important to our business. We rely on a combination of trade secrets, copyrights, trademarks, confidentiality agreements and other contractual provisions and technical security measures to protect certain aspects of our technology, especially where we do not believe that patent protection is appropriate or obtainable. We require our office holders, employees, consultants and distributors of our products and most third parties (such as contractors or clinical collaborators) to execute confidentiality agreements in connection with their relationships with us. However, these measures may not be adequate to safeguard our proprietary intellectual property and conflicts may, nonetheless, arise regarding ownership of inventions. Such conflicts may lead to the loss or impairment of our intellectual property or to expensive litigation to defend our rights against competitors who may be better funded and have superior resources. Our office holders, employees, consultants and other advisors may unintentionally or willfully disclose our confidential information to competitors. In addition, confidentiality agreements may be unenforceable or may not provide an adequate remedy in the event of unauthorized disclosure. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time consuming, and the outcome is unpredictable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary. As a result, other parties may be able to use our proprietary technology or information, and our ability to compete in the market would be harmed.
15
We could become subject to patent and other intellectual property litigation that could be costly, result in the diversion of management’s attention, require us to pay damages and force us to discontinue selling our products.
Our industry is characterized by competing intellectual property and a substantial amount of litigation over patent and other intellectual property rights. Determining whether a product infringes a patent involves complex legal and factual issues, and the outcome of a patent litigation action is often uncertain. No assurance can be given that patents containing claims covering our products, parts of our products, technology or methods do not exist, have not been filed or could not be filed or issued. Furthermore, our competitors or other parties may assert that our products and the methods we employ in the use of our products are covered by U.S. or foreign patents held by them. In addition, because patent applications can take many years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending of which we are unaware and which may result in issued patents which our current or future products infringe. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications with claims that we infringe. There could also be existing patents that one or more of our products or parts may infringe and of which we are unaware. As the number of competitors in the endoscopic procedure market grows, and as the number of patents issued in this area grows, the possibility of patent infringement claims against us increases.
Infringement actions and other intellectual property claims and proceedings brought against or by us, whether with or without merit, may cause us to incur substantial costs and could place a significant strain on our financial resources, divert the attention of management from our business and harm our reputation. Some of our competitors may be able to sustain the costs of complex patent or intellectual property litigation more effectively than we can because they have substantially greater resources.
We cannot be certain that we will successfully defend against allegations of infringement of patents and intellectual property rights of others. In the event that we become subject to a patent infringement or other intellectual property lawsuit and if the other party’s patents or other intellectual property were upheld as valid and enforceable and we were found to infringe the other party’s patents or violate the terms of a license to which we are a party, we could be required to pay damages. We could also be prevented from selling our products unless we could obtain a license to use technology or processes covered by such patents or will be able to redesign the product to avoid infringement. A license may not be available at all or on commercially reasonable terms or we may not be able to redesign our products to avoid infringement. Modification of our products or development of new products could require us to conduct clinical trials and to revise our filings with the applicable regulatory bodies, which would be time consuming and expensive. In these circumstances, we may be unable to sell our products at competitive prices or at all, our business and operating results could be harmed.
We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or, that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.
Certain of our employees and personnel were previously employed at universities, medical institutions, or other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee’s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Furthermore, universities or medical institutions who employ some of our key employees and personnel in parallel to their engagement by us may claim that intellectual property developed by such person is owned by the respective academic or medical institution under the respective institution intellectual property policy or applicable law.
16
We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
We may be subject to claims that former employees, collaborators, or other third parties have an ownership interest in our patents or other intellectual property. Ownership disputes may arise in the future, for example, from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.
Disruptions to the Group’s information technology systems due to cyber-attacks or the Group’s failure to upgrade and adjust our information technology systems, may materially impair the Group’s operations, hinder our growth and materially and adversely affect our business and results of operations.
We believe that an appropriate information technology, or IT, infrastructure is important in order to support the Group’s daily operations and the growth of our business. If we experience difficulties in implementing new or upgraded information systems or experience significant system failures, or if we are unable to successfully modify the Group’s management information systems or respond to changes in our business needs, we may not be able to effectively manage the Group’s business, and we may fail to meet our reporting obligations. Additionally, if our current back-up storage arrangements and our disaster recovery plan are not operated as planned, we may not be able to effectively recover our information system in the event of a crisis, which may materially and adversely affect our business and results of operations.
In the current environment, there are numerous and evolving risks to cybersecurity and privacy, including criminal hackers, hacktivists, state-sponsored intrusions, industrial espionage, employee malfeasance and human or technological error. High-profile security breaches at other companies and in government agencies have increased in recent years, and security industry experts and government officials have warned about the risks of hackers and cyber-attacks targeting businesses such as ours. Computer hackers and others routinely attempt to breach the security of technology products, services and systems, and to fraudulently induce employees, customers, or others to disclose information or unwittingly provide access to systems or data. We can provide no assurance that the Group’s current IT system or any updates or upgrades thereto and the current or future IT systems of our distributors use or may use in the future, are fully protected against third-party intrusions, viruses, hacker attacks, information or data theft or other similar threats. Legislative or regulatory action in these areas is also evolving, and we may be unable to adapt the Group’s IT systems or to manage the IT systems of third parties to accommodate these changes. We have experienced and expect to continue to experience actual or attempted cyber-attacks of our IT networks. Although none of these actual or attempted cyber-attacks has had a material adverse impact on our operations or financial condition, we cannot guarantee that any such incidents will not have such an impact in the future.
Risks Related to Regulatory Compliance
If we or our contractors or service providers fail to comply with regulatory laws and regulations, we or they could be subject to regulatory actions, which could affect our ability to develop, market and sell our products in the medical field and any other or future products that we may develop and may harm our reputation in the medical field.
If we or our manufacturers or other third-party contractors fail to comply with applicable federal, state or foreign laws or regulations, including with respect to healthcare and data privacy, we could be subject to regulatory actions, which could affect our ability to develop, market and sell our current products or any future products which we may develop in the future and could harm our reputation and lead to reduced demand for or non-acceptance of our proposed products by the market.
Regulatory reforms may adversely affect our ability to sell our products profitably.
From time to time, legislation is drafted and introduced in the United States, European Union or other countries in which we operate, that could significantly change the statutory provisions governing the clearance or approval, manufacture and marketing of our products, including in the medical devices industry. In addition, regulations and guidance may often be revised or reinterpreted by the regulatory authorities in ways that may significantly affect our business and our products. It is impossible to predict whether legislative changes will be enacted, or interpretations changed, and what the impact of such changes, if any, may be.
17
If we fail to comply with the extensive government regulations relating to our business, we may be subject to fines, injunctions and other penalties that could harm our business.
The application of our MUSE™ system as a medical device is subject to extensive regulation by the FDA, pursuant to the Federal Food, Drug, and Cosmetic Act, or FDCA, and various other federal, state and foreign governmental authorities. Government regulations and requirements specific to medical devices are wide ranging and govern, among other things:
● | design, development and manufacturing; |
● | testing, labeling and storage; |
● | clinical trials; |
● | product safety; |
● | marketing, sales and distribution; |
● | premarket clearance or approval; |
● | record keeping procedures; |
● | advertising and promotions; and |
● | product recalls and field corrective actions. |
We are subject to annual regulatory audits in order to maintain our quality system certifications, CE mark permissions, FDA Clearance and Canadian medical device license. We do not know whether we will be able to continue to affix the CE mark for new or modified products or that we will continue to meet the quality and safety standards required to maintain the permissions and license we have already received. If we are unable to maintain our quality system certifications and permission to affix the CE mark to our products, we will no longer be able to sell our products in member countries of the European Union or other areas of the world that require CE’s or FDA’s approval of medical devices. If we are unable to maintain our quality system certifications and Canadian medical device license, we will not be able to sell our products in Canada.
Our medical device products and operations are also subject to regulation by the Medical Devices and Accessories Division in the Israeli Ministry of Health, or AMAR, which is responsible for the registration of medical devices in Israel, issuance of import licenses and monitoring marketing of medical equipment. We have received an AMAR approval in Israel. If we fail to comply with the extensive government regulations relating to our business, we may be subject to fines, injunctions and other penalties that could harm our business.
Risks Related to Our Operations in Israel
Our headquarters and administrative offices are located in Israel and, therefore, our results may be adversely affected by political, economic and military instability in Israel.
Our employees, including management members operate from our offices that are located in Israel. In addition, a number of our officers and directors are residents of Israel. Accordingly, political, economic, and military conditions in Israel and the surrounding region may directly affect our business and operations. In recent years, Israel has been engaged in sporadic armed conflicts with Hamas, an Islamist terrorist group that controls the Gaza Strip, with Hezbollah, an Islamist terrorist group that controls large portions of southern Lebanon, and with Iranian-backed military forces in Syria. In addition, Iran has threatened to attack Israel and may be developing nuclear weapons. Some of these hostilities were accompanied by missiles being fired from the Gaza Strip against civilian targets in various parts of Israel, including areas in which our employees and some of our consultants are located, and negatively affected business conditions in Israel. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its trading partners could adversely affect our operations and results of operations.
Our commercial insurance does not cover losses that may occur as a result of events associated with war and terrorism. Although the Israeli government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or that it will sufficiently cover our potential damages. Any losses or damage incurred by us could have a material adverse effect on our business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm our results of operations. Further, in the past, the State of Israel and Israeli companies have been subjected to economic boycotts. Several countries still restrict business with the State of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial condition or the expansion of our business. A campaign of boycotts, divestment and sanctions has been undertaken against Israel, which could also adversely impact our business.
18
In addition, many Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they reach the age of 40 (or older, for reservists who are military officers or who have certain occupations) and, in the event of a military conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such call-ups, which may include the call-up of members of our management. Such disruption could materially adversely affect our business, prospects, financial condition and results of operations.
The Israeli government is currently pursuing extensive changes to Israel’s judicial system. In response to the foregoing developments, many individuals, organizations and institutions, both within and outside of Israel, have voiced concerns that the proposed changes may negatively impact the business environment in Israel due to the reluctance of foreign investors to invest or transact business in Israel, increased currency fluctuations, downgrades in credit rating, increased interest rates, increased volatility in security markets, and other changes in macroeconomic conditions. We cannot be certain whether the planned judicial overhaul will occur or in what form. To the extent that any of the negative developments stated above do occur, we cannot be certain on how investors will assess these matters and whether their assessment will adversely impact the perception of our business and our share price, or how these developments impact our business operations in Israel.
Exchange rate fluctuations between foreign currencies and the U.S. Dollar may negatively affect our earnings.
Our reporting and functional currency is the U.S. dollar. Our, ScoutCam and Jeffs’ Brands revenues are currently primarily payable in U.S. dollars, and we expect our future revenues to be denominated primarily in U.S. dollars. However, Eventer’s and Gix’s revenues and certain amount of our expenses and investments are in NIS and as a result, we are exposed to the currency fluctuation risks relating to the recording of our expenses and Eventer’s revenues in U.S. dollars. We may, in the future, decide to enter into currency hedging transactions. These measures, however, may not adequately protect us from material adverse effects.
The government tax benefits that we currently are entitled to receive require us to meet several conditions and may be terminated or reduced in the future.
Some of our operations in Israel may entitle us to certain tax benefits under the Law for the Encouragement of Capital Investments, 5719-1959, or the Investments Law once we begin to produce taxable income. From time to time, the government of Israel has considered reducing or eliminating the tax benefits available to Benefitted Enterprise programs such as ours. If we do not meet the requirements for maintaining these benefits, they may be reduced or cancelled and the relevant operations would be subject to Israeli corporate tax at the standard rate, which was set at 23% in 2018 and thereafter. In addition to being subject to the standard corporate tax rate, we could be required to refund any tax benefits that we have already received, plus interest and penalties thereon. Even if we continue to meet the relevant requirements, the tax benefits that our current “Benefitted Enterprise” is entitled to may not be continued in the future at their current levels, or at all. If these tax benefits were reduced or eliminated, the amount of taxes that we will have to pay if we produce revenues would likely increase, as all of our operations would consequently be subject to corporate tax at the standard rate, which could adversely affect our results of operations. Additionally, if we increase our activities outside of Israel, for example, by way of acquisitions, our increased activities may not be eligible for inclusion in Israeli tax benefits programs. See Item 10. “Additional Information — E. Taxation.”
19
Provisions of Israeli law and our amended and restated articles of association may delay, prevent or otherwise impede a merger with, or an acquisition of, our Company, which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.
Provisions of Israeli law and our amended and restated articles of association could have the effect of delaying or preventing a change in control and may make it more difficult for a third party to acquire us or our shareholders to elect different individuals to our board of directors, even if doing so would be considered to be beneficial by some of our shareholders, and may limit the price that investors may be willing to pay in the future for our Ordinary Shares. Among other things:
● | Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such types of transactions. For example, a merger may not be consummated unless at least 50 days have passed from the date on which a merger proposal is filed by each merging company with the Israel Registrar of Companies and at least 30 days have passed from the date on which the shareholders of both merging companies have approved the merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover, a tender offer for all of a company’s issued and outstanding shares can only be completed if the acquirer receives positive responses from the holders of at least 95% of the issued share capital. Completion of the tender offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless, following consummation of the tender offer, the acquirer would hold at least 98% of the Company’s outstanding shares. Furthermore, the shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, claim that the consideration for the acquisition of the shares does not reflect their fair market value, and petition an Israeli court to alter the consideration for the acquisition accordingly, unless the acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights, and the acquirer or the company published all required information with respect to the tender offer prior to the tender offer’s response date; |
● | our amended and restated articles of association divide our directors into three classes, each of which is elected once every three years; |
● | our amended and restated articles of association require a vote of the holders of a majority of our outstanding Ordinary Shares entitled to vote present and voting on the matter at a general meeting of shareholders (referred to as simple majority). The affirmative vote of at least three-quarters (3/4) of the directors, in addition to the approval of our shareholders, is required in order to amend our amended and restated articles of association; |
● | our amended and restated articles of association provide that director vacancies may be filled by our board of directors; |
● | subject to certain exceptions, our amended and restated articles of association restrict us from engaging in certain business combination transactions with any shareholder and/or its affiliates and/or investors for a period of three years following (i) any shareholder who holds 15% or more of our voting power, and (ii) with respect to all shareholders of the Company, each time as such shareholder and/or any of its affiliates and/or investors become(s) (other than due to a buyback, redemption or cancellation of shares by the Company) the holder(s) (beneficially or of record) of fifteen percent (15%) or more of the issued and outstanding voting power of our Ordinary Shares. The transactions subject to such restrictions include mergers, consolidations and dispositions of our assets with an aggregate market value of 10% or more of our assets or outstanding shares; and |
● | our amended and restated articles of association require an affirmative vote of at least three-quarters (3/4) of the then serving directors, to approve certain transactions which may have a significant effect on the Company’s structure, assets or business, including mergers acquisitions, consolidations and issuance of equity securities or debt securities convertible into equity in each case that would reasonably be expected to result in change of beneficial ownership of above than fifteen percent (15%) in the Company, material changes to the principal business of the Company and any resolution to transfer the headquarters of the Company outside of Israel. |
Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax.
These and other similar provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders.
20
It may be difficult to enforce a judgment of a U.S. court against us and our officers and directors and the Israeli experts named in this annual report on Form 20-F in Israel or the United States, to assert United States securities laws claims in Israel or to serve process on our officers and directors and these experts.
We are incorporated in Israel. Certain of our executive officers and directors reside in Israel and most of our assets and most of the assets of these persons are located outside of the United States. Therefore, a judgment obtained against us, or any of these persons in the United States, including one based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not necessarily be enforced by an Israeli court. It may also be difficult to affect service of process on these persons in the United States or to assert United States securities law claims in original actions instituted in Israel.
Even if an Israeli court agrees to hear such claim, it may determine that Israeli law, and not U.S. law is applicable to the claim. Under Israeli law, if U.S. law is found to be applicable to such claim, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process, and certain matters of procedure would also be governed by Israeli law. There is little binding case law in Israel that addresses the matters.
Our amended and restated articles of association provide that unless the Company consents otherwise, the competent courts of Tel Aviv, Israel shall be the sole and exclusive forum for substantially all disputes between the Company and its shareholders under the Companies Law and the Israeli Securities Law, which could limit its shareholders ability to brings claims and proceedings against, as well as obtain favorable judicial forum for disputes with the Company, its directors, officers and other employees.
The competent courts of Tel Aviv, Israel shall be the exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s shareholders, or (iii) any action asserting a claim arising pursuant to any provision of the Companies Law or the Israeli Securities Law. This exclusive forum provisions is intended to apply to claims arising under Israeli Law and would not apply to claims brought pursuant to the Securities Act or the Exchange Act or any other claim for which federal courts would have exclusive jurisdiction. Such exclusive forum provision in our amended and restated articles of association will not relieve the Company of its duties to comply with federal securities laws and the rules and regulations thereunder, and shareholders of the Company will not be deemed to have waived the Company’s compliance with these laws, rules and regulations. This exclusive forum provision may limit a shareholders ability to bring a claim in a judicial forum of its choosing for disputes with the Company or its directors or other employees which may discourage lawsuits against the Company, its directors, officers and employees.
The rights and responsibilities of a shareholder will be governed by Israeli law which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies.
The rights and responsibilities of the holders of our Ordinary Shares are governed by our amended and restated articles of association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in typical U.S.-registered corporations. In particular, a shareholder of an Israeli company has certain duties to act in good faith and fairness towards the company and other shareholders, and to refrain from abusing its power in the company. There is limited case law available to assist us in understanding the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our Ordinary Shares that are not typically imposed on shareholders of U.S. corporations.
The ability of any Israeli company to pay dividends is subject to Israeli law and the amount of cash dividends payable may be subject to devaluation in the Israeli currency.
We paid cash dividends in an amount of $1.6 million on December 28, 2022. We do not anticipate that we will pay any cash dividends on our securities in the foreseeable future. The ability of an Israeli company to pay dividends is governed by Israeli law, which provides that cash dividends may be paid only out of retained earnings or earnings derived over the two most recent fiscal years, whichever is higher, as determined for statutory purposes in Israeli currency, provided that there is no reasonable concern that payment of a dividend will prevent a company from satisfying its existing and foreseeable obligations as they become due. In the event of a devaluation of the Israeli currency against the U.S. dollar, the amount in U.S. dollars available for payment of cash dividends out of prior years’ earnings will decrease.
21
The termination or reduction of tax and other incentives that the Israeli Government provides to domestic companies may increase the costs involved in operating a company in Israel.
The Israeli government currently provides major tax and capital investment incentives to domestic companies, as well as grant and loan programs relating to research and development and marketing and export activities. In recent years, the Israeli Government has reduced the benefits available under these programs and the Israeli Governmental authorities have indicated that the government may in the future further reduce or eliminate the benefits of those programs. We currently take advantage of these programs. There is no assurance that such benefits and programs would continue to be available in the future to us. If such benefits and programs were terminated or further reduced, it could have an adverse effect on our business, operating results and financial condition.
We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business.
A significant portion of our intellectual property has been developed by our employees in the course of their employment for us. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee in the course and as a result of or arising from his or her employment with a company are regarded as “service inventions,” which belong to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Patent Law also provides that if there is no such agreement between an employer and an employee, the Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, will determine whether the employee is entitled to remuneration for his inventions. Recent case law clarifies that the right to receive consideration for “service inventions” can be waived by the employee and that in certain circumstances, such waiver does not necessarily have to be explicit. The Committee will examine, on a case-by-case basis, the general contractual framework between the parties, using interpretation rules of the general Israeli contract laws. Further, the Committee has not yet determined one specific formula for calculating this remuneration (but rather uses the criteria specified in the Patent Law). Although we generally enter into assignment-of-invention agreements with our employees pursuant to which such individuals assign to us all rights to any inventions created in the scope of their employment or engagement with us, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.
Risks Related to an Investment Our Securities
We may have been a passive foreign investment company, or PFIC, for U.S. federal income tax purposes in 2022 and may be a PFIC in any subsequent year. This may result in adverse U.S. federal income tax consequences for U.S. taxpayers that are holders of our securities.
We will be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either (1) at least 75% of our gross income is “passive income” or (2) on average at least 50% of our assets by value (generally determined on the basis of a quarterly average) produce passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account. There can be no assurance that we were not a PFIC in 2022 and will not be a PFIC in subsequent years, as our operating results for any such years may cause us to be a PFIC. If we were a PFIC in 2022, or are a PFIC in any subsequent year, and a U.S. shareholder does not make an election to treat us as a “qualified electing fund,” or QEF, or make a “mark-to-market” election, then “excess distributions” to a U.S. shareholder, and any gain realized on the sale or other disposition of our securities will be subject to special rules. Under these rules: (1) the excess distribution or gain would be allocated ratably over the U.S. shareholder’s holding period for the securities; (2) the amount allocated to the current taxable year and any period prior to the first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (3) the amount allocated to each of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year. In addition, if the U.S. Internal Revenue Service, or the IRS, determines that we are a PFIC for a year with respect to which we have determined that we were not a PFIC, it may be too late for a U.S. shareholder to make a timely QEF or mark-to-market election. You may make a QEF election with respect to your ordinary shares or ADSs only if we furnish you annually with certain tax information, and we currently do not intend to prepare or provide such information. U.S. shareholders who hold or have held our securities during a period when we were or are a PFIC will generally be subject to the foregoing rules unless we cease to be a PFIC and you make a “deemed sale” election with respect to our ordinary shares. If we are a PFIC in any year, U.S. shareholders may be subject to additional IRS filing requirements, including the filing of IRS Form 8621, as a result of directly or indirectly owning stock of a PFIC. U.S. shareholders are urged to consult their own tax advisors regarding the application of the PFIC rules. For more information, see Item 10. “Additional Information — Taxation — Certain Material U.S. Federal Income Tax Consequences.”
22
If a United States person is treated as owning at least 10% of our Ordinary Shares, such holder may be subject to adverse U.S. federal income tax consequences.
If a United States person is treated as owning (directly, indirectly, or constructively) at least 10% of the value or voting power of our Ordinary Shares, such person may be treated as a “United States shareholder” with respect to each controlled foreign corporation, or CFC, in our group (if any). Because our group includes a U.S. subsidiary, certain of our non-U.S. subsidiaries will be treated as CFCs (regardless of whether or not we are treated as a CFC). A United States shareholder of a CFC may be required to report annually and include in its U.S. taxable income its pro rata share of “Subpart F income,” “global intangible low-taxed income,” and investments in U.S. property by CFCs, regardless of whether we make any distributions. An individual that is a United States shareholder with respect to a CFC generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that is a U.S. corporation. Failure to comply with these reporting obligations may subject a United States shareholder to significant monetary penalties and may prevent the statute of limitations with respect to such shareholder’s U.S. federal income tax return for the year for which reporting was due from starting. We cannot provide any assurances that we will assist investors in determining whether we are or any of our non-U.S. subsidiaries is treated as CFC or whether any investor is treated as a United States shareholder with respect to any such CFC or furnish to any United States shareholders information that may be necessary to comply with the aforementioned reporting and tax paying obligations. The IRS has provided limited guidance on situations in which investors may rely on publicly available information to comply with their reporting and tax paying obligations with respect to foreign-controlled CFCs. A United States investor should consult its advisors regarding the potential application of these rules to an investment in our Ordinary Shares or ADSs.
Changes in U.S. and foreign tax laws could have a material adverse effect on our business, cash flow, results of operations or financial conditions.
We are subject to taxation in several countries, including the United States and Israel; changes in tax laws or challenges to our tax positions could adversely affect our business, results of operations, and financial condition. As such, we are subject to tax laws, regulations, and policies of the U.S. federal, state, and local governments and of comparable taxing authorities in foreign jurisdictions. Changes in tax laws, including the U.S. federal tax legislation enacted in 2017, commonly referred to as the Tax Cuts and Jobs Act of 2017, as well as other factors, could cause us to experience fluctuations in our tax obligations and effective tax rates in the future and otherwise adversely affect our tax positions and/or our tax liabilities. There can be no assurance that our effective tax rates, tax payments, tax credits, or incentives will not be adversely affected by changes in tax laws in various jurisdictions.
The market prices of our securities are subject to fluctuation, which could result in substantial losses by our investors.
The stock market in general and the market prices of our ADSs on Nasdaq, in particular, are or will be subject to fluctuation, and changes in these prices may be unrelated to our operating performance. We anticipate that the market prices of our securities will continue to be subject to wide fluctuations. The market price of our securities is, and will be, subject to a number of factors, including:
● | announcements of technological innovations or new products by us or others; |
● | announcements by us of significant acquisitions, strategic partnerships, in-licensing, out-licensing, ventures or capital commitments; |
● | expiration or terminations of licenses, research contracts or other collaboration agreements; |
● | public concern as to the safety of the equipment we sell; |
● | the volatility of market prices for shares of medical devices companies generally; |
● | developments concerning intellectual property rights or regulatory approvals; |
● | variations in our and our competitors’ results of operations; |
23
● | changes in revenues, gross profits and earnings announced by the Company; |
● | changes in estimates or recommendations by securities analysts, if our Ordinary Shares or the ADSs are covered by analysts; |
● | fluctuations in the stock price of our publicly traded subsidiaries; |
● | changes in government regulations or patent decisions; and |
● | general market conditions and other factors, including factors unrelated to our operating performance. |
These | factors may materially and adversely affect the market price of our securities s and result in substantial losses by our investors. |
We do not know whether a market for the ADSs will be sustained or what the trading price of the ADSs will be and as a result it may be difficult for you to sell your ADSs.
Although our ADSs trade on Nasdaq, an active trading market for the ADSs may not be sustained. It may be difficult for you to sell your ADSs without depressing the market price for the ADSs. As a result of these and other factors, you may not be able to sell your ADSs. Further, an inactive market may also impair our ability to raise capital by selling ADSs and may impair our ability to enter into strategic partnerships or acquire companies or products by using our ADSs as consideration.
We do not know whether a market for our Series C Warrants will be sustained or what the trading price of the Series C Warrants will be and as a result it may be difficult for you to sell your Series C Warrants.
Even though our Series C Warrant are listed on Nasdaq, there is no assurance that a market will be sustained or maintain a high enough per warrant trading price to maintain the national exchange listing requirements in the future. Without an active market, the liquidity of the Series C Warrants will be limited.
Our Series C Warrants are speculative in nature.
The Series C Warrants do not confer any rights of ownership of Ordinary Shares or ADSs on their holders, such as voting rights with the exception of the right to receive dividends, but only represent the right to acquire ADSs at a fixed price for a limited period of time. Holders of the Series C Warrants may exercise their right to acquire ADSs and pay the exercise price per ADS of $52.50, subject to adjustment upon certain events, prior to five years from the date of issuance, after which date any unexercised warrants will expire and have no further value.
Future sales of our securities could reduce their market price.
Substantial sales of our securities on Nasdaq, may cause the market price of our securities to decline. Sales by us or our security holders of substantial amounts of our securities, or the perception that these sales may occur in the future, could cause a reduction in the market price of our securities.
The issuance of any additional Ordinary Shares, ADSs, warrants or any securities that are exercisable for or convertible into our Ordinary Shares or ADSs, may have an adverse effect on the market price of our securities and will have a dilutive effect on our existing shareholders and holders of ADSs.
24
Holders of ADSs may not receive the same distributions or dividends as those we make to the holders of our Ordinary Shares, and, in some limited circumstances, you may not receive dividends or other distributions on our Ordinary Shares and you may not receive any value for them, if it is illegal or impractical to make them available to you.
The depositary for the ADSs has agreed to pay to you the cash dividends or other distributions it or the custodian receives on Ordinary Shares or other deposited securities underlying the ADSs, after deducting its fees and expenses. You will receive these distributions in proportion to the number of Ordinary Shares your ADSs represent. However, the depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act of 1933, as amended, or the Securities Act, but that are not properly registered or distributed under an applicable exemption from registration. In addition, conversion into U.S. dollars from foreign currency that was part of a dividend made in respect of deposited Ordinary Shares may require the approval or license of, or a filing with, any government or agency thereof, which may be unobtainable. In these cases, the depositary may determine not to distribute such property and hold it as “deposited securities” or may seek to affect a substitute dividend or distribution, including net cash proceeds from the sale of the dividends that the depositary deems an equitable and practicable substitute. We have no obligation to register under U.S. securities laws any ADSs, Ordinary Shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, Ordinary Shares, rights or anything else to holders of ADSs. In addition, the depositary may withhold from such dividends or distributions its fees and an amount on account of taxes or other governmental charges to the extent the depositary believes it is required to make such withholding. This means that you may not receive the same distributions or dividends as those we make to the holders of our Ordinary Shares, and, in some limited circumstances, you may not receive any value for such distributions or dividends if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of the ADSs.
Holders of ADSs must act through the depositary to exercise their rights as shareholders of our Company.
Holders of our ADSs do not have the same rights of our shareholders and may only exercise the voting rights with respect to the underlying Ordinary Shares in accordance with the provisions of the Deposit Agreement. Under Israeli law and our amended and restated articles of association, the minimum notice period required to convene a shareholders meeting is no less than 21 or 35 calendar days, depending on the proposals on the agenda for the shareholders meeting. When a shareholder meeting is convened, holders of ADSs may not receive sufficient notice of a shareholders’ meeting to permit them to withdraw their Ordinary Shares to allow them to cast their vote with respect to any specific matter. In addition, the Depositary and its agents may not be able to send voting instructions to holders of ADSs or carry out their voting instructions in a timely manner. We will make all reasonable efforts to cause the Depositary to extend voting rights to holders of the ADSs in a timely manner, but we cannot assure holders that they will receive the voting materials in time to ensure that they can instruct the Depositary to vote their Ordinary Shares underlying the ADSs. Furthermore, the Depositary and its agents will not be responsible for any failure to carry out any instructions to vote, for the manner in which any vote is cast or for the effect of any such vote. As a result, holders of ADSs may not be able to exercise their right to vote and they may lack recourse if their Ordinary Shares underlying the ADSs are not voted as they requested. In addition, in the capacity as a holder of ADSs, they will not be able to call a shareholders’ meeting.
We incur additional increased costs as a result of the listing of the ADSs for trading on Nasdaq, and our management is required to devote substantial time to new compliance initiatives and reporting requirements.
As a public company in the United States, we incur significant accounting, legal and other expenses as a result of the listing of the ADSs on Nasdaq. These include costs associated with corporate governance requirements of the Securities Exchange Commission, or the SEC, and the Marketplace Rules of the Nasdaq, as well as requirements under Section 404 and other provisions of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act. These rules and regulations increase our legal and financial compliance costs, introduce costs such as investor relations, stock exchange listing fees and shareholder reporting, and make some activities more time consuming and costly. Any future changes in the laws and regulations affecting public companies in the United States and Israel, including Section 404 and other provisions of the Sarbanes-Oxley Act, the rules and regulations adopted by the SEC and the rules of the Nasdaq Stock Market may result in increased costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.
25
As a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of applicable SEC and Nasdaq requirements, which may result in less protection than is accorded to investors under rules applicable to domestic issuers.
As a foreign private issuer, we are permitted to follow certain home country corporate governance practices instead of those otherwise required under the rules of the Nasdaq for domestic issuers. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the Nasdaq, may provide less protection than is accorded to investors under the rules of the Nasdaq applicable to domestic issuers. For more information, see “Item 16G. Corporate Governance - Nasdaq Stock Market Listing Rules and Home Country Practices.”
In addition, as a foreign private issuer, we are exempt from the rules and regulations under the Securities Exchange Act of 1934, as amended, or the Exchange Act, related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as domestic companies whose securities are registered under the Exchange Act.
We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.
We are a foreign private issuer, as such term is defined in Rule 405 under the Securities Act, and therefore, we are not required to comply with all the periodic disclosure and current reporting requirements of the Exchange Act and related rules and regulations. Under Rule 405, the determination of foreign private issuer status is made annually on the last business day of an issuer’s most recently completed second fiscal quarter and, accordingly, the next determination will be made with respect to us on June 30, 2023.
In the future, we would lose our foreign private issuer status if a majority of our shareholders, directors or management are U.S. citizens or residents, and we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. Although we have elected to comply with certain U.S. regulatory provisions, our loss of foreign private issuer status would make such provisions mandatory. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the U.S. Securities and Exchange Commission, or the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. For example, the annual report on Form 10-K requires domestic issuers to disclose executive compensation information on an individual basis with specific disclosure regarding the domestic compensation philosophy, objectives, annual total compensation (base salary, bonus, equity compensation) and potential payments in connection with change in control, retirement, death or disability, while the SEC forms applicable to foreign private issuers permit them to disclose compensation information on an aggregate basis if executive compensation disclosure on an individual basis is not required or otherwise has not been provided in the issuer’s home jurisdiction. We disclose individual compensation information, but this disclosure is not as comprehensive as that required of U.S. domestic issuers since we are not required to disclose more detailed information in Israel. We intend to continue this practice as long as it is permitted under the SEC’s rules and Israel’s rules do not require more detailed disclosure. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors and principal shareholders will become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. We may also be required to modify certain of our policies to comply with good governance practices associated with U.S. domestic issuers. Such conversion and modifications will involve additional costs. In addition, we may lose our ability to rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers.
We have concluded that our internal controls over financial reporting are not effective. If we fail to develop and maintain proper and effective internal controls over financial reporting, our ability to produce timely and accurate financial statements, comply with applicable laws and regulations, or access the capital markets could be impaired.
As a public company, we are actively evaluating our internal control over financial reporting in a manner that meets the standards of publicly traded companies required by Section 404(a) of the Sarbanes-Oxley Act, or Section 404. As disclosed in Item 15, our management concluded that, as of December 31, 2022, the Company’s internal controls over financial reporting are not effective since a significant subsidiary of the Company, Gix Internet, whose financial statements were initially consolidated in March 2022, was excluded from management’s evaluation of the effectiveness of internal controls over financial reporting as of December 31, 2022 due to post acquisition exclusion made by Viewbix, a subsidiary of Gix Internet in accordance with the SEC guidance during the fiscal year post acquisition.
The process of designing and implementing effective internal control over financial reporting is a continuous effort. If our management cannot favorably assess the effectiveness of our internal controls over financial reporting, or if our independent registered public accounting firm identifies material weaknesses in our internal control, investor confidence in our financial results may weaken, and the market price of our securities may suffer.
26
Our amended and restated articles of association provide that unless we consent to an alternate forum, the federal district courts of the United States shall be the exclusive forum of resolution of any claims arising under the Securities Act which may impose additional litigation costs on our shareholders.
Our amended and restated articles of association provide that the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both U.S. state and federal courts have jurisdiction to entertain such claims. This choice of forum provision may limit a shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees and may increase the costs associated with such lawsuits, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated articles of association inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition. Any person or entity purchasing or otherwise acquiring any interest in our share capital shall be deemed to have notice of and to have consented to the choice of forum provisions of our amended and restated articles of association described above. This provision would not apply to shall not apply to causes of action arising under the Exchange Act.
General Risk Factors
We do not intend to pay any cash dividends on our Ordinary Shares in the foreseeable future and, therefore, any return on your investment in our securities must come from increases in the value and trading price of our securities.
We paid cash dividends in an amount of $1.6 million on December 28, 2022. We do not anticipate that we will pay any cash dividends on our securities in the foreseeable future, therefore, any return on your investment in our securities must come from increases in the value and trading price of our securities.
We intend to retain our earnings to finance the development and expenses of our business. Any future determination relating to our dividend policy will be at the discretion of our board of directors and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions, capital requirements, business prospects, applicable Israeli law and other factors our board of directors may deem relevant.
Raising additional capital by issuing securities may cause dilution to existing shareholders.
We may seek additional capital through a combination of private and public equity offerings, debt financings and collaborations and strategic and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest will be diluted, and the terms of any such offerings may include liquidation or other preferences that may adversely affect the then existing shareholders rights. Debt financing, if available, would result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring debt or making capital expenditures. If we raise additional funds through collaboration, strategic alliance or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates, or grant licenses on terms that are not favorable to us.
If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.
The trading market for our securities will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. There can be no assurance that analysts will cover us, or provide favorable coverage. If one or more analysts downgrade our share or change their opinion of our securities, the price of our securities would likely decline. In addition, if one or more analysts cease coverage of our Company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.
27
Increased attention to, and evolving expectations for, environmental, social, and governance (ESG) initiatives could adversely impact our business.
In June 2022, the SEC published a proposed climate disclosure rule, subject to which we would be required to disclose certain climate-related information such as governance of climate-related risks and relevant risk management processes that could affect us, a climate related financial statements matrix and more. While the proposed rule has yet to be finalized and we cannot predict the ultimate scope and impact this will have on our business, if finalized, it would likely result in additional legal, accounting and financial compliance and increased general and administrative expenses. Moreover, this could result in increased management time and attention to ensure we are compliant with the regulations and expectations.
ITEM 4. INFORMATION ON THE COMPANY
A. History and Development of the Company
We were incorporated in the State of Israel on December 9, 1999, as a private company pursuant to the Israeli Companies Ordinance (New Version), 1983. In February 2006, we completed our initial public offering in Israel, and our Ordinary Shares traded on the TASE until January 25, 2021. In May 2015, we listed the ADSs on Nasdaq and since August 2015 the ADSs have been traded on Nasdaq under the symbol “MDGS”. Following a 20:1 reverse share split of our ordinary shares effected on July 7, 2022, together with a 1:15 ratio change of the ADSs on November 14, 2022 (the “Ratio Change”), each ADS represents fifteen (15) Ordinary Shares. Our Series C Warrants have been trading on Nasdaq under the symbol “MDGSW” since July 2018. Following the Ratio Change, the Series C Warrant were adjusted, such that the exercise price was increased by a factor of fifteen (15), and the number of ADSs issuable under the warrants was decreased by a factor of fifteen (15). Each Series C Warrant is exercisable into one/fifteen ADS at an exercise price of $52.50 and will expire in July 2023.
Principal Capital Expenditures
Our Group had capital expenditures of approximately $74,000, $139,000 and $324,000 in the years ended on December 31, 2022, 2021, and 2020, respectively. Our capital expenditures are primarily for network infrastructure, computer hardware, purchase of machinery and software and leasehold improvements of our facilities. We have financed our capital expenditures from our available cash. We expect to maintain our capital expenditures in 2023 with a consistent volume.
There are no significant capital expenditures or divestitures currently in progress by the Company.
B. Business Overview
Overview
The activities carried out by us and our subsidiaries are focused on internet and other online-related technologies, e-commerce, medical-related devices, products and safety systems for drones and the electric vehicle (EV) sector.
Our internet-related activities include ad-tech operations through our stake in Gix Internet in which we currently hold 42.25% of its outstanding share capital. Our internet related activities also include our investment in Eventer, an online – event management and ticketing platform in which we currently hold 46.21% of its outstanding share capital
Our e-commerce activity includes the operations of Jeffs’ Brands Ltd., a subsidiary in which we hold 34.87% of its outstanding share capital, and which operates online stores for the sale of various consumer products on the Amazon online marketplace.
28
Our medical related activities include; innovative surgical devices with direct visualization capabilities for the treatment of Gastroesophageal Reflux Disease using Ultrasonic Surgical Endostapler, or MUSE and Polyrizon’s development of biological gels designed to protect patients against biological threats and reduce intrusion of allergens and viruses through the upper airways and eye cavities.
Our activity in the EV sector includes our ownership of Charging Robotics Ltd. (“Charging Robotics”) and its 19.99% subsidiary Revoltz, both develop three modular EVs and wireless vehicle battery charging technology. On April 7, 2023, Charging Robotics consummated a share exchange transaction, whereby it became a wholly owned subsidiary of Fuel Doctor. As a result, we now hold 67% of the outstanding share capital of Fuel Doctor, with an option to increase our holdings to 71% of the outstanding share capital based on predetermined milestone.
Our activity in the products and safety for drones through our stake in Parazero Technologies Ltd. (“Parazero”) in which we hold 40.35% of its outstanding share capital.
Internet and other online related Activity Overview
Gix Internet – Ad-Tech and Online Advertising
Gix Internet is the parent of Viewbix which is the majority shareholder of Gix Media Ltd. following a corporate reorganization that consummated on September 19, 2022 (“Reorganization Transaction”). Gix Media Ltd., which is the majority holder of the Cortex Media Group Ltd., and of Viewbix, a digital advertising platform that develops and markets a variety of technological platforms that automate, optimize and monetize digital online campaigns
We have consolidated Gix Internet’s financial statement as of March 1, 2022.
We currently hold 42.25% of Gix Internet’s outstanding share capital. We have an option to increase our stakes in Gix Internet to 44.94% of its outstanding share capital.
Eventer Technologies Ltd. – Online Event Management
Eventer is a technology company engaged in the development of unique tools for automatic creation, management, promotion, and billing of events and ticketing sales. Eventer seeks to tap the growing demand for enterprise and private online communication. As such, Eventer’s systems offer and enable advanced, user-friendly solutions for online events such as online concerts, enterprise events and online conferences, in addition to management and ticket sales for events carried out in offline venues. In addition, Eventer’s platform provides individuals with the ability to create and sell tickets to custom small-scale private or public events. Eventer’s revenues are derived from commissions from sales of tickets for online and offline events planned and managed through its platform.
We currently hold 46.21% of Eventer’s outstanding share capital.
E-commerce Activity Overview
Jeffs’ Brands Ltd.
Jeffs’ Brands (Nasdaq: JFBR) is an e-commerce consumer products goods, or CPG, company, operating primarily on Amazon platform. Jeffs’ Brands is the owner of Smart Repair Pro, Inc., or Pro, Purex Corp., or Purex, and Top Rank Ltd. that operate online stores for the sale of various consumer products on the Amazon online marketplace, utilizing the Fulfillment by Amazon, or FBA, model. In addition to executing the FBA business model, Jeffs’ Brands utilizes artificial intelligence, or A.I., and machine learning technologies to analyze sales data and patterns on Amazon platform in order to identify existing stores, niches and products that have the potential for development and growth, and for maximizing sales of existing proprietary products.
On August 30, 2022, we participated in Jeffs’ Brands initial public offering on Nasdaq.
We currently hold 34.87% of Jeffs’ Brands outstanding share capital. We have 240,385 warrants to purchase up to 240,385 ordinary shares with an exercise price of $2.02 per ordinary share and additional 240,385 unlisted warrants to purchase up to 240,385 ordinary shares with an exercise price of $2.02 per ordinary share.
29
Medical Activity Overview
Our MUSE™ System
We have been engaged in the development, production and marketing of innovative surgical devices with direct visualization capabilities for the treatment of Gastroesophageal Reflux Disease, a common ailment, which is predominantly treated by medical therapy (e.g. proton pump inhibitors) or in chronic cases, conventional open or laparoscopic surgery. Our product, the MUSE™ system for transoral fundoplication is a single use innovative device for the treatment of GERD disorder. The MUSE™ system is an endoscopic, incisionless solution that is used to perform a procedure as an alternative to a surgical fundoplication.
On June 3, 2019, we entered into the Golden Grand Agreement for the know-how licensing and sale of good relating to the MUSE™ system in China, Hong Kong, Taiwan and Macao. Four out of five predetermined in the agreement milestones were completed during 2020 and 2021, and consequently 80% of the agreed payments were already transferred to us. The final milestones will be completed, and the final installment will be paid upon completion of a MUSE™ assembly line in China. Due to COVID-19, the implementation of certain actions required to be achieved under the milestones have been delayed and are expected to be completed during 2023.
Polyrizon – Protective Biological Gels
Polyrizon is a clinical development biotech company specializing in the development of innovative nasal gels to provide preventative treatment against a wide cross section of viruses, as well as bacteria, allergens, and other toxins. Polyrizon’s proprietary Capture and Contain hydrogel platform is delivered in the form of nasal sprays, and forms a thin gel-based protective shield containment barrier in the nasal cavity.
We currently hold 37.03% of Polyrizon’s outstanding share capital. Additionally, we have invested $314,000 in multiple SAFEs.
ClearMind – Psychedelic Medicine
ClearMind Medicine, Inc. (Nasdaq: CMND) (“ClearMind”) is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including mental health, alcohol use disorder, binge eating and depression. ClearMind’s patent portfolio consists of four utility patent families, which includes seven approved patents and 13 pending applications.
On February 8, 2022, we entered into a share purchase agreement with ClearMind. On November 15, 2022, we participated in ClearMind’s initial public offering on Nasdaq.
We currently hold 5.77% of ClearMind’s outstanding share capital and 39,747 warrants to purchase an additional 39,747 shares.
Electric Vehicle Activity Overview
Charging Robotics Ltd.
To date, we have invested an aggregated amount of $1,286,000, in Charging Robotics, which was previously our wholly owned subsidiary. Charging Robotics is developing an autonomous wireless charging system for electric vehicles. On March 28, 2023, the Company entered into a securities exchange agreement (the “Exchange Agreement”) with Fuel Doctor. Pursuant to the Exchange Agreement, at the closing, which occurred on April 7, 2023, Fuel Doctor acquired 100% of the issued and outstanding share capital of Charging Robotics, making Charging Robotics a wholly-owned subsidiary of Fuel Doctor, in exchange for the issuance of shares of the Fuel Doctor’s common stock. As a result, Charging Robotics became a subsidiary of Fuel Doctor and we now hold 67% ofFuel Doctor’s outstanding share capital, with an option to increase our holdings to up to 71% of its outstanding share capital based on pre-set milestones.
Revoltz Ltd.
On February 19, 2021, we entered into a joint venture agreement with Amir Zaid, Weijian Zhou and Charging Robotics, for the purpose of developing and commercializing three modular electric vehicle (EV) micro mobility vehicles for urban individual use and “last mile” cargo delivery, through a new subsidiary, Revoltz Ltd. (“Revoltz”) Pursuant to the terms of such agreement, Charging Robotics was issued 19.99% of the issued and outstanding share capital of the Revoltz.
30
Other Activities
ScoutCam – Miniaturized Imaging Equipment
We currently hold 18.45% of the outstanding share capital of ScoutCam, which is engaged in the development, production and marketing of innovative visual solutions composed of imaging equipment, cloud and software-based image processing (artificial intelligence (AI), machine learning (ML), and additional algorithm methodologies). Some of ScoutCam’s products that utilize its micro ScoutCam™ technology are used in medical procedures as well as various applications in other industries.
Automax Ltd.
We currently hold 6.46% of the outstanding share capital of Automax Motors Ltd. (TASE: AMX), or Automax (formerly known as Matomy Media Group Ltd., following several sales and purchases in the stock market during 2021). Automax is an indirect importer and distributor of vehicles in Israel.
Elbit Imaging Ltd.
During 2021 we completed a number of transactions for the purchase of shares of Elbit Imaging Ltd. (TASE: EMITF), or Elbit Imaging, and currently hold 5.72 % of its outstanding shares. Elbit Imaging is a holding company with interests in real estate, medical imaging, hotels, shopping malls and retail.
Furthermore, during 2022 we received cash dividends of $171,000.
Safee Cyber Technologies Ltd.
On October 13, 2021, we entered into a share purchase agreement with Safee Cyber Technologies Ltd., or Safee, a blockchain company and we currently hold 2.35% of its outstanding share capital. Safee’s social network allows creators and collectors to easily create, own, engage, control and trade digital goods. Safee’s platform expands the reach of NFTs to mass market buyers, creators, digital artists, illustrators, photographers, musicians, regular consumer digital content creators and more.
Parazero Ltd.
In 2022 we made multiple investments in Parazero, a company specializing in drone safety systems, through various transactions. We currently hold 40.35% of Parazero’s outstanding share capital and we are entitled to increase our holdings in Parazero by a conversion of our SAFE agreements. Parazero develops and provides drone safety solutions designed to protect people and payloads, providing a solution to reduce the risk of a drone’s malfunction in an urban environment.
Laminera Flow Optimization Ltd.
During 2021 and 2022 we engaged Laminera Flow Optimization Ltd., or Laminera, in a number of share purchase transactions and a bridge loan agreement, in which we currently hold 19.7% of the outstanding share capital. Laminera develops solutions to improve and optimize global water, oil, and gas pipeline infrastructure by reducing energy and maintenance costs while enhancing capacity, all without having to replace existing infrastructure.
Our Strategy
Our primary goal is to generate revenues through the activities of our consolidated subsidiaries, each in their respective market and field. In addition, we seek to generate revenues by pursuing potential opportunities to sell our MUSE™ technology, or alternatively grant a license or licenses for the use of the MUSE™ technology. Our strategy includes the following key elements:
31
Commercialization of the products and services provided by our consolidated subsidiaries as well as achieving organic growth and profitability. Our board of directors has determined that we support the growth, development and expansion of our consolidated subsidiaries businesses.
Sell or License MUSE™ technology. Our board of directors has determined to examine potential opportunities to sell our MUSE™ technology, or alternatively grant a license or licenses for the use of the MUSE™ technology.
General Pursuit of Opportunities. Our board of directors and management are constantly seeking and pursuing opportunities through which to leverage our assets and capabilities.
A substantial material portion of our revenues in 2022 derived from Gix Internet, Jeffs’ Brands and Eventer. In 2021 and 2020 revenues derived from Jeffs’ Brands, Eventer and from the e licensing and sale agreement The following data reflects our total revenue arising from the following services:
Revenues | ||||||||||||
Year Ended December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
(Thousands of U.S. dollars) | ||||||||||||
Sales of Miniature Cameras and related equipment | - | 24 | 491 | |||||||||
Sales of Products on the Amazon online marketplace | 5,859 | 6,509 | - | |||||||||
Online advertising | 83,534 | - | - | |||||||||
Revenues from commissions | 2,465 | 1,185 | 40 | |||||||||
Sales of the MUSE™System | - | 2,400 | - | |||||||||
Total | 91,858 | 10,118 | 531 |
The following data reflects our total revenue broken down by geographic region:
Revenues | ||||||||||||
Year Ended December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
(Thousands of U.S. dollars) | ||||||||||||
United States | 52,129 | 6,307 | 418 | |||||||||
Europe | 21,897 | 127 | 41 | |||||||||
Asia | 2,108 | 2,400 | - | |||||||||
Israel | 15,266 | 1,183 | 45 | |||||||||
Other | 459 | 101 | 27 | |||||||||
Total | 91,858 | 10,118 | 531 |
Seasonality of Business
During the last few years we have not seen any seasonality in our sales. However, our subsidiaries experience certain effects of seasonality in their operations.
In connection with our subsidiary, Eventer, there is an increase in events scheduled during the holiday season in Israel, which typically occurs in September and October, and which corresponds to an increase in ticket sales.
In connection with our subsidiary, Jeffs’ Brands, the fourth quarter of each fiscal year typically yields significant activity due to the holiday season. As a result, revenue generally declines and loss from operations generally increases in the first quarter sequentially from the fourth quarter of the previous year.
32
In connection with our subsidiary, Gix Internet, the digital advertising industry is not affected by much seasonality. However, there is a seasonality trend such that the fourth quarter is characterized by higher activity compared to average, while the first quarter is characterized in lower activity than average. This seasonality results from, among other things, changes in large advertising budgets, usually towards the end of each quarter and effective towards the end of each year. In addition, the last quarter of the year includes many leading events and an increase in advertising budgets and the volume of traffic on the network.
Marketing and Distribution
Sale or License of MUSE™ System
As part of our board of directors decision to examine potential opportunities to sell our MUSE™ technology, or alternatively grant a license or licenses for the use of the MUSE™ technology, our board of directors has reexamined the efforts and resources previously invested by us in our MUSE™ technology distribution agreements as well as the revenues obtained through such agreements in order to assess their financial viability. As a result of this analysis, our board of directors resolved to terminate our distribution agreements in order to redirect our resources to securing licensing agreements, which may in turn generate significant income in the short term, reduce operating expenses and lower our Company’s burn rate. On May 5, 2021, the Company engaged with a contractor into service agreement, which the contractor seek, develop, evaluate, filter and recommend suitable business opportunities for the Company in the fields of the Muse products and technology, and also Communicate and meet potential customers and introduce the Company and the Company’s products thereto, and, to the extent required by the Company from time to time, assistance and support with respect to negotiations with potential customers.
Intellectual Property
Our commercial success depends, in part, on obtaining and maintaining patent and other intellectual property protection, in the United States and internationally, for the technologies used in our products. We cannot be sure that any of our patents will be commercially useful in protecting our technology. Our commercial success also depends in part on our non-infringement of the patents or proprietary rights of third parties. The patent positions of medical device companies, including ours, can be highly uncertain and involve complex and evolving legal and factual questions. For additional information see “Item 3. Key information—D. Risk Factors—Risks Related to Our Intellectual Property.”
We, Charging Robotics and GERD IP (hereinafter in this paragraph: “We” or “Us”) own 17 U.S. patents and have one additional pending patent applications in the U.S. and one U.S. Provisional Patent Applications. In addition, We own 11 patents that were granted in other countries, including 7 European patent assets, which are not valid on their own unless validated in specific European countries as indeed were validated according to our list of chosen European countries and one allowed European Patent Office patent application and 8 pending patent applications in such other countries. We also have two pending Paris Convention Treaty (PCT) patent applications. We also have an exclusive license to three pending patent applications from an academic institute subject to terms agreed in such license agreement.
We cannot be sure that any patents will be granted with respect to any the pending patent applications or with respect to any patent applications filed by us in the future. There is also a significant risk that any issued patents will have substantially narrower claims than those that are currently sought.
Competition
Competition with the MUSE™ system
We have several competitors in the medical device and pharmaceutical industries. Patients and physicians may opt for more established existing therapies to treat GERD, including PPI pharmaceutical treatment or laparoscopic fundoplication surgery. PPIs are currently being offered by several large pharmaceutical manufacturers, most of whom have significantly greater financial, clinical, manufacturing, marketing, distribution and technical resources and experience than we have.
Over the last few years a number of different medical devices and treatments have been introduced to address the “treatment gap” in GERD treatments and therapies which is found between long-term pharmaceutical therapy on one hand and surgery on the other. These devices and treatments seek to treat GERD less invasively than fundoplication and without the need for long-term use of drug therapy.
33
Competition related to our Subsidiary Jeffs’ Brands
The consumer goods and e-commerce market is a highly competitive environment. Jeffs’ competitive landscape consists of various types of companies such as traditional and non-traditional consumer good companies, discount stores, traditional retailers, independent retail stores, the online platforms of these traditional retail competitors and e-commerce companies. Such competitors include: Thrasio Holdings, Inc., Aterian, Inc. (Nasdaq: ATER), Amazon.com, Helen of Troy Ltd., Newell Brands (Nasdaq: NWL), Frigidaire Appliance Company, and Trademark Global Inc.
The consumer goods and e-commerce market is a highly competitive environment. Our competitive landscape consists of various types of companies such as: traditional and non-traditional consumer good companies; discount stores; traditional retailers; independent retail stores; the online platforms of these traditional retail competitors; and e-commerce companies.
Among CPG companies, our competitors include: Thrasio Holdings, Inc.; Aterian, Inc. (Nasdaq: ATER); Amazon; Helen of Troy Ltd., Newell Brands (Nasdaq: NWL); Frigidaire Appliance Company; and Trademark Global Inc. Despite the seemingly harsh competitive landscape, we believe that our technology and experience enable us to successfully compete and achieve our financial goals.
Competition related to our Subsidiary Eventer
Eventer’s competitors are traditional ticketing offices and digital ticketing companies that operate online platforms similar to Eventer’s platform and/or offer ticket marketing and distribution services. There are many companies outside of Israel that offer event management services similar to Eventer. Specifically in Israel, however, competitors that operate in the digital ticket sales platform space include Eventbuzz and TickChak Ltd., and companies that market events include Kupat and Eventim. Likewise, there are three large companies in Israel engaged in the field of marketing and distribution of events, including Leaan Tickets Ltd., CTS Eventim New Co (Eventim), and Kupot Tel-Aviv Tickets and Shows Ltd. Eventer also enables the sale of tickets to various attractions and activities, such as skydiving, glamping and motorsport. For these types of events and activities, Eventer competes with companies, including BUYME and Groupon, which sell vouchers to consumers and businesses and generates revenue from such sales commissions.
Government Regulation
The healthcare industry, and, therefore, our business, is subject to extensive federal, state, local and foreign regulation. Some of the pertinent laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. In addition, these laws and their interpretations are subject to change.
34
Both federal and state governmental agencies continue to subject the healthcare industry to intense regulatory scrutiny, including heightened civil and criminal enforcement efforts. As indicated by work plans and reports issued by these agencies, the federal government will continue to scrutinize, among other things, the billing practices of healthcare providers and the marketing of healthcare products.
We believe that we have structured our business operations and relationships with our customers to comply with all applicable legal requirements. However, it is possible that governmental entities or other third parties could interpret these laws differently and assert otherwise. In addition, because there is a risk that our products are used off label, we believe we are subject to increased risk of prosecution under these laws and by these entities even if we believe we are acting appropriately. We discuss below the statutes and regulations that are most relevant to our business and most frequently cited in enforcement actions.
C. Organizational Structure
As of December 31, 2022, we have four significant subsidiaries, (i) Jeffs’ Brands, a company incorporated under the laws of the State of Israel, in which we hold 35.94% of its outstanding share capital, (ii) Eventer Technologies, a company incorporated under the laws of the State of Israel in which we hold 46.21% of its outstanding share capital, (iii) our wholly owned subsidiary, Charging Robotics, a company incorporated under the laws of the State of Israel and (iv) Gix Internet a company incorporated under the laws of the State of Israel in which we hold 42.25% of its outstanding share capital.
In April 2023 our formerly wholly owned subsidiary Charging Robotics consummated a share exchange transaction with Fuel Doctor and became its wholly owned subsidiary. See also “Item 4.B. – Business Overview – Electric Vehicle Activity Overview.”
D. Property, Plant and Equipment
Our offices and research and development facility are located at 10 HaNechoshet Street, Tel Aviv, Israel, 6971072, where we occupy approximately 102 square meters. We believe our facilities sufficiently meet our current needs.
35
ITEM 4A. UNRESOLVED STAFF COMMENTS
Not applicable.
ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS
The following discussion of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this annual report on Form 20-F. In addition to historical consolidated financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under “Item 3. Key Information—D. Risk Factors” and elsewhere in this annual report.
Certain information called for by this Item 5, including a discussion of the year ended December 31, 2021, compared to the year ended December 31, 2020, has been reported previously in our annual report on April 29, 2022, under Item 5 “Operating and Financial Review and Prospects”.
For the purpose of this Item 5., references to “Medigus”, the “Company”, “us”, “we” and “our” refer to Medigus and its consolidated subsidiaries.
Overview
Our legal and commercial name is Medigus Ltd. We were incorporated in the State of Israel on December 9, 1999, as a private company pursuant to the Israeli Companies Ordinance (New Version), 1983. In February 2006, we completed our initial public offering in Israel, and until January 25, 2021, our Ordinary Shares were traded on the TASE, under the symbol “MDGS”. On January 25, 2021, we delisted our Ordinary Shares from trading on TASE. In May 2015, we listed our ADSs on Nasdaq, and since August 2015 our ADSs have been traded on the Nasdaq under the symbol “MDGS”. Following a 1:15 ratio change of the ADSs on November 14, 2022 (the “Ratio Change”), each ADS represents fifteen (15) Ordinary Shares. In July 2018, we listed our Series C Warrants on the Nasdaq, and since then our Series C Warrants have been traded on Nasdaq under the symbol “MDGSW”. Following the Ratio Change, the Series C Warrant were adjusted, such that the exercise price was increased by a factor of fifteen (15), and the number of ADSs issuable under the warrants was decreased by a factor of fifteen (15). Each Series C Warrant is exercisable into one/fifteen ADSs for an exercise price of $52.50, and will expire five years from the date of issuance.
ScoutCam Ltd. was formed in Israel on January 3, 2019, as a wholly owned subsidiary of Medigus, in order to distinguish ScoutCam’s miniaturized imaging business, or the micro ScoutCam™ portfolio, from Medigus’ other operations. In December 2019, Medigus and ScoutCam Ltd. consummated an Amended and Restated Asset Transfer Agreement, effective March 1, 2019, which transferred and assigned certain assets and intellectual property rights to ScoutCam Inc., which became the sole owner of ScoutCam Ltd.. ScoutCam Inc. consummated a private placement offering of USD 20 million in March 2021, in which we did not participate, following that offering our holdings in ScoutCam Inc. were reduced to 28.06% of its outstanding share capital. Accordingly ScoutCam was deconsolidated as of such date and is accounted for as an equity investment as of April 1, 2021. As of today, we hold 18.45% of ScoutCam’s outstanding share capital.
36
On October 14, 2020, we signed a share purchase agreement and a revolving loan agreement with Eventer. The Eventer transaction closed on October 26, 2020. Pursuant to the share purchase agreement, we invested $750,000 and were issued 325,270 ordinary shares of Eventer, representing 58.7% of Eventer’s then issued and outstanding share capital. On April 8, 2021, Eventer consummated an additional share purchase agreement with certain investors in connection with the sale and issuance its ordinary shares for an aggregate amount of $2.25 million (the “Purchase Agreement).” According to the Purchase Agreement, if during the twelve months following the closing of the Purchase Agreement, or March 25, 2022, Eventer shall not consummate an IPO, then the price per share shall be adjusted by issuance of additional shares. By March 25, 2022, Eventer had not consummated an IPO, therefore, on May 25, 2022, Eventer issued additional shares to the Company and additional investors. As a result of such share issuance, our holding in Eventer decreased to 46.21% of Eventer’s outstanding share capital.
On October 8, 2020, we entered into a common stock purchase agreement with Pro Inc., Purex, and their respective stockholders pursuant to which we acquired 50.01% of Pro’s and 50.03% of Purex’s issued and outstanding share capital on a fully diluted basis through a combination of cash investments in the companies and acquisition of additional shares from the then current shareholders of the two companies in consideration for our restricted ADSs and a cash component. We agreed to; invest an aggregate amount of $1,250 thousand in Pro and Purex, pay $150 thousand in cash consideration to the current stockholders, and issue up to $500 thousand worth of restricted ADSs to the current stockholders of such companies subject to EBITDA milestones. Following the EBITDA results, the Company issued $71 thousand worth of restricted ADSs in June 20201. The transactions contemplated in the definitive agreements closed on January 4, 2021.
On May 16, 2021, we entered into a stock exchange and plan of restructuring agreement with Victor Hacmon, the other shareholder of Pro and Purex, and Jeffs’ Brands. Pursuant to which, among other things, we and Victor Hacmon transferred all our holdings in Pro and Purex to Jeffs’ Brands, in return for a consideration of Jeffs’ Brands ordinary shares that were issued respectively. As a result, Pro and Purex became wholly-owned subsidiaries of Jeffs’ Brands. The share exchange transaction was accounted in a manner similar to Pooling-of-Interests (“As Pooling”).
On August 30, 2022, we participated in Jeffs’ Brands initial public offering, and purchased 240,385 units comprised of 240,385 ordinary shares and warrants to purchase up to 240,385 ordinary shares with an exercise price of $2.02 per ordinary share.
We currently hold 34.87% of Jeffs’ Brands outstanding share capital.
As of December 31, 2021, Medigus held 34.58% of Gix Internet’s outstanding share capital. On February 14, 2022, we purchased 500,000 additional shares, increasing our holdings to 35.78% of Gix Internet's outstanding share capital.. On February 28, 2022, we purchased additional shares following which our holdings in Gix Internet increased to 38.03% of its outstanding share capital. As a result of this increase, and the fulfillment of additional conditions we consolidated Gix Internet’s financial statements as of February 28, 2023. On June 19, 2022, we purchased an additional 3,171,160 shares of Gix Internet, We currently hold 42.25% of Gix Internet’s outstanding share capital.
37
A. Operating results:
The following table sets forth a summary of our operating results:
Year ended December 31, | ||||||||
2022 | 2021 | |||||||
U.S. Dollars, in thousands, except per share and weighted average shares data | ||||||||
Revenues: | ||||||||
Products | 5,861 | 8,933 | ||||||
Services | 85,997 | 1,185 | ||||||
91,858 | 10,118 | |||||||
Cost of revenues: | ||||||||
Products | 5,059 | 4,938 | ||||||
Services | 72,347 | 379 | ||||||
77,406 | 5,317 | |||||||
Gross Profit | 14,452 | 4,801 | ||||||
Research and development expenses | 4,853 | 1,045 | ||||||
Sales and marketing expenses | 4,006 | 1,988 | ||||||
General and administrative expenses | 14,174 | 9,964 | ||||||
Net change in fair value of financial assets at fair value through profit or loss | 2,544 | (713 | ) | |||||
Share of net loss of associates accounted for using the equity method | 2,659 | 2,149 | ||||||
Amortization of excess purchase price of associates | - | 263 | ||||||
Operating loss | (13,784 | ) | (9,895 | ) | ||||
Changes in fair value of warrants issued to investors | (159 | ) | (484 | ) | ||||
Gain upon loss of control in a subsidiary | - | (11,465 | ) | |||||
Gain from initial recognition of assets and liabilities upon consolidation of Gix Internet | (2,300 | ) | - | |||||
Loss (gain) from sale of investments | 127 | (2,025 | ) | |||||
Changes in fair value of warrants issued to third party investors by a consolidated subsidiary | (3,619 | ) | 75 | |||||
Other expenses (income) | (45 | ) | (494 | ) | ||||
Financial (income) loss net | 2,309 | 347 | ||||||
Profit (loss) before taxes on income | (10,097 | ) | 4,151 | |||||
Taxes expense | 111 | 105 | ||||||
Net profit (loss) for the period | (10,208 | ) | 4,046 | |||||
Other comprehensive income for the period | 460 | 162 | ||||||
Total comprehensive income (loss) for the period | (9,748 | ) | 4,208 | |||||
Net Profit (loss) for the period is attributable to: | ||||||||
Owners of Medigus | (9,815 | ) | 6,794 | |||||
Non-controlling interest | (393 | ) | (2,748 | ) | ||||
(10,208 | ) | 4,046 | ||||||
Total comprehensive Profit (loss) for the period is attributable to: | ||||||||
Owners of Medigus | (9,503 | ) | 6,881 | |||||
Non-controlling interest | (245 | ) | (2,673 | ) | ||||
(9,748 | ) | 4,208 | ||||||
Basic Earnings (loss) per ordinary share | (0.40 | ) | 0.2 | |||||
Diluted Earnings (loss) per ordinary share | (0.40 | ) | 0.2 | |||||
Weighted average number of Ordinary Shares outstanding used to compute (in thousands): | ||||||||
Basic income/loss per share | 24,385 | 23,036 | * | |||||
Diluted income/loss per share | 24,385 | 23,036 | * |
*Restated | to reflect the Reverse Split at a ratio of 20:1 effected on July 7, 2022. |
38
Year ended December 31, 2022, compared to year ended December 31, 2021
Revenues
Revenues for the year ended December 31, 2022, were $91,858,000 representing an increase of $81,740,000 or 808%, compared to total revenues of $10,118,000 for the year ended December 31, 2021.
The increase in revenues was primarily due to the consolidation initiation of Gix Internet financial statements and the increase in revenues related to Eventer.
The tables below set forth our revenues, by region and by product for the periods presented:
U.S. dollars; in thousands
Year Ended December 31, | ||||||||||||||||
2022 | 2021 | |||||||||||||||
United States | 52,129 | 57 | % | 6,306 | 62 | % | ||||||||||
Europe | 21,897 | 24 | % | 128 | 1 | % | ||||||||||
Israel | 15,266 | 16.5 | % | 1,183 | 12 | % | ||||||||||
Asia | 2,108 | 2 | % | 2,400 | 24 | % | ||||||||||
Other | 458 | 0.5 | % | 101 | 1 | % | ||||||||||
Total | 91,858 | 100 | % | 10,118 | 100 | % |
U.S. dollars; in thousands
Year Ended December 31, | ||||||||||||||||
2022 | 2021 | |||||||||||||||
Products on the Amazon online marketplace | 5,861 | 6 | % | 6,509 | 64 | % | ||||||||||
Products- others | - | - | 2,400 | 24 | % | |||||||||||
Revenues from internet services | 83,532 | 91 | % | - | - | |||||||||||
Revenues from commissions | 2,465 | 3 | % | 1,185 | 12 | % | ||||||||||
Miniature camera and related equipment | - | - | 24 | 0 | % | |||||||||||
Total | 91,858 | 100 | % | 10,118 | 100 | % |
Our revenues in 2021 were primarily derived from the sale of products on Amazon online marketplace and sales from commission.
The decrease in revenues from Products on the Amazon Online Marketplace was primarily due to an increase in competition. The increase in revenues from commissions was primarily due to an increase in events during 2022. The increase in revenues from internet services is due to the consolidation initiation of Gix Internet’s financials commencing February 28, 2022.
Cost of revenues
Cost of revenues for the year ended December 31, 2022, were $77,406,000 representing an increase of $72,089,000, or 1,356%, compared to cost of revenues and of $5,317,000 for the year ended December 31, 2021. The increase was primarily due to the increase in cost of revenues related to the consolidation of Gix Internet commencing February 28, 2022.
Gross Profit
Gross profit for the year ended December 31, 2022, was $14,452,000, representing an increase of $9,651,000 compared to gross loss of $4,801,000 for the year ended December 31, 2021. The gross profit increase is a result mainly due to the consolidation of Gix Internet commencing February 28, 2022..
Research and Development Expenses
Research and development expenses for the year ended December 31, 2022, were $4,853,000, representing an increase of $3,808,000, or 364%, compared to $1,045,000 for the year ended December 31, 2021. The increase was primarily due to the consolidation of Gix Internet commencing February 28,2022. In addition to the increase in Charging Robotics Ltd. research and development activities.
Sales and Marketing Expenses
Sales and marketing expenses for the year ended December 31, 2022, were $4,006,000, representing an increase of $2,018,000, or 102%, compared to $1,988,000 for the year ended December 31, 2021. The increase was primarily due to the consolidation of Gix Internet commencing February 28, 2022.
39
General and Administrative Expenses
General and Administrative expenses for the year ended December 31, 2022, were $14,174,000, representing an increase of $4,210,000, or 42%, compared to $9,964,000, for the year ended December 31, 2021. The increase was primarily due to:
a. | The consolidation of Gix Internet commencing February 28, 2022. |
b. | Increase in Jeffs’ Brands general and administrative expenses - mainly due to professional services and consulting fees related to services provided in connection with Jeffs’ IPO. |
Net change in fair value of financial assets at fair value through profit or loss
During 2022 we recognized a loss of $2,544,000 from net change in the fair value of financial assets derived mainly due to expenses of USD 1,128 thousand from Clearmind Shares, expenses of USD 427 thousand from Gix Internet Anti-dilution rights and USD 578 thousand from Automax shares..
Share of net loss of accounted for using the equity method
The investment in Polyrizon, Revoltz, Laminera, Parazero, Fuel Doctor, Elbit (until October 2022), Gix (up to February 28, 2022) and ScoutCam are accounted for using the equity method. The share net loss of accounted for using the equity method for the year ended December 31, 2022, amounted to $2,659 thousand.
Operating loss
We incurred an operating loss of $13,784,000 for the year ended December 31, 2022, representing an increase of $3,889,000, or 39%, compared to operating loss of $9,895,000 for the year ended December 31, 2021. The increase was primarily due to an increase of $3,257,000 in net change in fair value of financial assets at fair value through profit or loss and an increase of the share of net loss of associates accounted for using the equity method of USD 510 thousand.
Change in Fair Value of Warrants Issued to Investors
Profit from change in the fair value of warrants issued to investors for the year ended December 31, 2022, was $159,000, representing a decrease of $325,000, compared to profit of $484,000 for the year ended December 31, 2021.
Warrants issued to investors are classified as either liabilities or as part of the shareholders’ equity based on the accounting guidance established in connection with the rights attached to the warrants. The warrants that were classified as liabilities due to a cashless exercise mechanism are subject to adjustment to fair value each statement of financial position cut-off date. This adjustment is presented separately within the consolidated statement of loss and other comprehensive loss.
Gain from initial recognition of assets and liabilities upon control obtained in an associate
The Company recognized a gain of $2,300,000 from initial recognition of assets and liabilities due to control obtained in Gix Internet commencing February 28, 2022.
Financial expenses net
Finance expenses, net for the year ended December 31, 2022, was $2,309,000, representing an increase of $1,962,000, compared to finance expenses of $347,000 for the year ended December 31, 2021, primarily due to interest accumulated on loans in Gix internet, Eventer and Jeffs’ Brands and due to exchange rate differences.
40
Profit (Loss) for the year
We incurred net loss of $10,208,000 for the year ended December 31, 2022, representing a decrease of $14,254,000, or 352%, compared to profit of $4,046,000 for the year ended December 31, 2021, which was primarily due to one-time gain in 2021 upon loss of control of a subsidiary in the amount of $11,465,000. The decrease was further due to an increase of $3,257,000 in net change in fair value of financial assets at fair value through profit or loss and an increase of the share of net loss of associates accounted for using the equity method of $510,000.
Year ended December 31, 2021, compared to year ended December 31, 2020
The discussion and analysis regarding the results of operations from the fiscal years ended December 31, 2021, and December 31, 2020, is contained in our annual report on Form 20-F, filed with the SEC, on April 29, 2022, and May 14, 2021.
Effective Corporate Tax Rate
Our effective consolidated tax rate for the years ended December 31, 2022, and 2021 was almost zero percent (0%), primarily due to the fact that the Company did not record a tax asset, Gix Internet, Jeffs' Brands and Eventer did not record a deferred tax asset in connection with the losses incurred in Israel, since it is not probable that we will be able to utilize such losses in the foreseeable future against taxable income.
Impact of Inflation, Devaluation and Fluctuation in Currencies on Results of Operations, Liabilities and Assets
We generate part of our revenues in different currencies than our functional currency (U.S. dollars), such as NIS and Euro. As a result, some of our financial assets are denominated in these currencies, and fluctuations in these currencies could adversely affect our financial results. A considerable amount of our expenses are generated in U.S. dollars, but a significant portion of our expenses such as salaries are generated in other currencies such as NIS. In addition to our operations in Israel, we are expanding our international operations in the European Union. Accordingly, we incur and expect to continue incurring additional expenses in non-U.S. dollar currencies, such as described above. Due to the mentioned, our results could be adversely affected as a result of a strengthening or weakening of the U.S. Dollar compared to these other currencies.
The inflation in Israel during the last several years was relatively immaterial and, therefore, had immaterial effect on our results of operations.
Effective January 1, 2016, we changed our functional currency to the U.S. dollar from NIS. This change was based on management’s assessment that the U.S. dollar is the primary currency of the economic environment in which we operate. Accordingly, the functional and reporting currency of our consolidated financial statements is the U.S. dollar.
41
B. Liquidity and Capital Resources
Liquidity
During the year ended December 31, 2022, we incurred a total comprehensive loss of approximately $9.7 million and a negative cash flow used in operating activities of approximately $5.6 million. As of December 31, 2022, we incurred accumulated deficit of approximately $85.6 million.
We will need to seek additional sources of funds, including selling additional equity, debt or other securities or entering into a credit facility, take costs reduction steps or modify our current business plan to achieve profitability. If we raise additional funds through the issuance of debt securities, these securities may have rights senior to those of our Ordinary Shares and could contain covenants that could restrict our operations and ability to issue dividends. We may also require additional capital beyond our currently forecasted amounts. Any required additional capital, whether forecasted or not, may not be available on reasonable terms, or at all. If we are unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of our planned research, development and commercialization activities, which could materially harm our business and results of operations.
Because of the numerous risks and uncertainties associated with the development of our products and the current economic situation, we are unable to estimate the exact amounts of capital outlays and operating expenditures necessary to complete the development of our products and successfully deliver commercial products to the market. Our future capital requirements will depend on many factors, including but not limited to the following:
● | the revenue generated by sales of our current and future products; | |
● | the expenses we incur in selling and marketing our products and supporting our growth; |
● | the costs and timing of regulatory clearance or approvals for new products or upgrades or changes to our products; | |
● | the expenses we incur in complying with domestic or foreign regulatory requirements imposed on medical device companies; |
● | the rate of progress, cost and success or failure of on-going development activities; | |
● | the emergence of competing or complementary technological developments; | |
● | the costs of filing, prosecuting, defending and enforcing any patent or license claims and other intellectual property rights; | |
● | the terms and timing of any collaborative, licensing, or other arrangements that we may establish; | |
● | the future unknown impact of recently enacted healthcare legislation; | |
● | the acquisition of businesses, products and technologies; and | |
● | general economic conditions and interest rates. |
Cash Flows
Net cash used in operating activities for the year ended December 31, 2022, was $5,656,000, compared to $5,250,000 for the year ended December 31, 2021. For the year ended December 31, 2022, the Company had net cash used in investing activities of $4,476,000 compared to net cash used in investing activities of $12,446,000 for the year ended December 31, 2021. For the year ended December 31, 2022, the Company had net cash generated from financing activities of $5,410,000 compared to $19,150,000 for the year ended December 31, 2021.
42
The change in our liquidity for the year ended December 31, 2022, resulted from several factors, including but not limited to:
● | net cash used in operating activities consists primarily of $2,300,000 gain from initial recognition of assets and liabilities upon consolidation of Gix Internet, Changes in fair value of warrants issued to third party investors by a consolidated subsidiary of $3,619,000 , net loss from change in the fair value of financial assets at fair value through profit or loss in the amount of $2,544,000, share of net loss of associates accounted for using the equity method in an amount of $2,659,000 and stock-based compensation in connection with options granted to employees and service providers of $787,000. |
● | net cash used in investing activities consists mainly of $5,099,000 purchases of investments accounted as associates or measured through profit and loss, $1,018,000 loan to others, $660,000 loans to associate and $2,737,000 consolidation of subsidiaries upon gain of control. |
● | net generated from financing activities consists mainly of $12,567,000 proceeds from issuance of shares and warrants by subsidiaries, $1,752,000 receipt of loans offset by $2,520,000 repayment of loans and $4,186,000 dividends. |
C. Research and Development, Patents and Licenses, etc.
Our research and development efforts are focused on continuous improvement of our products. We conduct all of our research activities in Israel.
As of December 31, 2022, our research and development team consisted of 16 employees and subcontractors for the development of our products in Gix, and Eventer as needed. We have assembled an experienced team with recognized expertise in, software, control algorithms and systems integration.
The table below set forth our research and development expenses for the periods presented:
Year Ended December 31, | ||||||||
2022 | 2021 | |||||||
(U.S. Dollars, in thousands) | ||||||||
Research and development expenses | $ | 4,853 | $ | 1,045 |
From time to time, we file applications for patent registration in certain countries, some in which we are active and some which we consider as potential markets in order to protect our developed intellectual property.
D. Trend Information
Other than as described in Item 3.D. “Risk Factors”, in Item 5.A. “Operating Results”, and in Item 5.B. “Liquidity and Capital Resources” of this Annual Report, we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect on our net revenues, income from operations, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future operating results or financial condition.
43
E. Critical Accounting Estimates
Our significant accounting policies and their effect on our financial condition and results of operations are more fully described in our audited consolidated financial statements included elsewhere in this Annual Report. We have prepared our financial statements in conformity with International Financial Reporting Standards or IFRS, which requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. These estimates are prepared using our best judgment, after considering past and current events and various other assumptions. While management believes the factors evaluated provide a meaningful basis for establishing and applying sound accounting policies, management cannot guarantee that the estimates will always be consistent with actual results. In addition, certain information relied upon by us in preparing such estimates includes internally generated financial and operating information, external market information, when available, and when necessary, information obtained from consultations with third parties. Actual results may differ from these estimates. We believe that the accounting policies discussed below are critical to our financial results and to the understanding of our past and future performance, as these policies relate to the more significant areas involving management’s estimates and assumptions. We consider an accounting estimate to be critical if: (1) it requires us to make assumptions because it included matters that were highly uncertain at the time, we were making our estimate or the assumption is material due to the levels of subjectivity and judgment involved, and (2) changes in the estimate could have a material impact on our financial condition or results of operations.
Warrants/options assets
Warrants/options assets, which measured as fair value through profit and loss, are subsequently measured using the Black-Scholes option-pricing model as follow:
The Black-Scholes option-pricing model requires us to make a number of assumptions, including the value of Ordinary Shares, expected volatility, expected term, risk-free interest rate and expected dividends.
Expected volatility of private company warrants was calculated based on the implied volatilities from market comparisons of certain publicly traded companies and other factors. Expected volatility for traded company warrants was calculated based upon their share prices. Share price as of the cut-off date for private company relies on the last finance round.
The risk-free interest rate was based on the U.S. treasury bonds yield with an equivalent term or Israel treasury bonds yield. There are no foreseeable plans to pay dividends. Future expense amounts for any period could be affected by changes in our assumptions and market conditions.
Stock-Based Compensation
We as well as our subsidiaries grant equity-based awards to certain employees, directors and other service providers. The expense is measured at the grant date fair value of the award and recognized as compensation expense over the service period. The fair value of the awards is estimated on the grant date using the Black Scholes option pricing model. The use of an option valuation model includes subjective assumptions, including the expected stock price volatility and average life of each grant, as well probability of successful completion of the IPOs of our subsidiaries that were in process at the date of grant or during subsequent periods to the extent the award terms included performance conditions.
Financial instruments at fair value through profit and loss / Financial instruments at cost that are initially measured at fair value
In estimating the fair value of such assets or a liabilities, the Group uses market-observable data. Where Level 1 or 2 inputs are not available, we determine the fair value of the financial instrument using acceptable valuation techniques and, as applicable, engage with qualified third party valuation specialists to perform the valuation.
We perform a purchase price allocation in regards with our investments, as needed. Following the consolidation of Gix to our financial statements, we performed a purchase price allocation to Goodwill and other intangible assets.
The fair value determination of acquired intangible assets for [these purchases price allocations require us to make significant estimates. These estimates include, among others, forecasted discounted cash flows which include, inter alia, significant assumptions for revenue growth rates and the selection of an appropriate discount rate.
Business Combinations
The results of an acquired business in a business combination are included in the Company’s consolidated financial statements from the date of acquisition according to IFRS 3R, “Business Combinations.” The Company allocates the purchase price, which is the sum of the consideration provided and may consist of cash, equity or a combination of the two, to the identifiable assets and liabilities of the acquired business at their fair values as of the acquisition date. The excess of the purchase price over the amount allocated to the identifiable assets and liabilities, if any, is recorded as goodwill. The non-controlling interest are measured upon the date of the business combination in the amount of their share at the fair value of assets, liabilities and contingent liabilities of the acquired acquisition other than their share in goodwill.
44
The estimated fair values and useful lives of identifiable intangible assets are based on many factors, including estimates and assumptions of future operating performance and cash flows of the acquired business, the nature of the business acquired and the specific characteristics of the identified intangible assets. The estimates and assumptions used to determine the fair values and useful lives of identified intangible assets could change due to numerous factors, including market conditions, technological developments, economic conditions and competition.
Contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of the fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period, with any adjustments in fair value recognized in earnings under general and administrative expenses.
Acquisition related costs incurred by the Company are not included as a component of consideration transferred but are accounted for as an expense in the period in which the costs are incurred.
Share-Based Compensation
We account for share-based compensation in accordance with IFRS 2, “Share-based Payment.” Share based awards are mainly granted to employees, service providers and members of our board of directors and measured at fair value at each grant date. We calculate the fair value of share-based compensation options, on the date of grant using the Black-Scholes option-pricing model and the expense is recognized over the requisite service period using the accelerated basis method.
We recognize forfeitures as they occur.
The requisite service period for share-based compensation options is generally 3 years and vesting equally on quarterly basis.
The Black-Scholes option-pricing model requires us to make a number of assumptions, including the value of our Ordinary Shares, expected volatility, expected term, risk-free interest rate and expected dividends.
We evaluate the assumptions used to value share-based compensation options upon grant date.
Expected volatility for share-based compensation options was calculated based upon the Company’s share prices.
The risk-free interest rate was based on the U.S. treasury bonds yield with an equivalent term. We have not paid dividends and have no foreseeable plans to pay dividends.
As it relates to the fair value estimate of equity awards granted by our subsidiaries, the assumptions with respect to the underlying share price are primarily based on recent financing rounds, and the assumptions with respect to volatility of the share price is based on comparable companies. In cases equity awards granted by our subsidiaries have contractual terms that dependents on the successful completion of an IPO, our fair value estimate with respect to these awards includes assumption with respect to the probability of occurrence of an IPO event.
Future expense amounts for any particular period could be affected by changes in our assumptions or market conditions.
Recent Accounting Pronouncements
Please see Note 2 to our audited consolidated financial statements included elsewhere in this Annual Report for information regarding recent accounting pronouncements.
45
ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
A. Directors and Senior Management
The following table lists the names and ages of our directors and senior management as of March 1, 2023:
Name | Age | Position(s) | ||
Liron Carmel | 39 | Chief Executive Officer | ||
Eliyahu Yoresh(1)(3)(4) | 53 | Chairman of the Board of Directors | ||
Ronen Rosenbloom(1)(2)(4) | 51 | Director | ||
Eli Cohen(1)(2)(3)(4) | 54 | Director | ||
Kineret Tzedef(2)(4) | 43 | Director | ||
Tali Dinar | 51 | Chief Financial Officer |
(1) | Member of the audit committee. |
(2) | Member of the compensation committee. |
(3) | Member of the investment committee. |
(4) | Indicates independent director under Nasdaq Stock Market rules. |
Liron Carmel has been serving as our Chief Executive Officer since April 2019. Mr. Carmel has vast experience in business and leadership across multiple industries, including bio pharma, internet technology, oil & gas exploration & production, real estate and financial services. In addition he serves as chairman of the Israel Tennis Table Association. Mr. Carmel also currently serves as a member of the board of directors of several of our subsidiaries including Gix Internet (TASE: GIX), beginning April 2021, Polyrizon Ltd., beginning July 2020, Jeffs’ Brands Ltd. beginning September 2021, Viewbix Inc. (OTC:VBIX) beginning September 2022 and as the chairman of the board of directors of Eventer Technologies Ltd. beginning October 2020.
Eliyahu Yoresh has been serving as a member of our Board since September 2018 and as our Chairman of the board since February 2020. Mr. Yoresh serves as chief financial officer of Foresight Autonomous Holdings Ltd. (Nasdaq, TASE: FRSX). In addition, Mr. Yoresh serves as Chairman of Gix (TASE: GIX) and serves as a director of Rail Vision (Nasdaq: RVSN), Jeff Brands (Nasdaq: JFBR), Viewbix Inc. (OTC:VBIX) and Elbit Imaging (TASE: EMITF). Mr. Yoresh served as the chief executive officer of Tomcar Global Holdings Ltd., a global manufacturer of off-road vehicles, from 2005 to 2008. Mr. Yoresh is an Israeli Certified Public Accountant. Yoresh acquired a B.A. in business administration from the Business College, Israel and an M.A. in Law Study from Bar-Ilan University, Israel.
Ronen Rosenbloom has been serving as a member of our Board since September 2018. Mr. Rosenbloom is an independent lawyer working out of a self-owned law firm specializing in white collar offences and AML. Mr. Rosenbloom serves as chairman of the Israeli Money Laundering Prohibition committee and the Prohibition of Money Laundering Committee of the Tel Aviv District, both of the Israel Bar Association. Mr. Rosenbloom previously served as a police prosecutor in the Tel Aviv District. Mr. Rosenbloom holds an LL.B. from the Ono Academic College, an Israeli branch of University of Manchester.
46
Eli Cohen has been serving as a member of our Board since September 2018. Mr. Cohen is an independent lawyer working out of a self-owned firm. He serves as chairman of Univo Pharmaceuticals Ltd., as director of Europe Hagag Ltd., and has previously served as director of Hagag Group Ltd., Multimatrixs Ltd., Matrat Mizug Ltd. and User Trend-M Ltd. Mr. Cohen also serves as a director of several private companies. Mr. Cohen holds an economics degree, an LL.B. and an LL.M. in Commercial Law from Tel-Aviv University, as well as an MBA from the Northwestern University and Tel-Aviv University joint program.
Kineret Tzedef has been serving as member of our Board since June 2019. Ms. Tzedef also serves as a director of sports division and served in other positions at Hapoel Organization (Israeli Sport Federation) since 2007. Ms. Tzedef serves as an external director at Upsellon Brands Holdings Ltd. (TASE: UPSL), and as an external director of Augwind Energy Tech Storage Ltd. (TASE: AUGN). Ms. Tzedef is admitted to the Israel Bar Association since 2014. Ms. Tzedef acquired a LL.B from the Academic Center for Law and Science, Israel and a B.Ed. in Law Study from the Academic College at Wingate, Israel.
Tali Dinar has been serving as our Chief Financial Officer since June 8, 2021 Mrs. Dinar served as Chief Financial Officer of Novomic Ltd., a private company between January 2019 and January 2023. Mrs. Dinar also currently serves as a member of the board of directors of Jeffs’ Brands, beginning September 30, 2021, Parazero. beginning February 13, 2022, and Charging Robotics Ltd. since November 2021. She has also served as a member of the board of directors of Micronet Ltd. (TASE: MCRNT) between July 2016 and February 2023. In addition, she has also served as a director of Canzon Israel Ltd. (TASE: CNZN) since August 2020 until March 2022. Between 2019 and 2020, Mrs. Dinar served as the Chief Financial Officer of TechCare Corp. (currently Citrine Global Corp.) (OTCQB: CTGL). Between 2009 and 2019, Mrs. Dinar worked at the MICT group and served in various positions, including as Chief Financial Officer of MICT Inc. (Nasdaq: MICT) and as Chief Financial Officer of MICT Telematics Ltd. From 2002 until 2006, Mrs. Dinar served as the chief controller of I.T.L. Optronics Ltd. From 1997 until 2000, Mrs. Dinar worked in the audit department of Ernst & Young Global. Mrs. Dinar is a certified public accountant in Israel and holds a B.A. degree in Accounting and Business Management from The College of Management, Israel.
Family Relationships
There are no family relationships between any members of our executive management and our directors.
Arrangements for Election of Directions and Members of Management
There are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management or our directors were appointed.
B. Compensation
Compensation of Directors and Executive Officers
In accordance with the provisions of the Companies Law, the compensation of our directors and officer holders must generally comply with the terms and conditions of our compensation policy, as approved by our compensation committee, board of directors and general meetings of our shareholders, subject to certain exceptions under the Companies Law.
47
The table below reflects the compensation granted to our six most highly compensated directors and officers during or with respect to the year ended December 31, 2022.
Name and Position | Salary | Bonus | Equity-Based Compensation(1) | Total | ||||||||||||
U.S. Dollars in thousands | ||||||||||||||||
Liron Carmel, Chief Executive Officer | 216 | 102 | 133 | 449 | ||||||||||||
Eliyahu Yoresh, Chairman of the Board of Directors(2) | 161 | 77 | 127 | 365 | ||||||||||||
Tali Dinar(3), Chief Financial Officer | 151 | 21 | 50 | 221 | ||||||||||||
Kineret Tzedef, Director | 39 | - | 48 | 87 | ||||||||||||
Eli Cohen, Ronen Rosenbloom, Directors | 39 | - | 42 | 81 |
(1) | Represents the equity-based compensation expenses recorded in the Company’s consolidated financial statements for the year ended December 31, 2022, based on the option’s fair value, calculated in accordance with accounting guidance for equity-based compensation. |
(2) | Mr. Yoresh has been serving as a member of our board of directors since September 2018 and as our Chairman of the board of directors since February 2020. |
(3) | Salary includes gross salary plus payment of social benefits made by us on behalf of such office holder. Such benefits may include, to the extent applicable to the office holder, payments, contributions and/or allocations for savings funds (such as managers’ life insurance policy), education funds (referred to in Hebrew as “keren hishtalmut”), pension, severance, risk insurances (e.g., life, or work disability insurance), payments for social security and tax gross-up payments, vacation, medical insurance and benefits, convalescence or recreation pay and other benefits and perquisites consistent with our policies. |
The aggregate compensation paid by us to our office holders, as defined in the Companies Law, for the year ended December 31, 2022, was approximately $1.2 million, which includes six persons. This amount includes, when applicable, set aside or accrued to provide pension, severance, retirement or similar benefits or expenses, car expenses and value of the Ordinary Shares underlying the options representing accounting expenses, but does not include business travel, relocation, professional and business association dues and expenses reimbursed to officers, and other benefits commonly reimbursed or paid by companies in Israel.
Compensation of Directors
Under the Companies Law and the rules and regulations promulgated thereunder, our directors are entitled to fixed annual compensation, up to the limits set forth in the compensation policy. We currently pay each of Mr. Ronen Rosenbloom, Ms. Kineret Tzedef and Mr. Eli Cohen an annual fee of NIS 132,000.
Each of our non-executive directors were also granted options to purchase 100,000 Ordinary Shares under the Plan (as defined herein). Such options were granted on June 29, 2021. The options vest over a period of three (3) years commencing on April 1, 2021, with 1/12 of such options vesting at the end of each subsequent three-month period following the grant, (ii) the term of the options is of six (6) years from the grant date, unless they have been exercised or cancelled in accordance with the terms of and conditions of the applicable incentive plan of the Company, (iii) unless previously exercised or cancelled, the options may be exercised until 180 days from the termination of the tenure of a director, (iv) the exercise price per share of the options is equal to the average share price of the 30 days prior to the date of grant, $1.783 (v) the options grant is in accordance and pursuant to Section 102 of the Income Tax Ordinance [New Version] (“Tax Ordinance”), if applicable, and (vi) the options will be accelerated upon the closing of a material transaction, resulting in change of control of the Company.
48
On April 25, 2021, and on May 4, 2021, our compensation committee and board of directors approved new compensation terms for Mr. Eliyahu Yoresh in connection with his services as an active chairman of the board of directors. For his services, Mr. Yoresh is entitled to receive a monthly payment of NIS 45,000 plus VAT, which constitutes the sole and complete compensation. In addition, Mr. Yoresh is entitled to an annual, target based bonus and an additional overachievement bonus of up to 6 monthly salaries, each. The weight afforded to each target and overachievement component, is to be decided by our board of directors and compensation committee in accordance with the following weights: (a) 35% Company performance measures of strategic goals and related objectives; (b) 25% Company performance measures of material transaction or material profitability/revenues; (c) 20% Company performance measures of revenues and/or loss reduction; and (d) 20% Company performance measures of achieving commercialization of Company’s technology. The aforementioned compensation terms are consistent with our current compensation policy.
Following the approval of the annual general meeting of our shareholders held on August 30, 2021, Mr. Yoresh was granted with a one-time grant of options to purchase 300,000 Ordinary Shares in accordance with the terms of the Plan. The options vest over a period of three (3) years commencing on April 1,2021, with 1/12 of such options vesting at the end of each subsequent three-month period following the grant, (ii) the term of the options is of six (6) years from the grant date, unless they have been exercised or cancelled in accordance with the terms of and conditions of the applicable incentive plan of the Company, (iii) unless previously exercised or cancelled, the options may be exercised until 180 days from the termination of Mr. Yoresh’ tenure as a chairman, (iv) the exercise price per share of the options is equal to the average share price of the 30 days prior to the date of grant, $1.783 (v) the options grant will be in accordance and pursuant to Section 102 of the Tax Ordinance, if applicable, and (vi) the options will be accelerated upon the closing of a material transaction, resulting in change of control of the Company.
Equity Based Compensation of our Executive Officers and Directors
As of March 1, 2023, options to purchase 1,212,500 of our Ordinary Shares were outstanding and held by current executive officers and directors (consisting of 6 persons) with an average exercise price of NIS 6.78 per ordinary share, of which, options to purchase 867,708 of our Ordinary Shares are currently exercisable or exercisable within 60 days as of March 1, 2023. See “Item 6. Directors, Senior Management and Employees—E. Share Ownership” in this annual report on Form 20-F.
Agreements with our Executive Officers
We have entered into written agreements with each of our executive officers. All of these agreements contain customary provisions regarding non-competition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director pursuant to which we have agreed to indemnify each of them to the fullest extent permitted by law to the extent that these liabilities are not covered by directors and officers insurance.
Our office holders are generally eligible for bonuses each year. The bonuses are established and granted in accordance with our compensation policy and are generally payable upon meeting objectives and targets that are approved by our compensation committee and board of directors (and if required by our shareholders).
Consulting Agreement with Mr. Carmel
On July 25, 2019, our shareholders approved that as of April 2, 2019, our Company would enter into a consulting agreement with Mr. Carmel, who serves as our Chief Executive Officer. The term is for an indefinite period, however the agreement may be terminated by either party by giving 60 days advance notice, or shorter periods in some cases, such as termination for “cause.” During the notice period, Mr. Carmel will be entitled to consulting fees only to the extent that he provides services to the Company during the notice period. The agreement also includes customary covenants regarding confidentiality, IP assignment, non-competition and non-solicitation.
49
Mr. Carmel’s monthly consulting fee is NIS 60,000 plus VAT, effective as of May 2021, as approved by our shareholders at our annual general meeting held on August 30, 2021. In addition, Mr. Carmel is entitled to an annual target based bonus and an additional overachievement bonus of up to 6 monthly salaries each, subject to a performance matrix to be approved by the Company’s compensation committee and board of directors on an annual basis, while up to 30% of such annual bonus may be discretionary and not subject to measurable performance indexes. The annual target bonus may be reduced by our board of directors according to our financial position and Mr. Carmel’s performance, and must be returned by Mr. Carmel if it is later shown to be granted in error which shall be restated in our financial statements.
In addition, Mr. Carmel was granted with options to purchase up to 62,500 Ordinary Shares of the Company (the “Options”), in accordance with the following terms: (i) the Options vest over a period of four (4) years commencing April 1, 2019, 25% of the Options vest on the first anniversary (i.e., April 1, 2020), and 75% of the Options vest on a quarterly basis over a period of three (3) years thereafter; (ii) the term of the Options is of six (6) years from the date of grant, unless they have been exercised or cancelled in accordance with the terms of and conditions of the applicable incentive plan of the Company, (iii) unless previously exercised or cancelled, the Options may be exercised until 180 days from the date of termination of the service, (iv) the exercise price per share of the Options shall be NIS 11.8, (v) the Options’ grant shall be in accordance and pursuant to Section 102 of the Income Tax Ordinance [New Version], and (vi) the Options shall be accelerated upon the closing of a material transaction, resulting in change of control of the Company.
At the annual general meeting of our shareholders held on August 30, 2021, Mr. Carmel was granted with additional grant of options to purchase 300,000 Ordinary Shares. The options vest over a period of three (3) years commencing on April 1, 2021, with 1/12 of such options vesting at the end of each subsequent three-month period following the grant, (ii) the term of the options is of six (6) years from the grant date, unless they have been exercised or cancelled in accordance with the terms of and conditions of the applicable incentive plan of the Company, (iii) unless previously exercised or cancelled, the options may be exercised until 180 days following the termination of the engagement, (iv) the exercise price per share of the options is equal to the average share price of the 30 days prior to the date of grant, $1.783 (v) the options grant will be in accordance and pursuant to Section 102 of the Tax Ordinance, if applicable, and (vi) the options will be accelerated upon the closing of a material transaction, resulting in change of control of the Company.
C. Board Practices
Introduction
Under the Companies Law and our amended and restated articles of association, the management of our business is vested in our board of directors. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management. Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors.
Under our amended and restated articles of association, our board of directors must consist of at least three and not more than six directors, including two external directors appointed as required under the Companies Law. Our board of directors currently consists of four members, none of which are external directors, including our chairman of the board of directors, which is also appointed by the general meeting of our shareholders.
Our directors are divided into three classes with staggered three-year terms. At each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the term of office of the directors of that class of directors is for a term of office that expires on the third annual general meeting following such election or re-election, such that at each annual general meeting the term of office only one class of directors will expire. Each director holds office until the annual general meeting of our shareholders for the year in which his or her term expires and until his or her successor is duly appointed, unless the tenure of such director expires earlier pursuant to the Companies Law upon the occurrence of certain events or unless removed from office by a vote of the holders of at least 65% of the total voting power of our shareholders at a general meeting of our shareholders in accordance with our amended and restated articles of association.
50
Our directors are divided among the three classes as follows:
● | the Class I directors consist of Mr. Eli Cohen, and his terms will expire at our annual general meeting of shareholders to be held in 2023; |
● | the Class II directors consist of Ms. Kineret Tzedef and her terms will expire at our annual general meeting of shareholders to be held in 2024; and |
● | the Class III directors consist of Mr. Eliyahu Yoresh and Mr. Ronen Rosenbloom and their terms will expire at our annual general meeting of shareholders to be held in 2025. |
In addition, our amended and restated articles of association allow our Board of Directors to appoint directors to fill vacancies on our Board of Directors or in addition to the acting directors (subject to the limitation on the number of directors and their qualifications), until the next general meeting in which directors may be appointed or such appointment terminated.
The board of directors (and, if so determined by the board of directors, the general meeting) may at any time and from time to time appoint any person as a director to fill a vacancy (whether such vacancy is due to a director no longer serving or due to the number of directors serving being less than the maximum number of six directors. In the event of one or more such vacancies in the board of directors, the continuing directors may continue to act in every matter, provided, however, that if the number of directors serving is less than three, than our board of directors may only act in an emergency or to fill the office of a director which has become vacant up to three directors, or for the purpose of convening a general meeting of the Company’s shareholders for the purpose of electing directors to fill any or all vacancies. The office of a director that was appointed by the board of directors to fill any vacancy shall only be for the remaining period of time during which the director whose service has ended was filled would have held office, or in case of a vacancy due to the number of directors serving being less than six, the board of directors shall determine at the time of appointment the class to which the additional director shall be assigned.
Pursuant to the Companies Law and our amended and restated articles of association, a resolution proposed at any meeting of our board of directors at which a quorum is present is adopted if approved by a vote of a majority of the directors present and eligible to vote. A quorum of the board of directors requires at least a majority of the directors then in office who are lawfully entitled to participate in the meeting.
According to the Companies Law, the board of directors of a public company must determine the minimum number of board members that should have financial and accounting expertise while considering, among other, the nature of the company, its size, the scope and complexity of its operations and the number of directors stated in the articles of association. Our board of directors resolved that the minimum number of board members that need to have financial and accounting expertise is one, and that Mr. Eliyahu Yoresh has accounting and financial expertise as required under the Companies Law.
External Directors
Under the Companies Law, companies incorporated under the laws of the State of Israel that are “public companies,” including companies with shares listed on the Nasdaq Capital Market, are required to appoint at least two external directors. External directors must meet certain independence criteria to ensure that they are unaffiliated with the company and its controlling shareholder, as well certain other criteria. External directors are elected for three-year terms in accordance with specific rules set forth in the Companies Law and the regulations promulgated thereunder and may be removed from office only under limited circumstances. Under the Companies Law, each committee of a company’s board of directors that is authorized to exercise powers of the board of directors is required to include at least one external director, and all external directors must be members of the company’s audit committee and compensation committee.
Pursuant to regulations promulgated under the Companies Law, companies with shares traded on a U.S. stock exchange, including the Nasdaq Capital Market, may, subject to certain conditions, “opt out” from the Companies Law requirements to appoint external directors and related Companies Law rules concerning the composition of the audit committee and compensation committee of the board of directors. In accordance with these regulations, effective as of June 28, 2017, we have “opted out” from the Companies Law requirements to appoint external directors and related Companies Law rules concerning the composition of the audit committee and compensation committee of the board of directors.
51
Under these regulations, the exemptions from such Companies Law requirements will continue to be available to us so long as: (i) we do not have a “controlling shareholder” (as such term is defined under the Companies Law), (ii) our shares are traded on a U.S. stock exchange, including the Nasdaq Capital Market, and (iii) we comply with the director independence requirements, the audit committee and the compensation committee composition requirements, under U.S. laws (including applicable Nasdaq Rules) applicable to U.S. domestic issuers. We believe that Mr. Eli Cohen, Mr. Eliyahu Yoresh, Mr. Ronen Rosenbloom and Ms. Kineret Tzedef are “independent” for purposes of the Nasdaq Stock Market rules.
Alternate directors
Our amended and restated articles of association provide, as allowed by the Companies Law, that any director may, by written notice to us, appoint another person who is qualified to serve as a director to serve as an alternate director and to terminate such appointment. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as a director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director. Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a committee of the board of directors as long as he or she is not already serving as a member of such committee.
Board committees
The board of directors may, subject to the provisions of the Companies Law, delegate any or all of its powers to committees, each consisting of one or more directors (except the audit and compensation committees, as described below), and it may, from time to time, revoke such delegation or alter the composition of any such committees. Unless otherwise expressly provided by the board of directors, the committees will not be empowered to further delegate such powers. The composition and duties of our audit committee and compensation committee are described below.
Audit committee
Our audit committee is currently comprised of Mr. Eli Cohen, Mr. Eliyahu Yoresh, and Mr. Ronen Rosenbloom. Mr. Eli Cohen acts as the chairperson of our audit committee.
Companies Law Requirements
Under the Companies Law, our board of directors is required to appoint an audit committee, which is responsible, among others, for:
(i) | determining whether there are deficiencies in the business management practices of our Company, including in consultation with our internal auditor or the independent auditor, and making recommendations to our board of directors to improve such practices; |
(ii) | determining the approval process for transactions that are ‘non-negligible’ (i.e., transactions with a controlling shareholder that are classified by the audit committee as non-negligible, even though they are not deemed extraordinary transactions), as well as determining which types of transactions would require the approval of the audit committee, optionally based on criteria which may be determined annually in advance by the audit committee; |
(iii) | determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under Companies Law. See “— Fiduciary duties and approval of specified related party transactions and compensation under Israeli law.”; |
(iv) | where the board of directors approves the working plan of the internal auditor, to examine such working plan before its submission to our board of directors and proposing amendments thereto; |
(v) | examining our internal controls and internal auditor’s performance, including whether the internal auditor has sufficient resources and tools to dispose of its responsibilities; |
(vi) | examining the scope of our auditor’s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment of our auditor; and |
(vii) | establishing procedures for the handling of employees’ complaints as to the management of our business and the protection to be provided to such employees. |
52
Nasdaq requirements
Under the Nasdaq corporate governance rules, we are required to maintain an audit committee consisting of at least three independent directors, all of whom are financially literate and one of whom has accounting or related financial management expertise. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the Nasdaq corporate governance rules. Our board of directors has determined that Mr. Eliyahu Yoresh is an audit committee financial expert as defined by the SEC rules and has the requisite financial experience as defined by the Nasdaq Marketplace Rules.
Each of the members of the audit committee is required to be “independent” as such term is defined in Rule 10A-3(b)(1) under the Exchange Act, which is different from the general test for independence of board and committee members. Our board of directors has determined that each member of our audit committee is independent as such term is defined in Rule 10A-3(b)(1) of the Exchange Act.
Audit committee role
Our board of directors has adopted an audit committee charter setting forth the responsibilities of the audit committee consistent with the rules of the SEC and the Nasdaq Rules, which include, among others:
● | retaining and terminating our independent auditors, subject to the ratification of the board of directors, and in the case of retention, to that of the shareholders; |
● | pre-approving of audit and non-audit services and related fees and terms, to be provided by the independent auditors; |
● | overseeing the accounting and financial reporting processes of our Company and audits of our financial statements, the effectiveness of our internal control over financial reporting and making such reports as may be required of an audit committee under the rules and regulations promulgated under the Exchange Act; |
● | reviewing with management and our independent auditor our annual and quarterly financial statements prior to publication or filing (or submission, as the case may be) to the SEC; |
● | recommending to the board of directors the retention and termination of the internal auditor, and the internal auditor’s engagement fees and terms, in accordance with the Companies Law as well as approving the yearly or periodic work plan proposed by the internal auditor; |
● | reviewing with our general counsel and/or external counsel, as deem necessary, legal and regulatory matters that could have a material impact on the financial statements; |
● | identifying irregularities in our business administration, inter alia, by consulting with the internal auditor or with the independent auditor, and suggesting corrective measures to the board of directors; and |
● | reviewing policies and procedures with respect to transactions (other than transactions related to the compensation or terms of services) between the Company and officers and directors, or affiliates of officers or directors, or transactions that are not in the ordinary course of the Company’s business and deciding whether to approve such acts and transactions if so required under the Companies Law. |
The audit committee charter states that in fulfilling its obligations, the committee is entitled to demand from the Company any document, file, report or any other information that is required for the fulfillment of its roles and duties and to interview any of our employees or any employees of our subsidiaries in order to receive more details about his or her line of work or other issues that are connected to the roles and duties of the audit committee.
53
Compensation Committee
Our compensation committee is currently comprised of Mr. Ronen Rosenbloom, Mr. Eli Cohen and Ms. Kineret Tzedef. Mr. Ronen Rosenbloom acts as the chairperson of our compensation committee.
Companies Law requirements
Under the Companies Law, the board of directors of a public company must appoint a compensation committee which roles are, among others, as follows:
● | to recommend to the board of directors the approval of compensation policy for directors and officers in accordance with the requirements of the Companies Law; |
● | to oversee the development and implementation of such compensation policy and recommending to the board of directors regarding any amendments or modifications that the compensation committee deems appropriate; |
● | to determine whether to approve transactions concerning the terms of engagement and employment of office holders that require approval of the compensation committee; and |
● | to resolve whether to exempt a transaction with a candidate for chief executive officer from shareholder’s approval. |
Nasdaq requirements
Our board of directors has adopted a compensation committee charter setting forth the responsibilities of the committee consistent with the Nasdaq Rules, which include among others:
● | recommending to our board of directors for its approval a compensation policy in accordance with the requirements of the Companies Law as well as other compensation policies, incentive-based compensation plans and equity-based compensation plans, and overseeing the development and implementation of such policies and recommending to our board of directors any amendments or modifications to the committee deems appropriate, including as required under the Companies Law; |
● | reviewing and approving the granting of options and other incentive awards to our chief executive officer and other executive officers, including reviewing and approving corporate goals and objectives relevant to the compensation of our chief executive officer and other executive officers, including evaluating their performance in light of such goals and objectives; |
● | approving and exempting certain transactions regarding office holders’ compensation pursuant to the Companies Law; and |
● | administer our equity-based compensation plans, including without limitation to approve the adoption of such plans, to amend and interpret such plans and the awards and agreements issued pursuant thereto, and to make awards to eligible persons under the plans and determine the terms of such awards. |
The compensation committee is also authorized to retain and terminate compensation consultants, legal counsel or other advisors to the committee and to approve the engagement of any such consultant, counsel or advisor, to the extent it deems necessary or advisable.
Our board of directors has determined that each member of our compensation committee is independent under the Nasdaq Rules, including the additional independence requirements applicable to the members of a compensation committee.
Compensation policy
Under the Companies Law, companies incorporated under the laws of the State of Israel, whose shares are listed for trading on a stock exchange or have been offered to the public in or outside of Israel, such as us, are required to adopt a policy governing the compensation of “office holders” (as defined in the Companies Law). Following the recommendation of our compensation committee and approval by our board of directors, our shareholders approved a new compensation policy for directors and officers on August 30, 2021. Our compensation policy must be approved at least once every three years, first, by our board of directors, upon recommendation of our compensation committee, and second, by a simple majority of the Ordinary Shares present, in person or by proxy, and voting at a shareholders meeting, provided that either:
● | such majority includes at least a majority of the shares held by shareholders who are not controlling shareholders and shareholders who do not have a personal interest in such compensation policy; or |
● | the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in the compensation policy and who vote against the policy, does not exceed 2% of the company’s aggregate voting rights. |
54
Such majority determined in accordance with the majority requirement described above is hereinafter referred to as the Compensation Special Majority Requirement.
To the extent a compensation policy is not approved by shareholders at a duly convened shareholders meeting or by the Compensation Special Majority Requirement, the board of directors of a company may override the resolution of the shareholders following a re-discussion of the matter by the board of directors and the compensation committee and for specified reasons, and after determining that despite the rejection by the shareholders, the adoption of the compensation policy is in the best interest of the company. A compensation policy that is for a period of more than three years must be approved in accordance with the above procedure once every three years.
The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the company’s objectives, the company’s business plan and its long-term strategy, and creation of appropriate incentives for office holders. It must also consider, among other things, the company’s risk management, size and the nature of its operations; and with respect to variable compensation, the contribution of the office holder towards the achievement of the company’s long-term goals and the maximization of its profits, all with a long-term objective and according to the position of the office holder. The compensation policy must furthermore consider the following additional factors:
● | the education, skills, experience, expertise and accomplishments of the relevant office holder; |
● | the office holder’s position and responsibilities; |
● | prior compensation agreements with the office holder; |
● | the ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of the company, including employees employed through contractors who provide services to the company, in particular the ratio between such cost to the average and median salary of such employees of the company, as well as the impact of disparities between them on the work relationships in the company; |
● | the terms of employment include variable components — the possibility of reducing variable components at the discretion of the board of directors and the possibility of setting a limit on the value of non-cash variable equity-based components; and |
● | if the terms of employment include severance compensation — the term of employment or office of the office holder, the terms of the office holder’s compensation during such period, the company’s performance during such period, the office holder’s individual contribution to the achievement of the company goals and the maximization of its profits and the circumstances under which he or she is leaving the company. |
The compensation policy must also include the following principles:
● | with regards to variable components; |
55
● | with the exception of office holders who report to the chief executive officer, a means of determining the variable components on the basis of long-term performance and measurable criteria; provided that the company may determine that an immaterial part of the variable components of the compensation package of an office holder shall be awarded based on non-measurable criteria, or if such amount is not higher than three months’ salary per annum, taking into account such office holder’s contribution to the company; |
● | the ratio between variable and fixed components, as well as the limit of the values of variable components at the time of their payment, or in the case of equity-based compensation, at the time of grant; |
● | a condition under which the office holder will return to the company, according to conditions to be set forth in the compensation policy, any amounts paid as part of the office holder’s terms of employment, if such amounts were paid based on information later to be discovered to be wrong, and such information was restated in the company’s financial statements; | |
● | the minimum holding or vesting period of variable equity-based components to be set in the terms of office or employment, as applicable, while taking into consideration long-term incentives; and | |
● | a limit to retirement grants. |
Our compensation policy is designed to promote retention and motivation of directors and executive officers, incentivize superior individual excellence, align the interests of our directors and executive officers with our long-term performance and provide a risk management tool. To that end, a portion of our executive officer compensation package is targeted to reflect our short and long-term goals, as well as the executive officer’s individual performance. On the other hand, our compensation policy includes measures designed to reduce the executive officer’s incentives to take excessive risks that may harm us in the long-term, such as limits on the value of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive officer and minimum vesting periods and performance based vesting for equity-based compensation.
Our compensation policy also addresses our executive officers’ individual characteristics (such as their respective position, education, scope of responsibilities and contribution to the attainment of our goals) as the basis for compensation variation among our executive officers and considers the internal ratios between compensation of our executive officers and directors and other employees. Pursuant to our compensation policy, the compensation that may be granted to an executive officer may include: base salary, annual bonuses and other cash bonuses (such as a signing bonus and special bonuses with respect to any special achievements, such as outstanding personal achievement, outstanding personal effort or outstanding Company performance), equity-based compensation, benefits and retirement and termination of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer’s base salary.
An annual cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may be granted to our executive officers other than our Chief Executive Officer will be based on performance objectives and a discretionary evaluation of the executive officer’s overall performance by our Chief Executive Officer and subject to minimum thresholds. The annual cash bonus that may be granted to executive officers other than our Chief Executive Officer may alternatively be based entirely on a discretionary evaluation. Furthermore, our Chief Executive Officer will be entitled to approve performance objectives for executive officers who report to him.
The measurable performance objectives of our Chief Executive Officer will be determined annually by our compensation committee and board of directors. A non-material portion of the Chief Executive Officer’s annual cash bonus, as provided in our compensation policy, may be based on a discretionary evaluation of the Chief Executive Officer’s overall performance by the compensation committee and the board of directors.
The equity-based compensation under our compensation policy for our executive officers (including members of our board of directors) is designed in a manner consistent with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the alignment between the executive officers’ interests with our long-term interests and those of our shareholders and to strengthen the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive officer compensation in the form of share options or other equity-based awards, such as restricted shares and restricted share units, in accordance with our equity incentive plan then in place. The equity-based compensation shall be granted from time to time and be individually determined and awarded according to the performance, educational background, prior business experience, qualifications, role and the personal responsibilities of the executive officer.
56
In addition, our compensation policy contains compensation recovery provisions which allow us under certain conditions to recover bonuses paid in excess, enable our Chief Executive Officer to approve an immaterial change in the terms of employment of an executive officer who reports directly him (provided that the changes of the terms of employment are in accordance with our compensation policy) and allow us to exculpate, indemnify and insure our executive officers and directors to the maximum extent permitted by Israeli law subject to certain limitations set forth therein.
Our compensation policy also provides for compensation to the members of our board of directors either (i) in accordance with the amounts provided in the Companies Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such regulations may be amended from time to time, or (ii) in accordance with the amounts determined in our compensation policy.
Investment Committee
Our investment committee is comprised of Mr. Eli Yoresh and Mr. Eli Cohen. The investment committee is authorized to approve certain investments in accordance with the Company’s investment policy approved by the board of directors. The investment committee monitors the management of the portfolio for compliance with the investment policies and guidelines and considers the merits of time sensitive investments that could be beneficial to the Company.
Internal auditor
Under the Companies Law, the board of directors of a public company must appoint an internal auditor based on the recommendation of the audit committee. Under the Companies Law, each of the following may not be appointed as internal auditor:
● | a person (or a relative of a person) who holds more than 5% of the company’s outstanding shares or voting rights; |
● | a person (or a relative of a person) who has the power to appoint a director or the general manager of the company; |
● | an office holder (including a director) of the company (or a relative thereof); or |
● | a member of the company’s independent accounting firm, or anyone on his or her behalf. |
The role of the internal auditor is, among other things, to examine whether a company’s actions comply with applicable law and orderly business procedure. The audit committee is required to oversee the activities and to assess the performance of the internal auditor as well as to review the internal auditor’s work plan. Our internal auditor is Daniel Spira, Certified Public Accountant (Isr.).
Fiduciary duties and approval of specified related party transactions and compensation under Israeli law
Fiduciary duties of office holders
The Companies Law imposes fiduciary duties on all office holders of a company comprised of a duty of care and a duty of loyalty.
The duty of care requires an office holder to act in the same degree of proficiency with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of care includes, among other things, a duty to use reasonable means, in light of the circumstances, to obtain:
● | information on the business advisability of a given action brought for his or her approval or performed by virtue of his or her position; and |
● | all other important information pertaining to such action. |
57
The duty of loyalty requires an office holder to act in good faith and for the benefit of the company, and includes, among other things, the duty to:
● | refrain from any act involving a conflict of interest between the performance of his or her duties in the company and his or her other duties or personal affairs; |
● | refrain from any activity that is competitive with the business of the company; |
● | refrain from exploiting any business opportunity of the company for the purpose of gaining a personal advantage for himself or herself or others; and |
● | disclose to the company any information or documents relating to the company’s affairs which the office holder received as a result of his or her position as an office holder. |
Under the Companies Law, we may approve an act specified above, provided that the office holder acted in good faith, the act or its approval does not harm the company’s best interest, and the office holder discloses his or her personal interest a sufficient time before the approval of such act, including any relevant document.
Disclosure of personal interests of an office holder and approval of transactions
The Companies Law requires that an office holder promptly disclose to the company any personal interest that he or she may have and all related material information or documents relating to any existing or proposed transaction by the company. An interested office holder’s disclosure must be made promptly and, in any event, no later than the first meeting of the board of directors at which the transaction is considered. Under the Companies Law, once an office holder complies with the above disclosure requirement, the board of directors at which the transaction is considered. An office holder is not obliged to disclose such information if the personal interest of the office holder derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction.
Under the Companies Law, a company may approve a transaction between the company and the office holder or a third party in which the office holder has a personal interest only if the office holder has complied with the above disclosure requirement, provided, however, that a company may not approve a transaction or action that is not to the company’s benefit.
Under the Companies Law, unless the articles of association of a company provide otherwise, a transaction with an office holder or with a third party in which the office holder has a personal interest, which is not an extraordinary transaction, requires approval by the board of directors. Our amended and restated articles of association do not state otherwise. If the transaction considered with an office holder or third party in which the office holder has a personal interest is an extraordinary transaction, then the audit committee’s approval is required prior to approval by the board of directors. For the approval of compensation arrangements with directors and executive officers, see “Item 6. Directors, Senior Management and Employees —C. Board Practices—Compensation of directors and executive officers.”
Any person who has a personal interest in the approval of a transaction that is brought before a meeting of the board of directors or the audit committee may not be present at the meeting or vote on the matter. However, if the chairperson of the board of directors or the chairperson of the audit committee has determined that the presence of an office holder with a personal interest is required, such office holder may be present at the meeting for the purpose of presenting the matter. Notwithstanding the foregoing, a director who has a personal interest may be present at the meeting and vote on the matter if a majority of the directors or members of the audit committee have a personal interest in the approval of such transaction’ provided, however, that if a majority of the directors at a board of directors meeting have a personal interest in the approval of the transaction, such transaction also requires the approval of the shareholders of the company.
A “personal interest” is defined under the Companies Law as the personal interest of a person in an action or in a transaction of the company, including the personal interest of such person’s relative or the interest of any other corporate body in which such person and/or such person’s relative is a director or general manager, a 5% shareholder or holds 5% or more of the voting rights, or has the right to appoint at least one director or the general manager, but excluding a personal interest stemming solely from the fact of holding shares in the company. A personal interest also includes (1) a personal interest of a person who votes according to a proxy of another person, including in the event that the other person has no personal interest, and (2) a personal interest of a person who gave a proxy to another person to vote on his or her behalf regardless of whether the discretion of how to vote lies with the person voting or not.
58
An “extraordinary transaction” is defined under the Companies Law as any of the following:
● | a transaction other than in the ordinary course of business; |
● | a transaction that is not on market terms; or |
● | a transaction that may have a material impact on the company’s profitability, assets or liabilities. |
An extraordinary transaction in which an office holder has a personal interest requires approval of the company’s audit committee followed by the approval of the board of directors.
Disclosure of personal interests of a controlling shareholder and approval of transactions
The Companies Law also requires that a controlling shareholder promptly disclose to the company any personal interest that he or she may have and all related material information or documents relating to any existing or proposed transaction by the company. A controlling shareholder’s disclosure must be made promptly and, in any event, no later than the first meeting of the board of directors at which the transaction is considered. The following require the approval of each of (i) the audit committee (or the compensation committee with respect to the terms of engagement of the controlling shareholder or relative thereof with the company related for the provision of service, including among others as an office holder or employee of the company), (ii) the board of directors and (iii) the shareholders (in that order): (a) extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest (including a private placement in which a controlling shareholder has a personal interest), (b) the engagement with a controlling shareholder or his or her relative, directly or indirectly, for the provision of services to the company, (c) the terms of engagement and compensation of a controlling shareholder or his or her relative as an office holder, and (d) the employment of a controlling shareholder or his or her relative by the company, other than as an office holder (collectively referred as Transaction with a Controlling Shareholder). In addition, the shareholder approval must fulfill one of the following requirements:
● | at least a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or | |
● | the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than two percent (2%) of the voting rights in the company. |
In addition, any extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest with a term of more than three years requires the abovementioned approval every three years, however, unless, with respect to certain transactions the audit committee determines that such longer term is reasonable under the circumstances.
Pursuant to regulations promulgated under the Companies Law, certain transactions with a controlling shareholder, a relative thereof, or with a director, that would otherwise require approval of a company’s shareholders may be exempt from shareholder approval upon certain determinations of the audit committee and board of directors.
The Companies Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question. Failure to so indicate will result in the invalidation of that shareholder’s vote.
Approval of the compensation of directors and executive officers
The compensation of, or an undertaking to indemnify, insure or exculpate, an office holder who is not a director requires the approval of the company’s compensation committee, followed by the approval of the company’s board of directors, and, if such compensation arrangement or an undertaking to indemnify or insure is inconsistent with the company’s stated compensation policy, or if the said office holder is the chief executive officer of the company (apart from a number of specific exceptions), then such arrangement is subject to the approval of our shareholders, subject to the Compensation Special Majority Requirement.
59
Directors. Under the Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board of directors and, unless exempted under the regulations promulgated under the Companies Law, the approval of the general meeting of our shareholders. If the compensation of our directors is inconsistent with our stated compensation policy, then, provided that those provisions that must be included in the compensation policy according to the Companies Law have been considered by the compensation committee and board of directors, shareholder approval will also be required to be approved by the Compensation Special Majority Requirement.
Executive officers other than the chief executive officer. The Companies Law requires the approval of the compensation of a public company’s executive officers (other than the chief executive officer) in the following order: (i) the compensation committee, (ii) the company’s board of directors, and (iii) if such compensation arrangement is inconsistent with the company’s stated compensation policy, the company’s shareholders by the Compensation Special Majority Requirement. However, if the shareholders of the company do not approve a compensation arrangement with an executive officer that is inconsistent with the company’s stated compensation policy, the compensation committee and board of directors may override the shareholders’ decision if each of the compensation committee and the board of directors provide detailed reasons for their decision.
Chief executive officer. Under the Companies Law, the compensation of a public company’s chief executive officer is required to be approved by: (i) the company’s compensation committee; (ii) the company’s board of directors, and (iii) the company’s shareholders by the Compensation Special Majority Requirement. However, if the shareholders of the company do not approve the compensation arrangement with the chief executive officer, the compensation committee and board of directors may override the shareholders’ decision if each of the compensation committee and the board of directors provide a detailed reasoning for their decision. The approval of each of the compensation committee and the board of directors must be in accordance with the company’s stated compensation policy; however, under special circumstances, the compensation committee and the board of directors may approve compensation terms of a chief executive officer that are inconsistent with the company’s compensation policy provided that they have considered those provisions that must be included in the compensation policy according to the Companies Law and that shareholder approval was obtained by the Compensation Special Majority Requirement. In addition, the compensation committee may resolve that the shareholder approval is not required for the approval of the engagement terms of a candidate to serve as the chief executive officer, if the compensation committee determines that the compensation arrangement is consistent with the company’s stated compensation policy, that the chief executive officer did not have a prior business relationship with the company or a controlling shareholder of the company, and that subjecting the approval to a shareholder vote would impede the company’s ability to attain the candidate to serve as the company’s chief executive officer.
Duties of shareholders
Under the Companies Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in exercising its rights and performing its obligations to the company and other shareholders, including, among other things, when voting at meetings of shareholders on the following matters:
● | an amendment to the articles of association; |
● | an increase in the company’s authorized share capital; |
● | a merger; and |
● | the approval of related party transactions and acts of office holders that require shareholder approval. |
A shareholder also has a general duty to refrain from discriminating against other shareholders.
The remedies generally available upon a breach of contract will also apply to a breach of the shareholder duties mentioned above, and in the event of discrimination against other shareholders, additional remedies are available to the injured shareholder.
60
In addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under a company’s articles of association, has the power to appoint or prevent the appointment of an office holder, or any other power with respect to a company, is under a duty to act with fairness towards the company. The Companies Law does not describe the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness, taking each shareholder’s position in the company into account.
Approval of private placements
Under the Companies Law and the regulations promulgated thereunder, a private placement of securities does not require approval at a general meeting of the shareholders of a company; provided however, that in special circumstances, such as a private placement completed in lieu of a special tender offer or a private placement which qualifies as a related party transaction (See “Item 6. Directors, Senior Management and Employees —C. Board Practices—Fiduciary duties and approval of specified related party transactions and compensation under Israeli law”), for which approval at a general meeting of the shareholders of a company is required.
Exemption, Insurance and Indemnification of Directors and Officers
Under the Companies Law, a company may not exculpate an office holder from liability for a breach of a fiduciary duty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision. The company may not exculpate in advance a director from liability arising out of a prohibited dividend or distribution to shareholders.
Under the Companies Law and the Securities Law, 5738-1968, or the Securities Law, a company may indemnify an office holder in respect of the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification:
● | a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator’s decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company’s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking will detail the abovementioned foreseen events and amount or criteria; |
● | reasonable litigation expenses, including reasonable attorneys’ fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding; (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction; |
● | reasonable litigation expenses, including attorneys’ fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was convicted of an offense that does not require proof of criminal intent; |
● | a monetary liability imposed on the office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Securities Law; |
● | expenses incurred by an office holder or certain compensation payments made to an injured party that were instituted against an office holder in connection with an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys’ fees; and |
● | any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law. |
61
An “Administrative Procedure” is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.
Under the Companies Law and the Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company’s articles of association:
● | a breach of a fiduciary duty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; |
● | a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; |
● | a monetary liability imposed on the office holder in favor of a third party; |
● | a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities Law; and |
● | expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys’ fees. |
Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:
● | a breach of fiduciary duty, except for indemnification and insurance for a breach of the fiduciary duty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company; |
● | a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; |
● | an act or omission committed with intent to derive illegal personal benefit; or |
● | a civil or administrative fine, monetary sanction or forfeit levied against the office holder. |
Under the Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which such controlling shareholders have a personal interest, also by the shareholders.
Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. On February 18, 2021, our board of directors approved a new directors’ and officers’ liability insurance policy, following the recent amended of our compensation policy approved by our shareholders on February 12, 2021.
Employment and consulting agreements with executive officers
We have entered into written employment or service agreements with each of our executive officers. See “Item 7. Major Shareholders and Related Party Transactions — B. Related Party Transactions – Employment Agreements” for additional information.
Directors’ service contracts
There are no arrangements or understandings between us, on the one hand, and any of our directors, on the other hand, providing for benefits upon termination of their employment or service as directors of our Company.
62
D. Employees
Number of Employees
As of December 31, 2022, the Group employed 77 employees, which include our chief executive officer that is engaged by the Company as a consultant.
As of December 31, 2021, we employed 26 employees, including those employed by our subsidiaries Jeffs’ Brands, Charging Robotics and Eventer, which include our chief executive officer that is engaged by the Company as a consultant.
As of December 31, 2020, we employed 39 employees in Israel including those employed by our indirect subsidiaries ScoutCam Ltd. and Eventer.
Distribution of Employees
The breakdown of our employees, by areas of engagement and geographic location, as of the end of each of the past three fiscal years is as follows:
As of December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
Numbers of employees by category of activity | ||||||||||||
Management and administrative | 32 | 20 | 21 | |||||||||
Research and development | 16 | 3 | 9 | |||||||||
Sales and marketing | 29 | 3 | 1 | |||||||||
Production | - | - | 8 | |||||||||
Total workforce | 77 | 26 | 39 | |||||||||
Numbers of employees by geographic location | ||||||||||||
Israel | 75 | 26 | 39 | |||||||||
Europe | 1 | - | - | |||||||||
Other | 1 | - | - | |||||||||
Total workforce | 77 | 26 | 39 | |||||||||
Numbers of employees by employer | ||||||||||||
Medigus Ltd. | 5 | 6 | 3 | |||||||||
Eventer | 16 | 15 | 9 | |||||||||
Jeff Brands | 4 | 4 | ||||||||||
Gix Internet | 51 | - | - | |||||||||
ScoutCam Ltd. | - | - | 27 | |||||||||
Charging Robotics | 1 | 1 | - | |||||||||
77 | 26 | 39 |
During the years covered by the above table, we did not employ a significant number of temporary employees. We consider our relations with our employees excellent and have never experienced a strike or work stoppage. None of our employees is represented by a labor union.
In Israel we are subject to certain labor statutes and national labor court precedent rulings, as well as to certain provisions of the collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations including the Industrialists’ Associations. These provisions of collective bargaining agreements are applicable to our Israeli employees by virtue of extension orders issued in accordance with relevant labor laws by the Israeli Ministry of Economy and Industry, and which apply such agreement provisions to our employees even though they are not directly part of a union that has signed a collective bargaining agreement. The laws and labor court rulings that apply to our employees principally concern the minimum wage laws, length of the work day and workweek, overtime payment, procedures for dismissing employees, determination of severance pay, leaves of absence (such as annual vacation or maternity leave), sick pay and other conditions for employment. The general extension orders which apply to our employees principally concern mandatory contributions to a pension fund or managers’ insurance, annual recreation allowance, travel expenses payment and other conditions of employment. We generally provide our employees with benefits and working conditions beyond the required minimums.
63
Israeli law generally requires severance pay upon a dismissal of an employee by the employer without “cause” (as defined in the law), which equal to the employee’s latest monthly salary multiplied by the number of years of continuous employment with the same employer or at the same employment facilities (the “Statutory Severance Pay”). The severance pay is usually funded by the employer allocating monthly payments to employees’ managers’ insurance and/or pension fund described below, on account of the Statutory Severance Pay. The monthly payments to the managers’ insurance and/or pension fund in respect of severance pay usually amount to 8.33% or 6% of an employee’s monthly wages. Upon an event that entitles an employee to severance pay, the employer will generally release in favor of the employee the amounts accrued in the severance fund, as described above and will complete any shortfall amount between the Statutory Severance Pay and the amounts accrued in the severance fund. An alternative, and commonly used, pension and severance contribution scheme is known as the Section 14 Arrangement under the General Approval issued under the Severance Pay Law (the “Section 14 Arrangement”). Where the Section 14 Arrangement is properly applied, the amounts accrued in the severance fund are in lieu of the Statutory Severance Pay and the employer’s sole obligation with respect to severance pay would be to release the amounts accrued in the severance and pension funds in any event of termination of employment (dismissal or resignation), without the need to complete any amounts on account the Statutory Severance Pay. Furthermore, Israeli employees and employers are required to pay predetermined sums to the National Insurance Institute, which is similar to the United States Social Security Administration. Such amounts also include payments for national health insurance.
E. Share Ownership
Share ownership by Directors and Executive Officers
For information regarding ownership of our Ordinary Shares by our directors and executive officers, see Item 7. “Major Shareholders and Related Party Transactions — A. Major Shareholders.”
2013 Share Option and Incentive Plan
In August 2013, our board of directors approved and adopted our 2013 Share Option and Incentive Plan, or the Plan, which expires in August 2023. The Plan provides for the issuance of shares and the granting of options, restricted shares, restricted share units and other share-based awards to employees, directors, officers, consultants, advisors, and our and Medigus U.S.’s service providers. The Plan provides for awards to be issued at the determination of our board of directors in accordance with applicable law.
The Plan provides for the grant to residents of Israel of options that qualify under the provisions of Section 102 Tax Ordinance, as well as for the grant of options that do not qualify under such provisions. The 2013 Plan was submitted to the ITA, as required by applicable law. The Plan also provides for the grant of options to U.S. resident employees that are “qualified”, i.e., incentive stock options, under the U.S. Internal Revenue Code of 1986, as amended, or the Code, and options that are not qualified. In addition to the grant of awards under the relevant tax regimes of the United States and Israel, the Plan allows for the grant of awards to grantees in other jurisdictions, with respect to which our board of directors is empowered to make the requisite adjustments in the plan.
Options granted under the Plan which are currently outstanding generally may not expire later than six years from the date of grant, unless otherwise specified. Unvested awards that are cancelled and/or forfeited go back into the plan.
F. Disclosure of a Registrant’s Action to Recover Erroneously Awarded Compensation
Not applicable.
64
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
A. Major Shareholders
The following table sets forth information with respect to the beneficial ownership of our Ordinary Shares as of March 1, 2023 (unless otherwise noted below), the beneficial ownership of our Ordinary Shares by:
● | each person, or group of affiliated persons, known to us to be the beneficial owner of more than 5% of our voting securities; | |
● | each of our directors and executive officers individually; and |
● | all of our executive officers and directors as a group. |
The beneficial ownership of our Ordinary Shares is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the security. For purposes of the table below, we deem Ordinary Shares issuable pursuant to options that are currently exercisable or exercisable within 60 days as of March 1, 2023, if any, to be outstanding and to be beneficially owned by the person holding the options or warrants for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. The percentage of Ordinary Shares beneficially owned is based on 24,661,470 Ordinary Shares outstanding as of March 1, 2023.
Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners of the Ordinary Shares listed below have sole investment and voting power with respect to such shares. In addition, none of our shareholders will have different voting rights from other shareholders. To the best of our knowledge, we are not owned or controlled, directly or indirectly, by another corporation or by any foreign government. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our Company.
As of March 1, 2023, there was one shareholder of record of our Ordinary Shares. The number of record holders is not representative of the number of beneficial holders of our Ordinary Shares, as the shares of all shareholders for a publicly traded company such as our Ordinary Shares underlying our ADSs are recorded in the name of our transfer agent, Computershare Trust Company, N.A.
Unless otherwise noted below, each beneficial owner’s address is Medigus Ltd., 10 Hanechoshet Street, Tel Aviv, Israel, 6971072.
Our principal shareholders do not have different or special voting rights.
* | less than 1%. |
(1) | Beneficial ownership is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security if that person, even if not the record owner, has or shares the underlying benefits of ownership. These benefits include the power to direct the voting or the disposition of the securities or to receive the economic benefit of ownership of the securities. A person also is considered to be the “beneficial owner” of securities that the person has the right to acquire within 60 days by option or other agreement. Beneficial owners include persons who hold their securities through one or more trustees, brokers, agents, legal representatives or other intermediaries, or through companies in which they have a “controlling interest,” which means the direct or indirect power to direct the management and policies of the entity. |
65
(2) | The percentages shown are based on 24,661,470 Ordinary Shares issued and outstanding as of March 1, 2023. |
(3) | Includes options to purchase (i) 34,375 Ordinary Shares at an exercise price of NIS 8.96 per share, and (ii) 66,667 Ordinary Shares at an exercise price of NIS 5.81 per share that are exercisable within 60 days of March 1, 2023. In addition, Ms. Tzedef holds (i) options to purchase 3,125 Ordinary Shares that are not exercisable within 60 days of March 1, 2023, which have expiration date of July 8, 2026 and an exercise price of NIS 8.96, and (ii) options to purchase 33,333 Ordinary Shares that are not exercisable within 60 days of March 1, 2023, which have expiration date June 29, 2027 and an exercise price of NIS 5.81. |
(4) | Includes 1,500 Ordinary Shares. In addition options to purchase (i) 62,500 Ordinary Shares at an exercise price of NIS 11.8 per share that are exercisable within 60 days of March 1, 2023, and (ii) options to purchase 200,000 Ordinary Shares at an exercise price of NIS 5.81 per share that are exercisable within 60 days of March 1, 2023. In addition, Mr. Carmel holds options to purchase 100,000 Ordinary Shares that are not exercisable within 60 days of March 1, 2023, which have expiration date of June 29, 2027 and an exercise price of NIS 5.81. |
(5) | Includes options to purchase (i) 37,500 Ordinary Shares at an exercise price of NIS 11.8 per share that are exercisable within 60 days of March 1, 2023, which have an expiration date of January 9, 2025 and (ii) 66,667 Ordinary Shares at an exercise price of NIS 5.81 per share that are exercisable within 60 days of March 1, 2023., In addition, Mr. Rosenbloom holds options to purchase 33,333 Ordinary Shares that are not exercisable within 60 days of March 1, 2023, which have an expiration date of June 29, 2027 and an exercise price of NIS 5.81. |
(6) | Includes 8,330 Ordinary Shares and options to purchase 37,500 Ordinary Shares at an exercise price of NIS 11.8 per share that are exercisable within 60 days of March 1, 2023, which have an expiration date of January 9, 2025, and (ii) 200,000 Ordinary Shares at an exercise price of NIS 5.81 per share that are exercisable within 60 days of March 1, 2023. In addition, Mr. Yoresh holds options to purchase 100,000 Ordinary Shares that are not exercisable within 60 days of March 1, 2023, which have an expiration date of June 29, 2027 and an exercise price of NIS 5.81. |
(7) | Includes options to purchase 37,500 Ordinary Shares at an exercise price of NIS 11.8 per share that are exercisable within 60 days of March 1, 2023. which have an expiration date of January 9, 2025, and (ii) 66,667 Ordinary Shares at an exercise price of NIS 5.81 per share that are exercisable within 60 days of March 1, 2023, 2023., In addition, Mr. Cohen holds options to purchase 33,333 Ordinary Shares that are not exercisable within 60 days of March 1, 2023, which have an expiration date of June 29, 2027 and an exercise price of NIS 5.81. |
(8) | Includes options to purchase 58,333 Ordinary Shares at an exercise price of NIS 5.81 per share that are exercisable within 60 days of March 1, 2023. In addition, Ms. Dinar holds options to purchase 41,667 Ordinary Shares that are not exercisable within 60 days of March 1, 2023, which have an expiration date of June 1, 2027, and an exercise price of NIS 5.81. |
Significant Changes in Percentage Ownership by Major Shareholders
Over the course of 2022 and as of March 1, 2023, there were no changes in the percentage ownership of our major shareholders.
Over the course of 2021, there were no changes in the percentage ownership of our major shareholders.
66
Over the course of 2020, there were no increases in the percentage ownership of our major shareholders. On the other hand, there were decreases in the percentage ownership of our former significant shareholders: (i) L.I.A. Pure Capital Ltd., from 6.02% to 3.68%; (ii) Sabby Management, LLC, from 6.78% to 0.34%; (iii) Hal Mintz, from 6.78% to 0.34%; (iv) Ryan M. Lane from 9.99% to 0.99%; and (v) Martin D. Hoe from 9.99% to 0.99%.
Over the course of 2020, there were decreases in the percentage of ownership held by Gix Internet Ltd. (formerly known as Algomizer Ltd.) from more than 5% of its outstanding share capital to below 5% of its outstanding share capital.
B. Related Party Transactions
Agreements with our Executive Officers
We have entered into written agreements with each of our executive officers. All of these agreements contain customary provisions regarding non-competition, confidentiality of information and assignment of inventions. However, the enforceability of the non-competition provisions may be limited under applicable law. In addition, we have entered into agreements with each executive officer and director pursuant to which we have agreed to indemnify each of them to the fullest extent permitted by law to the extent that these liabilities are not covered by directors and officers insurance.
Our office holders are generally eligible for bonuses each year. The bonuses are established and granted in accordance with our compensation policy and, are generally payable upon meeting objectives and targets that are approved by our compensation committee and board of directors (and if required by our shareholders).
Directors and Officers Insurance Policy and Indemnification Agreements
Our amended and restated articles of association permit us to exculpate, indemnify and insure our directors and officeholders to the fullest extent permitted by the Companies Law.
We have entered into agreements with each of our current director and officers exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law, to the extent that these liabilities are not covered by insurance. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable by the board of directors based on our activities. The maximum aggregate amount of indemnification that we may pay to our directors and officers based on such indemnification agreement is equal to 25% of our shareholders’ equity pursuant to our latest audited or unaudited consolidated financial statements, as applicable, as of the date of the indemnification payment. Such indemnification amounts are in addition to any insurance amounts. Each director or officer who agrees to receive this letter of indemnification also gives his approval to the termination of all previous letters of indemnification that we have provided to him or her in the past, if any.
Our current compensation policy determines, among others, that we may provide our directors and officers, including those serving in any of our subsidiaries from time or time and those who are controlling shareholders, with liability insurance policies provided that the engagement is in the ordinary course of business, in market terms and is not expected to materially influence our profits, properties and undertakings. The coverage limit is of up to the greater of $50 million or 50% of the Company’s shareholders equity based on the most recent financial statements of the Company at the time of approval of the insurance policy by our compensation committee.
On March 2, 2023, our compensation committee approved a new directors’ and officers’ liability insurance policy. The new directors’ and officers’ liability insurance policy provides total coverage of $4 million in the aggregate, for the benefit of all of our directors and officers, in respect of which we are charged a twelve-month premium of $195,000, and which includes a deductible of $300,000 per claim, other than securities related claims filed in the United States or Canada, for which the deductible will not exceed $1 million.
67
Agreements with our Subsidiaries
On October 14, 2020, we signed a share purchase agreement and a revolving loan agreement with Eventer (the “Revolving Loan Agreement”). As part of the share purchase agreement and the revolving loan agreement, we invested $750,000, and following the completion thereof we held 58.7% of Eventer’s issued and outstanding share capital.
On April 8, 2021, Eventer consummated a share purchase agreement for an aggregate amount of $2.25 million out of which we invested $300,000. We currently hold approximately 46.21% of Eventer’s outstanding share capital.
In November 2021 we agreed with Eventer that the repayment of the initial advance under the Revolving Loan Agreement will occur on the earlier of (i) six months following the maturity date of the initial advance; or (ii) immediately following an initial public offering of Eventer.
On April 12, 2022, we amended the Revolving Loan Agreement, such that the repayment of the initial advance will occur at the earlier of (i) twelve months following the Maturity Date of the Initial Advance; or (ii) immediately following an initial public offering of Eventer.
On April 19, 2020, we entered into an Asset Transfer Agreement, effective January 20, 2020, with our majority owned subsidiary GERD IP. Pursuant to the Asset Transfer Agreement, we transferred certain of our patents in consideration for seven capital notes issued to us by GERD IP, of $2,000,000 each.
On February 2, 2021, we entered into two loans and pledges agreements with Jeffs’ Brands and its other stockholder, to finance Smart Repair Pro’s additional purchases of three new brands on the Amazon online marketplace. Pursuant to the forgoing agreements, the Company extended USD 4 million loans, with an annual interest of 4%, to be repaid on the fifth anniversary of the effective date. On August 30, 2022 all the loans were converted into shares of Jeffs’ Brands as part of Jeffs’ Brands IPO, in which we invested an additional USD 1 million. As a result, we currently hold approximately 34.87% of Jeffs’ Brands outstanding share capital.
On May 20, 2021, we entered into a sublease agreement with Jeffs’ Brands pursuant to which we subleased office space of approximately 97 square meters to Jeffs’ Brands, which terminated on October 30, 2022.
On October 12, 2021, we entered into a loan agreement with Gix Internet (the “Gix Loan Agreement”), pursuant to which we lent to Gix Internet NIS 4 million. On August 25, 2022, we entered into an amendment to the Gix Loan Agreement, effective as of July 1, 2022 (the “Amendment to the Gix Loan Agreement), pursuant to which, on November 2, 2022, the Company received a total of NIS 1 million as repayment of the original loan and the accrued interest thereon up to such date. The Repayment of the balance of the loan fund, in the amount of NIS 3 million, was postponed until June 30, 2023. In addition, the Company is entitled to convert all or part of the balance of the extended loan into shares of Gix Internet. The Gix Loan Agreement and the Amendment to the Gix Loan Agreement are filed as Exhibit 4.5 and 4.6, respectively, to this annual report on Form 20-F, and are incorporated herein by reference.
On April 7, 2023, our formerly wholly owned subsidiary Charging Robotics consummated a share exchange transaction with Fuel Doctor and became its wholly owned subsidiary. As a result of the transaction, we now hold 67% of Fuel Doctor’s outstanding share capital, with options to acquire up to 71% of its outstanding share capital based on predetermined milestones.
C. Interests of Experts and Counsel
Not applicable.
ITEM 8. FINANCIAL INFORMATION
A. Consolidated Statements and Other Financial Information.
See “Item 18. Financial Statements.”
Export Sales
The following table presents total export sales for each of the fiscal years indicated ($, in thousands):
For the year ended December 31, |
||||||||||||
2022 | 2021 | 2020 | ||||||||||
Total export sales* | 89,393 | 8,935 | 481 | |||||||||
as a percentage of total revenues | 97 | % | 85 | % | 82 | % |
* | Export sales, as presented, are defined as sales to customers located outside of Israel. |
68
Legal Proceedings
From time to time we may assert or be subject to various asserted or unasserted legal proceedings and claims. Any such claims, regardless of merit, could be time-consuming and expensive to defend and could divert management’s attention and resources from our operations. While the management believes that we have adequate insurance coverage and we accrue loss contingencies for all known matters that are probable and can be reasonably estimated, we cannot assure that the outcome of all current or future litigation will not have a material adverse effect on us and our results of operations.
Dividends
On December 28, 2022, we paid cash dividends on our Ordinary Shares and our Series C Warrants. We do not anticipate that we will further pay any cash dividends on our Ordinary Shares or ADSs in the foreseeable future.
We intend to retain our earnings to finance the development and expenses of our business. Any future determination relating to our dividend policy will be at the discretion of our board of directors and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions, capital requirements, business prospects, applicable Israeli law and other factors our board of directors may deem relevant.
B. Significant Changes
No significant change, other than as otherwise described in this annual report, has occurred in our operations since the date of our consolidated financial statements included in this annual report.
ITEM 9. THE OFFER AND LISTING
A. Offer and Listing Details
Our Ordinary Shares were traded on the TASE under the symbol “MDGS” from February 2006 to January 25, 2021, when we delisted our Ordinary Shares from TASE. In August 2015, our ADSs commenced trading on Nasdaq under the symbol “MDGS.” Each ADS currently represents 15 Ordinary Shares.
For a description of the ADSs, see “Item 12. Description of Securities Other Than Equity Securities – D. American Depositary Shares.”
Our Series C Warrants have been trading on Nasdaq under the symbol “MDGSW” since July 2018. Each Series C Warrant is exercisable into one/fifteen ADSs for an exercise price of $52.50 and will expire in July 2023.
B. Plan of Distribution
Not Applicable.
C. Markets
Our Ordinary Shares are no longer listed on TASE. Our ADSs are traded on Nasdaq under the symbol “MDGS.” Our Series C Warrants are traded on the Nasdaq under the symbol “MDGSW.”
D. Selling Shareholders
Not Applicable.
E. Dilution
Not Applicable.
F. Expenses of the Issue
Not Applicable.
69
ITEM 10. ADDITIONAL INFORMATION
A. Share Capital
Not Applicable.
B. Memorandum and Articles of Association
A copy of our amended and restated articles of association is attached as Exhibit 1.1 to this annual report on Form 20-F. The information called for by this Item is set forth in Exhibit 2.3 to this annual report on Form 20-F and is incorporated by reference into this annual report on Form 20-F.
C. Material Contracts
The following is a summary of each material contract, other than material contracts entered into in the ordinary course of business, to which we are or have been a party, for the two years immediately preceding the date of this annual report on Form 20-F:
● | Loan and Pledge Agreement by and among Medigus Ltd., Smart Repair Pro, Inc., and Julia Gerasimova, dated February 2, 2021, filed as Exhibit 4.19 to the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2021, and incorporated herein by reference. | |
● | Amendment No. 1 to Loan and Pledge Agreement by and between Medigus Ltd., Smart Repair Pro, Inc., and Julia Gerasimova, dated February 5, 2021, filed as Exhibit 4.20 to the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2021, and incorporated herein by reference. | |
● | Loan Agreement by and between the Company and Gix Internet dated October 12, 2021 (the “Loan Agreement”), filed as Exhibit 4.6 to this annual report on Form 20-F, and incorporated herein by reference. | |
● | Amendment to the Loan Agreement by and between the Company and Gix Internet dated August 25, 2022, and effective as of July 1, 2022, filed as Exhibit 4.7 to this annual report on Form 20-F, and incorporated herein by reference. | |
● | Share Purchase Agreement, by and among the Company, Parazero, Delta Drone International Ltd., L.I.A Pure Capital Ltd. and other entities listed therein, dated January 28, 2022, filed as Exhibit 4.8 to this annual report on Form 20-F, and incorporated herein by reference. | |
● | Securities Exchange Agreement by and between Medigus Ltd., the additional shareholders of Charging Robotics Ltd. and Fuel Doctor Holdings, Inc. dated March 28, 2023, filed as Exhibit 4.9 to this annual report on Form 20-F, and incorporated herein by reference. |
D. Exchange Controls
There are currently no Israeli currency control restrictions on payments of dividends or other distributions with respect to our securities or the proceeds from the sale of our securities, except or otherwise as set forth in this section and under “Item 10E. Additional Information — Taxation.” However, legislation remains in effect pursuant to which currency controls can be imposed by administrative action at any time.
The ownership or voting of our Ordinary Shares by non-residents of Israel, except with respect to citizens of countries that are in a state of war with Israel, is not restricted in any way by our amended and restated articles or by the laws of the State of Israel.
E. Taxation
The following description is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our Ordinary Shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.
Israeli Tax Considerations and Government Programs
The following is a summary of the material Israeli tax laws applicable to us, and some Israeli Government programs benefiting us. This section also contains a discussion of some Israeli tax consequences to persons owning our Ordinary Shares. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind of investor include traders in securities or persons that own, directly or indirectly, 10% or more of our outstanding means of control, all of whom are subject to special tax regimes not covered in this discussion. Some parts of this discussion are based on a new tax legislation which has not been subject to judicial or administrative interpretation. The discussion should not be construed as legal or professional tax advice and does not cover all possible tax considerations.
SHAREHOLDERS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS AS TO THE ISRAELI OR OTHER TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES, INCLUDING, IN PARTICULAR, THE EFFECT OF ANY FOREIGN, STATE OR LOCAL TAXES.
70
General Corporate Tax Structure in Israel
Israeli resident companies are generally subject to corporate tax on their taxable income at the rate of 23% of a company’s taxable income. However, the effective tax rate payable by a company that derives income from a Benefited Enterprise, a Preferred Enterprise, a Special Preferred Enterprise, a Preferred Technological Enterprise or a Special Preferred Technological Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli resident company are generally subject to tax at the prevailing corporate tax rate.
Law for the Encouragement of Industry (Taxes), 5729-1969
The Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for “Industrial Companies.”
The Industry Encouragement Law defines an “Industrial Company” as an Israeli resident company incorporated in Israel, of which 90% or more of its income in the tax year, other than income from certain government loans, derived from an “Industrial Enterprise” owned by it and located in Israel or in the “Area”, in accordance with the definition under section 3A of Tax Ordinance (New Version) 1961 (the “Tax Ordinance”). An “Industrial Enterprise” is defined as an enterprise which is held by an Industrial Company whose principal activity in any given tax year is industrial production.
The following corporate tax benefits, among others, are available to Industrial Companies:
● | Amortization over an eight-year period commencing on the year in which such rights were first exercised, of the cost of purchased patents, rights to use a patent and know-how which are used for the development or advancement of the Industrial Enterprise; | |
● | Under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies controlled by it; and | |
● | Under certain conditions, expenses related to a public offering are deductible in equal amounts over a three years period commencing on the year of the offering. |
We may qualify as an Industrial Company and may be eligible for the benefits described above.
Eligibility for benefits under the Industry Encouragement Law is not contingent upon approval of any governmental authority.
Tax Benefits and Grants for Research and Development
Israeli tax law allows, under certain conditions, a tax deduction for research and development expenditures, including capital expenditures, over three-years period. Expenditures are deemed related to scientific research and development projects, if:
● | The expenditures are approved by the relevant Israeli government ministry, determined by the field of research; | |
● | The research and development must be for the promotion of the company; and | |
● | The research and development is carried out by or on behalf of the company seeking such tax deduction. |
The amount of such deductible expenses is reduced by the sum of any funds received through government grants for the finance of such scientific research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested in an asset depreciable under the general depreciation rules of the Tax Ordinance. Expenditures not so approved are deductible in equal amounts over a three-year period.
From time to time, we may apply the Israel Innovation Authority (previously known as the Israeli Office of the Chief Scientist) (the “IIA”) for approval to allow a tax deduction for all research and development expenses during the year incurred. There can be no assurance that such application will be accepted.
71
Law for the Encouragement of Capital Investments, 5719-1959
The Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in production facilities (or other eligible assets) by “Industrial Enterprises” (as defined under the Investment Law).
The Investment Law has been amended several times over the recent years, with the three most significant changes effective as of April 1, 2005 (referred to as the 2005 Amendment), as of January 1, 2011 (referred to as the 2011 Amendment) and as of January 1, 2017 (referred to as the 2017 Amendment).
Tax Benefits Subsequent to the 2005 Amendment
The 2005 Amendment applies to investment programs commencing after 2004, but does not apply to investment programs approved prior to April 1, 2005. The 2005 Amendment provides that terms and benefits included in any certificate of approval that was granted before the 2005 Amendment became effective (April 1, 2005) will remain subject to the provisions of the Investment Law as in effect on the date of such approval. Pursuant to the 2005 Amendment, the Israeli Authority for Investments and Development of the Israeli Ministry of Economy (referred to as the Investment Center) will continue to grant Approved Enterprise status to qualifying investments. The 2005 Amendment, however, limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as an Approved Enterprise, such as provisions generally requiring that at least 25% of the Approved Enterprise’s income be derived from exports. An enterprise that qualifies under the new provisions is referred to as a “Benefited Enterprise”, rather than “Approved Enterprise”. The 2005 Amendment provides that Approved Enterprise status will only be necessary for receiving cash grants. As a result, it was no longer necessary for a company to obtain Approved Enterprise status in order to receive the tax benefits previously available under the alternative benefits track. Rather, a company may claim the tax benefits offered by the Investment Law directly in its tax returns, provided that its facilities meet the criteria for tax benefits set forth in the 2005 Amendment. Such a position may be subject to a future tax audit. Companies are entitled to approach the Israeli Tax Authority for a pre-ruling regarding their eligibility for benefits under the Investment Law, as amended.
Tax benefits are available under the 2005 Amendment to production facilities (or other eligible facilities) which are generally required to derive 25% or more of their business income from export to specific markets with a population of at least 14 million in 2012 (such export criteria will further be increased in the future by 1.4% per annum). In order to receive the tax benefits, the 2005 Amendment states that a company must make an investment which meets all of the conditions, including exceeding a minimum investment amount specified in the Investment Law. Such investment allows a company to receive “Benefited Enterprise” status, and may be made over a period of no more than three years that will end at the year in which the company requested to have the tax benefits apply to its Benefited Enterprise. The benefits period under the Benefited Enterprise status is limited to 12 years from the year the company chose to have its tax benefits apply. Where the company requests to apply the tax benefits to an expansion of existing facilities, only the expansion will be considered to be a Benefited Enterprise and the company’s effective tax rate will be the weighted average of the applicable rates. In this case, the minimum investment required in order to qualify as a Benefited Enterprise is required to exceed a certain percentage of the value of the company’s production assets before the expansion.
The extent of the tax benefits available under the 2005 Amendment to qualifying income of a Benefited Enterprise depend on, among other things, the geographic location in Israel of the Benefited Enterprise. The location will also determine the period for which tax benefits are available. Such tax benefits include an exemption from corporate tax on undistributed income for a period of between two to ten years, depending on the geographic location of the Benefited Enterprise in Israel, and a reduced corporate tax rate of between 10% to 25% for the remainder of the benefits period, depending on the level of foreign investment in the company in each year. The benefits period is limited to 12 or 14 years from the year the company first chose to have the tax benefits apply, depending on the location of the company within Israel.
A company qualifying for tax benefits under the 2005 Amendment which pays a dividend out of income derived by its Benefited Enterprise during the tax exemption period will be subject to corporate tax in respect of the gross amount of the dividend, or a lower rate in the case of a qualified Foreign Investors’ Company, to which we refer as a FIC, which is at least 49% owned by non-Israeli residents. Dividends paid to Israeli shareholders out of income attributed to a Benefited Enterprise (or out of dividends received from a company whose income is attributed to a Benefited Enterprise) are generally subject to withholding tax at source at the rate of 15% (in the case of non-Israeli shareholders - subject to the receipt in advance of a valid certificate from the ITA allowing the reduced 15% tax rate, or such lower rate as may be provided in an applicable tax treaty). The reduced rate of 15% is limited to dividends and distributions out of income attributed to a Benefited Enterprise during the benefits period and actually paid at any time up to 12 years thereafter except with respect to a FIC (as such term is defined in the Investment Law), in which case the 12-year limit does not apply.
72
The benefits available to a Benefited Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law and its regulations. If a company does not meet these conditions, it may be required to refund the amount of tax benefits, as adjusted by the Israeli consumer price index, and interest, or other monetary penalties.
Tax Benefits under the 2011 Amendment
The Investment Law was significantly amended as of January 1, 2011 (the “2011 Amendment”). The 2011 Amendment introduced new benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment.
The 2011 Amendment introduced new tax benefits for income generated by a “Preferred Company” through its “Preferred Enterprise” in accordance with the definition of such term in the Investments Law. A “Preferred Company” is defined as either: (i) a company incorporated in Israel which is not wholly owned by a governmental entity, or (ii) a limited partnership that: (a) was registered under the Israeli Partnerships Ordinance and; (b) all of its limited partners are companies incorporated in Israel, but not all of them are governmental entities; which has, among other things, Preferred Enterprise status and is controlled and managed from Israel.
A Preferred Company is entitled to a reduced flat tax rate with respect to the income attributed to the Preferred Enterprise, at the following rates:
Tax Year | Development Region “A” | Other Areas within Israel | ||||||
2011 – 2012 | 10 | % | 15 | % | ||||
2013 | 7 | % | 12.5 | % | ||||
2014 | 9 | % | 16 | % | ||||
2017 onwards(1) | 7.5 | % | 16 | % |
(1) | In December 2016, the Israeli Parliament (the Knesset) approved an amendment to the Investment Law pursuant to which the tax rate applicable to Preferred Enterprises in Development Region “A” would be reduced to 7.5% as of 2017. |
73
In addition, Income derived by a Preferred Company from a “Special Preferred Enterprise” (as such term is defined in the Investment Law) would be entitled, during a benefits period of 10 years, to further reduced tax rates of 8%, or to 5% if the Special Preferred Enterprise is located in a Development Region “A”. Since January 1, 2017, the definition for “Special Preferred Enterprise” includes less stringent conditions.
Dividends distributed from income which is attributed to a “Preferred Enterprise” or to a “Special Preferred Enterprise” will be subject to withholding tax at source at the following rates: (i) Israeli resident corporations — 0%, (ii) Israeli resident individuals — 20%, and (iii) non-Israeli residents — 20% or a reduced tax rate under the provisions of an applicable double tax treaty, subject to the receipt in advance of a valid certificate from the Israel Tax Authority (“ITA”) allowing for a reduced tax rate.
Under the 2011 Amendment, a company located in Development Region “A” may be entitled to cash grants and the provision of loans under certain conditions, if approved. The rates for grants and loans shall not be fixed, but up to 20% of the amount of the approved investment (may be increased with additional 4%). In addition, a company owning a Preferred Enterprise under the Grant Track may be entitled also to the tax benefits which are prescribed for a Preferred Company.
The 2011 Amendment also provided transitional provisions to address companies already enjoying current benefits under the Investment Law. These transitional provisions provide, among other things, that unless an irrevocable request is made to apply the provisions of the Investment Law as amended in 2011 with respect to income to be derived as of January 1, 2011: (i) the terms and benefits included in any certificate of approval that was granted to an Approved Enterprise, which chose to receive grants, before the 2011 Amendment became effective, will remain subject to the provisions of the Investment Law as in effect on the date of such approval, and subject to certain conditions; (ii) the terms and benefits included in any certificate of approval that was granted to an Approved Enterprise, that had participated in an alternative benefits program, before the 2011 Amendment became effective will remain subject to the provisions of the Investment Law as in effect on the date of such approval, provided that certain conditions are met; and (iii) a Benefited Enterprise can elect to continue to benefit from the benefits provided to it before the 2011 Amendment came into effect, provided that certain conditions are met.
The tax benefits under the 2011 Amendment also include accelerated depreciation and amortization for tax purposes.
The termination or substantial reduction of any of the benefits available under the Investment Law could materially increase our tax liabilities.
As the Company does not have taxable income as of today, it does not use tax benefits under the said regime.
New Tax benefits under the 2017 Amendment that became effective on January 1, 2017
The 2017 Amendment provides new tax benefits for two types of Technology Enterprises, as described below, and is in addition to the other existing tax beneficial programs under the Investment Law.
The 2017 Amendment provides that a technology company satisfying certain conditions will qualify as a Preferred Technology Enterprise and will thereby enjoy a reduced corporate tax rate of 12% on income that qualifies as Preferred Technology Income, as defined in the Investment Law. The tax rate is further reduced to 7.5% for a Preferred Technology Enterprise located in development zone “A”. In addition, a Preferred Technology Company will enjoy a reduced corporate tax rate of 12% on capital gain derived from the sale of certain Benefited Intangible Assets (as defined in the Investment Law) to a related foreign company if the Benefited Intangible Assets were acquired from a foreign company after January 1, 2017, for at least NIS 200 million, and the sale receives prior approval from the IIA.
74
The 2017 Amendment further provides that a technology company satisfying certain conditions will qualify as a “Special Preferred Technology Enterprise” (an enterprise for which, among others, total consolidated revenues of its parent company and all subsidiaries is at least NIS 10 billion) and will thereby enjoy a reduced corporate tax rate of 6% on Preferred Technology Income regardless of the company’s geographic location within Israel. In addition, a Special Preferred Technology Enterprise will enjoy a reduced corporate tax rate of 6% on capital gain derived from the sale of certain “Benefited Intangible Assets” to a related foreign company if the Benefited Intangible Assets were either developed by the Special Preferred Technology Enterprise or acquired from a foreign company after January 1, 2017, and the sale received prior approval from IIA. A Special Preferred Technology Enterprise that acquires Benefited Intangible Assets from a foreign company for more than NIS 500 million will be eligible for these benefits for at least ten years, subject to certain approvals as specified in the Investment Law.
Dividends distributed to Israeli shareholders by a Preferred Technology Enterprise or a Special Preferred Technology Enterprise, paid out of Preferred Technology Income, are generally subject to withholding tax at source at the rate of 20% (in the case of non-Israeli shareholders - subject to the receipt in advance of a valid certificate from the ITA allowing the reduced 20% tax rate, or such lower rate as may be provided in an applicable tax treaty). However, if such dividends are paid to an Israeli company, no tax is required to be withheld (although, if such dividends are subsequently distributed to individuals or a non-Israeli company, the aforesaid will apply). If such dividends are distributed to a foreign company that holds solely or together with other foreign companies 90% or more in the Israeli company and other conditions are met, the withholding tax rate will be 4% or a lower rate under a tax treaty, if applicable subject to the receipt in advance of a valid certificate from the ITA.
Taxation of Our Shareholders
Capital Gains
Capital gain tax is imposed on the disposition of capital assets by an Israeli resident, and on the disposition of such assets by a non-Israeli resident if those assets are either (i) located in Israel; (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent, directly or indirectly, rights to assets located in Israel, unless a tax treaty between Israel and the seller’s country of residence provides otherwise. The Tax Ordinance distinguishes between “Real Capital Gain” and the “Inflationary Surplus”. Real Capital Gain is the excess of the total capital gain over Inflationary Surplus computed generally on the basis of the increase in the Israeli Consumer Price Index or, in certain circumstances, a foreign currency exchange rate between the date of purchase and the date of disposition. Inflationary Surplus is not subject to tax in Israel if accrued after 1993.
Generally, Real Capital Gain accrued by individuals on the sale of our Ordinary Shares will be taxed at the rate of 25%. However, if the individual shareholder is a “Substantial Shareholder” (i.e., a person who holds, directly or indirectly, alone or together with such person’s relative or another person who collaborates with such person on a permanent basis, 10% or more of one of the Israeli resident company’s means of control (including, among other things, the right to receive profits of the company, voting rights, the right to receive the company’s liquidation proceeds, the right to appoint a director or an executive officer and order someone who holds any of the aforesaid rights how to act, regardless of the source of such right) at the time of sale or at any time during the preceding 12 months period, such gain will be taxed at the rate of 30%.
Real Capital Gain derived by corporations will be generally subject to a corporate tax rate of 23% (in 2022).
Individuals and corporate shareholders dealing in securities in Israel are taxed at the tax rates applicable to business income — 23% for corporations in 2022 and a marginal tax rate of up to 47% in 2022 for individuals (excluding excess tax as discussed below), unless the benefiting provisions of an applicable treaty applies.
Notwithstanding the foregoing, capital gains derived from the sale of our Ordinary Shares by a non-Israeli shareholder may be exempt under the Tax Ordinance from Israeli taxation provided that the following cumulative conditions are met: (i) the shares were purchased upon or after the registration of the securities on the stock exchange (ii) the seller does not have a permanent establishment in Israel to which the derived capital gain is attributed, (iii) neither the shareholder nor the particular capital gain is otherwise subject to the Israeli Income Tax Law (Inflationary Adjustments) 5745-1985), (iv) if the seller is a corporation, no more than 25% of its means of control are held, directly and indirectly, by an Israeli resident shareholders, and there is no Israeli Resident that is entitled to 25% or more of the revenues or profits of the corporation directly or indirectly. In addition, such an exemption would not be available to a person whose gains from selling or otherwise disposing of the securities are deemed to be business income.
75
In addition, the sale of shares may be exempt from Israeli capital gain tax under the provisions of an applicable tax treaty. For example, the U.S.-Israel Double Tax Treaty exempts a U.S. resident from Israeli capital gain tax in connection with such sale, provided that (i) the U.S. resident owned, directly or indirectly, less than 10% of an Israeli resident company’s voting power at any time within the 12 month period preceding such sale; (ii) the seller, being an individual, is present in Israel for a period or periods of less than 183 days in the aggregate at the taxable year; and (iii) the capital gain from the sale was not derived through a permanent establishment of the U.S. resident in Israel; (iv) the capital gain arising from such sale, exchange or disposition is not attributed to real estate located in Israel; (v) the capital gains arising from such sale, exchange or disposition is not attributed to royalties; and (vi) the shareholder is a U.S. resident (for purposes of the U.S.-Israel Treaty) is holding the shares as a capital asset. Under the U.S.-Israel Double Tax Treaty, a U.S. resident would be permitted to claim a credit for the Israeli tax against the U.S. federal income tax imposed with respect to the sale, exchange or disposition, subject to the limitations in U.S. laws applicable to foreign tax credits. The U.S-Israel Double Tax Treaty does not provide such credit against any U.S. state or local taxes.
Regardless of whether our shareholders (including non-Israeli shareholders) may be liable for Israeli tax on the sale of their Ordinary Shares, the payment of the consideration may be subject to the withholding of Israeli tax at source. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. Specifically, the ITA may require shareholders who are not liable for Israeli tax to sign declarations in forms specified by this authority, provide documentation (including, for example, a certificate of residency) or to obtain a specific exemption from the ITA to confirm their status as non-Israeli resident, and, in the absence of such declarations or exemptions, may require the purchaser of the shares to withhold taxes at source.
At the sale of securities traded on a stock exchange a detailed return, including a computation of the tax due, must be filed and an advanced payment must be paid on January 31 and July 31 of every tax year in respect of sales of securities made within the previous six months. However, if all tax due was withheld at source according to applicable provisions of the Tax Ordinance and regulations promulgated thereunder the aforementioned return need not be filed and no advance payment must be paid provided that (i) such income was not generated from business conducted in Israel by the taxpayer, (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed and an advance payment does not need to be made, and (iii) the taxpayer is not obligated to pay excess tax (as further explained below). Capital gain is also reportable on the annual income tax return.
Dividend Income
Generally, a distribution of a dividend to Israeli shareholders by our Company from income attributed to a Benefited Enterprise will be subject to withholding tax in Israel at a rate of 15% (in the case of non-Israeli shareholders - subject to the receipt in advance of a valid certificate from the ITA allowing the reduced 15% tax rate or such a reduced tax rate as may be provided under an applicable tax treaty). A distribution of dividend by our Company from income attributed to a Preferred Enterprise or Preferred Technology Enterprise (if the Company will be entitled to tax benefits of a Preferred Enterprise or Preferred Technology Enterprise) will generally be subject to withholding tax in Israel at the following tax rates: Israeli resident individuals — 20%; Israeli resident companies — 0%; Non-Israeli residents — 20% (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate,20% , or such lower rate as may be provided in an applicable tax treaty),.
A distribution of dividends from income, which is not attributed to a Preferred Enterprise or a Benefited Enterprise to an Israeli resident individual, will generally be subject to withholding tax at a rate of 25%. However, a 30% tax rate will apply if the dividend recipient is a “Substantial Shareholder” (as defined above) at the time of distribution or at any time during the preceding 12 months period. If the recipient of the dividend is an Israeli resident corporation, such dividend will be exempt from withholding tax provided the income from which such dividend is distributed was derived or accrued within Israel and was subject to tax in Israel. An average rate will be set in case the dividend is distributed from mixed types of income (regular and preferred income).
The Tax Ordinance provides that a non-Israeli resident (either individual or corporation) is generally subject to an Israeli income tax on the receipt of dividends at the rate of 25% (30% if the dividends recipient is a “Substantial Shareholder” (as defined above), at the time of distribution or at any time during the preceding 12 months period). Dividends paid on publicly traded shares, like our Ordinary Shares, to non-Israeli residents, are generally subject to Israeli withholding tax at a rate of 25%, so long as the shares are registered with a nominee company (whether or not the recipient is a substantial shareholder); those rates are subject to a reduced tax rate under the provisions of an applicable double tax treaty (subject to the receipt in advance of a valid certificate from the ITA allowing for a reduced tax rate). Thus, under the U.S.-Israel Double Tax Treaty the following rates will apply in respect of dividends not attributed to a Benefited Enterprise or Preferred Enterprise distributed by an Israeli resident company to a U.S. resident: (i) if the U.S. resident is a corporation which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding shares of the voting share capital of the Israeli resident paying corporation and not more than 25% of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain type of interest or dividends — the tax rate is 12.5%. Notwithstanding the foregoing, dividends distributed from income attributed to a Benefited Enterprise or Preferred Enterprise are not entitled to such reduction under such tax treaty but are subject to withholding tax at the rate of 15% or 20% for such a United States corporate shareholder, provided that the conditions related to the holding of 10% of our voting capital and to our gross income for the previous year (as set forth in the previous sentence) are met. The aforementioned rates under the Israel U.S. Double Tax Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel.
76
A non-Israeli resident who receives dividends from which tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect to such income, provided that (i) such income was not generated from business conducted in Israel by the taxpayer, (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed, and (iii) the taxpayer is not obligated to pay excess tax (as further explained below).
Payers of dividends on our Ordinary Shares, including the Israeli stockbroker effectuating the transaction, or the financial institution through which the securities are held, are generally required, subject to any of the foregoing exemptions, reduced tax rates and the demonstration of a shareholder regarding his, her or its foreign residency, to withhold tax upon the distribution of dividend at the rate of 25%, so long as the shares are registered with a nominee company.
We paid a dividend in December 2022 but do not expect to further pay any cash dividends in the near future. Following the receipt of a tax ruling from the Israeli Tax Authorities, the payment was not subject to tax withholding in Israel and the Company will pay the cash capital amount in full.
Excess Tax
Subject to the provisions of an applicable tax treaty, individuals who are subject to tax in Israel (whether any such individual is an Israeli resident or non-Israeli resident) are also subject to an additional tax at a rate of 3% on annual income (including, but not limited to, income derived from dividends, interest and capital gains) exceeding NIS 663,240 for 2022, which amount is linked to the annual change in the CPI.
Foreign Exchange Regulations
Non-residents of Israel who hold our Ordinary Shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and winding up of our affairs, repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli income tax is generally required to have been paid or withheld on these amounts. In addition, the statutory framework for the potential imposition of currency exchange control has not been eliminated and may be restored at any time by administrative action.
Estate and Gift Tax
Israeli law presently does not impose estate or gift taxes.
Certain Material U.S. Federal Income Tax Consequences
The following discussion describes certain material U.S. federal income tax consequences to U.S. Holders (as defined below) under present law of an investment in our Ordinary Shares or ADSs. This discussion applies only to U.S. Holders that hold our Ordinary Shares or ADSs as capital assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the “Code”), that have acquired their Ordinary Shares or ADSs and that have the U.S. dollar as their functional currency.
This discussion is based on the tax laws of the United States, including the Code, as in effect on the date hereof and on U.S. Treasury regulations as in effect or, in some cases, as proposed, on the date hereof, the United States-Israel Tax Treaty (the “Treaty”), as well as judicial and administrative interpretations thereof available on or before such date. All of the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax consequences described below. We have not sought, and will not seek, a ruling from the IRS or an opinion of counsel as to any U.S. federal income tax consequence described herein. There can be no assurances that the IRS will not take a different position concerning the tax consequences of the acquisition, ownership and disposition of our Ordinary Shares or ADSs or that such a position would not be sustained. This summary does not address any estate or gift tax consequences, the alternative minimum tax, the Foreign Account Tax Compliance Act or any state, local, or non-U.S. tax consequences.
77
The following discussion neither deals with the tax consequences to any particular investor nor describes all of the tax consequences applicable to persons in special tax situations such as:
● | banks; |
● | certain financial institutions; |
● | insurance companies; |
● | regulated investment companies; |
● | real estate investment trusts; |
● | broker-dealers; |
● | traders that elect to mark to market; |
● | certain former citizens or residents of the United States; |
● | tax-exempt entities; |
● | persons holding our Ordinary Shares or ADSs as part of a straddle, hedging, constructive sale, conversion or integrated transaction; |
● | persons that actually (directly or indirectly) or constructively own 10% or more of our total voting power or value; |
● | persons that are residents or ordinarily resident in or have a permanent establishment in a jurisdiction outside the United States; |
● | persons who acquired our Ordinary Shares or ADSs pursuant to the exercise of any employee share option or otherwise as compensation; |
● | S-corporation and partnerships, including entities classified as partnerships for U.S. federal income tax purposes; |
● | governments or agencies or instrumentalities thereof; |
● | grantor trusts; |
● | passive foreign investment companies; or |
● | controlled foreign corporations. |
INVESTORS ARE URGED TO CONSULT THEIR TAX ADVISORS ABOUT THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE STATE, LOCAL, NON-U.S. AND OTHER TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES OR ADSs.
The discussion below of the U.S. federal income tax consequences to “U.S. Holders” will apply to you if you are the beneficial owner of our Ordinary Shares or ADSs and you are, for U.S. federal income tax purposes,
● | an individual who is a citizen or resident of the United States; |
● | a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in the United States or under the laws of the United States, any state thereof or the District of Columbia; |
78
● | an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or |
● | a trust that (1) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. |
If an entity or other arrangement treated as a partnership for U.S. federal income tax purposes holds our Ordinary Shares or ADSs, the tax treatment of a partner will generally depend upon the status of the partner and the activities of the partnership. A person that would be a U.S. Holder if it held our Ordinary Shares or ADSs directly and that is a partner of a partnership holding our Ordinary Shares or ADSs is urged to consult its own tax advisor.
Ownership of ADSs
For U.S. federal income tax purposes, a holder of ADSs generally will be treated as the owner of the Ordinary Shares represented by such ADSs. Gain or loss will generally not be recognized on account of exchanges of Ordinary Shares for ADSs, or of ADSs for ordinary shares. References to ordinary shares in the discussion below are deemed to include ADSs, unless context otherwise requires.
Passive Foreign Investment Company
Based on our anticipated income and the composition of our income and assets, there is a significant risk that we will be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes at least until we start generating a substantial amount of active revenue. Because PFIC status is a factual determination based on actual results for the entire taxable year, there can be no assurance that we were not a PFIC in 2022 and will not be a PFIC in subsequent years, as our operating results for any such years may cause us to be a PFIC. A non-U.S. entity treated as a corporation for U.S. federal income tax purposes will generally be a PFIC for U.S. federal income tax purposes for any taxable year after applying certain look-through rules with respect to the income and assets of subsidiaries if either:
● | at least 75% of its gross income for such year is passive income (such as interest income); or |
● | at least 50% of the value of its assets (based on an average of the quarterly values of the assets) during such year is attributable to assets that produce passive income or are held for the production of passive income. |
Passive income for this purpose generally includes dividends, interest, royalties, rents, gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income, and includes amounts derived by reason of the temporary investment of funds raised in offerings of our shares.
For this purpose, we will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other entity treated as a corporation for U.S. federal income tax purposes in which we own, directly or indirectly, 25% or more (by value) of the stock.
A separate determination must be made after the close of each taxable year as to whether we were a PFIC for that year. Because the value of our assets for purposes of the PFIC test will generally be determined by reference to the market price of our Ordinary Shares, our PFIC status may depend in part on the market price of our Ordinary Shares, which may fluctuate significantly. In addition, there may be certain ambiguities in applying the PFIC test to us. No rulings from the U.S. Internal Revenue Service, or IRS, however, have been or will be sought with respect to our status as a PFIC. If we are a PFIC for any taxable year during which you hold our Ordinary Shares, we generally will continue to be treated as a PFIC with respect to your investment in our Ordinary Shares for all succeeding years during which you hold our Ordinary Shares, unless we cease to be a PFIC and you make a “deemed sale” election with respect to our Ordinary Shares. If such election is made, you will be deemed to have sold our Ordinary Shares you hold at their fair market value on the last day of the last taxable year in which we were a PFIC, and any gain from such deemed sale would be subject to taxation under the excess distribution regime described below. After the deemed sale election, your Ordinary Shares with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently become a PFIC.
79
For each taxable year that we are treated as a PFIC with respect to you, you will be subject to special tax rules with respect to any “excess distribution” (as defined below) you receive and any gain you realize from a sale or other disposition (including a pledge) of our Ordinary Shares, unless you make a valid “mark-to-market” election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable years or your holding period for our Ordinary Shares will be treated as an excess distribution. Under these special tax rules:
● | the excess distribution or gain will be allocated ratably over your holding period for our Ordinary Shares; |
● | the amount allocated to the current taxable year, and any taxable years in your holding period prior to the first taxable year in which we were a PFIC, will be treated as ordinary income; and |
● | the amount allocated to each other taxable year will be subject to the highest tax rate in effect for individuals or corporations, as applicable, for each such year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year. |
The tax liability for amounts allocated to taxable years prior to the year of disposition or excess distribution cannot be offset by any net operating losses, and gains (but not losses) realized on the sale of our Ordinary Shares cannot be treated as capital gains, even if you hold our Ordinary Shares as capital assets.
If we are treated as a PFIC with respect to you for any taxable year, to the extent any of our subsidiaries are also PFICs, you may be deemed to own shares in such lower-tier PFICs that are directly or indirectly owned by us in that proportion which the value of our Ordinary Shares you own bears to the value of all of our Ordinary Shares, and you may be subject to the adverse tax consequences described above with respect to the shares of such lower-tier PFICs you would be deemed to own. As a result, you may incur liability for any excess distribution described above if we receive a distribution from our lower-tier PFICs or if any shares in such lower-tier PFICs are disposed of (or deemed disposed of). You should consult your tax advisor regarding the application of the PFIC rules to any of our subsidiaries.
A U.S. Holder of “marketable stock” (as defined below) in a PFIC may make a mark-to-market election for such stock to elect out of the tax treatment discussed above. If you make a valid mark-to-market election for our Ordinary Shares, you will include in income for each year that we are treated as a PFIC with respect to you an amount equal to the excess, if any, of the fair market value of our Ordinary Shares as of the close of your taxable year over your adjusted basis in such Ordinary Shares. You will be allowed a deduction for the excess, if any, of the adjusted basis of our Ordinary Shares over their fair market value as of the close of the taxable year. However, deductions will be allowable only to the extent of any net mark-to-market gains on our Ordinary Shares included in your income for prior taxable years. Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition of our Ordinary Shares, will be treated as ordinary income. Ordinary loss treatment will also apply to the deductible portion of any mark-to-market loss on our Ordinary Shares, as well as to any loss realized on the actual sale or disposition of our Ordinary Shares, to the extent the amount of such loss does not exceed the net mark-to-market gains for such Ordinary Shares previously included in income. Your basis in our Ordinary Shares will be adjusted to reflect any such income or loss amounts. If you make a mark-to-market election, any distributions we make would generally be subject to the rules discussed below under “— Taxation of dividends and other distributions on our Ordinary Shares,” except the lower rates applicable to qualified dividend income would not apply.
The mark-to-market election is available only for “marketable stock,” which is stock that is regularly traded on a qualified exchange or other market, as defined in applicable U.S. Treasury regulations. We expect our Ordinary Shares will continue to be listed on Nasdaq. Because a mark-to-market election cannot be made for equity interests in any lower-tier PFICs we own, you generally will continue to be subject to the PFIC rules with respect to your indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. The Nasdaq is a qualified exchange, but there can be no assurance that the trading in our Ordinary Shares will be sufficiently regular to qualify our Ordinary Shares as marketable stock. You should consult your tax advisor as to the availability and desirability of a mark-to-market election, as well as the impact of such election on interests in any lower-tier PFICs. Alternatively, if a non-U.S. entity treated as a corporation is a PFIC, a holder of shares in that entity may avoid taxation under the PFIC rules described above regarding excess distributions and recognized gains by making a “qualified electing fund” election to include in its income, on a current basis: (1) as ordinary income, its pro rata share of the “ordinary earnings” of the qualified electing fund; and (2) as long-term capital gain, its pro rata share of the “net capital gain” of the qualified electing fund. However, you may make a qualified electing fund election with respect to your Ordinary Shares only if we furnish you annually with certain tax information, and we currently do not intend to prepare or provide such information.
80
A U.S. Holder of a PFIC may be required to file an IRS Form 8621. The failure to file this form when required could result in substantial penalties. If we are a PFIC, you should consult your tax advisor regarding any reporting requirements that may apply to you. You are urged to consult your tax advisor regarding the application of the PFIC rules to the acquisition, ownership and disposition of our Ordinary Shares.
YOU ARE STRONGLY URGED TO CONSULT YOUR TAX ADVISOR REGARDING THE IMPACT OF OUR BEING A PFIC ON YOUR INVESTMENT IN OUR ORDINARY SHARES OR ADSs AS WELL AS THE APPLICATION OF THE PFIC RULES AND THE POSSIBILITY OF MAKING A MARK-TO-MARKET ELECTION.
Taxation of Dividends and Other Distributions on our Ordinary Shares
Subject to the PFIC rules discussed above, the gross amount of any distributions we make to you (including the amount of any tax withheld) with respect to our Ordinary Shares generally will be includible in your gross income as dividend income on the date of receipt by the holder, but only to the extent the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). The dividends will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations. To the extent the amount of the distribution exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles), such excess amount will be treated first as a tax-free return of your tax basis in your Ordinary Shares, and then, to the extent such excess amount exceeds your tax basis in your Ordinary Shares, as capital gain. We currently do not, and we do not intend to, calculate our earnings and profits under U.S. federal income tax principles. Therefore, you should expect that a distribution will generally be reported as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above.
With respect to certain non-corporate U.S. Holders, including individual U.S. Holders, dividends may be taxed at the lower capital gain rates applicable to “qualified dividend income,” provided (1) our Ordinary Shares are readily tradable on an established securities market in the United States (such as Nasdaq), (2) we are neither a PFIC nor treated as such with respect to you (as discussed above) for either the taxable year in which the dividend was paid or the preceding taxable year, (3) certain holding period requirements are met and (4) you are not under an obligation to make related payments with respect to positions in substantially similar or related property. As discussed above under “Passive Foreign Investment Company,” there is a significant risk that we will be a PFIC for U.S. federal income tax purposes, and, as a result, the qualified dividend rate may be unavailable with respect to dividends we pay.
The amount of any distribution paid in a currency other than U.S. dollars will be equal to the U.S. dollar value of such currency on the date such distribution is includible in your income, regardless of whether the payment is in fact converted into U.S. dollars at that time. If the foreign currency is converted into U.S. dollars on the date of receipt, a U.S. Holder generally will not be required to recognize foreign currency gain or loss in respect of the distribution. A U.S. Holder may have foreign currency gain or loss if the foreign currency is converted into U.S. dollars after the date of receipt, depending on the exchange rate at the time of conversion. Any gains or losses resulting from the conversion of foreign currency into U.S. dollars generally will be treated as ordinary income or loss, as the case may be, and generally will be treated as U.S. source. In addition, proposed Treasury regulations (which taxpayers may rely upon pending publication of final regulations) issued on December 18, 2017, provide that certain taxpayers may elect to ‘mark to market’ gain or loss resulting from exchange rate fluctuations. The proposed regulations are complex, and you should consult your tax advisor regarding the availability of the proposed regulations in your particular circumstances. The amount of any distribution of property other than cash will be equal to the fair market value of such property on the date of distribution.
Subject to certain significant conditions and limitations, including potential limitations under the Treaty, U.S. Holders may be entitled to a credit against their U.S. federal income tax liability or a deduction against U.S. federal taxable income in an amount equal to the non-refundable Israeli tax withheld on distributions on our Ordinary Shares. The election to deduct, rather than credit, foreign taxes, is made on a year-by-year basis and applies to all foreign taxes paid by a U.S. Holder or withheld from a U.S. Holder that year. Distributions paid on our Ordinary Shares will generally be treated as passive income that is foreign source for U.S. foreign tax credit purposes. As a result of recent changes to the U.S. foreign tax credit rules, a withholding tax generally will need to satisfy certain additional requirements in order to be considered a creditable tax for a U.S. Holder. We have not determined whether these requirements have been met and, accordingly, no assurance can be given that any withholding tax on dividends paid by us will be creditable. U.S. Holders should consult their own tax advisors to determine whether and to what extent they would be entitled to such credit.
81
Taxation of Disposition of Ordinary Shares
Subject to the PFIC rules discussed above, upon a sale or other disposition of Ordinary Shares, you will generally recognize capital gain or loss for U.S. federal income tax purposes in an amount equal to the difference between the amount realized (including the amount of any tax withheld) and your tax basis in such Ordinary Shares. If the consideration you receive for our Ordinary Shares is not paid in U.S. dollars, the amount realized will be the U.S. dollar value of the payment received determined by reference to the spot rate of exchange on the date of the sale or other disposition. However, if our Ordinary Shares are treated as traded on an “established securities market” and you are either a cash basis taxpayer or an accrual basis taxpayer that has made a special election (which must be applied consistently from year to year and cannot be changed without the consent of the IRS), you will determine the U.S. dollar value of the amount realized in a non-U.S. dollar currency by translating the amount received at the spot rate of exchange on the settlement date of the sale. If you are an accrual basis taxpayer that is not eligible to or does not elect to determine the amount realized using the spot rate on the settlement date, you will recognize foreign currency gain or loss to the extent of any difference between the U.S. dollar amount realized on the date of sale or disposition and the U.S. dollar value of the currency received at the spot rate on the settlement date. In addition, proposed Treasury regulations (which taxpayers may rely upon pending publication of final regulations) issued on December 18, 2017, provide that certain taxpayers may elect to “mark to market” gain or loss resulting from exchange rate fluctuations. The proposed regulations are complex, and you should consult your tax advisor regarding the availability of the proposed regulations in your particular circumstances.
Your tax basis in our Ordinary Shares generally will equal the cost of such Ordinary Shares. If you are a non-corporate U.S. Holder, capital gain from the sale, exchange or other disposition of shares is generally eligible for a preferential rate of taxation applicable to capital gains, if your holding period determined at the time of such sale, exchange or other disposition for such shares exceeds one year (i.e., such gain is long-term capital gain). The deductibility of capital losses is subject to significant limitations.
To the extent that, the sale, exchange or disposition of our Ordinary Shares would be subject to Israeli tax, a U.S. Holder generally will not be entitled to claim a foreign tax credit for such tax unless the U.S. Holder is eligible for benefits under the Treaty, is considered a resident of the United States for purposes of the Treaty, and otherwise meets the requirements for claiming benefits under the Treaty. In lieu of claiming a credit, a U.S. Holder may be able to elect to deduct the Israeli taxes in computing taxable income, subject to applicable limitations. An election to deduct foreign taxes instead of claiming foreign tax credits applies to all foreign taxes paid or accrued in the relevant taxable year. U.S. Holders should consult their own tax advisors regarding the deduction or credit for any such Israeli tax and their eligibility for the benefits of the Treaty.
Information with respect to Net Investment Income Tax
Certain U.S. Holders who are individuals, estates or trusts may be required to pay an additional 3.8% Net Investment Income Tax, or NIIT, on, among other things, dividends and capital gains from the sale or other disposition of our shares. For individuals, the additional NIIT tax applies to the lesser of (i) “net investment income” or (ii) the excess of “modified adjusted gross income” over $200,000 ($250,000 if married and filing jointly or $125,000 if married and filing separately). “Net investment income” generally equals the taxpayer’s gross investment income reduced by the deductions that are allocable to such income. U.S. Holders will likely not be able to credit foreign taxes against the 3.8% NIIT.
Information with respect to Reporting Requirements
Certain U.S. Holders may be required to file IRS Form 926, Return by U.S. Transferor of Property to a Foreign Corporation and IRS Form 5471, Information Return of U.S. Persons With Respect to Certain Foreign Corporations, reporting transfers of cash or other property to us and information relating to the U.S. Holder and us. Substantial penalties may be imposed upon a U.S. Holder that fails to comply.
82
Certain U.S. Holders owning “specified foreign financial assets” may be required to file IRS Form 8938, or Statement of Specified Foreign Financial Assets, with respect to such assets with their tax returns. “Specified foreign financial assets” generally include any financial accounts maintained by foreign financial institutions, as well as any of the following, but only if they are not held in accounts maintained by financial institutions: (i) stocks and securities issued by non-U.S. persons (ii) financial instruments and contracts held for investment that have non-U.S. issuers or counterparties and (iii) interests in foreign entities. The IRS has issued guidance exempting “specified foreign financial assets” held in a financial account from reporting under this provision (although the financial account itself, if maintained by a foreign financial institution, may remain subject to this reporting requirement). The failure to file this form when required could result in substantial penalties. You are urged to consult your tax advisors regarding the application of these requirements to your ownership of our shares.
In addition, certain U.S. Holders may be required to report additional information relating to an interest in our Ordinary Shares, subject to certain exceptions. You are urged to consult your tax advisors regarding your information reporting obligations, if any, with respect to your ownership and disposition of our Ordinary Shares.
Backup Withholding Tax
Generally, information reporting requirements will apply to distributions on our Ordinary Shares or proceeds on the disposition of our Ordinary Shares paid within the United States (and, in certain cases, outside the United States) to U.S. Holders other than certain exempt recipients, such as corporations. Furthermore, backup withholding may apply to such amounts if the U.S. Holder fails to (i) provide a correct taxpayer identification number, (ii) report interest and dividends required to be shown on its U.S. federal income tax return, or (iii) make other appropriate certifications in the required manner. U.S. Holders who are required to establish their exempt status generally must provide such certification on IRS Form W-9.
Backup withholding is not an additional tax. Amounts withheld as backup withholding from a payment may be credited against a U.S. Holder’s U.S. federal income tax liability and such U.S. Holder may obtain a refund of any excess amounts withheld by timely filing the appropriate claim for refund with the IRS and furnishing any required information in a timely manner.
THE SUMMARY OF CERTAIN MATERIALU.S. FEDERAL INCOME TAX CONSEQUENCES SET OUT ABOVE IS FOR GENERAL INFORMATIONAL PURPOSES ONLY. INVESTORS ARE URGED TO CONSULT THEIR TAX ADVISORS ABOUT THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE STATE, LOCAL, NON-U.S. AND OTHER TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES OR ADSs.
F. Dividends and Paying Agents
Not applicable.
G. Statements by Experts
Not applicable.
H. Documents on Display
You may read and copy this annual report on Form 20-F, including the related exhibits and schedules, and any document we file with the SEC through the SEC’s website at www.sec.gov.
As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Furthermore, as a foreign private issuer, we are also not subject to the requirements of Regulation FD (Fair Disclosure) promulgated under the Exchange Act. In addition, we are not be required under the Exchange Act to file annual or other reports and consolidated financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. Instead, we must file with the SEC, within 120 days after the end of each fiscal year, or such other applicable time as required by the SEC, an annual report on Form 20-F containing consolidated financial statements audited by an independent registered public accounting firm. We also intend to furnish certain other material information to the SEC under cover of Form 6-K.
83
We maintain a corporate website at www.medigus.com. Information contained on, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 20-F. We have included our website address in this annual report on Form 20-F solely as an inactive textual reference.
I. Subsidiary Information
Not applicable.
J. Annual Report to Security Holders
Not Applicable.
ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Market risk is the risk of loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely impact our consolidated financial position, results of operations or cash flows.
Risk of Interest Rate Fluctuation
Currently, our investments consist primarily of cash and cash equivalents and short-term bank deposits. We follow an investment policy that was set by our board of directors, pursuant to which we currently invest in tradable short term Israeli government loans or bank deposits. Our investments are exposed to market risk due to fluctuation in interest rates, which may affect our interest income and the fair market value of our investments. Our interest income is not material and a changes in interest rates would not have a significant impact on us. We manage this exposure by performing ongoing evaluations of our investments. Due to the short-term maturities of our investments to date, their carrying value has always approximated their fair value. It is our current policy to hold investments to maturity in order to limit our exposure to interest rate fluctuations.
Foreign Currency Exchange Risk
Our reporting and functional currency is the U.S. dollar. Our revenues are currently primarily payable in the U.S. dollars and Euros, and we expect our future revenues to be denominated primarily in U.S. dollars and Euros. However, certain amount of our expenses are in NIS and as a result, we are exposed to the currency fluctuation risks relating to the recording of our expenses in the U.S. dollars. We may, in the future, decide to enter into currency hedging transactions. These measures, however, may not adequately protect us from material adverse effects.
To date, we have not engaged in hedging transactions, however we hold our investments in both NIS and US dollars. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations.
Our interest rate risk exposure is in respect to bank deposits, which expose us to risk due to change in fair value interest rates. As of December 31, 2022, these deposits carried relatively low interest rates and under these low interest rates, reasonable changes in interest rates are expected have negligible impact on the fair value of these assets.
ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
A. Debt Securities.
Not applicable.
B. Warrants and rights.
Not applicable.
C. Other Securities.
Not applicable.
D. American Depositary Shares.
General
The following is a summary description of the ADSs and does not purport to be complete. Each ADS represents 15 Ordinary Shares (or a right to receive 15 Ordinary Shares) deposited with The Bank of New York Mellon, located in Manchester, as custodian for the Bank of New York Mellon as the Depositary. Each ADS also represents any other securities, cash or other property which may be held by the Depositary. The Depositary’s office at which the ADSs will be administered is located at 240 Greenwich Street, New York, New York 10286.
84
The form of the deposit agreement for the ADSs and the form of American Depositary Receipt (ADR) that represents an ADS as filed as exhibits to the Company’s registration statement on Form F-6 with the SEC on May 7, 2015, as amended on October 26, 2020. Copies of the deposit agreement are available for inspection at the principal office of the Bank of New York Mellon, located at 240 Greenwich Street, New York, New York 10286.
Fees and Expenses
Persons
depositing or withdrawing shares or ADS holders must pay: |
For: | ||
$5.00 (or less) per 100 ADSs (or portion of 100 ADSs) | ● | Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property | |
● | Cancellation of ADSs for the purpose of withdrawal, including if the deposit agreement terminates | ||
$0.05 (or less) per ADS | ● | Any cash distribution to ADS holders | |
A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs | ● | Distribution of securities distributed to holders of deposited securities which are distributed by the Depositary to ADS holders | |
$0.05 (or less) per ADS per calendar year | ● | Depositary services | |
Registration or transfer fees | ● | Transfer and registration of shares on our share register to or from the name of the Depositary or its agent when you deposit or withdraw shares | |
Expenses of the Depositary | ● | Cable, telex and facsimile transmissions (when expressly provided in the deposit agreement) | |
● | converting foreign currency to U.S. dollars | ||
Taxes and other governmental charges the Depositary or the custodian has to pay on any ADSs or shares underlying ADSs, such as stock transfer taxes, stamp duty or withholding taxes | ● | As necessary | |
Any charges incurred by the depositary or its agents for servicing the deposited securities | ● | As necessary |
The Depositary collects its fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The Depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The Depositary may collect its annual fee for depositary services by deduction from cash distributions or by directly billing investors or by charging the book-entry system accounts of participants acting for them. The Depositary may collect any of its fees by deduction from any cash distribution payable to ADS holders that are obligated to pay those fees. The Depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.
From time to time, the Depositary may make payments to us to reimburse and/or share revenue from the fees collected from ADS holders, or waive fees and expenses for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the ADS program. In performing its duties under the deposit agreement, the Depositary may use brokers, dealers or other service providers that are affiliates of the Depositary and that may earn or share fees or commissions.
Payment of Taxes
You will be responsible for any taxes or other governmental charges payable on your ADSs or on the deposited securities represented by any of your ADSs. The Depositary may refuse to register any transfer of your ADSs or allow you to withdraw the deposited securities represented by your ADSs until such taxes or other charges are paid. It may apply payments owed to you or sell deposited securities represented by your ADSs to pay any taxes owed and you will remain liable for any deficiency. If the Depositary sells deposited securities, it will, if appropriate, reduce the number of ADSs to reflect the sale and pay to ADS holders any proceeds, or send to ADS holders any property, remaining after it has paid the taxes.
85
PART II
ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
There are no defaults, dividend arrangements or delinquencies that are required to be disclosed.
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
Not applicable.
ITEM 15. CONTROLS AND PROCEDURES
(a) Disclosure controls and procedures
Our management, including our chief executive officer and chief financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2022. The term “disclosure controls and procedures”, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms of the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to the our management, including our chief executive officer and chief financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Based on the foregoing, our chief executive officer and chief financial officer have concluded that, as of December 31, 2022, our disclosure controls and procedures were effective.
(b) Management report on internal control over financial reporting
Our management, under the supervision of our chief executive officer and chief financial officer, is responsible for establishing and maintaining adequate internal control over our financial reporting. The Company’s internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act, means a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes policies and procedures that:
● | pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and asset dispositions. |
● | provide reasonable assurance that transactions are recorded as necessary to permit the preparation of our financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and |
● | provide reasonable assurance regarding the prevention or timely detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements. |
Due to its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management evaluated the effectiveness of our internal control over financial reporting as of December 31, 2022, based on the criteria established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this evaluation, our management concluded that, as of December 31, 2022, the Company’s internal control over financial reporting was not effective since a significant subsidiary of the Company, Gix Internet, whose financial statements were initially consolidated in March 2022, was excluded from management’s evaluation of the effectiveness of internal control over financial reporting as of December 31, 2022 due to post acquisition exclusion made by Viewbix, a subsidiary of Gix Internet in accordance with the SEC guidance during the fiscal year post acqusition. Gix Internet’s assets constitute 52% of the Company’s assets as of December 31, 2022.
(c) Attestation Report of the Registered Public Accounting Firm
Not applicable.
(d) Changes in internal control over financial reporting
Other than the changes to our internal control over financial reporting resulting from the consolidation of the financial statements of Gix Internet in March 2022, there were no changes in internal control over financial reporting during the year ended December 31, 2022, that have materially affected or are reasonably likely to materially affect the Company’s internal control over financial reporting.
86
ITEM 16. RESERVED
ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT
Our board of directors has determined that Mr. Eliyahu Yoresh is an audit committee financial expert as defined under the rules under the Exchange Act, and is independent in accordance with applicable Exchange Act rules and Nasdaq Stock Market rules.
ITEM 16B. CODE OF ETHICS
In March 2016, we adopted a written code of ethics and business conduct, which applies to all our directors, officers and employees, including without limitation our, Chief Executive Officer, Chief Financial Officer, and controller, or persons performing similar functions. This code of ethics is posted on our website, www.medigus.com.
ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES
Fees and services
Brightman Almagor Zohar and Co., Certified Public Accountant (Isr.), a firm in the Deloitte Global Network, has served as our principal independent registered public accounting firm for the years ended December 31, 2022, and 2021.
The following table provides information regarding consolidated fees related to Brightman Almagor Zohar and Co., for all services, including audit services, for the year ended December 31, 2022, and for the year ended December 31, 2021:
Year
Ended December 31, 2022 | Year
Ended December 31, 2021 | |||||||
(USD in thousands) | ||||||||
Audit fees(1) | 575 | 721 | ||||||
Audit-Related Fees(2) | 100 | 369 | ||||||
Tax fees(3) | 96 | 33 | ||||||
Total | 771 | 1,123 |
(1) | Includes professional services rendered in connection with the audit of our annual financial statements and the review of our interim financial statements. This category also includes services that generally the independent accountant provides, such as consents and assistance with and review of documents filed with the SEC.
For the year ended December 31, 2022, audit fee included are for Medigus, Eventer, Gix Internet and Jeffs’ Brands.
For the year ended December 31, 2021, audit fee included are for Medigus, ScoutCam, Eventer, Gix Internet and Jeffs’ Brands.
|
(2) | Includes mainly offering costs and related services by the principal accountant that are reasonably related to the performance of the audit or review of the registrant’s financial statements.
For the year ended December 31, 2022, audit related fee included Medigus, Eventer, Gix Internet and Jeffs’ Brands.
For the year ended December 31, 2021, audit related fee included for Medigus, Scoutcam, Jeffs’ Brands, and Eventer.
|
(3) | Represents fees for professional services rendered by our independent registered public accounting firm for tax compliance and tax advice on actual or contemplated transactions. |
Audit committee’s pre-approval policies and procedures
Our audit committee’s specific responsibilities in carrying out its oversight of the quality and integrity of the accounting, auditing and reporting practices of our Company include the approval of audit and non-audit services to be provided by the external auditor. The audit committee approves in advance the particular services or categories of services to be provided to us during the following yearly period and also sets forth a specific budget for such audit and non-audit services. Additional non-audit services may be pre-approved by the audit committee
87
ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES
None.
ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS
Not applicable.
ITEM 16F. CHANGE IN REGISTRANT’S CERTIFYING ACCOUNTANT
Not applicable.
ITEM 16G. CORPORATE GOVERNANCE
Nasdaq Stock Market Listing Rules and Home Country Practices
As a foreign private issuer, we are permitted to follow Israeli corporate governance practices instead of Nasdaq Marketplace rules, provided that we disclose which requirements we are not following and the equivalent Israeli requirement. We rely on this “foreign private issuer exemption” with respect to the following items:
● | Quorum. While the Marketplace Rules of the Nasdaq Stock Market require that the quorum for purposes of any meeting of the holders of a listed company’s common voting stock, as specified in the company’s bylaws, be no less than 33 1/3% of the company’s outstanding common voting stock, under Israeli law, a company is entitled to determine in its articles of association the number of shareholders and percentage of holdings required for a quorum at a shareholders meeting. Our amended and restated articles of association provide that a quorum of two or more shareholders holding at least 10% of the voting rights in person or by proxy is required for commencement of business at a general meeting so long as (i) such general meeting was initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii) at the time of such general meeting the Company is qualified to use the forms of a “foreign private issuer” under US securities laws. However, the quorum set forth in our amended and restated articles of association with respect to an adjourned meeting consists of any number of shareholders present in person or by proxy. |
● | Approval of Related Party Transactions. All related party transactions are approved in accordance with the requirements and procedures for approval of interested party acts and transactions, set forth in sections 268 to 275 of the Companies Law, and the regulations promulgated thereunder, which require the approval of the audit committee, the compensation committee, the board of directors and shareholders, as may be applicable, for specified transactions, rather than approval by the audit committee or other independent body of our board of directors as required under the Listing Rules of the Nasdaq Stock Market. |
● | Equity Compensation Plans. We do not necessarily seek shareholder approval for the establishment of, and amendments to, stock option or equity compensation plans (as set forth in Nasdaq Listing Rule 5635(c)), as such matters are not subject to shareholder approval under Israeli law. We will attempt to seek shareholder approval for our stock option or equity compensation plans (and the relevant annexes thereto) to the extent required in order to ensure they are tax qualified for our employees in the United States. However, even if such approval is not received, then the stock option or equity compensation plans will continue to be in effect, but we will not be able to grant options to our U.S. employees that qualify as Incentive Stock Options for U.S. federal tax purpose. Our stock option or other equity compensation plans are also available to our non-U.S. employees, and provide features necessary to comply with applicable non-U.S. tax laws. |
● | Shareholder approval. Rather than follow the Nasdaq rules requiring shareholder approval for the issuance of securities in certain circumstances, we follow Israeli law, under which a private placement of securities requires approval by our board of directors and shareholders if it will cause a person to become a controlling shareholder (generally presumed at 25% ownership) or if: (a) the securities issued amount to 20% or more of our outstanding voting rights before the issuance; (b) some or all of the consideration is other than cash or listed securities or the transaction is not on market terms; and (c) transaction will increase the relative holdings of a shareholder that holds 5% or more of our outstanding share capital or voting rights or will cause any person to become, as a result of the issuance, a holder of more than 5% of our outstanding share capital or voting rights. |
Otherwise, we comply with the rules generally applicable to U.S. domestic companies listed on the Nasdaq Stock Market. We may in the future decide to use the foreign private issuer exemption with respect to some or all of the other Nasdaq Marketplace Rules related to corporate governance. We also comply with Israeli corporate governance requirements under the Israeli Companies Law applicable to public companies.
ITEM 16H. MINE SAFETY DISCLOSURE
Not applicable.
ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS
Not Applicable.
88
PART III
ITEM 17. FINANCIAL STATEMENTS
Not applicable.
ITEM 18. FINANCIAL STATEMENTS
The consolidated financial statements and the related notes required by this Item are included in this annual report on Form 20-F beginning on page F-1.
ITEM 19. EXHIBITS
89
* | Filed herewith. |
** | Furnished herewith. |
*** | Certain confidential information contained in this exhibit, marked by brackets, was omitted because it is both (i) not material and (ii) would likely cause competitive harm to the Company if publicly disclosed. “[***]” indicates where the information has been omitted from this exhibit. |
† | Indicates management contract or compensatory plan or arrangement. |
Certain agreements filed as exhibits to this Annual Report contain representations and warranties that the parties thereto made to each other. These representations and warranties have been made solely for the benefit of the other parties to such agreements and may have been qualified by certain information that has been disclosed to the other parties to such agreements and that may not be reflected in such agreements. In addition, these representations and warranties may be intended as a way of allocating risks among parties if the statements contained therein prove to be incorrect, rather than as actual statements of fact. Accordingly, there can be no reliance on any such representations and warranties as characterizations of the actual state of facts. Moreover, information concerning the subject matter of any such representations and warranties may have changed since the date of such agreements.
90
SIGNATURE
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this registration statement on its behalf.
Medigus Ltd. | ||
Date: May 3, 2023 | By: | /s/ Liron Carmel |
Liron Carmel | ||
Chief Executive Officer | ||
By: | /s/ Tali Dinar | |
Tali Dinar | ||
Chief Financial Officer |
91
MEDIGUS LTD.
Index to Consolidated Financial Statements
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and the Board of Directors of Medigus Ltd.
Opinion on the Financial Statements
We have audited the accompanying consolidated statements of financial position of Medigus Ltd. and its subsidiaries (the “Company”) as of December 31, 2022, and 2021, and the related consolidated statements of income (loss) and other comprehensive income (loss), changes in equity and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and 2021, and the results of its operations and its cash flows for the each of the three years in the period ended December 31, 2022, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.
F-2
Business Combination - Initial Consolidation of Gix Internet Ltd. – Refer to Note 2C and 4F to the Consolidated Financial Statements
Critical Audit Matter Description
On March 1, 2022, the Company acquired a controlling interest in Gix Internet Ltd., an equity investee of the Company prior to the acquisition. The acquisition purchase price was approximately USD 7.7 million. The Company allocated the purchase price between tangible and intangible assets acquired and liabilities assumed based on estimated fair values, with the residual of the purchase price recorded as goodwill. The intangible assets identified in the acquisition were technology and customer relations.
Management estimated the fair value of these intangible assets using the income approach, which is based on the present value of the future cash flows attributable to each identifiable intangible asset. The income approach to valuation required management to make significant estimates and assumptions related to future cash flows and discount rates.
We identified the fair value of the intangible assets acquired as a critical audit matter because of the significant judgments, estimates and assumptions made by management to estimate their fair value. This required a high degree of auditor judgment and an increased extent of effort, in relation to our audit as whole, including the need to involve our fair value specialists when performing audit procedures to evaluate the reasonableness of future cash flows and discount rates.
How the Critical Audit Matter Was Addressed in the Audit
Our audit procedures related to the purchase price allocation included the following, among others:
● | We evaluated the reasonableness of management’s assumptions and forecasts of future cash flows by comparing these forecasts to historical results, as well as by testing the other underlying source information for accuracy and completeness. |
● | With the assistance of our fair value specialists, we evaluated the valuation methodologies and the reasonableness of the discount rates and royalty rates, including testing the mathematical accuracy of the calculations, and developing a range of independent estimates and comparing those to the discount and royalty rates selected by management. |
/s/ Brightman Almagor Zohar & Co.
Certified Public Accountants
A Firm in the Deloitte Global Network
Tel Aviv, Israel
May 3, 2023
We have served as the Company’s auditor since 2020.
F-3
(Concluded) - 1
MEDIGUS LTD.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
The accompanying notes are an integral part of these consolidated financial statements.
F-4
(Concluded) – 2
MEDIGUS LTD.
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(*) | Share and per share data in these financial statements have been retrospectively adjusted, for all periods presented, to reflect a number of shares that is equivalent to the number of shares of the Company post the Reverse Split (see note 14a(7)). |
The accompanying notes are an integral part of these consolidated financial statements.
F-5
MEDIGUS LTD.
CONSOLIDATED STATEMENTS OF INCOME/LOSS AND OTHER COMPREHENSIVE INCOME/LOSS
Year Ended December 31 | ||||||||||||||
Note | 2022 | 2021 | 2020 | |||||||||||
USD in thousands | ||||||||||||||
Revenue | 18 | |||||||||||||
Products | 5,861 | 8,933 | 491 | |||||||||||
Services | 85,997 | 1,185 | 40 | |||||||||||
91,858 | 10,118 | 531 | ||||||||||||
Cost of revenues: | 15 | |||||||||||||
Products | 5,059 | 4,938 | 988 | |||||||||||
Services | 72,347 | 379 | 46 | |||||||||||
77,406 | 5,317 | 1,034 | ||||||||||||
Gross profit (loss) | 14,452 | 4,801 | (503 | ) | ||||||||||
Research and development expenses | 15 | 4,853 | 1,045 | 997 | ||||||||||
Sales and marketing expenses | 15 | 4,006 | 1,988 | 471 | ||||||||||
General and administrative expenses | 15 | 14,174 | 9,964 | 5,494 | ||||||||||
Net change in fair value of financial assets at fair value through profit or loss | 5 | 2,544 | (713 | ) | (797 | ) | ||||||||
Share of net loss of associates accounted for using the equity method | 4B2 | 2,659 | 2,149 | 170 | ||||||||||
Amortization of excess purchase price of associates | 263 | 546 | ||||||||||||
Operating loss | (13,784 | ) | (9,895 | ) | (7,384 | ) | ||||||||
Gain upon loss of control in a subsidiary | 4C | (11,465 | ) | |||||||||||
Gain from initial recognition of assets and liabilities upon consolidation of Gix Internet | 4F | (2,300 | ) | |||||||||||
Loss (gain) from sale of investments | 4G | 127 | (2,025 | ) | ||||||||||
Other income | (45 | ) | (494 | ) | ||||||||||
Changes in fair value of warrants issued to investors | 5 | (159 | ) | (484 | ) | (338 | ) | |||||||
Changes in fair value of warrants issued to third party investors by a consolidated subsidiary | 4E | (3,619 | ) | 75 | ||||||||||
Financial (income) loss, net | 2,309 | 347 | (205 | ) | ||||||||||
Profit (loss) before taxes on income | (10,097 | ) | 4,151 | (6,841 | ) | |||||||||
Tax expense | 12 | (111 | ) | (105 | ) | (9 | ) | |||||||
Net profit (loss) for the year | (10,208 | ) | 4,046 | (6,850 | ) | |||||||||
Other comprehensive income | ||||||||||||||
Items that may be reclassified to profit or loss | ||||||||||||||
Share of other comprehensive income of consolidated subsidiaries and associates accounted for using the equity method | 460 | 191 | 8 | |||||||||||
Items that will not be reclassified to profit or loss | ||||||||||||||
Share of other comprehensive income (loss) of consolidated subsidiaries and associates accounted for using the equity method | (29 | ) | 27 | |||||||||||
Other comprehensive income for the year | 460 | 162 | 35 | |||||||||||
Total comprehensive income (loss) for the year | (9,748 | ) | 4,208 | (6,815 | ) | |||||||||
Net profit (loss) for the year is attributable to: | ||||||||||||||
Owners of Medigus | (9,815 | ) | 6,794 | (4,325 | ) | |||||||||
Non-controlling interests | (393 | ) | (2,748 | ) | (2,525 | ) | ||||||||
(10,208 | ) | 4,046 | (6,850 | ) | ||||||||||
Total comprehensive income (loss) for the year is attributable to: | ||||||||||||||
Owners of Medigus | (9,503 | ) | 6,881 | (4,278 | ) | |||||||||
Non-controlling interests | (245 | ) | (2,673 | ) | (2,537 | ) | ||||||||
(9,748 | ) | 4,208 | (6,815 | ) | ||||||||||
Earnings (Loss) per ordinary share attributed to Medigus ltd | ||||||||||||||
Basic | 16 | (0.4 | ) | 0.2 | (0.6 | ) | ||||||||
Diluted | 16 | (0.4 | ) | 0.2 | (0.6 | ) | ||||||||
Weighted average ordinary shares outstanding (in thousands) | ||||||||||||||
Basic | 24,385 | (*)23,036 | (*)6,672 | |||||||||||
Diluted | 24,385 | (*)23,036 | (*)6,672 |
(*) | Share and per share data in these financial statements have been retrospectively adjusted, for all periods presented, to reflect a number of shares that is equivalent to the number of shares of the Company post the Reverse Split (see note 14a(7)). |
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
F-6
MEDIGUS LTD.
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
Equity attributable to owners of Medigus Ltd. | ||||||||||||||||||||||||||||||||||||||||||||||
Note | Ordinary shares (*) | Share premium | Capital reserves from options granted | Other reserves | Capital reserves from transactions with non- controlling interests | Currency translation differences | Warrants | Accumulated deficit | Total | Non- controlling interests | Total equity | |||||||||||||||||||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||||||||||||||||||||||||
BALANCE AS OF JANUARY 1, 2022 | 110,562 | 2,579 | 634 | 10,408 | (1,002 | ) | 197 | (74,188 | ) | 49,190 | 2,243 | 51,433 | ||||||||||||||||||||||||||||||||||
Loss for the year | - | - | - | - | - | - | (9,815 | ) | (9,815 | ) | (393 | ) | (10,208 | ) | ||||||||||||||||||||||||||||||||
Other comprehensive income (loss) | - | 312 | 312 | 148 | 460 | |||||||||||||||||||||||||||||||||||||||||
TOTAL COMPREHENSIVE LOSS FOR THE YEAR | - | 312 | (9,815 | ) | (9,503 | ) | (245 | ) | (9,748 | ) | ||||||||||||||||||||||||||||||||||||
TRANSACTIONS WITH SHAREHOLDERS: | ||||||||||||||||||||||||||||||||||||||||||||||
Issuance of warrants and shares by Gix Internet | 4F | (567 | ) | (567 | ) | 682 | 115 | |||||||||||||||||||||||||||||||||||||||
Deemed contributions to Jeffs’ Brands | 4E | 148 | (598 | ) | (450 | ) | 743 | 293 | ||||||||||||||||||||||||||||||||||||||
Issuance of shares in consideration for investments | 4N, 4O | 900 | 900 | 900 | ||||||||||||||||||||||||||||||||||||||||||
Issuance of shares by Eventer | 4D | (12 | ) | (12 | ) | 11 | (1 | ) | ||||||||||||||||||||||||||||||||||||||
Consolidation of Gix Internet | 4F | (144 | ) | (144 | ) | 7,849 | 7,705 | |||||||||||||||||||||||||||||||||||||||
Subsidiaries’ share-based compensation to employees and service providers | 4D | 102 | 102 | |||||||||||||||||||||||||||||||||||||||||||
Share based compensation to employees and service providers | 14 | 685 | 685 | 685 | ||||||||||||||||||||||||||||||||||||||||||
Amendment of long-term related party payable by Eventer | 167 | 167 | 253 | 420 | ||||||||||||||||||||||||||||||||||||||||||
Issuance of shares and warrants by Jeffs’ Brands upon completion of IPO | 4E | 504 | 504 | 5,885 | 6,389 | |||||||||||||||||||||||||||||||||||||||||
Dividend | 14(d) | (1,583 | ) | (1,583 | ) | (1,583 | ) | |||||||||||||||||||||||||||||||||||||||
Dividends declared by subsidiaries | 4F | (2,021 | ) | (2,021 | ) | |||||||||||||||||||||||||||||||||||||||||
Reorganization transaction by Gix Internet | 4F | (46 | ) | (46 | ) | 46 | ||||||||||||||||||||||||||||||||||||||||
Expiration of options | 4 | (4 | ) | |||||||||||||||||||||||||||||||||||||||||||
TOTAL TRANSACTIONS WITH SHAREHOLDERS | 760 | 681 | 315 | (719 | ) | - | (1,583 | ) | (546 | ) | 13,550 | 13,004 | ||||||||||||||||||||||||||||||||||
BALANCE AS OF DECEMBER 31, 2022 | 111,322 | 3,260 | 949 | 9,689 | (690 | ) | 197 | (85,586 | ) | 39,141 | 15,548 | 54,689 |
(*) | Share and per share data in these financial statements have been retrospectively adjusted, for all periods presented, to reflect a number of shares that is equivalent to the number of shares of the Company post the Reverse Split (see note 14a(7)). |
The accompanying notes are an integral part of these consolidated financial statements.
F-7
MEDIGUS LTD.
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
Equity attributable to owners of Medigus Ltd. | ||||||||||||||||||||||||||||||||||||||||||||||
Note | Ordinary shares | Share premium | Capital reserves from options granted | Other reserves | Capital reserves from transactions with non- controlling interests | Currency translation differences | Warrants | Accumulated deficit | Total | Non- controlling interests | Total equity | |||||||||||||||||||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||||||||||||||||||||||||
BALANCE AS OF JANUARY 1, 2021 | 93,021 | 1,450 | 545 | 9,848 | (1,118 | ) | 197 | (80,982 | ) | 22,961 | 3,233 | 26,194 | ||||||||||||||||||||||||||||||||||
Income (Loss) for the year | - | - | - | - | - | - | - | 6,794 | 6,794 | (2,748 | ) | 4,046 | ||||||||||||||||||||||||||||||||||
Other comprehensive income | (29 | ) | 116 | 87 | 75 | 162 | ||||||||||||||||||||||||||||||||||||||||
TOTAL COMPREHENSIVE LOSS FOR THE YEAR | (29 | ) | 116 | 6,794 | 6,818 | (2,673 | ) | 4,208 | ||||||||||||||||||||||||||||||||||||||
TRANSACTIONS WITH SHAREHOLDERS: | ||||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares and warrants | 14 | 49,398 | (32,062 | ) | 17,336 | 17,336 | ||||||||||||||||||||||||||||||||||||||||
Cancellation of par value | 14 | (142,419 | ) | 142,419 | ||||||||||||||||||||||||||||||||||||||||||
Consolidation of Jeffs’ Brands | 4E | 71 | 71 | 1,156 | 1,227 | |||||||||||||||||||||||||||||||||||||||||
Exercise of warrants issued by ScoutCam | 4C | 264 | 264 | 518 | 782 | |||||||||||||||||||||||||||||||||||||||||
Issuance of shares by Eventer | 4D | 717 | 717 | 1,138 | 1,855 | |||||||||||||||||||||||||||||||||||||||||
Loss of control in ScoutCam | 4C | (2,760 | ) | (2,760 | ) | |||||||||||||||||||||||||||||||||||||||||
Deemed contributions to Jeffs’ Brands | 4E | 108 | (421 | ) | (313 | ) | 529 | 216 | ||||||||||||||||||||||||||||||||||||||
Deemed contribution to an affiliate | 4F | 10 | 10 | 10 | ||||||||||||||||||||||||||||||||||||||||||
Expiration of options | 74 | (74 | ) | |||||||||||||||||||||||||||||||||||||||||||
Subsidiaries’ share-based compensation to employees and service providers | 4C, 4I, 4E, 4D | 1,102 | 1,102 | |||||||||||||||||||||||||||||||||||||||||||
Share based compensation to employees and service providers | 14 | 60 | 1,203 | 1,263 | 1,263 | |||||||||||||||||||||||||||||||||||||||||
TOTAL TRANSACTIONS WITH SHAREHOLDERS | (93,021 | ) | 110,562 | 1,129 | 118 | 560 | 19,348 | 1,683 | 21,031 | |||||||||||||||||||||||||||||||||||||
BALANCE AS OF DECEMBER 31, 2021 | 110,562 | 2,579 | 634 | 10,408 | (1,002 | ) | 197 | (74,188 | ) | 49,190 | 2,243 | 51,433 |
The accompanying notes are an integral part of these consolidated financial statements.
F-8
MEDIGUS LTD.
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
Equity attributable to owners of Medigus Ltd. | ||||||||||||||||||||||||||||||||||||||||||||||
Note | Ordinary shares | Share premium | Capital reserves from options granted | Other reserves | Capital reserves from transactions with non- controlling interests | Currency translation differences | Warrants | Accumulated deficit | Total | Non- controlling interests | Total equity | |||||||||||||||||||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||||||||||||||||||||||||
BALANCE AS OF JANUARY 1, 2020 | 22,802 | 47,873 | 1,351 | 525 | 11,761 | (1,145 | ) | 197 | (76,657 | ) | 6,707 | 1,424 | 8,131 | |||||||||||||||||||||||||||||||||
Loss for the year | - | (4,325 | ) | (4,325 | ) | (2,525 | ) | (6,850 | ) | |||||||||||||||||||||||||||||||||||||
Other comprehensive income | 20 | 27 | 47 | (12 | ) | 35 | ||||||||||||||||||||||||||||||||||||||||
TOTAL COMPREHENSIVE LOSS FOR THE YEAR | 20 | 27 | (4,325 | ) | (4,278 | ) | (2,537 | ) | (6,815 | ) | ||||||||||||||||||||||||||||||||||||
TRANSACTIONS WITH SHAREHOLDERS: | ||||||||||||||||||||||||||||||||||||||||||||||
Purchase of a subsidiary | 381 | 381 | ||||||||||||||||||||||||||||||||||||||||||||
Issuance of shares and warrants | 14 | 53,278 | (35,369 | ) | (3,766 | ) | 3,632 | 17,775 | 17,775 | |||||||||||||||||||||||||||||||||||||
Exercise of warrants | 16,941 | (12,596 | ) | (3,632 | ) | 713 | 713 | |||||||||||||||||||||||||||||||||||||||
Issuance of shares and warrants by the Subsidiary | 1,956 | 1,956 | 2,632 | 4,588 | ||||||||||||||||||||||||||||||||||||||||||
Conversion into shares and warrants of loan granted to the Subsidiary | (136 | ) | (136 | ) | 136 | |||||||||||||||||||||||||||||||||||||||||
Share in capital reserve of an associate | 33 | 33 | 33 | |||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation in connection with options granted to employees and service providers | 14 | 191 | 191 | 1,197 | 1,388 | |||||||||||||||||||||||||||||||||||||||||
Expiration of options | 92 | (92 | ) | |||||||||||||||||||||||||||||||||||||||||||
TOTAL TRANSACTIONS WITH SHAREHOLDERS | 70,219 | (47,873 | ) | 99 | (1,913 | ) | 20,532 | 4,346 | 24,878 | |||||||||||||||||||||||||||||||||||||
BALANCE AS OF DECEMBER 31, 2020 | 93,021 | 1,450 | 545 | 9,848 | (1,118 | ) | 197 | (80,982 | ) | 22,961 | 3,233 | 26,194 |
The accompanying notes are an integral part of these consolidated financial statements.
F-9
(Continued) – 1
MEDIGUS LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
The accompanying notes are an integral part of these consolidated financial statements.
F-10
(Continued) – 2
MEDIGUS LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
APPENDIX A TO THE CONSOLIDATED STATEMENTS OF CASH FLOWS:
The accompanying notes are an integral part of these consolidated financial statements.
F-11
MEDIGUS LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
For the year ended December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
USD in thousands | ||||||||||||
Right of use assets obtained in exchange for lease liabilities | 152 | |||||||||||
Non-cash investment in Gix Internet and Gix Media (note 4F) | 4,417 | |||||||||||
Issuance of shares in exchange for media and advertising services rights (note 4E) | 1,250 | |||||||||||
Purchase of a software license on credit (note 4D) | 35 | 1,346 | ||||||||||
Increase in Screenz payable balance due to modification into a debt (note 4D) | - | 115 | - | |||||||||
Deferred offering costs included in other current liabilities | - | 423 | - | |||||||||
Dividend included in other payables | 580 | - | ||||||||||
Decrease in long-term related party payable in exchange for advertising services (note 4D) | 656 | |||||||||||
Substantial modification of shareholders loans recorded in equity (note 4E) | 222 | - | ||||||||||
Issuance of ordinary shares upon conversion of shareholders loans (note 4E) | 587 | |||||||||||
Non-cash investment in Laminera (note 4N) | 400 | |||||||||||
Non-cash investment in ClearMind (note 4O) | 500 |
APPENDIX B TO THE CONSOLIDATED STATEMENTS OF CASH FLOWS:
APPENDIX C TO THE CONSOLIDATED STATEMENTS OF CASH FLOWS:
As of March 31, 2021 | ||||
USD in thousands | ||||
Deconsolidation of ScoutCam upon loss of control: | ||||
Net working capital other than cash | 340 | |||
Property and equipment, net | (370 | ) | ||
Lease liability- long term | 144 | |||
ScoutCam investment at fair value | 11,843 | |||
ScoutCam warrants | 97 | |||
Derecognition of non-controlling interests | 2,760 | |||
Gain arising from deconsolidation upon loss of control | (11,562 | ) | ||
Net cash deconsolidated upon loss of control | 3,252 |
F-12
MEDIGUS LTD.
CONSOLIDATED STATEMENTS OF CASH FLOWS
APPENDIX D TO THE CONSOLIDATED STATEMENTS OF CASH FLOWS:
As of January 04, 2021 | ||||
USD in thousands | ||||
Consolidation of Jeffs’ Brands upon gain of control: | ||||
Net working capital other than cash and inventory | (1,576 | ) | ||
Intangible assets | 1,312 | |||
Related party loans fair value adjustment | 98 | |||
Inventory | 778 | |||
Deferred tax liability | (188 | ) | ||
Non-controlling interests | (1,156 | ) | ||
Non-cash consideration | (71 | ) | ||
Goodwill | 563 | |||
Net cash acquired | (240 | ) |
APPENDIX E TO THE CONSOLIDATED STATEMENTS OF CASH FLOWS:
February 28, | ||||
2022 | ||||
Consolidation of Gix Internet upon gain of control: | ||||
Net working capital other than cash | 646 | |||
Intangible assets | 17,705 | |||
Accrued severance pay, net | (125 | ) | ||
Derecognition of investments accounted for using the equity method | (4,606 | ) | ||
Deferred taxes | (1,999 | ) | ||
Rights of use assets, property and equipment, net | 888 | |||
Lease liabilities | (570 | ) | ||
Non-controlling interests | (7,849 | ) | ||
Short- term borrowings | (6,296 | ) | ||
Long- term borrowings | (6,394 | ) | ||
Goodwill | 8,164 | |||
Gain arising from consolidation upon gain of control | (2,300 | ) | ||
Net cash acquired | (2,736 | ) |
F-13
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – GENERAL
A. | Medigus Ltd. (the “Company” or “Medigus”) was incorporated in Israel on December 9, 1999. The Company’s registered office and principal place of business are located in Israel. The address of its registered office is Hanehoshet 10, 4th Floor, Tel-Aviv POB 6971072, Israel. |
The Company, together with its subsidiaries and associates, operates in the technology sector, focusing on medical-related devices and products (through its associate Polyrizon), on visualization and AI based solutions (through its associate ScoutCam), on internet related activities (through its subsidiaries Eventer and Gix Internet), on e-commerce (through its subsidiary Jeffs’ Brands), on safety systems for commercial drones (through its associate Parazero), on energy efficiency technology (through its associate Laminera) and on the electric vehicle sector (through its subsidiary Charging Robotics).
Additionally, through its corporate, the Company is engaged in the licensing of intellectual property relating to its legacy product, the Medigus Ultrasonic Surgical Endostapler (“MUSE”), to Golden Grand Medical Instruments Ltd., a China based medical services provider, and in the investment of its excess cash resources, primarily in equity securities.
“Group” – the Company together with, Jeffs’ Brands Ltd., Charging Robotics Ltd., GERD IP, Inc., Eventer Technologies Ltd. and Gix Internet Ltd.
“Subsidiaries” – entities under the control of the Company.
ScoutCam Inc.
ScoutCam Inc (“ScoutCam”) has executed a number of capital raising transactions during 2021 and 2023, of which the last was a private placement that occurred on March 21, 2023 (see note 21(4)). The private placement during 2021 diluted the Company’s holdings in ScoutCam and lead to a deconsolidation of ScoutCam and the remaining holdings were accounted for under the equity method. The private placement during 2023 diluted the Company’s holdings in ScoutCam and the remaining holdings were accounted for as investment at fair value through profit or loss (FVTPL). For additional information, see note 4C.
GERD IP Inc.
On January 13, 2020, together with the Company’s advisor Mr. Kfir Zilberman, the Company formed a subsidiary in Delaware, of which the Company holds 90% of the stock capital, under the name GERD IP Inc. (“GERD IP”). The Company transferred certain of its patents in consideration for seven capital notes issued to the Company by GERD IP in the amount of USD 2,000 thousand each. For additional information, see note 4Q.
Eventer Technologies Ltd.
As of December 31, 2022, the Company holds approximately 46.21% of the issued and outstanding share capital of Eventer Technologies Ltd. (“Eventer”). Eventer is a technology company engaged in the development of tools for automatic creation, management, promotion, and billing of events and ticketing sales. For additional information, see note 4D.
F-14
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – GENERAL: (continued)
A. | (continued) |
Gix Internet Ltd.
On February 28, 2022, the Company purchased additional shares of Gix Internet Ltd. (“Gix Internet”) and the Company holdings interests in Gix Internet increased to 38.03% and as of this date the Company started to consolidate Gix Internet.
As of December 31, 2022, the Company holds 42.25% of the issued and outstanding share capital of Gix Internet. For additional information, see note 4F.
Charging Robotics Ltd.
On January 7, 2021, the Company entered into an agreement to purchase a provisional patent filed with the United States Patent and Trademark Office and know-how relating to wireless vehicle battery charging technology. Furthermore, the Company entered into a collaboration agreement with the seller, whereby the Company committed to invest in a newly incorporated wholly owned subsidiary of the Company, Charging Robotics Ltd. (“Charging Robotics”), incorporated on February 1, 2021, which will focus on the Company’s new electric vehicle and wireless charging activities. On February 19, 2021, the Company entered into a venture agreement with Amir Zaid, Weijian Zhou and Charging Robotics, under which the Company formed a venture, under the name Revoltz Ltd., or Revoltz, to develop and commercialize three modular electric vehicle (EV) micro mobility vehicles for urban individual use and “last mile” cargo delivery. For additional information, see note 4I.
Jeffs’ Brands Ltd.
On October 8, 2020, the Company entered into a common stock purchase agreement with Smart Repair Pro, Inc. (“Pro”), Purex, Corp. (“Purex”), and their respective stockholders (the “Pro and Purex SPA”). Pro and Purex both are in the e-Commerce field and operate online stores for the sale of various consumer products on the Amazon online marketplace. The transactions contemplated in the Pro and Purex SPA closed on January 4, 2021.
On May 16, 2021, the Company entered into a stock exchange and plan of restructuring agreement with Victor Hakmon, the other shareholder of Pro and Purex, and Jeffs’ Brands Ltd. (“Jeffs’ Brands”), a newly incorporated entity, pursuant to which, among other things, the Company and Victor Hakmon transferred all their holdings in Pro and Purex to Jeffs’ Brands, in return for a consideration of Jeffs’ Brands ordinary shares that were issued respectively. As a result, Pro and Purex became wholly owned subsidiaries of Jeffs’ Brands.
On August 30, 2022, as a result of an initial public offering of Jeffs’ Brands (“IPO”), and the closing of a portion of the underwriter’s over-allotment option, Jeffs’ Brands received aggregate gross proceeds of approximately USD 15.5 million before deducting underwriting discounts and other estimated offering expenses.
As of December 31, 2022, the Company holds 35.94% of the issued and outstanding share capital of Jeffs’ Brands. For additional information, see note 4E.
F-15
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – GENERAL: (continued)
A. | (continued) |
Interests in other entities
As of December 31, 2022, the Company also holds 40.35% in Parazero Technologies Ltd. (“Parazero”) (see note 4M), 37.03% in Polyrizon Ltd. (“Polyrizon”) (see note 4H), 35.06% in Fuel Doctor Holding Inc. (“Fuel Doctor”) (see note 4L), 19.7% in Laminera Flow Optimization Ltd. (“Laminera”) (formerly known as ABI Energy Ltd.) (see note 4N), 5.72% in Elbit Imaging Ltd. (“Elbit Imaging”) (see note 4J), 6.46% in Automax Ltd. (“Automax”) (formerly known as Matomy Ltd.) (see note 4G), 5.77% in ClearMind Medicine, Inc. (“ClearMind”) (see note 4O), 1.6% in SciSparc Ltd. (“SciSparc”) (see note 4K), 2.35% in Safee Cyber Technologies Ltd. (“Safee”) (see note 4P), 1.28% in Maris-Tech Ltd. (“Maris”), 0.97% in Colugo Systems Ltd. (“Colugo”), 0.47% in Safe Foods, Inc. ( “SAFO”) and 0.67% in Tondo Smart Ltd. (“Tondo”) and 1.49% in Bubbles Intergroup Ltd. (“Bubbles”).
The Company’s ordinary shares were listed on the Tel Aviv Stock Exchange Ltd. (“TASE”) from February 2006 until January 25, 2021, when the Company voluntarily delisted its shares from trading on the TASE. As of May 20, 2015, the Company’s American Depository Shares (“ADSs”) evidenced by American Depositary Receipts (“ADRs”) are listed on the Nasdaq Capital Market. The Company’s depositary agent for the ADR program is the Bank of New York Mellon. The Company’s Series C Warrants have been traded on Nasdaq Capital Market since July 2018.
B. | As of the approval date of these financial statements, the Company has cash and cash equivalents in the amount of USD 4.9 million. The Company anticipates such cash and cash equivalents will provide sufficient liquidity for more than a twelve-month period from the date of these financial statements. |
However, since inception, the Company’s activities have been funded mainly by its shareholders. Furthermore, in the recent years the Company has suffered recurring losses from operations, negative cash flows from operating activities, and has an accumulated deficit as of December 31, 2022. As such, the Company’s ability to continue operating may be dependent on several factors, amongst which is its ability to raise sufficient additional funding, which funding may not necessarily be available to the Company, obtained on terms favorable to the Company, or provide the Company with sufficient funds to meet its objectives.
C. | Russia-Ukraine War |
In late February 2022, Russia invaded Ukraine. As military activity proceeds and sanctions, export controls and other measures are imposed against Russia, Belarus and specific areas of Ukraine, the war is increasingly affecting the global economy and financial markets, as well as exacerbating ongoing economic challenges, including rising inflation and global supply-chain disruption. Although the group do not have direct suppliers based in Russia or Ukraine, additional supply delays and possible shortages of critical components may arise as the conflict progresses and if certain suppliers’ operations and/or subcomponent supply from affected countries are disrupted further.
F-16
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES:
A. | Basis of accounting |
The financial statements of the Group have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).
The financial statements have been prepared on the historical cost basis, except for the revaluation of certain financial instruments that are measured at revalued amounts or fair values at the end of each reporting period, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for goods and services.
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of IFRS 2, leasing transactions that are within the scope of IFRS 16, and measurements that have some similarities to fair value but are not fair value, such as net realizable value in IAS 2 Inventories or value in use in IAS 36 Impairment of Assets.
The consolidated financial statements were authorized for issuance by the Board of Directors on May 3, 2023.
The significant accounting policies set out below have been consistently applied to in the preparation of these consolidated financial statements for all years presented, unless otherwise stated.
B. | Basis of consolidation |
The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company (its subsidiaries) made up to 31 December each year. Control is achieved when the Company:
● | Has the power over the investee. |
● | Is exposed, or has rights, to variable returns from its involvement with the investee. |
● | Has the ability to use its power to affect its returns. |
The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.
When the Company has less than a majority of the voting rights of an investee, it considers that it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company’s voting rights in an investee are sufficient to give it power, including:
● | The size of the Company’s holding of voting rights relative to the size and dispersion of holdings of the other vote holders. |
● | Potential voting rights held by the Company, other vote holders or other parties. |
● | Rights arising from other contractual arrangements. |
● | Any additional facts and circumstances that indicate that the Company has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders’ meetings. |
F-17
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
B. | Basis of consolidation (continued) |
Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, the results of subsidiaries acquired or disposed of during the year are included in the consolidated statements of income/loss and other comprehensive income/loss from the date the Company gains control until the date when the Company ceases to control the subsidiary.
Where necessary, adjustments are made to the financial statements of subsidiaries to bring the accounting policies used into line with the Group’s accounting policies.
All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between the members of the Group are eliminated on consolidation.
Non-controlling interests in subsidiaries are identified separately from the Group’s equity therein. Those interests of non-controlling shareholders that are present ownership interests entitling their holders to a proportionate share of net assets upon liquidation may initially be measured at fair value or at the non-controlling interests’ proportionate share of the fair value of the acquiree’s identifiable net assets. The choice of measurement is made on an acquisition-by-acquisition basis. Other non-controlling interests are initially measured at fair value. Subsequent to acquisition, the carrying amount of non-controlling interests is the amount of those interests at initial recognition plus the non-controlling interests’ share of subsequent changes in equity.
Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. Total comprehensive income of the subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.
Changes in the Group’s interests in subsidiaries that do not result in a loss of control are accounted for as equity transactions. The carrying amount of the Group’s interests and the non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiaries. Any difference between the amount by which the noncontrolling interests are adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the Company.
When the Group loses control of a subsidiary, the gain or loss on disposal recognized in profit or loss is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), less liabilities of the subsidiary and any non-controlling interests. All amounts previously recognized in other comprehensive income in relation to that subsidiary are accounted for as if the Group had directly disposed of the related assets or liabilities of the subsidiary (i.e., reclassified to profit or loss or transferred to another category of equity as required/permitted by applicable IFRS Accounting Standards). The fair value of any investment retained in the former subsidiary at the date when control is lost is regarded as the fair value on initial recognition for subsequent accounting under IFRS 9 Financial Instruments when applicable, or the cost on initial recognition of an investment in an associate.
C. | Business combinations |
Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of assets transferred by the Group, liabilities incurred by the Group to the former owners of the acquiree and the equity interest issued by the Group in exchange for control of the acquiree. Acquisition-related costs are recognized in profit or loss as incurred.
At the acquisition date, the identifiable assets acquired and the liabilities assumed are recognized at their fair value at the acquisition date, except that:
● | Deferred tax assets or liabilities and assets or liabilities related to employee benefit arrangements are recognized and measured in accordance with IAS 12 Income Taxes and IAS 19 Employee Benefits respectively |
● | Liabilities or equity instruments related to share-based payment arrangements of the acquiree or share-based payment arrangements of the Group entered into to replace share-based payment arrangements of the acquiree are measured in accordance with IFRS 2 at the acquisition date (see below) |
● | Assets (or disposal groups) that are classified as held for sale in accordance with IFRS 5 Non-current Assets Held for Sale and Discontinued Operations are measured in accordance with that Standard. |
F-18
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
C. | Business combinations (continued) |
Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer’s previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. If, after reassessment, the net of the acquisition-date amounts of the identifiable assets acquired and liabilities assumed exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer’s previously held interest in the acquiree (if any), the excess is recognized immediately in profit or loss as a bargain purchase gain.
A contingent consideration incurred in a business combination is included as part of the acquisition price and recorded at a probability weighted assessment of the fair value as of the acquisition date. The fair value of the contingent consideration is re-measured at each reporting period, with any adjustments in fair value recognized in earnings under general and administrative expenses.
When the consideration transferred by the Group in a business combination includes a contingent consideration arrangement, the contingent consideration is measured at its acquisition-date fair value and included as part of the consideration transferred in a business combination. Changes in fair value of the contingent consideration that qualify as measurement period adjustments are adjusted retrospectively, with corresponding adjustments against goodwill. Measurement period adjustments are adjustments that arise from additional information obtained during the ‘measurement period’ (which cannot exceed one year from the acquisition date) about facts and circumstances that existed at the acquisition date.
The subsequent accounting for changes in the fair value of the contingent consideration that do not qualify as measurement period adjustments depends on how the contingent consideration is classified. Contingent consideration that is classified as equity is not remeasured at subsequent reporting dates and its subsequent settlement is accounted for within equity. Other contingent consideration is remeasured to fair value at subsequent reporting dates with changes in fair value recognized in profit or loss.
D. | Goodwill |
Goodwill is initially recognized and measured as set out above.
Goodwill is not amortized but is reviewed for impairment at least annually. For the purpose of impairment testing, goodwill is allocated to each of the Group’s cash-generating units (or groups of cash-generating units) expected to benefit from the synergies of the combination. Cash-generating units to which goodwill has been allocated are tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit. An impairment loss recognized for goodwill is not reversed in a subsequent period.
On disposal of a cash-generating unit, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.
The Group’s policy for goodwill arising on the acquisition of an associate is described below.
F-19
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
E. | Investments in associates |
An associate is an entity over which the Group has significant influence. Significant influence is the power to participate in the financial and operating policy decisions of the investee. The Group is presumed to have significant influence when it holds 20 percent or more of the voting rights of an investee, unless it can be clearly demonstrated that this is not the case. The Group does not control its associates.
The results and assets and liabilities of associates are incorporated in these financial statements using the equity method of accounting, except when the investment is classified as held for sale, in which case it is accounted for in accordance with IFRS 5.
Under the equity method, an investment in an associate is recognized initially in the consolidated statements of financial position at cost and adjusted thereafter to recognize the Group’s share of the profit or loss and other comprehensive income of the associate. Dividends received or receivable from associates are recognized as a reduction in the carrying amount of the investment. When the Group’s share of losses of an associate or exceeds the Group’s interest in that associate (which includes any long-term interests that, in substance, form part of the Group’s net investment in the associate), the Group discontinues recognizing its share of further losses. Additional losses are recognized only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the associate.
An investment in an associate is accounted for using the equity method from the date on which the investee becomes an associate. On acquisition of the investment in an associate, any excess of the cost of the investment over the Group’s share of the net fair value of the identifiable assets and liabilities of the investee is recognized as goodwill, which is included within the carrying amount of the investment. Any excess of the Group’s share of the net fair value of the identifiable assets and liabilities over the cost of the investment, after reassessment, is recognized immediately in profit or loss in the period in which the investment is acquired.
If there is objective evidence that the Group’s net investment in an associate is impaired, the requirements of IAS 36 are applied to determine whether it is necessary to recognize any impairment loss with respect to the Group’s investment. When necessary, the entire carrying amount of the investment (including goodwill) is tested for impairment in accordance with IAS 36 as a single asset by comparing its recoverable amount (higher of value in use and fair value less costs of disposal) with its carrying amount. Any impairment loss recognized is not allocated to any asset, including goodwill that forms part of the carrying amount of the investment. Any reversal of that impairment loss is recognized in accordance with IAS 36 to the extent that the recoverable amount of the investment subsequently increases.
The Group discontinues the use of the equity method from the date when the investment ceases to be an associate. When the Group retains an interest in the former associate and the retained interest is a financial asset, the Group measures the retained interest at fair value at that date and the fair value is regarded as its fair value on initial recognition in accordance with IFRS 9. The difference between the carrying amount of the associate at the date the equity method was discontinued, and the fair value of any retained interest and any proceeds from disposing of a part interest in the associate is included in the determination of the gain or loss on disposal of the associate. In addition, the Group accounts for all amounts previously recognized in other comprehensive income in relation to that associate on the same basis as would be required if that associate had directly disposed of the related assets or liabilities. Therefore, if a gain or loss previously recognized in other comprehensive income by that associate would be reclassified to profit or loss on the disposal of the related assets or liabilities, the Group reclassifies the gain or loss from equity to profit or loss (as a reclassification adjustment) when the associate is disposed of.
When the Group reduces its ownership interest in an associate but the Group continues to use the equity method, the Group reclassifies to profit or loss the proportion of the gain or loss that had previously been recognized in other comprehensive income relating to that reduction in ownership interest if that gain or loss would be reclassified to profit or loss on the disposal of the related assets or liabilities.
When a Group entity transacts with an associate of the Group, profits and losses resulting from the transactions with the associate are recognized in the Group’s consolidated financial statements only to the extent of interests in the associate that are not related to the Group.
F-20
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
F. | Foreign currencies |
The functional currency and the presentation currency
The reporting and functional currency of the Company and each of its subsidiaries, GERD IP, Charging Robotics and Jeffs’ Brands is USD while Eventer and Gix Internet is NIS.
The consolidated financial statements are presented in USD and rounded to the nearest thousand.
The consolidation of Gix Internet’s and Eventer’s financial statements is accounted for as a foreign operation using IAS 21, the Effects of Changes in Foreign Exchange Rates.
Transactions and balances
In preparing the financial statements of the Group entities, transactions in currencies other than the entity’s functional currency (“Foreign Currencies”) are recognized at the rates of exchange prevailing on the dates of the transactions. At each reporting date, monetary assets and liabilities that are denominated in Foreign Currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in Foreign Currencies are translated at the rates prevailing at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.
Exchange differences are recognized in profit or loss in the period in which they arise.
Foreign Operations
For the purpose of presenting consolidated financial statements, the assets and liabilities of the Group’s foreign operations are translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the date of transactions are used. Exchange differences arising, if any, are recognized in other comprehensive income and accumulated in a foreign exchange translation reserve (attributed to non-controlling interests as appropriate).
On the disposal of a foreign operation (i.e. a disposal of the Group’s entire interest in a foreign operation, or a disposal involving loss of control over a subsidiary that includes a foreign operation or a partial disposal of an interest in an associate that includes a foreign operation of which the retained interest becomes a financial asset), all of the exchange differences accumulated in a foreign exchange translation reserve in respect of that operation attributable to the owners of the Company are reclassified to profit or loss.
In addition, in relation to a partial disposal of a subsidiary that includes a foreign operation that does not result in the Group losing control over the subsidiary, the proportionate share of accumulated exchange differences is re-attributed to non-controlling interests and are not recognized in profit or loss. For all other partial disposals (i.e., partial disposals of associates that do not result in the Group losing significant influence), the proportionate share of the accumulated exchange differences is reclassified to profit or loss.
Goodwill and fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and translated at the closing rate. Exchange differences arising are recognized in other comprehensive income.
F-21
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
G. | Property and equipment |
Property and equipment are initially recognized at purchased cost. Subsequent costs are included in the asset’s carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of replaced items is derecognized. All other repairs and maintenance are charged to profit or loss during the financial period in which they are incurred.
Property and equipment are measured at cost less accumulated depreciation and accumulated impairment loss.
Depreciation is calculated using the straight-line method over the estimated useful life of the asset as follows:
Machinery and equipment | 6 – 10 years (primarily 10) | |
Leasehold improvements and furniture | 7 – 14 years | |
Computers and programs | 3 years |
Leasehold improvements are depreciated using the straight-line method over the shorter of the term of the lease or the estimated useful lives of the assets.
The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.
An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from the continued use of the asset. The gain or loss arising on the disposal or retirement of an asset is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognized in profit or loss.
H. | Financial instruments |
Financial assets and financial liabilities are recognized in the Group’s consolidated statements of financial position when the Group becomes a party to the contractual provisions of the instrument.
Financial assets and financial liabilities are initially measured at fair value, except for trade receivables that do not have a significant financing component which are measured at transaction price. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognized immediately in profit or loss.
Financial assets
Classification
The Group classifies its financial assets in the following measurement categories:
● | those to be measured subsequently at fair value through profit or loss, and |
● | those to be measured at amortized cost. |
The classification depends on the entity’s business model for managing the financial assets and the contractual terms of the cash flows.
For assets measured at fair value, gains and losses will be recorded in profit or loss.
F-22
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
H. | Financial instruments (continued) |
Recognition
Regular way purchases and sales of financial assets are recognized on trade date, being the date on which the Group commits to purchase or sell the asset. Financial assets are derecognized when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.
Measurement
At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (“FVTPL”), transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVTPL are expensed in profit or loss.
Financial assets with embedded derivatives are considered in their entirety when determining whether their cash flows are solely payment of principal and interest.
Debt instruments
Subsequent measurement of investments in debt instruments depends on the Group’s business model for managing the asset and the cash flow characteristics of the asset. There are two measurement categories into which the Group classifies its investments in debt instruments:
● | Amortized cost: Financial assets are measured at amortized cost if both of the following conditions are met: |
- | the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and |
- | the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. |
Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognized directly in profit or loss and presented in other gains/(losses) together with foreign exchange gains and losses.
● | Fair value through profit or loss: A gain or loss on a debt investment that is subsequently measured at FVTPL is recognized in profit or loss and presented net within other gains/(losses) in the period in which it arises. |
Equity instruments
The Group subsequently measures investments in equity instruments at fair value through profit or loss except when the Group has control or significant influence. Dividends from such investments continue to be recognized in profit or loss as other income when the Group’s right to receive payments is established.
Changes in the fair value of financial assets at FVTPL are recognized in “net change in fair value of financial assets at fair value through profit or loss” in the Consolidated statements of loss and other comprehensive loss, as applicable.
F-23
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
H. | Financial instruments (continued) |
Impairment of financial assets
The Group recognizes a loss allowance for expected credit losses on financial assets at amortized cost.
At each reporting date, the Group assesses whether the credit risk on a financial instrument has increased significantly since initial recognition. If the financial instrument is determined to have a low credit risk at the reporting date, the Company assumes that the credit risk on a financial instrument has not increased significantly since initial recognition.
The Group measures the loss allowance for expected credit losses on trade receivables and on financial instruments for which the credit risk has increased significantly since initial recognition based on lifetime expected credit losses based on information available on their credit condition, current aging, historical experience, future economic and market conditions. The Group has determined that the estimates of current and expected credit losses are immaterial.
Derecognition of financial assets
The Group derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another entity. If the Group neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Group recognizes its retained interest in the asset and an associated liability for amounts it may have to pay. If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the Group continues to recognize the financial asset and also recognizes a collateralized borrowing for the proceeds received.
On derecognition of a financial asset measured at amortized cost, the difference between the asset’s carrying amount and the sum of the consideration received and receivable is recognized in profit or loss.
Financial liabilities and equity
Classification as debt or equity
Debt and equity instruments are classified as either financial liabilities or as equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument.
Equity instruments
An equity instrument is any contract that evidences a residual interest in the assets of an entity after deducting all of its liabilities. Equity instruments issued by the Group are recognized at the proceeds received, net of direct issue costs.
Repurchase of the Company’s own equity instruments is recognized and deducted directly in equity. No gain or loss is recognized in profit or loss on the purchase, sale, issue or cancellation of the Company’s own equity instruments.
Compound instruments
The component parts of convertible loan notes issued by the Group are classified separately as financial liabilities and equity in accordance with the substance of the contractual arrangements and the definitions of a financial liability and an equity instrument. A conversion option that will be settled by the exchange of a fixed amount of cash or another financial asset for a fixed number of the Company’s own equity instruments is an equity instrument.
At the date of issue, the fair value of the liability component is estimated using the prevailing market interest rate for a similar non-convertible instrument. This amount is recorded as a liability on an amortized cost basis using the effective interest method until extinguished upon conversion or at the instrument’s maturity date.
The conversion option classified as equity is determined by deducting the amount of the liability component from the fair value of the compound instrument as a whole. This is recognized and included in equity, net of income tax effects, and is not subsequently remeasured. In addition, the conversion option classified as equity will remain in equity until the conversion option is exercised, in which case the balance recognized in equity will be transferred to share premium. Where the conversion option remains unexercised at the maturity date of the convertible loan note, the balance recognized in equity will be transferred to retained earnings. No gain or loss is recognized in profit or loss upon conversion or expiration of the conversion option.
F-24
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
H. | Financial instruments (continued) |
Compound instruments (continued)
Transaction costs that relate to the issue of the convertible loan notes are allocated to the liability and equity components in proportion to the allocation of the gross proceeds. Transaction costs relating to the equity component are recognized directly in equity. Transaction costs relating to the liability component are included in the carrying amount of the liability component and are amortized over the lives of the convertible loan notes using the effective interest method.
Financial liabilities
Financial liabilities are initially recognized at their fair value minus, in the case of a financial liability not at fair value through profit or loss, transaction costs that are directly attributable to the issue of the financial liability.
Financial liabilities are subsequently measured at amortized cost using the effective interest method, except for derivative financial instruments, which are subsequently measured at fair value through profit or loss (FVTPL).
The Group has early adopted the narrow-scope amendment to IAS 1. Accordingly, financial liabilities are classified as non-current if the Group has a substantive right to defer settlement for at least 12 months at the end of the reporting period, otherwise, they are classified as current liabilities.
The Group’s financial liabilities at amortized cost are included in accounts payable, accrued expenses, other current liabilities, payable in respect of the intangible asset and lease liabilities.
The derivative financial instruments represent warrants that confer the right to net share settlement.
The Group derecognizes a financial liability (or a part of a financial liability) when, and only when, it is extinguished (when the obligation specified in the contract is discharged, cancelled or expired).
Derecognition of financial liabilities
The Group derecognizes financial liabilities when, and only when, the Group’s obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability derecognized and the consideration paid and payable is recognized in profit or loss.
When the Group exchanges with the existing lender one debt instrument into another one with substantially different terms, such exchange is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Similarly, the Group accounts for substantial modification of terms of an existing liability or part of it as an extinguishment of the original financial liability and the recognition of a new liability. It is assumed that the terms are substantially different if the discounted present value of the cash flows under the new terms, including any fees paid net of any fees received and discounted using the original effective interest rate is at least 10 per cent different from the discounted present value of the remaining cash flows of the original financial liability. If the modification is not substantial, the difference between: (1) the carrying amount of the liability before the modification; and (2) the present value of the cash flows after modification is recognized in profit or loss as the modification gain or loss within other gains and losses.
I. | Inventory |
Inventories are stated at the lower of cost and net realizable value. Cost comprises direct materials and, where applicable, direct labor costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Cost is calculated using the weighted average cost method. Net realizable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.
The Group periodically evaluates the condition and age of inventories and makes provisions for slow moving inventories accordingly.
F-25
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
J. | Cash and cash equivalents |
In the statement of financial position, cash and bank balances comprise cash (i.e., cash on hand and demand deposits) and cash equivalents. Cash equivalents are short-term (generally with original maturity of three months or less), highly liquid investments that are readily convertible to a known amount of cash and which are subject to an insignificant risk of changes in value. Cash equivalents are held for the purpose of meeting short-term cash commitments rather for investment or other purposes.
For the purposes of the statement of cash flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of outstanding bank overdrafts which are repayable on demand and form an integral part of the Group’s cash management. Such overdrafts are presented as short-term borrowings in the statement of financial position.
K. | Taxation |
The income tax expense represents the sum of the tax currently payable and deferred tax.
Current Tax
The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in profit or loss because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The Group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
A provision is recognized for those matters for which the tax determination is uncertain, but it is considered probable that there will be a future outflow of funds to a tax authority. The provisions are measured at the best estimate of the amount expected to become payable. The assessment is based on the judgement of tax professionals within the Company supported by previous experience in respect of such activities and in certain cases based on specialist independent tax advice.
Deferred Tax
Deferred tax is the tax expected to be payable or recoverable on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit and is accounted for using the liability method. Deferred tax liabilities are generally recognized for all taxable temporary differences and are recognized to the extent that it is probable that taxable profits will be available against which deductible temporary differences can be utilized. Such assets and liabilities are not recognized if the temporary difference arises from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. In addition, a deferred tax liability is not recognized if the temporary difference arises from the initial recognition of goodwill.
Deferred tax liabilities are recognized for taxable temporary differences arising on investments in subsidiaries and associates, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments are only recognized to the extent that it is probable that there will be sufficient taxable profits against which to utilize the benefits of the temporary differences and they are expected to reverse in the foreseeable future.
No deferred tax assets have been recorded in the Group’s books and records with respect to accumulated losses since it is not probable that the Group will be able to utilize such losses in the foreseeable future against taxable income.
The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled, or the asset is realized based on tax laws and rates that have been enacted or substantively enacted at the reporting date.
The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the Group expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
F-26
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
K. | Taxation (continued) |
Deferred Tax (continued)
Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis.
Current tax and deferred tax for the year
Current and deferred tax are recognized in profit or loss, except when they relate to items that are recognized in other comprehensive income or directly in equity, in which case the current and deferred tax are also recognized in other comprehensive income or directly in equity respectively. Where current tax or deferred tax arises from the initial accounting for a business combination, the tax effect is included in the accounting for the business combination.
L. | Short-term and other long-term employee benefits |
Pension and severance pay obligations
Israeli labor law generally requires payment of severance pay upon dismissal of an employee or upon termination of employment in certain other circumstances. Pursuant to Section 14 of the Severance Compensation Act, 1963 (“Section 14”), all of the Company’s employees in Israel are entitled a monthly contribution, at a rate of 8.33% of their monthly salary, made in their name with insurance companies. Contributions under Section 14 relieve the Company from any future severance payment obligation with respect to those employees. The aforementioned contributions are not recorded as an asset on the Company’s consolidated statements of financial position, and there is no liability recorded as the Company does not have a future obligation to make any additional payments.
The asset and the liability for severance pay presented in the consolidated statements of financial position reflects employees that began employment prior to automatic application of Section 14.
The severance pay liability of the Company to its employees that began employment prior to automatic application of Section 14 based upon the number of years of service and the latest monthly salary and is partly covered by regular deposits with recognized pension funds and deposits with severance pay funds. Under labor laws, these deposits are in the employees’ names and, subject to certain limitations, are the property of the employees. The Company records the obligation as if it were payable at each statement of financial position date on an undiscounted basis.
Vacation and recreation pay
Under the Israeli law, each employee is legally entitled to vacation and recreation benefits. The entitlement is based on term of employment. The Group records such obligations as incurred.
Bonus plans
The Group record bonus obligation when a contractual or constructive obligation exists. Such bonus obligation is record in the amount expected to be paid, to the extent that the Group can reliably estimate the amount expected to be paid.
M. | Provisions |
Provisions are recognized when the Group has a present obligation (legal or constructive) as a result of a past event, it is probable that the Group will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.
The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).
F-27
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
N. | Share-based payments |
Equity-settled share-based payments to employees and others providing similar services are measured at the fair value of the equity instruments at the grant date. The fair value excludes the effect of non-market-based vesting conditions. Details regarding the determination of the fair value of equity-settled share-based transactions are set out in note 14.
The fair value determined at the grant date of the equity-settled share-based payments is expensed on a straight-line basis over the vesting period, based on the Group’s estimate of the number of equity instruments that will eventually vest. At each reporting date, the Group revises its estimate of the number of equity instruments expected to vest as a result of the effect of non-market-based vesting conditions. The impact of the revision of the original estimates, if any, is recognized in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding adjustment to reserves.
Equity-settled share-based payment transactions with parties other than employees are measured at the fair value of the goods or services received, except where that fair value cannot be estimated reliably, in which case they are measured at the fair value of the equity instruments granted, measured at the date the entity obtains the goods or the counterparty renders the service.
O. | Revenue recognition |
The Group recognizes revenue from the following major sources:
● | Product revenue | |
● | Service revenue |
Revenue is measured based on the consideration to which the Group expects to be entitled in a contract with a customer and excludes amounts collected on behalf of third parties. The Group recognizes revenue when it transfers control of a product or service to a customer.
Product Revenue
Revenues from product sales of Jeffs’ Brands, conducted directly to customers through Jeffs’ Brands own online Amazon stores.
For sales of goods to retail customers, revenue is recognized when control of the goods has transferred to the customer, being at the point the goods are delivered to the customer. Payment of the transaction price is due immediately at the point the customer purchases the goods.
Under Jeffs’ Brands standard contract terms, customers have a right of return within 30 until 90 days. Jeffs’ Brands uses its accumulated historical experience to estimate the number of returns on a portfolio level using the expected value method. It is considered highly probable that a significant reversal in the cumulative revenue recognized will not occur given the consistent level of returns over previous years.
Service Revenue through Gix Internet
Gix Internet generates revenues from obtaining internet user traffic and routing such traffic to its customers. Gix Internet is entitled to receive consideration for its service upon each individual internet user traffic routed to and monetized by its customers.
Gix Internet’s revenues are measured and recognized according to the fair value of the consideration expected to be received in accordance with the terms of the contract, less the amounts collected for the benefit of third parties (such as taxes).
Revenues from the search sector and the digital content sector in which Gix Internet operates as the main supplier are presented on a gross basis.
Revenues from the search sector and the digital content sector are recognized immediately upon the provision of the service.
Service Revenues through Eventer
The Group provides through the subsidiary Eventer services for using the event production platform in exchange for a commission from the sale of tickets for events. These services constitute a performance obligation that is fulfilled at one point in time and therefore the Group recognizes revenues at the time of the event.
The essence of the Group’s promise to the customer is to arrange for the consideration for the tickets to be provided by another party, therefore the Group’s revenues from these transactions are presented on a net basis.
F-28
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
P. | Leases |
The Group assesses whether a contract is or contains a lease, at inception of the contract. The Group recognizes a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets (such as tablets and personal computers, small items of office furniture and telephones). For these leases, the Group recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.
The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Group uses its incremental borrowing rate.
The incremental borrowing rate depends on the term, currency and start date of the lease and is determined based on a series of inputs including: the risk-free rate based on government bond rates; a country-specific risk adjustment; a credit risk adjustment based on bond yields; and an entity-specific adjustment when the risk profile of the entity that enters into the lease is different to that of the Group and the lease does not benefit from a guarantee from the Group.
Lease payments included in the measurement of the lease liability comprise:
● | Fixed lease payments (including in-substance fixed payments), less any lease incentives receivable |
● | Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date |
● | The amount expected to be payable by the lessee under residual value guarantees |
● | The exercise price of purchase options, if the lessee is reasonably certain to exercise the options |
● | Payments of penalties for terminating the lease, if the lease term reflects the exercise of an option to terminate the lease |
The lease liability is presented as a separate line in the consolidated statement of financial position.
The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made.
The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever:
● | The lease term has changed or there is a significant event or change in circumstances resulting in a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate |
● | The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used) |
● | A lease contract is modified, and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification |
F-29
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
P. | Leases (continued) |
The Group did not make any such adjustments during the periods presented.
The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.
Right-of-use assets are depreciated over the shorter period of lease term and useful life of the right-of-use asset. The depreciation starts at the commencement date of the lease.
The right-of-use assets are presented as a separate line in the consolidated statement of financial position.
The Group applies IAS 36 to determine whether a right-of-use asset is impaired and accounts for any identified impairment loss as described in the ‘Property and Equipment’ policy.
As a practical expedient, IFRS 16 permits a lessee not to separate non-lease components, and instead account for any lease and associated non-lease components as a single arrangement. The Group has not used this practical expedient. For contracts that contain a lease component and one or more additional lease or non-lease components, the Group allocates the consideration in the contract to each lease component on the basis of the relative stand-alone price of the lease component and the aggregate stand-alone price of the non-lease components.
Q. | Loss (Earning) per share |
Loss (Earning) per share is based on the loss (earning) that is attributed to the shareholders holding ordinary shares, divided by the weighted average number of ordinary shares in issue during the period.
For purposes of the calculation of the diluted loss (earning) per share, the Company adjusts the loss (earning) that is attributed to the holders of the Company’s ordinary shares, and the weighted average number of ordinary shares in issue, to assume conversion of all of the dilutive potential shares.
The potential shares are taken into account only if their effect is dilutive (increases loss/ decrease earning per share).
F-30
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
R. | Intangible assets |
Intangible assets acquired separately
Intangible assets with finite useful lives that are acquired separately are carried at cost less accumulated amortization and accumulated impairment losses. Amortization is recognized on a straight-line basis over their estimated useful lives. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses.
Internally generated intangible assets - research and development expenditure
Expenditure on research activities is recognized as an expense in the period in which it is incurred.
An internally generated intangible asset arising from development (or from the development phase of an internal project) is recognized if, and only if, all of the following conditions have been demonstrated:
● | The technical feasibility of completing the intangible asset so that it will be available for use or sale |
● | The intention to complete the intangible asset and use or sell it |
● | The ability to use or sell the intangible asset |
● | How the intangible asset will generate probable future economic benefits |
● | The availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset |
● | The ability to measure reliably the expenditure attributable to the intangible asset during its development |
The amount initially recognized for internally generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally generated intangible asset can be recognized, development expenditure is recognized in profit or loss in the period in which it is incurred.
F-31
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
R. | Intangible assets (continued) |
Internally generated intangible assets - research and development expenditure (continued)
Subsequent to initial recognition, internally generated intangible assets are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.
Intangible assets acquired in a business combination
Intangible assets acquired in a business combination and recognized separately from goodwill are recognized initially at their fair value at the acquisition date (which is regarded as their cost).
Subsequent to initial recognition, intangible assets acquired in a business combination are reported at cost less accumulated amortization and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.
Derecognition of intangible assets
An intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from derecognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset, and are recognized in the consolidated statements of income/loss and other comprehensive income/loss as profit/loss when the asset is derecognized.
At each reporting date, the Company reviews the carrying amounts of its intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss (if any). Where the asset does not generate cash flows that are independent from other assets, the Company estimates the recoverable amount of the cash-generating unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified. Intangible assets with an indefinite useful life are tested for impairment at least annually and whenever there is an indication at the end of a reporting period that the asset may be impaired.
Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in the consolidated statements of income/loss and other comprehensive income/loss as profit/loss.
F-32
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
S. | Impairment of property and equipment and intangible assets excluding goodwill |
At each reporting date, the Group reviews the carrying amounts of its property and equipment and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss (if any). Where the asset does not generate cash flows that are independent from other assets, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified.
Intangible assets with an indefinite useful life are tested for impairment at least annually and whenever there is an indication at the end of a reporting period that the asset may be impaired.
Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.
If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognized immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease and to the extent that the impairment loss is greater than the related revaluation surplus, the excess impairment loss is recognized in profit or loss.
Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss to the extent that it eliminates the impairment loss which has been recognized for the asset in prior years. Any increase in excess of this amount is treated as a revaluation increase.
T. | Segments |
The Group reports financial and descriptive information about its reportable segments. Reportable segments are operating segments or aggregations of operating segments that meet specified criteria as defined in IFRS 8, Operating Segments.
Operating segments are distinguishable components of an entity for each of which a separate financial information is available and is reported in a manner consistent with the internal reporting provided to the entity’s Chief Operating Decision Maker (“CODM”) in making decisions about how to allocate resources and in assessing performance.
When the Group is committed to a sale plan involving disposal of an investment in an associate or, a portion of an investment in an associate, the investment, or the portion of the investment in the associate that will be disposed of is classified as held for sale when the criteria described above are met.
The Group then ceases to apply the equity method in relation to the portion that is classified a held for sale. Any retained portion of an investment in an associate that has not been classified as held for sale continues to be accounted for using the equity method.
F-33
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
U. | Deferred offering costs |
The Group capitalizes certain legal and other third-party fees that are directly related to the Group’s in-process equity financing until such financing is consummated. After the consummation of such equity financing, these costs are recorded as a reduction of the respective gross proceeds. Should a planned equity financing be abandoned, terminated, or significantly delayed, the deferred offering costs are written off to operating expenses.
V. | New and revised IFRS Accounting Standards in issue but not yet effective |
Amendments to IFRS 10 Consolidated Financial Statements and IAS 28 Investments in Associates and Joint Ventures - Sale or Contribution of Assets between an Investor and its Associate or Joint Venture
The amendments to IFRS 10 and IAS 28 deal with situations where there is a sale or contribution of assets between an investor and its associate or joint venture. Specifically, the amendments state that gains or losses resulting from the loss of control of a subsidiary that does not contain a business in a transaction with an associate or a joint venture that is accounted for using the equity method, are recognized in the parent’s profit or loss only to the extent of the unrelated investors’ interests in that associate or joint venture. Similarly, gains and losses resulting from the remeasurement of investments retained in any former subsidiary (that has become an associate or a joint venture that is accounted for using the equity method) to fair value are recognized in the former parent’s profit or loss only to the extent of the unrelated investors’ interests in the new associate or joint venture.
The effective date of the amendments has yet to be set by the IASB; however, earlier application of the amendments is permitted. The directors of the Company anticipate that the application of these amendments may have an impact on the Group’s consolidated financial statements in future periods should such transactions arise.
Amendments to IAS 1 Presentation of Financial Statements and IFRS Practice Statement 2 Making Materiality Judgements - Disclosure of Accounting Policies
The amendments change the requirements in IAS 1 with regard to disclosure of accounting policies. The amendments replace all instances of the term ‘significant accounting policies’ with ‘material accounting policy information’. Accounting policy information is material if, when considered together with other information included in an entity’s financial statements, it can reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements.
The supporting paragraphs in IAS 1 are also amended to clarify that accounting policy information that relates to immaterial transactions, other events or conditions is immaterial and need not be disclosed. Accounting policy information may be material because of the nature of the related transactions, other events or conditions, even if the amounts are immaterial. However, not all accounting policy information relating to material transactions, other events or conditions is itself material.
The IASB has also developed guidance and examples to explain and demonstrate the application of the ‘four-step materiality process’ described in IFRS Practice Statement 2.
The amendments to IAS 1 are effective for annual periods beginning on or after 1 January 2023, with earlier application permitted and are applied prospectively. The amendments to IFRS Practice Statement 2 do not contain an effective date or transition requirements.
F-34
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES: (continued)
V. | New and revised IFRS Accounting Standards in issue but not yet effective (continued) |
Amendments to IAS 8 Accounting Policies, Changes in Accounting Estimates and Errors - Definition of Accounting Estimates
The amendments replace the definition of a change in accounting estimates with a definition of accounting estimates. Under the new definition, accounting estimates are “monetary amounts in financial statements that are subject to measurement uncertainty”.
The definition of a change in accounting estimates was deleted. However, the IASB retained the concept of changes in accounting estimates in the Standard with the following clarifications:
● | A change in accounting estimate that results from new information or new developments is not the correction of an error |
● | The effects of a change in an input or a measurement technique used to develop an accounting estimate are changes in accounting estimates if they do not result from the correction of prior period errors |
The amendments are effective for annual periods beginning on or after 1 January 2023 to changes in accounting policies and changes in accounting estimates that occur on or after the beginning of that period, with earlier application permitted.
Amendments to IAS 12 Income Taxes - Deferred Tax related to Assets and Liabilities arising from a Single Transaction
The amendments introduce a further exception from the initial recognition exemption. Under the amendments, an entity does not apply the initial recognition exemption for transactions that give rise to equal taxable and deductible temporary differences.
Depending on the applicable tax law, equal taxable and deductible temporary differences may arise on initial recognition of an asset and liability in a transaction that is not a business combination and affects neither accounting nor taxable profit.
Following the amendments to IAS 12, an entity is required to recognize the related deferred tax asset and liability, with the recognition of any deferred tax asset being subject to the recoverability criteria in IAS 12.
The amendments apply to transactions that occur on or after the beginning of the earliest comparative period presented.
The amendments are effective for annual reporting periods beginning on or after 1 January 2023, with earlier application permitted.
The management of the Company anticipate that the application of these amendments may have an impact on the Group’s consolidated financial statements in future periods should such transactions arise.
F-35
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 3 – CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY:
In applying the Group’s accounting policies, which are described in note 2, the management is required to make judgements (other than those involving estimations) that have a significant impact on the amounts recognize and to make estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimate are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
F-36
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 3 – CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY: (continued)
Key sources of estimation uncertainty
The key assumptions concerning the future, and other key sources of estimation uncertainty at the reporting period that may have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are discussed below.
Fair value measurements and valuation process
Some of the Group’s assets and liabilities are measured at fair value for financial reporting purposes.
In estimating the fair value of an asset or a liability, the Group uses market-observable data to the extent it is available. Where Level 1 inputs are not available, the Group engages third party qualified valuers to perform the valuation. The Company works closely with the qualified external valuers to establish the appropriate valuation techniques and inputs to the model.
The valuations of private equity investments as well as goodwill and other intangible assets of certain of the Company’s subsidiaries are sensitive to changes in one or more unobservable inputs which are considered reasonably possible within the next financial year. Further information on the carrying amounts of these assets and the relevant unobservable inputs are provided in note 4.
F-37
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES:
A. | Investments in subsidiaries: |
1. | Additional information about subsidiaries held by the Company: |
General information
Ownership rights held by non- controlling | ||||||
Main place of the business | interest % | |||||
December 31, 2022 | ||||||
Jeffs’ Brands Ltd. | Israel | 64.06 | % | |||
Eventer Technologies Ltd. | Israel | 53.79 | % | |||
Charging Robotics Ltd. | Israel | |||||
GERD IP Inc. | USA | 10 | % | |||
Gix Internet Ltd. | Israel | 57.75 | % |
December 31, 2021 | ||||||
Jeffs’ Brands Ltd. | Israel | 49.97 | % | |||
Eventer Technologies Ltd. | Israel | 52.31 | % | |||
Charging Robotics Ltd. | Israel | |||||
GERD IP Inc. | USA | 10 | % |
2. | Summarized financial information of subsidiaries: |
Eventer Technologies Ltd.
Summarized statement of financial position:
December 31, 2022 | December 31, 2021 | |||||||
USD in thousands (*) | ||||||||
Current assets | 1,829 | 3,469 | ||||||
Non-current assets | 1,379 | 1,521 | ||||||
Current liabilities | 2,766 | 3,571 | ||||||
Non-current liabilities | 476 | 711 | ||||||
Equity (Deficit) | (34 | ) | 708 |
(*) | Translated according to the exchange rate at the date of each statement of financial position. |
F-38
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
2. | Summarized financial information of subsidiaries: (continued) |
Eventer Technologies Ltd. (continued)
Summarized statement of comprehensive income:
Year ended December 31, 2022 | Year ended December 31, 2021 | October 15, 2020 – December 31, 2020 | ||||||||||
USD in thousands (**) | ||||||||||||
Revenue | 2,465 | 1,185 | 40 | |||||||||
Net loss | (1,316 | ) | (2,612 | ) | (490 | ) |
Summarized statement of cash flows:
Year ended 2022 | Year ended December 31, 2021 | October 15, 2020 – December 31, 2020 | ||||||||||
USD in thousands (**) | ||||||||||||
Cash flow from (used in) operating activities | (16 | ) | 407 | (347 | ) | |||||||
Cash flow from (used in) investing activities | (34 | ) | (370 | ) | 52 | |||||||
Cash flow from (used in) financing activities | (163 | ) | 703 | 1032 | ||||||||
Gain (losses) from exchange differences on cash and cash equivalents | (215 | ) | ||||||||||
Net increase (decrease) in cash and cash equivalents | (428 | ) | 740 | 737 |
(**) | Translated according to the average exchange rates for each period. |
Jeffs’ Brands Ltd.
Summarized statement of financial position:
December 31, 2022 | December 31, 2021 | |||||||
USD in thousands | ||||||||
Current assets | 11,033 | 2,022 | ||||||
Non-current assets | 4,743 | 5,390 | ||||||
Current liabilities | 5,133 | 2,211 | ||||||
Non-current liabilities | 98 | 3,948 | ||||||
Equity | 10,545 | 1,253 |
Summarized statement of comprehensive income:
Year ended December 31, 2022 | Year ended December 31, 2021 | |||||||
USD in thousands | ||||||||
Revenue | 5,859 | 6,509 | ||||||
Net loss | (1,134 | ) | (1,540 | ) |
F-39
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
2. | Summarized financial information of subsidiaries: (continued) |
Jeffs’ Brands Ltd. (continued)
Summarized statement of cash flows:
Year ended December 31, 2022 | Year ended December 31, 2021 | |||||||
USD in thousands | ||||||||
Cash flow used in operating activities | (4,823 | ) | (863 | ) | ||||
Cash flow used in investing activities | (41 | ) | (4,730 | ) | ||||
Cash flow from financing activities | 12,611 | 5,695 | ||||||
Net increase in cash and cash equivalents | 7,747 | 102 |
Gix Internet Ltd.
Summarized statement of financial position:
December 31, 2022 | December 31, 2021 | |||||||
USD in thousands (*) | ||||||||
Current assets | 26,481 | 23,145 | ||||||
Non-current assets | 16,549 | 19,191 | ||||||
Current liabilities | 29,529 | 26,832 | ||||||
Non-current liabilities | 4,127 | 6,543 | ||||||
Equity | 9,374 | 8,960 | ||||||
Equity attributable to Gix Internet shareholders | 4,804 | 4,130 | ||||||
Non-controlling interests | 4,570 | 4,830 |
(*) | Translated according to the exchange rate at the date of each statement of financial position. |
Summarized statement of comprehensive income:
March 1, 2022 – December 31, 2022 | January 01, 2022 – February 28, 2022 | Year ended December 31, 2021 | ||||||||||
USD in thousands (**) | ||||||||||||
Revenue | 83,532 | 12,193 | 44,827 | |||||||||
Net profit (loss) | 414 | (438 | ) | (1,510 | ) | |||||||
Other comprehensive income (loss) | 499 | (295 | ) | (396 | ) | |||||||
Total comprehensive income (loss) | 913 | (733 | ) | (1,905 | ) |
Summarized statement of cash flows:
February 28, 2022 – December 31, 2022 | ||||
USD in thousands (**) | ||||
Cash flow from operating activities | 4,232 | |||
Cash flow from investing activities | 13 | |||
Cash flow used in financing activities | (3,309 | ) | ||
Loss from exchange differences on cash and cash equivalents | (127 | ) | ||
Net increase in cash and cash equivalents | 809 |
(**) | Translated according to the average exchange rates for the period from February 28, 2022 until December 31, 2022. |
F-40
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
3. | Information related to non-controlling interests: |
Balance of non-controlling interests:
December 31, 2022 | December 31, 2021 | |||||||
USD in thousands | ||||||||
Eventer | 721 | 1,136 | ||||||
Jeffs’ Brands | 7,199 | 965 | ||||||
Charging Robotics | 91 | 91 | ||||||
Gix Internet | 7,480 | |||||||
GERD IP | 57 | 51 | ||||||
15,548 | 2,243 |
Profit (Loss) attributed to non-controlling interests:
Year ended December 31, 2022 | Year ended December 31, 2021 | |||||||
USD in thousands | ||||||||
ScoutCam | (892 | ) | ||||||
Eventer | (691 | ) | (1,112 | ) | ||||
Jeffs’ Brands | (396 | ) | (795 | ) | ||||
GERD IP | 7 | 51 | ||||||
Gix Internet | 687 | |||||||
(393 | ) | (2,748 | ) |
4. | Information related to loss of control in subsidiary: |
On March 22, 2021, the Company’s holdings in ScoutCam were diluted, therefore it was deconsolidated. For additional information see note 4C.
5. | Additional information: |
The Company consolidated Eventer as of October 15, 2020, because the Company has exclusive rights regarding determination of a business plan and budget, appointing or dismissing the CEO, determining his compensation package and on declaration or payment of any dividend or distribution of cash, securities and other assets. Additionally, the Company has the power to appoint or remove half of the members of the board. All of the above indicates the Company’s control of Eventer.
The Company consolidated Gix Internet as of February 28, 2022, as the Company increased its holdings interests to 38.03% on February 28, 2022, making the Company the largest shareholder in Gix Internet, on a fully diluted basis. Additionally, the Company has appointed 3 out of 5 of the members of the Board of Directors of Gix Internet. These reasons indicate the Company’s control of Gix Internet.
On August 30, 2022, Jeffs’ Brands completed an initial public offering (“IPO”), therefore the Company’s holdings in Jeffs’ Brands were diluted to below 50% of the voting rights. However, the Company continues to consolidate Jeffs’ Brands for the following reasons: the Company is the largest shareholder in Jeffs’ Brands and holds as of the date of the completion of the IPO 35.27% of the voting rights. The composition of the Board of Directors will remain the same until the next annual meeting, which will be scheduled during 2023. These reasons indicate the Company’s continued control of Jeffs’ Brands.
F-41
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
B. | Investments according to the equity method: |
1. | This table summarizes the total investments according to the equity method: |
December 31, 2022 | December 31, 2021 | |||||||
USD in thousands | ||||||||
ScoutCam (note 4C) | 9,375 | 10,735 | ||||||
Gix Internet (note 4F) | 4,867 | |||||||
Parazero (note 4M) | 976 | |||||||
Laminera (note 4N) | 1,176 | |||||||
Polyrizon (note 4H) | 214 | 447 | ||||||
Elbit Imaging (note 4J) | 975 | |||||||
Revoltz (note 4I) | 151 | 216 | ||||||
11,892 | 17,240 |
2. | This table summarizes the total share of loss (profit) of investments according to the equity method: |
For the year ended December 31, 2022 | For the year ended December 31, 2021 | |||||||
USD in thousands | ||||||||
ScoutCam (note 4C) | 1,360 | 1,401 | ||||||
Automax (note 4G) | (275 | ) | ||||||
Gix Internet (note 4F) | 215 | 822 | ||||||
Parazero (note 4M) | 615 | |||||||
Laminera (note 4N) | 157 | |||||||
Polyrizon (note 4H) | 234 | 74 | ||||||
Elbit Imaging (note 4J) | 36 | 83 | ||||||
Revoltz (note 4I) | 42 | 44 | ||||||
2,659 | 2,149 |
3. | This table summarize the Company’s rights in share capital and voting rights: |
Main place of | Company rights in share capital and voting rights | |||||
the business | % | |||||
December 31, 2022 | ||||||
Parazero | Israel | 40.35 | % | |||
Laminera | Israel | 19.70 | % | |||
Polyrizon | Israel | 37.03 | % | |||
ScoutCam | Israel | 27.02 | % | |||
Fuel Doctor | Israel | 28.63 | % | |||
Revoltz | Israel | 19.9 | % | |||
December 31, 2021 | ||||||
Gix Internet | Israel | 34.58 | % | |||
Polyrizon | Israel | 36.81 | % | |||
ScoutCam | Israel | 27.02 | % | |||
Elbit Imaging | Israel | 5.72 | % | |||
Fuel Doctor | Israel | 35.06 | % | |||
Revoltz | Israel | 19.9 | % |
F-42
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
B. | Investment according to the equity method: (continued) |
4. | Summarized financial information of material investments: |
ScoutCam
Summarized statements of financial position:
December 31, 2022 | December 31, 2021 | |||||||
USD in thousands | ||||||||
Current assets | 14,117 | 20,212 | ||||||
Non-current assets | 2,778 | 3,334 | ||||||
Current liabilities | 4,187 | 1,309 | ||||||
Non-current liabilities | 2,550 | 2,621 | ||||||
Equity | 10,158 | 19,616 |
Summarized statement of comprehensive income:
Year ended December 31, 2022 | Nine months ended December 31, 2021 (*) | Three months ended March 31, 2021 (*) |
Year | |||||||||||||
USD in thousands | ||||||||||||||||
Revenue | 665 | 363 | 24 | 491 | ||||||||||||
Net loss | (6,575 | ) | (7,381 | ) | (1,606 | ) | (4,667 | ) |
(*) | ScoutCam was deconsolidated on March 31, 2021, and the investment was accounted for as an equity method investment from April 1, 2021 (refer to note 4C). |
Summarized statement of cash flows:
Parazero
Summarized statements of financial position:
December 31, 2022 | ||||
Current assets | 1,438 | |||
Non-current assets | 98 | |||
Current liabilities | 2,422 | |||
Non-current liabilities | 772 | |||
Equity | (1,658 | ) |
F-43
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
B. | Investment according to the equity method: (continued) |
4. | Summarized financial information of material investments: (continued) |
Parazero (continued)
Summarized statement of comprehensive income:
Period February 2 - December 31, 2022 | ||||
Revenue | 514 | |||
Net loss | (1,205 | ) |
Laminera
Summarized statements of financial position:
December 31, 2022 | ||||
USD in thousands | ||||
Current assets | 193 | |||
Non-current assets | 748 | |||
Current liabilities | 420 | |||
Non-current liabilities | 40 | |||
Equity | 481 |
Summarized statement of comprehensive income:
Period March 31- December 31, 2022 | ||||
Revenue | ||||
Net loss | (689 | ) |
5. | Fair value of investments in material affiliated companies for which there is a market price on the stock exchange: |
December 31, 2022 | December 31, 2021 | |||||||||||||||
Carrying amount | Quoted fair value | Carrying amount | Quoted fair value | |||||||||||||
USD in thousands | ||||||||||||||||
ScoutCam | 9,375 | 9,623 | 10,735 | 15,397 | ||||||||||||
Gix Internet (*) | 4,867 | 5,854 | ||||||||||||||
Elbit Imaging (**) | 723 | 974 |
(*) | Gix Internet was consolidated as of February 28, 2022 (note 4F). |
(**) | Elbit Imaging investment was accounted for as assets at fair value through profit or loss as of October 18, 2022 (note 4J). |
F-44
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
C. | ScoutCam |
On December 30, 2019, the Company and ScoutCam Inc. (“ScoutCam”) consummated a securities exchange agreement (the “Exchange Agreement”), pursuant to which the Company delivered 100% of its holdings in ScoutCam Ltd. to ScoutCam in exchange for shares of ScoutCam’s common stock representing 60% of the issued and outstanding share capital of ScoutCam immediately upon the consummation of the Exchange Agreement.
On March 22, 2021, ScoutCam issued to investors (the “Investors”) 2,469,156 units (the “Units”) in exchange for an aggregate purchase price of USD 20 million. As the Company did not participate in the March 2021 funding, its interest in ScoutCam reduced to 28.06%, which resulted in loss of control in ScoutCam as of April 2021. Accordingly, ScoutCam was deconsolidated as of such date and accounted for using the equity method, with the purchase price being the fair value of ScoutCam’s shares held by ScoutCam as of such date. As a result of deconsolidation of ScoutCam and initial recognition of the investment in shares of ScoutCam at fair value, the Company recorded a gain of USD 11,465 in the consolidated statement of income/loss and other comprehensive income/loss. Additionally, the Company recognized its holdings in ScoutCam’s warrants as financial asset through profit or loss and recorded an additional gain of USD 97 thousand. As of December 31, 2021, part of the warrants was exercised and the rest expired.
On August 9, 2021, ScoutCam amended its Articles of Incorporation to affect a 9 to 1 reverse stock split of ScoutCam’s outstanding Common Stock.
As of December 31, 2022, the Company owns approximately 27.02% of the outstanding common stock of ScoutCam.
On March 21, 2023, ScoutCam executed a capital raising transaction which diluted the Company’s holdings in ScoutCam to 18.45% and the remaining holding was accounted for as an investment at fair value through profit or loss (FVTPL) (see note 21(4)).
F-45
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
C. | ScoutCam (continued) |
Purchase price allocation upon deconsolidation and initial measurement under the equity method:
Activity in investment account:
F-46
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
C. | ScoutCam (continued) |
Reconciliation to carrying amounts:
F-47
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
D. | Eventer |
General
On October 14, 2020, the Company signed a share purchase agreement and a revolving loan agreement with Eventer, a technology company engaged in the development of unique tools for automatic creation, management, promotion, and billing of events and ticketing sales. Pursuant to the share purchase agreement, the Company invested USD 750 thousand and was issued an aggregate of 325,270 ordinary shares of Eventer, representing 58.7% of the issued and outstanding share capital (50.01% of Eventer’s issued and outstanding share capital on a fully diluted basis). The share purchase agreement provides that the Company will invest an additional USD 250 thousand in a second tranche, subject to Eventer achieving certain post-closing EBITDA based milestones during the fiscal years 2021 through 2023, or the “Milestones”. The Milestones will be examined in each of the years 2021 through 2023. The fair value of the earn-out was calculated by using a Monte Carlo Simulation. According to this model, the fair value of the earn-out was NIS 233 thousand (USD 69 thousand) as of October 14, 2020. As of December 31, 2022, the Milestones have not been achieved and the fair value of the earn-out was determined to be immaterial.
In addition, the Company granted a loan to Eventer in the amount of USD 250 thousand (“Initial Advance”), and the loan was valued at USD 204 thousand. According to the loan agreement, the Company committed to lend up to USD 1,250 thousand to Eventer through advances of funds upon Eventer’s request and subject to the Company’s approval. Advances extended under the Loan Agreement may be repaid and borrowed, in part or in full, from time to time. The Initial Advance should be repaid in twenty-four equals monthly instalments, commencing on the first anniversary of the Loan Agreement. Other advances extended under the Loan Agreement will be repaid immediately following, and in no event later than thirty days following the completion of the project or purpose for which they were made. Outstanding principal balances on the advances will bear interest at a rate equal to the higher of (i) 4% per year, or (ii) the interest rate determined by the Israeli Income Tax Ordinance [New Version] 5721-1961 and the rules and regulation promulgated thereunder. Interest payments will be made on a monthly basis.
Additionally, on October 14, 2020, the Company entered the Exchange Agreement with Eventer’s shareholders, pursuant to which, during the period commencing on the second anniversary of the Exchange Agreement and ending fifty-four (54) months following the date of the Exchange Agreement, Eventer’s shareholders may elect to exchange all of their Eventer shares for ordinary shares of the Company. The number of ordinary shares of the Company to which Eventer’s shareholders would be entitled pursuant to an exchange will be calculated by dividing the fair market value of each of Eventer’s ordinary share, as mutually determined by the Company and the shareholders, by the average closing price of an ordinary share of the Company on the principal market on which its ordinary shares or ADSs are traded during the sixty days prior to the exchange date, rounded down to the nearest whole number. The Company board of directors may defer the exchange’s implementation in the event it determines in good faith that doing so would be materially detrimental to the Company and its shareholders. In addition, the exchange may not be affected for so long as USD 600 thousand or more remains outstanding under the Loan Agreement, or if an event of default under the Loan Agreement has occurred. The Company treated the Exchange Agreement at the date of the business combination from accounting perspective as recognition of non-controlling interests, in addition to the recognition of a liability in respect of a derivative (exchange options) which will be measured at fair value at each cut-off date and will be revalued. The changes in the fair value at each cut-off date will be recorded as a financial income/expense. The Company concluded that the fair value of this derivative is immaterial, as this is an exchange of Eventer shares held by the other party, a fixed number in consideration for a variable number of the Company’s shares whose total value is equal to the value of the Eventer shares exchanged.
On March 25, 2021, Eventer completed a finance round of approximately USD 2,250 thousand (approximately NIS 7,300 thousand) from a group of 7 investors, in exchange for 146,637 shares, representing 20% of Eventer’s outstanding shares after consummation of the investment. As part of the investment agreement, Keshet Holdings LP (“Keshet”), one of the 7 investors, committed to provide Eventer with advertising services for USD 1,250 thousand (approximately NIS 4,000 thousand), over a period of 1 year, until June 30, 2022. The agreement further provided that the investment proceeds to be paid by Keshet are to be netted by the USD 1,250 thousand to be paid as consideration of the above-mentioned advertising services. Accordingly, the net amount Eventer raised in the finance round amounted to USD 1,000 thousand, with advertising services recorded as prepaid expense in the amount of USD 1,250 thousand. Eventer is not entitled to a refund in the event these advertising services are unutilized through the entire period until June 30, 2022. Following lack of usage of advertising services by Eventer till 30 June 2022 Eventer and Keshet agreed to extend the entitlement period till December 31, 2023, such that the original volume would be utilized. As the extension in time period does not entitle Eventer to additional advertisement services, the Company concluded that the fair value of the additional benefit represented by the extension is immaterial. Following the finance round, the Company’s holding in Eventer decreased to 47.69% of Eventer’s issued and outstanding share capital.
Additionally, the investment agreement further provided that if in the following twelve months of the closing, Eventer shall not consummate an IPO, then the price per share (“PPS“) shall be adjusted downward to reflect 50% of the PPS at the time of the closing Date (the “Adjusted PPS”), and the Investors shall be issued with additional Ordinary Shares of Eventer, at no additional consideration. Eventer did not consummate an IPO, therefore on May 25, 2022, Eventer issued to the investors 65,310 shares from which the Company received 19,518 shares. The Company’s holding in Eventer decreased to 46.21% from that date.
During November 2021, the Company and Eventer agreed that the Initial Advance will be repaid the earlier of (i) six months following the Maturity Date of the Initial Advance; or (ii) immediately following an initial public offering of Eventer. The Company concluded the change in terms does not constitute a material modification of the loan. Accordingly, the loan’s carrying value was retained and no profit or loss outcome was recorded as a result of the change in terms.
F-48
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
D. | Eventer (continued) |
General (continued)
In November 2021, the Company loaned an amount of USD 250 thousand to Eventer which is to be repaid 6 months after the loan was received. The loan bears 4% interest per year.
On October 30, 2022, the Company and Eventer signed an amendment according to which the maturity date of the Initial Advance and the loan will be May 30, 2024. In an event Eventer will issue securities in consideration of at least USD 2 million or in the event of an IPO or right offering (the” Investment”), then the outstanding Initial Advance and the loan will automatically be converted into shares. The number of shares will be calculated by dividing the outstanding balance loan as of the closing date of the Investment by a price per share which shall reflect a 20% discount off the lowest price per share paid in the Investment.
The Company concluded the fair value of the benefit represented by the change in terms is immaterial.
Loan agreement with Safee Cyber Technologies Inc.
On August 1, 2022, the Company and Eventer signed a loan agreement with Safee Cyber Technologies Inc. (“Safee”). For more details about the Company’s investment in Safee, see note 4P.
According to the loan agreement, the Company loaned Safee an amount of NIS 250 thousand (USD 74 thousand) and Eventer loaned Safee an amount of NIS 300 thousand (USD 89 thousand) consisting of NIS 100 thousand (USD 30 thousand) in cash and by assigning to Screenz NIS 200 thousand (USD 59 thousand) of the unutilized advertising rights Eventer had purchased from Keshet in March 2021 as mentioned above.
Additionally, for the purpose of loan repayment, Eventer’s loan will be considered as NIS 200 thousand (USD 59 thousand) in total. As a result, Eventer recorded an expense of NIS 100 thousand (USD 29 thousand).
Safee shall repay the loans and the interest out of the proceeds that it will receive, directly and/or indirectly, from the sale of NFT, in a way that the company and Eventer will be entitled to receive the relative part of the loans (excluding 10% of such proceeds). Safee shall not use the NFT proceeds for any other purpose and shall not grant any rights to any third party in the proceeds, until the full repayment of the loans and the interest.
Following the full repayment of the loans and the interest, Safee will be entitled to receive 43.3% of the NFT proceeds and each the Company and Eventer will be entitled to receive 28.35% of the NFT proceeds.
In the event that the net proceeds shall not be sufficient to repay the loans within the period of 2 years or in case the Cooperation Agreement shall be terminated prior to the full payment of the loans, the Company and Eventer shall waive all unpaid amounts of the loans.
The loans bear a fixed annual interest at the minimal rate required according to the applicable tax law, starting from the date the loan was provided and until its full repayment.
As of December 31, 2022, the fair value of the loan is USD 104 thousand.
Contingent liabilities
On September 19, 2022, a lawsuit was filed against Eventer and others in the amount of NIS 280 thousand (USD 80 thousand), alleging a violation of the Prohibition of Discrimination in Products, Services, and Entry into Places of Entertainment and Public Places Law. According to the opinion of Eventer’s legal counsel, the chances of the lawsuit to be rejected are more likely than not.
On December 14, 2022, a request for a class action was filed against Eventer and its two directors, alleging the violation of the provisions of the Prohibition of Discrimination in Products, Services, and Entry into Places of Entertainment and Public Places Law. The plaintiff claims that Eventer allows the allocation of different kinds of tickets to different groups (such as women, children etc.), thereby allowing structured discrimination.
According to the opinion of Eventer’s legal counsel, the chances of the class action to be rejected are more likely than not both against the Eventer and its directors. Eventer must submit its response to the class action request by May 14, 2023.
F-49
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
D. | Eventer (continued) |
Agreement with Screenz Cross Media Ltd.
On February 4, 2021, Eventer signed an addendum to the agreement with Screenz Cross Media Ltd. (a company indirectly controlled and managed by Eli Uzan who serves as Eventer’s Director) (hereafter “Screenz”). The agreement was signed during November 2020 for the purpose of collaborating in the field of virtual conferences. According to the provisions of the addendum to the agreement, Eventer will receive an exclusive license for using the broadcasting system of Screenz with respect to the field of virtual conferences and development services, and in exchange will pay Screenz an amount of USD 1,500 thousand (approximately NIS 4,280 thousand) over a period of eight months, as well as 8% from the revenues earned from using the broadcasting system in the field of virtual conferences.
On December 30, 2021, the Board of Directors approved an amendment to the agreement between Eventer and Screenz effective September 30, 2021 (the “Effective Date”). As per the amendment, instead of USD 1,500, Eventer will pay in exchange for the license an aggregate amount of USD 1,800 thousand, and the repayment term is to be extended to a period of three years, in monthly instalments of approximately USD 50 thousand each. Eventer evaluated the change in the terms of the commitment in accordance with IFRS 9 and concluded that the change does constitute a material modification of the loan. As of September 30, 2021, the loan’s book value was USD 1,300 thousands and the fair value of the debt was valued at USD 1,415 thousand. The difference of USD 115 thousand was recorded as finance expenses.
As of December 31, 2021, the balance of Eventer’s debt to Screenz for the license was a total of USD 1,217 thousand. For additional information see note 17b4.
On March 20, 2022, Eventer and Screenz agreed to reduce the monthly payments for the license from 50 thousand dollars to 25 thousand dollars for a period of 5 months. The modified loan terms did not represent a substantial modification in accordance with IFRS 9.
The aforementioned payments ceased in August 2022 and in December 2022 an amendment was signed pursuant to which Eventer repaid its debt to Screenz by assigning to Screenz the remaining unutilized advertising rights Eventer had purchased from Keshet in March 2021 as mentioned above. The prepaid expense balance in respect of these advertising rights in the books of Eventer as of the repayment date, which approximates the advertising rights’ fair value, was USD 660 thousand. The debt balance as of the date of the amendment was USD 1,062 thousand (NIS 3,862 thousand). The difference between the debt balance and the advertising rights of USD 402 thousand was recorded as a capital contribution from Screenz to Eventer. It was also determined that Screenz will have the first right to receive any money received from Eventer and resulting from a digital ticketing platform for interactive virtual events up to a total amount of USD 480 thousand. The Company concluded the fair value of this commitment is immaterial given the uncertainty of revenues to be generated by Eventer from interactive virtual events.
Deferred offering costs
During 2021, Eventer recorded USD 470 thousand as deferred offering costs in relation to a planned initial public offering (“IPO”). During 2022, Eventer recorded these deferred offering costs as an expense due to the fact that the offering did not occur.
Share based compensation grants
On March 30, 2021, Eventer’s Board of Directors approved a contractual agreement with Eventer’s CEO. The date of the commencement of the agreement is January 1, 2021. The CEO will be entitled to a salary of NIS 33 thousand (USD 10 thousand). In addition, Eventer granted the CEO 29,944 options to purchase one share at an exercise price of 0.001 NIS per share. The options shall vest over a period of three years commencing from the engagement date with 1/12 of such options vesting at the end of each subsequent three-month period following the grant. The fair value of the option granted is estimated on the grant date, using the Black-Scholes Model using the following inputs: (a) risk-free interest rate– 0.15%; (b) expected dividend – 0%; (c) expected volatility – 47.02%; (d) forecasted life – 10 years.
The value of this grant was estimated at approximately NIS 1,668 thousand (USD 473 thousand). For the years ended December 31, 2022, and 2021, approximately NIS 418 thousand (USD 124 thousand) and NIS 1,123 thousand (USD 347 thousand), respectively, were recognized and recorded as expenses.
On March 30, 2021, Eventer’s Board of Directors approved a contractual agreement with Round Robin Ltd. Which is one of the founding partners of Eventer. The date of the commencement of the agreement is January 1, 2021. Under the agreement, Round Robin Ltd. will provide Eventer with 12 monthly hours of technological consulting, and in exchange, Eventer will grant Round Robin Ltd. 29,944 options to purchase one share at exercise price of 0.001 NIS per share. The options shall vest over a period of three years commencing the engagement date with 1/12 of such options vesting at the end of each subsequent three-month period following the grant. The fair value of the option granted is estimated on the grant date, using the Black-Scholes Model, according to the following parameters: (a) risk-free interest rate – 0.15%; (b) expected dividend – 0%; (c) expected volatility – 47.02%; (d) forecasted life – 10 years.
F-50
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
D. | Eventer (continued) |
Share based compensation grants (continued)
The value of this grant was estimated at approximately NIS 1,668 thousand (USD 473 thousand). For the years ended December 31, 2022, and 2021, approximately NIS 418 thousand (USD 124 thousand) and NIS 1,123 thousand (USD 347 thousand), respectively, were recognized and recorded as expenses.
On February 4, 2021, Eventer’s Board of Directors approved a contractual agreement with Mr. Roee Grinblat as Eventer’s Chief Business Manager. According to the agreement, the engagement between Eventer and Mr. Greenblatt commenced on January 1, 2021. The monthly professional fee will be approximately NIS 20 thousand (USD 6 thousand). In addition to the professional fee, Eventer will grant a quantity of shares, that will constitute approximately 2% of Eventer’s issued and outstanding capital immediately after the public offering is completed, as options grant. The options shall vest over a period of three years commencing on engagement date with 1/12 of such options vesting at the end of each subsequent three-month period following the grant. The exercise price of 50% of the options will be equal to the public offering and 50% will equal the share price of the capital raising round that preceded the public offering price. The fair value of the options as at the grant date was estimated on the grant date, using the Black-Scholes Model, according to the following parameters: (a) risk-free interest rate– 0.49%; (b) expected dividend – 0%; (c) expected volatility – 47.02%; (d) forecasted life – 5 years.
The value of this grant was estimated at approximately NIS 277 thousand (USD 83 thousand). For the year ended December 31, 2021, approximately NIS 186 thousand (USD 58 thousand) were recognized and recorded as expense. During 2022 Eventer reversed the expense due to the fact that the offering did not occur.
On February 4, 2021, Eventer’s Board of Directors approved a contractual agreement with Mr. Liron Carmel as the Chairman of the Board of Directors of Eventer. According to the agreement, the engagement between Eventer and Mr. Carmel commenced on January 1, 2021. The monthly professional fee will be approximately NIS 20 thousand (USD 6 thousand). In addition to the professional fee, Eventer granted options to purchase a quantity of ordinary shares, that will constitute approximately 2% of the Eventer’s issued and outstanding ordinary shares immediately after the public offering is completed, as options grant. The options shall vest over a period of three years, commencing on engagement date. The exercise price of 50% of the options granted will be equal to the public offering price, and 50% will equal to the share price of the capital raising round that preceded the public offering price. The fair value of the options granted is estimated on the grant date, using the Black-Scholes Model, according to the following parameters: (a) risk-free interest rate – 0.49%; (b) expected dividend – 0%; (c) expected volatility – 47.02%; (d) forecasted life – 5 years.
The value of this grant was estimated at approximately NIS 277 thousand (USD 86 thousand). For the year ended December 31, 2021, approximately NIS 186 thousand (USD 58 thousand) were recognized and recorded as expense. During 2022 Eventer reversed the expense due to the fact that the offering did not occur.
On February 4, 2021, Eventer’s Board of Directors approved a contractual agreement with Mr. Eli Uzan as Eventer’s President and Director. According to the agreement, the engagement between Eventer and Mr. Uzan commenced on January 1, 2021. The monthly professional fee will be approximately NIS 20 thousand (USD 6 thousand). In addition to the professional fee, Eventer granted options to purchase a quantity of ordinary shares, that will constitute approximately 2% of Eventer issued and outstanding ordinary shares immediately after the public offering is completed, as options grant. The options shall vest over a period of three years commencing on engagement date with 1/12 of such options vesting at the end of each subsequent three-month period following the grant. The exercise price of 50% of the options granted will be equal to the public offering price, and 50% will equal the share price of the capital raising round that preceded the public offering. The fair value of the option granted is estimated on the grant date, using the Black-Scholes Model, according to the following parameters: (a) risk-free interest rate – 0.49%; (b) expected dividend – 0%; (c) expected volatility – 47.02%; (d) forecasted life – 5 years.
The fair value of this grant was estimated at approximately NIS 219 thousand (USD 68 thousand). For the year ended December 31, 2021, approximately NIS 147 thousand (USD 46 thousand) were recognized and recorded as expenses. During 2022 Eventer reversed the expense due to the fact that the offering did not occur.
F-51
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
D. | Eventer (continued) |
Share based compensation grants (continued)
On December 30, 2021, Eventer’s board of directors approved a grant of NIS 8 thousand (USD 2 thousand) to Eventer’s chief executive officer as a bonus for the results and achievements of Eventer for the year 2021. Additionally, Eventer’s board of directors approved a bonus of USD 90 thousand to the chief executive officer which shall be paid in 9 equal instalments per month commencing January 2022.
During April 2022, Eventer’s board of directors approved a salary increase to Eventer’s chief executive officer to NIS 50 thousand (USD 15 thousand) per month, effective as of January 1, 2022.
E. | Jeffs’ Brands Ltd.: |
General
On October 8, 2020, the Company entered into the Pro and Purex SPA. Pro and Purex (as defined in note 1) both are in the e-Commerce field and operate online stores for the sale of various consumer products on the Amazon Online Marketplace. Pursuant to the Pro and Purex SPA, the Company acquired 50.01% of Pro’s and 50.03% of Purex’ issued and outstanding share capital on a fully diluted basis through a combination of cash investments in the companies and acquisition of additional shares from the current shareholders of the two companies in consideration for the Company’s ADSs and a cash component. The Company agreed to invest an aggregate amount of USD 1,250 thousand in Pro and Purex, pay USD 150 thousand in cash consideration to the former stockholders, and issue up to USD 500 thousand worth of ADSs to the former stockholders of such companies subject to EBITDA milestones. On July 2021, and following EBITDA results the Company issued USD 71 thousand worth of ADSs.
In addition, the companies’ former shareholders are entitled to additional milestone issuances of up to an aggregate USD 750 thousand in ADSs subject to the achievement by Pro and Purex of certain milestones throughout 2021. The transactions closed on January 4, 2021. Also, the Company agreed to financing arrangements including (i) providing financing by way of a stockholder loan of a principal amount equal to USD 250 thousand which may be extended up to an aggregate cap of USD 1 million of which the Company will finance 60% with the remaining 40% to be financed by the other Pro’s and Purex’ stockholders; and (ii) additional financing of up to a principal amount of USD 1 million, to finance the acquisition of additional online Amazon stores provided that such acquisition financing will constitute 80% of the applicable acquisition cost, with the remaining 20% to be financed by the other Pro’s and Purex’ stockholders. Subsequently, according to the terms of the Pro and Purex SPA, the Company entered into a loan and pledge agreement, effective January 5, 2021, with its majority owned subsidiaries Pro and Purex.
Pursuant to this loan and pledge agreement, the Company extended a USD 250 thousand loan, with an annual interest of 4%, to be repaid on the second anniversary of the effective date.
The table set forth below summarizes the estimates of the fair value of assets acquired and liabilities assumed and the allocation of the purchase price as of the acquisition date:
F-52
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
E. | Jeffs’ Brands Ltd.: (continued) |
General (continued)
On May 10, 2021, the Company entered into a stock exchange and plan of restructuring agreement with Victor Hakmon, the other shareholder of Pro and Purex, and Jeffs’ Brands, a newly incorporated entity, Pursuant to which, among other things, the Company and Victor Hakmon transferred all holdings in Pro and Purex to Jeffs’ Brands, in return for a consideration of Jeffs’ Brands ordinary shares issued respectively. As a result, Pro and Purex became wholly owned subsidiaries of Jeffs’ Brands. The share exchange transaction was accounted for as a common control transaction, such that the carrying values of the assets and liabilities of Pro and Purex were retained through the transaction. To date, the Company invested approximately USD 6.5 million in Jeffs’ Brands and holds 35.94% of its shares.
In April 2021, Top Rank Ltd., an Israeli company, was established as a wholly owned subsidiary of Jeffs’ Brands.
On July 23, 2021, the Company granted Mr. Victor Hakmon, the CEO of Jeffs’ Brands, 32,202 ADSs at fair value of USD 60 thousand as a special bonus for his achievements in the six months period ended June 30, 2021. The grant was recorded as an expense in the consolidated statements of income/loss and other comprehensive income/loss.
On August 3, 2022, Jeffs’ Brands Board of Directors approved to increase Mr. Hakmon’s monthly salary to NIS 55 thousand (USD 23 thousand) plus applicable value added taxes (“VAT”), retroactively from February 1, 2022, until the closing of the IPO. Effective on September 1, 2022, Jeffs Brands Board of Directors approved an increase to Mr. Hakmon’s monthly salary to NIS 80 thousand (USD 24 thousand) plus VAT and a one-time bonus of NIS 480 thousand (USD 140 thousand).
In February 2023, Jeffs’ Brands Holding Inc., was established as a wholly owned subsidiary of Jeffs’ Brands.
On March 9, 2023, Jeffs’ Brands purchased all of the issued and outstanding share capital of Fort, a company incorporated under the laws of England and Wales. For additional information see note 21(6).
Initial Public Offering
On August 30, 2022, Jeffs’ Brands completed its initial public offering (“IPO”). In connection with the IPO, Jeffs’ Brands sold 3,717,473 units at a public offering price of USD 4.16 per unit, with each unit consisting of one ordinary share, no par value per share (“Ordinary Share”), and one warrant (“IPO Warrant”), to purchase one Ordinary Share, at an exercise price of USD 4.04 per Ordinary Share. Additionally, Jeffs’ Brands issued warrants to the underwriter to purchase up to 185,873 ordinary shares at an exercise price of USD 5.20 per Ordinary Share (“Underwriter’s Warrants”). The underwriter partially exercised its right to purchase an additional 425,912 warrants for total consideration of USD 4 thousand. Jeffs’ Brands received total net proceeds of USD 13.4 million after deducting issuance costs of USD 2.1 million. Following the IPO completion, the Company’s holdings in Jeffs’ Brands decreased to 35.94% of the issued and outstanding share capital of Jeffs’ Brands.
On September 7, 2022, Jeffs’ Brands’ volume weighted average stock price was less than the exercise floor of USD 4.04 for the IPO Warrants. Accordingly, and based on the contractual terms of the IPO Warrants, effective after the closing of trading on November 28, 2022 (the 90th calendar day immediately following the issuance date of the IPO Warrants), the IPO Warrants were adjusted (“As-Adjusted IPO Warrants”) pursuant to their terms, including, but not limited to, the reduction of the exercise price of the IPO Warrants to USD 2.02.
Additionally, Additional Warrants were issued to each qualified buyer who continued to hold at least 120,192 IPO Warrants as of November 28, 2022. Accordingly, Jeffs’ Brands issued Additional Warrants to purchase 2,824,525 Ordinary Shares. Each Additional Warrant has substantially the same terms as the As-Adjusted IPO Warrant; provided, however, that the term of each Additional Warrant will be five (5) years from the issuance date and such Additional Warrant will not be listed on any securities exchange. In addition, as long as the Additional Warrants are outstanding, each holder of at least 120,192 IPO Warrants will receive semi-annual payments based on the Jeffs’ Brands consolidated revenues, dependent on the amount of the Additional Warrants outstanding. As of December 31, 2022, the payment will be equal to approximately 2.3% of Jeffs’ Brands consolidated revenues for the period ended December 31,2022.
The IPO Warrants and the Additional Warrants were accounted for derivative liabilities measured at fair value through profit or loss (see note 5).
The Ordinary Shares and IPO Warrants trade on the Nasdaq under the symbol “JFBR” and “JFBRW”, respectively.
F-53
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
E. | Jeffs’ Brands Ltd.: (continued) |
Related parties’ loans
On February 2, 2021, the Company entered into a loan and pledge agreement (the “Pro Loan and Pledge Agreement”) with Pro and Pro’s other shareholder, to finance Pro’s additional purchases of three new brands on the Amazon Online Marketplace. Pursuant to the Pro Loan and Pledge Agreement, the Company and Pro’s other shareholder extended a USD 3.76 million and a USD 940 thousand loans, respectively, with an annual compound interest of 4%, to be repaid on February 2, 2026.
The Company concluded the stated interest is materially lower than its market price. Accordingly, the difference between the fair value and face value of the loan attributable to the Company was recorded as a deemed contribution by the Company to Jeffs’ Brands. Similarly, the difference between the fair value and face value of the loan attributable to the non-controlling interest was recorded as a deemed contribution by the non-controlling interest to Jeffs’ Brands.
Until May 3, 2022, the loans were measured at amortized cost.
As of May 3, 2022, Pro had outstanding loans to the Company, Mr. Hakmon and L.I.A. Pure Capital Ltd. of USD 4.1 million, USD 940 thousand, and USD 109 thousand, respectively. On May 3, 2022, Jeffs’ Brands entered into Assignments to Loan Agreements with the Company, Pro, Mr. Hakmon and L.I.A. Pure Capital Ltd., pursuant to which Jeffs’ Brands assumed Pro’s obligations under the outstanding loans and agreed that unless previously repaid, pursuant to the terms of the respective loan agreements with such parties, effective immediately upon the consummation of IPO, all outstanding principal due to each such party shall be automatically converted into a number of Jeffs’ Brands ordinary shares equal to the quotient obtained by dividing the outstanding principal amount due to such party, by the per ordinary share price obtained by dividing USD 10 million by the fully diluted issued and outstanding ordinary shares as of immediately prior to the closing of the IPO. Any accrued and unpaid interest due to such party as of such date will be paid in cash.
The Company concluded the modified loan terms (“Modified Loan”) including an equity conversion feature upon IPO, represent a substantial modification in accordance with IFRS 9 and is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Accordingly, the difference between the fair value and face value of the loan attributable to the Company was recorded as a deemed contribution by the Company to Jeffs’ Brands. Similarly, the difference between the fair value and face value of the loan attributable to the non-controlling interest was recorded as a deemed contribution by the non-controlling interest to Jeffs’ Brands.
In connection with the IPO that was consummated on August 30, 2022, the loans between the Company, Jeffs’ Brands, Mr. Hakmon and L.I.A. Pure Capital Ltd. were converted into 1,463,619 ordinary shares.
Short term loans
December 31, 2022 | December 31, 2021 | |||||||
USD in thousands | ||||||||
Amazon loans | 86 | 101 | ||||||
Related party loan | 111 | |||||||
Third parties’ loans | 715 | |||||||
86 | 927 |
F-54
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
E. | Jeffs’ Brands Ltd.: (continued) |
Amazon Loans
On April 8, 2021, Pro entered into a loan agreement with Amazon.com. Pursuant to which, Pro received from Amazon.com an aggregated amount of USD 78 thousand. The loan matures within 12 months and bears an annual interest at a rate of 10.99% per year. In order to secure the loan, Pro pledged its financial balances on its Amazon account on Amazon.com and its inventories held in Amazon’s warehouses, in favor of Amazon.com. In September 2021, the loan was fully repaid.
On September 22, 2021, Pro entered into a loan agreement with Amazon.com. Pursuant to the loan agreement, Pro received from Amazon.com an aggregated amount of USD153 thousand, of which USD14 thousand of such amount offset from the received amount on the account of repayment of previous Amazon loan balance. The loan matures within 9 months and bears an annual interest at a rate of 9.99% per year. In order to secure the loan, Pro pledged its financial balances on its Amazon account on Amazon.com and its inventories held in Amazon’s warehouses, in favor of Amazon. On May 9, 2022, the loan was fully repaid.
On May 09, 2022, Pro entered into a loan agreement with Amazon.com. Pursuant to the loan agreement, Pro received from Amazon.com an aggregate amount of USD 153 thousand. The loan matures within 12 months and bears an annual interest at a rate of 9.99% per year. In order to secure the loan, Pro pledged its financial balances on its Amazon account on Amazon.com and its inventories held in Amazon’s warehouses, in favor of Amazon.
Third parties’ loans
July 1, 2021, loan:
On July 1, 2021, Pro entered into a loan agreement with a third party. The loan bore annual interest rate of 10% and was payable on January 1, 2022. Pro was entitled to extend the loan by an additional sixty days, with additional interest of 1% per month. In addition, pursuant to the loan agreement, in the event of an IPO of Jeffs’ Brands, the lender will be entitled to Ordinary Shares of the Company at an aggregate value of USD 125 thousand with a conversion price at the IPO price. On July 6, 2021, the loan principal of USD 375 thousand was received. The proceeds from the lender were first allocated to the liability to issue a variable number of shares based on its fair value at the date of issuance in an amount of USD 31, with a corresponding discount recorded on the third-party loan. The derivate liability is revalued at each period-end and amounted to USD 69 as of December 31, 2021 (see note 5).
On November 23, 2021, the loan agreement was amended to extend the maturity date of the loan to the earlier of (i) March 31, 2023, or (ii) the closing of an IPO of the Company. Based on Jeffs’ Brands management’s assessment, the amendment resulted in a significant modification to the loan in accordance with IFRS 9. As a result of the debt extinguishment, Jeffs’ Brands recorded a financial gain in the amount of USD 7 thousand.
Following the IPO, Jeffs’ Brands repaid the third-party loan and issued the third-party 30,048 warrants.
July 5, 2021, loan:
On July 5, 2021, Pro entered into a loan agreement with a third party. The loan bore annual interest rate of 10% and was payable on January 5, 2022. Pro had the right to extend the loan period by an additional sixty days, with additional interest of 1% per month. In addition, pursuant to the loan agreement, in the event of an IPO of Jeffs’ Brands, the lender would be entitled to Ordinary Shares of Jeffs’ Brands at an aggregate value of USD 125 thousand, with a conversion price based on the IPO price per share, exercisable for a three-year period beginning on the closing date of the IPO. On July 9, 2021, the loan principal of USD 375 thousand was received. The proceeds from the lender were first allocated to the liability to issue a variable number of shares based on its fair value at the date of issuance in an amount of USD 31, with a corresponding discount recorded on the third-party loan. The derivate liability is revalued at each period-end and amounted to USD 69 as of December 31, 2021 (see note 5).
F-55
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
E. | Jeffs’ Brands Ltd.: (continued) |
Third parties’ loans (continued)
July 5, 2021, loan: (continued)
On November 23, 2021, the loan agreement was amended to extend the maturity date of the loan to the earlier of (i) March 31, 2023, or (ii) the closing of an IPO of the Company. Based on Jeffs’ Brands management’s assessment, the amendment resulted in a significant modification to the loan in accordance with IFRS 9. As a result of the debt extinguishment, Jeffs’ Brands recorded a financial gain in the amount of USD 7 thousand.
Following the IPO, Jeffs’ Brands repaid the third-party loan and issued the third-party 30,048 warrants.
Bank Leumi Loan
On February 22, 2022, Jeffs’ Brands entered into a loan agreement with Bank Leumi Le-Israel (“Bank Leumi”) to provide a line of credit in an aggregate amount of up to USD 1 million, which Jeffs’ Brands may draw in two tranches at its request, but in no event after July 21, 2022. Pursuant to the loan agreement, amounts drawn bear interest at a rate of Secured Overnight Financing Rate (“SOFR”) plus 3.25% annually. Unless otherwise provided with respect to a particular draw, any unpaid principal together with accrued and unpaid interest under the line of credit is required to be repaid no later than August 21, 2022. In order to induce Bank Leumi to provide the loan, Jeffs’ Brands and the Company entered into a controlling shareholders’ comfort letter, subordination agreements and a negative pledge. On March 3, 2022, Jeffs’ Brands drew USD 400 thousand under the line of credit. On June 2, 2022, Jeffs’ Brands drew additional USD 200 thousand under the line of credit. Following the IPO, Jeffs’ Brands repaid the bank loan.
Related parties’ loans
For more information on related parties’ transactions see note 17b4.
Deferred offering costs
Jeffs’ Brands capitalized certain legal and other third-party fees that were directly related to the Jeffs’ Brands IPO. As of December 31, 2021, there were USD 366 thousand of deferred offering costs included in other non-current assets on the balance sheet.
The total gross consideration from the IPO was initially allocated to the derivative warrant liability based on its fair value and the remaining amount was allocated to the Ordinary Shares issued and recognized as a component of equity. Issuance costs were allocated between the warrant liability and Ordinary Shares based on their relative fair values.
Ordinary shares and incentive plan
As of December 31, 2021, Jeffs’ Brands issued and outstanding ordinary shares are comprised of 10 thousand shares.
On January 19, 2022, Jeffs’ Brands board of directors approved Jeffs’ Brands 2022 Incentive Option Plan (the “Plan”). A total of 1,765 ordinary shares were reserved and subject to the Plan. The Plan was amended on February 17, 2022, and the number of options increased to 3,000,000 ordinary shares (the total number of ordinary shares reserved for the exercise of options granted under the Plan is 1,307,027 following the effectiveness of the two reverse share splits). The Plan is intended as an incentive to retain directors, officers, employees, consultants and advisers of Jeffs’ Brands.
On February 17, 2022, Jeffs’ Brands board of directors approved the issuance of bonus shares (equivalent to a stock dividend) on a basis of 664 (prior to adjustments for subsequent reverse share split) Ordinary Shares for each Ordinary Share issued and outstanding as of the close of business on February 17, 2022 (provided that any fractional shares be rounded down to the nearest whole number), pursuant to which holders of Jeffs’ Brands ordinary shares received 664 (prior to adjustments for subsequent reverse share split) ordinary shares for every one ordinary share held as of such date, resulting in an aggregate issuance by Jeffs’ Brands of 6,630,547 (prior to adjustments for subsequent reverse share split) Ordinary Shares on such date.
Additionally, Jeffs’ Brands’ board of directors approved an increase of the authorized share capital of Jeffs’ Brands to 100 million (43,567,567 after giving effect to the two reverse share splits) ordinary shares subject to Jeffs’ Brands’ shareholder approval and effective upon the effective date of the registration statement.
F-56
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
E. | Jeffs’ Brands Ltd.: (continued) |
Ordinary shares and incentive plan (continued)
On May 3, 2022, Jeffs’ Brands’ board of directors approved a 0.806-for-1 reverse split of the Jeffs’ Brands issued and outstanding ordinary shares, effective as of May 3, 2022, pursuant to which, holders of the Jeffs’ Brands ordinary shares received 0.806 of ordinary shares for one ordinary share held as of immediately prior to such date. The reverse stock split proportionally reduced the number of authorized share capital to 5,352,281 shares.
On June 16, 2022, Jeffs’ Brands’ board of directors approved a 1-for-1.85 reverse split of Jeffs’ Brands issued and outstanding ordinary shares, effective as of June 16, 2022, pursuant to which, holders of Jeffs’ Brands ordinary shares received one ordinary share for every 1.85 ordinary shares held as of such date. The reverse stock split proportionally reduced the number of authorized share capital to 2,893,125 shares.
All share and stock option information related to Jeffs’ Brands, have been adjusted to reflect the bonus share issuance and the reverse share splits.
Consultant agreement with Pure Capital
On October 26, 2022, Jeffs’ Brands and Pure Capital entered into a consulting agreement, pursuant to which Pure Capital will provide consulting services to Jeffs’ Brands for a monthly fee of NIS 57.5 thousand (approximately USD 16.5 thousand). Jeffs’ Brands paid Pure Capital a one-time signing bonus in the amount of NIS 425 thousand (approximately USD 121 thousand) for their services to Jeffs’ Brands from the day of Jeffs’ Brands inception until the closing of the IPO. As part of the consulting agreement, Pure Capital is also entitled to the following payment: (i) an amount equal to 7% of the gross proceeds paid to Jeffs’ Brands in connection with any exercise of warrants, whether or not currently outstanding; and (ii) 8% of the total consideration paid in connection with any purchase of a new brand, businesses, or similar events initiated or assisted by Pure Capital and approved by the Chief Executive Officer and Chairman of the Board based on agreement with Pure Capital. The consulting agreement is for an undefined period of time and may be terminated after 3 years from October 26, 2022, by either party upon 30 days advance notice.
Additionally, on October 26, 2022, Jeffs’ Brands and Pure NJ Logistics LLC, owned by Pure Capital and a director of Jeffs’ Brands, entered into a warehouse lease agreement for a warehouse located in the USA. As of December 31, 2022, the advances to suppliers comprised of USD 228 thousand that were paid to Pure NJ Logistics LLC.
Short-term lease agreement with the Company
On May 21, 2022, Jeffs’ Brands entered into a short-term lease agreement for its offices from the Company and participated in 50% of the related lease and maintenance expenses. Jeffs’ Brands paid USD 86 thousand plus VAT on December 30, 2022. The outstanding payable to the Company as of December 31, 2022, was USD 32 thousand plus VAT.
Leases
Jeffs’ Brands leases office space since October 1, 2022, for a period of 3 years.
As of December 31, 2022, Jeffs’ Brands’ right of use asset and lease liabilities totaled USD 138 thousand and USD 141 thousand, respectively.
Jeffs’ Brands uses its incremental borrowing rate as the discount rate for its leases, as the implicit rate in the lease is not readily determinable. As of December 31, 2022, Jeffs’ Brands’ leases had a weighted average remaining lease term of 3 years and a weighted average borrowing rate of 10%.
F-57
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
F. | Gix Internet Ltd: |
General
On June 19, 2019, the Company signed an agreement with Gix Internet and its then wholly owned subsidiary Gix Media, for an investment of approximately USD 5 million (the “Investment Agreement”). The investment was subject to certain pre-conditions, which were met on September 3, 2019. As part of the investment, the Company received 729,508 ordinary shares of Gix Media, 2,168,675 ordinary shares of Gix Internet and 2,898,183 warrants to purchase 2,898,183 Gix Internet’s shares.
Medigus was also entitled, for a period of three years following the closing of the investment, to convert any and all of its Gix Media’s shares into Gix Internet shares with a 20% discount over the average share price of Gix Internet on TASE within the 60 trading days preceding the conversion (“Conversion Right”).
As part of the investment agreement, an anti-dilution mechanism was included that would occur under a certain event set in the agreement in the three-year period since September 3, 2019. Until September 3, 2022, such event had not occurred. On September 3, 2022, the Anti-dilution has expired.
The Company also held 2,898,183 warrants to purchase 2,898,183 Gix Internet shares at an exercise price of NIS 5.25 per share (“Gix Warrants”), with the expected term of 3 years following the closing. The warrants were measured at fair value through profit or loss using Black-Scholes model. The warrants expired on September 3, 2022.
In March and June 2021, the Company exercised its rights to convert Gix Media’s shares to Gix Internet shares such that after those conversions the Company owned 33.17% of Gix Internet.
These increases were accounted for as additional purchases, using the “step by step” method, with the purchase price being the fair value of Gix Media shares and the fair value to the conversion option as of the conversion option exercise date.
On October 14, 2021, Gix Media completed the acquisition of 70% of the outstanding and issued shares of Cortex Media Group Ltd. (“Cortex”), a media-tech company that has developed expertise in turning original content into a profit center through user traffic acquisition.
During February 2022, the Company purchased 1,318,426 shares of Gix Internet for a total consideration of USD 731 thousand (NIS 2.4 million) (“Cash Consideration”).
Through the period from February 14, 2022, up to February 28, 2022, following several purchases of Gix Internet’s shares, the Company’s interest in Gix increased to 38.03%, which resulted in gain of control in Gix Internet. Accordingly, Gix Internet was consolidated as of March 1, 2022. The acquisition purchase price of approximately USD 7.7 million. As a result, the Company recorded a gain of USD 2.3 million in the consolidated statement of income/loss and other comprehensive income/loss.
The Company allocated the purchase price between tangible and intangible assets acquired and liabilities assumed based on estimated fair values, with the residual of the purchase price recorded as goodwill. The intangible assets identified in the acquisition were technology and customer relations.
The table set forth below summarizes the allocation of the purchase price between tangible and intangible assets acquired and liabilities assumed as of the acquisition date:
F-58
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
F. | Gix Internet Ltd: (continued) |
General (continued)
As of February 28, 2022, Gix Internet held 78% and 58% of the outstanding and issued shares of Gix Media and ViewBix Inc. respectively. Gix Media held 70% of the outstanding and issued shares of Cortex.
On June 21, 2022, Gix Internet issued 3,450,800 rights to units for a total consideration of NIS 5.7 million. Each unit comprised of shares and tradable warrants The Company purchased 3,171,160 units in consideration for USD 1.5 million (NIS 5.2 million). The transaction was accounted for in the Group’s consolidated financial statements as a transaction with non-controlling interest.
As a result of the rights offering the Company’s interest in Gix Internet increased to 42.69%.
On August 28, 2022, the General Meeting of Gix Internet shareholders approved the issuance of 155,427 shares (an expenses of USD 66 thousand) and 260,492 shares (an expenses of USD 110 thousand) to Gix Internet CEO and former chairman of the board of directors, respectively, as a special bonus. Additionally, the General Meeting of Gix Internet shareholders approved the issuance of 400,000 options to four of Gix Internet directors (an expense of USD 24 thousand). The shares and the warrants were issued on September 18, 2022. Following the issuance of shares the Company holdings in Gix Internet was 42.25%.
On September 19, 2022, Gix Internet completed a reverse triangle merger (“merger”) between Gix Internet, Gix Media and ViewBix Inc. After the merger, Gix Media became a wholly owned subsidiary of ViewBix Inc.
For the year ended December 31, 2022, Cortex distributed dividends in the amount of USD 1,698 thousand.
On December 25, 2022, Cortex declared a dividend in the total amount of USD 445 thousand which was partially distributed in February 2023.
On September 14, 2022, Gix Media declared a dividend in the amount of USD 1,000 thousand. The amount, net of tax, was distributed partially as of December 31, 2022. The remaining amount was distributed by Gix Media in January 2023
Loans
Short term loans:
December 31, 2022 | ||||
USD in thousands | ||||
Short term bank loans | 5,025 | |||
Current maturities of long-term loans | 1,500 | |||
Total consideration | 6,525 |
Long term loans:
December 31, 2022 | ||||
USD in thousands | ||||
Long term bank loans | 2,881 |
F-59
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
F. | Gix Internet Ltd: (continued) |
Loans (continued)
On December 18, 2020, ViewBix Inc. entered into an agreement with certain investors (“Investors”) in connection with the sale and issuance of shares of common stock. In addition, and on the same date, ViewBix Inc. entered into a loan agreement with the Investors, pursuant to which the Investors loaned an aggregated amount of USD 69 thousand (the “Principal Amount”). In accordance with the terms of the loan agreement, ViewBix Inc. repaid the interest on the Principal Amount (8% compounded annually) to the Investors in the form of an issuance of shares of common stock. During 2023 ViewBix repaid the loan to investors in 3 equal payments.
On October 13, 2021, Gix Media entered into a loan agreement with Bank Leumi Le-Israel (“Bank Leumi”) to provide for a line of credit in an aggregate amount of up to USD 3.5 million and a long-term loan in an aggregate amount of up to USD 6 million. Additionally, Gix Internet also signed on a loan agreement with Bank Leumi in an aggregate amount of up to NIS 3 million. The main points of the agreement with Bank Leumi include:
● | NIS 3 million loan to Gix Internet for 48 months period. The loan shall bear interest at rate of prime plus 2.92% annually. The loan was classified as long-term loan. |
● | USD 6 million loan to Gix Media for 48 months period. The loan shall bear interest at rate of LIBOR plus 4.12% annually. The loan was classified as long-term loan. |
● | Credit line to Gix Media in an aggregate amount of up to USD 3.5 million to be utilized for a period of up to 48 months. The amounts that will be drawn from the credit line will bear interest of LIBOR plus 3.2% annually. The credit line was classified as short-term loan. |
On April 7 ,2022 Cortex, a subsidiary of Gix Media, entered into an amendment to the loan agreement dated August 15, 2021, with Bank Leumi Le-Israel (“Bank Leumi”) to provide for additional credit line in an aggregate amount of up to USD 1 million, such that the total allocated credit line sum up to USD 2.5 million to be utilized till September 24 ,2022. The initial credit line shall bear an interest rate of LIBOR plus 3.45% annually while the additional credit shall bear an interest rate of SOFR plus 3.52% annually. The credit line was classified as short-term loan. As of December 31, 2022, the additional credit line was not renewed.
Loan agreement between the Company and Gix Internet
On October 13, 2021, the Company entered into a loan agreement with Gix Internet. Pursuant to the loan agreement, Gix Internet received an aggregate amount of USD 1,240 thousand (NIS 4,000 thousand) from the Company. The loan bears interest at a rate equivalent to the minimal interest rate recognized and attributed by the Israel Tax Authority (3.23% in 2022). The loan will be repaid in full, together with the accrued interest, in one (1) instalment upon the earliest of: (i) the closing of a rights offering by Gix Internet for an aggregate amount of at least NIS 12,000 thousand (approximately USD 3,858 thousand); or (ii) June 30, 2022. Upon consolidation of Gix Internet as of February 28, 2022, as further described above, the loan is eliminated in consolidation.
The Company concluded the stated interest is materially lower than its market price. The loan was initially measured at fair value in accordance with IFRS 9, Financial Instruments. Accordingly, the difference between the fair value and face value of the loan attributable to the Company was recorded as a capital reserve. The difference between the fair value and face value of the loan attributable to Gix Internet was recorded as deemed contribution by the Company to Gix Internet.
On August 25, 2022, the Company and Gix Internet signed an addendum to the Loan Agreement, effective as of July 1, 2022. Pursuant to the addendum, on November 2, 2022, the company received a total of NIS 1 million as repayment of the loan and the accrued interest up to that date. Repayment of the balance of the loan fund, in the amount of NIS 3 million, will be postponed until June 30, 2023. In addition, the Company will be entitled to request the conversion of all or part of the balance of the extended loan in exchange for Gix Internet’s shares.
Based on the Company’s management assessment, the modified loan terms (“Modified Loan”) including an equity conversion feature, represent a substantial modification in accordance with IFRS 9 and is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability.
F-60
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
F. | Gix Internet Ltd: (continued) |
Investment accounted for using the equity method
The tables set forth below summarizes the activity in the investment account and the reconciliation to carrying amounts:
Activity in investment account:
F-61
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
F. | Gix Internet Ltd: (continued) |
Investment accounted for using the equity method (continued)
Reconciliation to carrying amounts:
F-62
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
G. | Automax: |
On January 19, 2021, and March 9, 2021, the Company sold 2,300,000 and 11,000,000 shares of Matomy, respectively. Subsequently, following such sales and the merger of Matomy with Automax, which is now traded on TASE (AMX.TA), the Company’s aggregate holdings in Automax decreased to 4.73% of its issued and outstanding share capital. Therefore, the investment since March 9, 2021, was treated as fair value through profit or loss, (see also note 5). The total gain recognized through profit or loss related to these sales sums up to USD 2,025 thousand in the consolidated statements of income/loss and other comprehensive income / loss for the year ended December 31, 2021.
During August and October 2021, the Company purchased additional shares in the amount of USD 280 thousand, which increased the Company’s interest in Automax to 5.63%.
On March 6, 2022, the Company purchased 220 thousand tradeable Automax bonds at a price of NIS 1 thousand per bond at a total amount of USD 70 thousand (NIS 220 thousand). During April and May 2022, the company sold 190 thousand tradeable Automax bonds. The Automax bonds were accounted for as assets through profit or loss measured at fair value.
During July 2022, the Company purchased 2,000,000 additional shares of Automax in the amount of USD 213 thousand.
As of December 31, 2022, the Company owned 6.46% of Automax.
For additional information see note 5.
The activity in the investment account of Automax for the period ended on March 9 ,2021 was as follows:
H. | Polyrizon |
Polyrizon Ltd. (“Polyrizon”) is a private company engaged in developing biological gels designed to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities.
As of December 31, 2022, the Company holds 37.03% of Polyrizon shares and the investment is accounted for using the equity method.
On January 27, 2022, Polyrizon entered into a Simple Agreement for Future Equity (“SAFE”) with several investors for aggregated proceeds of USD 250 thousand. The Company invested USD 110 thousand.
On May 8, 2022, Polyrizon entered into an additional SAFE with several investors for aggregated proceeds of USD 550 thousand. The Company invested USD 203 thousand.
F-63
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
H. | Polyrizon (continued) |
Upon completion of IPO, the SAFE will be automatically converted into a number of Ordinary Shares equal to the purchase amount divided by the per unit price in this offering discounted by 20%. If an IPO will not occur by July 31, 2023, the SAFE will be automatically converted into such number of the most senior class of Equity Shares of Polyrizon then outstanding, equal to, the purchase amount, divided by the lowest price per share actually paid to Polyrizon for such most senior class of Equity Shares of the Company then outstanding, discounted by 20%.
The SAFE investments were accounted for as assets through profit or loss measured at fair value. The main assumptions used in estimating the fair value were: risk-free interest rate as of December 31, 2022, 4.76%, probabilities of five difference scenarios (equity financing, liquidity event, IPO, drop date and failure).
As of December 31, 2022, the fair value of the SAFE is USD 302 thousand. See note 5.
On May 30, 2022, Polyrizon entered into a collaboration agreement with SciSparc. As part of the collaboration, Polyrizon will work with SciSparc to develop a unique technology for the treatment of pain, based on SciSparc’s SCI-160 platform and Polyrizon’s T&T platform technology.
Under the collaboration agreement, SciSparc will pay development fees to Polyrizon of up to USD 2.5 million upon the completion of certain milestones, as well as royalties upon sales of products. Until December 31, 2022, no funds have been transferred between the companies and the terms of the agreement have not been fulfilled.
The activity in the investment account of Polyrizon during the years ended December 31, 2022, and 2021, was as follows:
For the year ended December 31, 2022 | ||||
USD in thousands | ||||
Balance as of January 01, 2022 | 447 | |||
Group share in losses | (233 | ) | ||
Balance as of December 31, 2022 | 214 |
For the year ended December 31, 2021 | ||||
USD in thousands | ||||
Balance as of January 01, 2021 | 103 | |||
Group share in losses | (50 | ) | ||
Excess cost amortization | (24 | ) | ||
Additional purchase on March 9, 2021 | 297 | |||
Additional purchase on August 25, 2021 | 121 | |||
Balance as of December 31, 2021 | 447 |
F-64
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
I. | Charging Robotics Ltd: |
On January 7, 2021, the Company entered an agreement to purchase a provisional patent filed with the United States Patent and Trademark Office and know-how relating to wireless vehicle battery charging technology in consideration for USD 75 thousand. Furthermore, the Company entered a collaboration agreement with the seller, whereby the Company committed to invest USD 150 thousand in a newly incorporated wholly owned subsidiary of the Company, Charging Robotics Ltd. (hereinafter – “Charging Robotics”), incorporated on February 1, 2021, which will focus on the Company’s new electric vehicle and wireless charging activities. Pursuant to the collaboration agreement, the seller is entitled to a monthly consultant fee as well as options to purchase 15 shares, which represents 15% of Charging Robotics’ fully diluted share capital as of its incorporation date, at an exercise price of USD 150 thousand. The option was fully vested on July 30, 2021. The fair value of the options granted was estimated on the grant date, using the Black-Scholes Model, according to the following parameters: (a) risk-free interest rate – 0.85%; (b) expected dividend – 0%; (c) expected volatility – 85%; (d) forecasted life –4.44 years. For the year ended December 31, 2022, and 2021 approximately USD 0 thousand and USD 91 thousand were recognized and recorded as expenses.
During 2021 the Company invested in Charging Robotics an additional amount of USD 741 thousand.
On February 19, 2021, the Company entered into the Venture Agreement, with Mr. Amir Zaid and Mr. Weijian Zhou (the founders of Emuze Ltd., a privately held company that designs and develops electric mobility micro vehicles), and Charging Robotics (the “Venture Agreement”), under which the Company formed a venture, under the name Revoltz, to develop and commercialize three modular electric vehicle (“EV”) micro mobility vehicles for urban individual use and “last mile” cargo delivery.
Under the terms of the Venture Agreement, the Company invested an initial amount of USD 250 thousand in consideration of 19,990 ordinary shares of Revoltz Ltd. (“Revoltz”), representing 19.99% of Revoltz’s issued and outstanding share capital on a fully diluted basis. The Venture Agreement requires the Company to invest an additional USD 400 thousand in a second tranche, subject to Revoltz achieving certain post-closing milestones, for 37.5% of Revoltz’s issued and outstanding share capital. As of December 31, 2022, the milestones were not achieved, therefore no additional investments occurred. The investment in Revoltz was accounted for using the equity method. The additional investment requirement was accounted for as a derivative liability measured at fair value through profit or loss. As of December 31, 2022, the fair value of the derivative liability was concluded to be immaterial.
On March 11, 2022, the Company and Charging Robotics signed a non-binding letter of intent for a planned securities exchange agreement with Fuel Doctor (see note 4L). The securities exchange agreement, if signed, will be subject to customary closing conditions. The transaction will result in Charging Robotics becoming a wholly owned subsidiary of Fuel Doctor, and in exchange, the Company will receive 80% of the issued and outstanding share capital of Fuel Doctor. Upon closing, the Company will appoint nominees as officers and directors of Fuel Doctor. As of the closing, Fuel Doctor shall have net cash in an amount of no less than USD 1 million, excluding Fuel Doctor’s expenses in connection with the contemplated transaction. On March 28, 2023, a security exchange agreement between the company and Fuel Doctor Holdings Inc. was signed.
On July 28, 2022, Charging Robotics entered into a convertible loan agreement with Revoltz pursuant to which Charging Robotics was required to invest an amount of USD 60 thousand in Revoltz (the “Loan Principal Amount”). In addition, Charging Robotics provided Revoltz an additional loan of up to USD 340 thousand (the “Additional Amount”, and together with the Loan Principal, the “Total Loan Amount”). The Total Loan Amount shall carry interest at the minimum rate prescribed by Israeli law.
The Total Loan Amount shall be converted into shares of Revoltz, upon the occurrence of any of the following events (each a “Trigger Event”):
a. The consummation of funding by Revoltz of an aggregate amount of USD 1 million at a pre-money Revoltz valuation of at least USD 7 million (in the form of SAFE, equity or otherwise).
b. Revoltz has generated an aggregate of USD 1 million or more revenues.
In the event that a Trigger Event shall not have occurred on or prior to the 24-month anniversary of the date on which the Loan Principal Amount was extended to Revoltz, the Loan shall be due and repayable by Revoltz to Charging Robotics.
F-65
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
J. | Elbit Imaging Ltd.: |
Elbit Imaging Ltd. operates in the following principal fields of business: (i) medical industries through indirect holdings in Insightec Ltd. and Gamida Cell Ltd.; and (ii) land plots in India which are designated for sale (and which were initially designated for residential projects).
During June 2021 the Company purchased 5.12% of the outstanding shares of Elbit Imaging Ltd in total amount of USD 1.06 million.
On June 30, 2021, the Company submitted a request to convene a special meeting to replace some of the directors in Elbit Imaging Ltd. The meeting took place on August 4, 2021, and the Company appointed 3 directors out of the 8 directors in Elbit Imaging Ltd. Therefore, since that date, the Company concluded to have a significant influence in Elbit Imaging Ltd. and the investment was accounted for as an equity investment.
During July 2021, the Company invested additional amount of USD 134 thousand and the holdings increased to 5.72%.
In April and June 2022, Elbit Imaging paid dividends to shareholders. The Company received a total amount of USD 172 thousand.
In the general shareholders meeting held on October 18, 2022, two of the directors who were previously appointed by the Company ceased their roles as directors of Elbit Imaging Ltd. As a result, and as of that date, the Company’s investment was treated as an investment at fair value through profit or loss. See also note 5.
The activity in the investment account of Elbit Imaging Ltd. for the period ended October 18, 2022, was as follows:
The activity in the investment account of Elbit Imaging Ltd. during the year ended December 31, 2021, was as follows:
F-66
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
K. | SciSparc Ltd. |
SciSparc Ltd. (“SciSparc”) is an Israeli company. SciSparc listed its American Depository Shares on the OTCQB until December 7, 2021, after which SciSparc uplisted to Nasdaq.
Buffalo Investments Ltd. (“Buffalo”), an Israeli private company, owned 150,000 options to purchase 150,000 shares of SciSparc at an exercise price of USD 5.02 per share. On December 7, 2021, the Company entered into an option purchase agreement with Buffalo (the “Buffalo Agreement”) for the purchase of the 150,000 options in consideration for USD 0.72 per option. The Company paid USD 72 thousand in this transaction. Additionally, the Company was obligated to immediately exercise all such options into shares and the Company paid to SciSparc an additional USD 753 thousand in this transaction. According to the Buffalo Agreement, Buffalo undertook to purchase 85% of the shares back from the Company within 3 months following the Buffalo Agreement (the “Purchase Period”) in consideration for USD 6.05 per share. On April 27, 2022, the Buffalo Agreement was amended such that the Company extended the Purchase Period until June 7, 2021. On June 30, 2022, the Buffalo Agreement was amended such that the Company extended the Purchase Period until December 31, 2022, and Buffalo undertook to purchase 90% of the shares back from the Company.
On December 26, 2021, the Company’s Board of Directors approved to sell all the interests in SciSparc Ltd. in the next twelve months. The investment is SciSparc was therefore classified as a short-term investment as of December 31, 2021. See also note 5.
During March 2022 the company purchased additional 7,971 shares of Scisparc and during December 2022, the company sold 49,157 shares of Scisparc. As of December 31, 2022, the Company holds 108,814 shares of SciSparc which represents 1.6% of SciSparc’s issued and outstanding share capital.
As of December 31, 2022, the Company treated the investment as a short-term forward contract such that the difference between the quoted price and the sale price will be recognized as a provision and the difference between the total cost paid by the Company (USD 5.5 per share) and the price in the forward transaction (USD 6.05 per share) will be recognized as financing income. See note 5.
On January 25, 2023, the Company sold all its holdings in SciSparc.
On March 16, 2023, the Company and Buffalo signed an amendment to the Buffalo Agreement. See note 21(7).
The following table provides the activity in the investment of SciSparc during the year ended December 31, 2022:
Year ended December 31, | ||||
USD in thousands | ||||
Investment as of December 31, 2021 | 911 | |||
Additional purchases | 33 | |||
Sales | (46 | ) | ||
Revenues – Capital losses | (224 | ) | ||
Revaluation – Capital loss | (614 | ) | ||
Revaluation – Finance income | 599 | |||
Revaluation – Forward contract | 576 | |||
Provision- Forward contract | (576 | ) | ||
Investment as of December 31, 2022 | 659 |
The following table provides the activity in the investment of SciSparc Ltd during the year ended December 31, 2021:
December
7, December 31, | ||||
USD in thousands | ||||
Cash investment | 825 | |||
Revaluation – capital gain | 16 | |||
Revaluation – Finance income | 70 | |||
Revaluation – Forward contract | 23 | |||
Provision- Forward contract | (23 | ) | ||
Investment as of December 31, 2021 | 911 |
F-67
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
L. | Fuel Doctor Holdings Inc. |
On December 21, 2021, the Company purchased 90,000,000 shares of Fuel Doctor Holdings Inc. (“Fuel Doctor”), which represent 35.06% of the issued and outstanding shares of Fuel Doctor for a total consideration of USD 262.5 thousand (the “Fuel Doctor Investment”). The Company gained a significant influence over Fuel Doctor and aforementioned investment was accounted for using the equity method.
As of the purchase date Fuel Doctor had total liabilities of USD 5 thousand and had no assets and a negative equity. According to IFRS-3R, the investment was not considered a business acquisition and the transaction was recognized during 2021 as an expense in the consolidated statements of income/loss and other comprehensive income/loss under the item of amortization of the excess cost of an associate.
M. | Parazero Technologies Ltd. |
Parazero was incorporated in Israel on June 30, 2013. Parazero specializes in the design, development, manufacturing, distribution, and sales of safety systems for commercial drones. Parazero’s technology enables real-time identification of critical failures of drones, and upon detection of an emergency, a parachute is autonomously deployed in fractions of a second, thus ensuring safe landings at all times. Parazero sells its products internationally with a focus on the U.S. market.
On January 28, 2022, the Company and additional investors (the “Acquirers”), entered into a share purchase agreement with Delta drone International Ltd. (“Delta”), an Australian corporation (the “Seller”) to purchase 100% of Parazero’s share capital for a total consideration of AUD 6 million (USD 4,335 million) in cash (the “Consideration Amount”).
The Company purchased 674,362 of Parazero shares as part of this agreement for total consideration of AUD 2,235 thousand (USD 1,613 thousand), which represent 40.35% holdings of the issued and outstanding shares of Parazero. The investment was accounted for as an equity investment. During April 2022, the Consideration Amount was adjusted. As a result of this adjustment, the company received USD 18 thousand. The Company invested the USD 18 thousand as additional SAFE investments.
On January 28, 2022, prior to the closing of the acquisition, all outstanding liabilities between Parazero and Delta were converted into equity.
On February 2, 2022 (the “Issue Date”), Parazero issued to Delta a warrant to purchase shares. The exercise price of such warrant is (A) if a Trigger Event (defined below) occurs, the price per share in the IPO, or, (B) if a Trigger Event has not occurred, USD 5.9834 per each share, reflecting a pre-money valuation of USD 10,000,000 on a fully diluted as-converted basis as of the Issue Date. Further, (A) if an initial public offering of Parazero occurs before the fifth anniversary of the Issue Date, then the warrant shall expire after the lapse of 90 days from the earlier of (“Trigger Event”): (i) the fifth anniversary of the Issue Date; or (ii) the price per each share has increased by at least 50% compared to the listing price per share as part of the IPO (to be determined based upon one-calendar-month Volume Weighted Average Price. (B) if an initial public offering of the Company occurs before the lapse of the fifth anniversary of the Issue Date, then the warrant shall expire after the lapse of 12 months from the fifth anniversary of the Issue Date. This Warrant shall be exercisable for 51,689 Shares of Parazero, in the event of a Trigger Event, or for 50,139 Shares of Parazero in the event there is no Trigger Event. The fair value of the warrants as of February 2, 2022, was estimated at USD 25 thousand. The fair value was calculated using the Black & Scholes option price model. This amount was deducted from the equity as of February 2 ,2022.
The closing date of the transaction occurred on February 2, 2022.
F-68
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
M. | Parazero Technologies Ltd. (continued) |
As of December 31, 2022, the Company holds 40.35% of the issued and outstanding shares of Parazero.
In February, March and May 2022, Parazero entered into a Simple Agreements for Future Equity, or SAFE. Parazero had received USD 1.5 thousand under the SAFE. The Company invested USD 521 thousand through this SAFE.
Parazero is in process of Initial Public Offering (“IPO”). Upon completion of IPO, the SAFE will be automatically converted into a number of Ordinary Shares equal to the purchase amount divided by the per unit price in this offering discounted by 25%. The right to receive shares upon conversion of the SAFE shall also include the right to receive warrants similar to those granted to the investors in the IPO. However, warrants issued upon the conversion of the SAFE will not be tradable warrants nor carry any registration rights.
The SAFE investments were accounted for as assets through profit or loss measured at fair value.
As of December 31, 2022, there were no material differences between the cost and the fair value of the SAFE.
On October 30, 2022, the Company signed a credit facility agreement with Parazero with an aggregate amount of up to USD 625 thousand. The credit facility shall not bear interest and shall be repaid on the earlier of: (i) first anniversary date (ii) the closing of an IPO (iii) default event. As of December 31, 2022, Parazero withdrew USD 500 thousand.
The loan was accounted for as an asset through profit or loss measured at fair value. As of December 31, 2022, the fair value of the loan is USD 391 thousand.
Purchase price allocation summary following a purchase of shares on February 2, 2022:
February 2, 2022 | ||||
USD in thousands | ||||
Purchase price | 1,595 | |||
Adjusted equity | (252 | ) | ||
Excess to allocate | 1,847 | |||
Excess purchase price to allocate to technology | 745 | |||
Goodwill | 1,102 | |||
Total | 1,847 |
The activity in the investment account:
February 2, 2022- December 31, 2022 | ||||
USD in thousands | ||||
Balance as of February 02, 2022 | 1,595 | |||
Group share in losses | (553 | ) | ||
Excess cost amortization | (66 | ) | ||
Balance as of December 31, 2022 | 976 |
F-69
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
M. | Parazero Technologies Ltd. (continued) |
Reconciliation to carrying amounts:
N. | Laminera Flow Optimization Ltd. |
Laminera (formerly “ABI Energy Ltd.”), an Israeli company, is a development stage company that aims to disrupt fluid transportation. Laminera is exploring ways to improve and optimize the global infrastructure of water, oil and gas pipeline transportation by reducing energy costs, maintenance costs, and enhancing capacity without having to replace infrastructure. Laminera was incorporated on June 27, 2017, and started its operation on January 1, 2018. On November 1, 2018, Laminera entered into an agreement with Mekorot Water Company Ltd. (“Mekorot”), the national water company of Israel, to conduct a beta testing and to evaluate Laminera’s beta product to examine the qualification, performance, and other features of the beta product for commercial production. In conjunction with the Mekorot agreement, the Company granted Mekorot warrants to purchase 3,401 Ordinary Shares of Laminera, all of which are fully vested upon grant.
On December 22, 2021, the Company purchased 6,355 shares of Laminera, which represent 11.18% of the issued and outstanding shares, for consideration of USD 126 thousand. The investment was treated in the Company’s consolidated financial statements at fair value through profit or loss.
On March 31, 2022, the Company and a group of investors (each an “Investor”) entered into share purchase agreement with Laminera (“Laminera Agreement”). Laminera raised in a private placement USD 1,105 thousand in cash and USD 400 thousand in share consideration. The Company participated in this finance round and invested USD 300 thousand in cash and issued 324,675 shares of the Company, which fair value at the time of the closing was USD 400 thousand. The closing occurred on March 31, 2022 (“Closing”).
According to the Laminera Agreement, the Company purchased 7,028 shares of Laminera’s ordinary shares. Following the purchase, the Company’s share in Laminera increased to 19.7% of Laminera’s issued and outstanding shares. As of the closing, the Company’s holdings were accounted in the Company’s consolidated financial statements under the equity method. The Company recorded a gain of USD 507 thousand in the consolidated statement of income / loss and other comprehensive income / loss as a result of the revaluation of the investment in Laminera from its initial purchase date through the date of transition to equity method.
In addition, pursuant to the terms of the Laminera Agreement, in the event that Laminera issues new securities on one or more occasions, during the period of 24 months from the closing, without consideration or for a consideration per share of less than the price per share in this agreement (subject to any share split, combination or similar changes), or the “Reduced price per share”, then on each such issuance of new securities Laminera shall issue to each Investor additional ordinary shares, at no cost to the Investor, in such number equal to the difference between (i) the number of Investor shares which would be held by the Investor if it had made the investment under the Reduced price per share; and (ii) the number of Investor’s shares issued to such Investor for its investment under this Agreement (based on the price per share in this Laminera Agreement), or the March 2022 Anti-Dilution Protection. The March 2022 Anti-Dilution Protection expires immediately prior to the earlier of (a) the closing of an initial public offering, and (b) the lapse of 24 months following the date of the Closing. The March 2022 Anti-Dilution Protection is measured at fair value through profit or loss using the Black-Scholes model. As of December 31, 2022, the fair value of the Anti-Dilution Protection was estimated to be inconsequential.
On August 10, 2022, the Company signed a bridge loan agreement with Laminera in the amount of USD 100 thousand. The loan will bear annual interest of 8% and will be repaid up to September 1, 2024. The loan repayment will be accelerated earlier in the event of closing an equity financing round or right offering, an IPO or a default event as described in the bridge loan agreement. As of December 31, 2022, there were no material differences between the cost and the fair value of the bridge loan.
F-70
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
N. | Laminera Flow Optimization Ltd. (continued) |
Purchase price allocation summary following a purchase of shares on March 31, 2022:
The activity in the investment account:
March 31, 2022- December 31, 2022 | ||||
USD in thousands | ||||
Balance as of March 31, 2022 | 1,333 | |||
Group share in losses | (136 | ) | ||
Excess cost amortization | (21 | ) | ||
Balance as of December 31, 2022 | 1,176 |
Reconciliation to carrying amounts:
F-71
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
O. | ClearMind Medicine Inc. |
ClearMind Medicine Inc. (“ClearMind”) was incorporated in the province of British Columbia on July 18, 2017. ClearMind ’s previous business was carrying out mining exploration operations and was involved in the exploration of the Lorn mineral property located in the Clinton and Lillooet Mining Divisions of British Columbia. As of May, 2021, ClearMind is in the business of researching and developing and marketing of proprietary formulations of psychedelic designer therapeutics with an initial focus of developing products.
On February 3, 2022, the Company entered into a subscription agreement with ClearMind, for a private placement in which ClearMind raised approximately CAD 1.6 million (USD 1.25 million) (“Subscription Agreement”). Pursuant to the Subscription Agreement ClearMind issued to the Company 1,987,344 units, at a subscription price of CAD 0.80 (USD 0.63) per unit. Each unit is comprised of one Common Share and one warrant to purchase one Common Share of ClearMind. Each warrant will be exercisable for a period of 18 months into one additional Common Share at an exercise price of CAD 2.00 per share. CAD 960 thousand (USD 750 thousand) of the investment amount was paid by the Company in cash and CAD 640 thousand (USD 500 thousand) of the investment amount was paid through the issuance of the Company’s ordinary shares, at a price per share of USD 1.20. The Company issued to ClearMind 416,666 shares. The Company’s holdings in ClearMind’s issued and outstanding shares were 5.02%.
The transaction closed on April 25, 2022, (“Closing”).
In addition, and pursuant to the Subscription Agreement, if at any time after the Closing, but prior to the earlier of: 18 months after the Closing; and The first business day following the closing of initial public offering on a recognized exchange in the USA, except OTC quotation in the USA; ClearMind shall issue or propose to issue any additional shares, warrants, options to the Company, excluding any of the following:
(a)Option granted to employees of ClearMind ; (b) Common shares upon conversion or exercise of any convertible instruments issued and outstanding, prior to the Closing or other rights or instruments of any kind convertible into or exercisable or exchangeable for common shares (the “Additional Securities”), The Company shall receive for no consideration the Additional Securities necessary to maintain a fully diluted ownership percentage in ClearMind only in respect of the units acquired by way of the Cash Investment. Provided however that in the case of unexercised warrants the purchaser shall receive the Additional Securities in the form of warrants.
On November 14, 2022, ClearMind completed an underwritten public offering of 1,153,847 shares at a price to the public of USD 6.50 per share, for aggregated gross proceeds of USD 7.5 million, prior to deducting underwriting discounts and offering expenses.
In connection with the offering, ClearMind’s common shares were approved for listing on the Nasdaq and began trading on the Nasdaq under the symbol “CMND” on November 15, 2022. Following the public offering, and as agreed on the Subscription Agreement, the Company is entitled to receive 44,829 shares and 2,241 warrants. As of the date of this report, the shares and warrants have not yet been issued.
As of December 31, 2022, the Company holds 5.77% of the issued and outstanding shares of ClearMind. The investment was treated at fair value through profit or loss (see note 5).
P. | Safee Cyber Technologies Ltd. |
On October 13, 2021, the Company entered into a share purchase agreement with Safee Cyber Technologies Ltd., or Safee, a technology company focused on non-fungible tokens (NFTs), pursuant to which the Company invested USD 400 thousand in exchange to approximately 2.35% of Safee’s shares capital on a fully diluted basis. The investment was treated at fair value through profit or loss. See also note 5.
For additional information about the loan agreement between the Company and Safee, see note 4D above.
F-72
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 4 – INTEREST IN OTHER ENTITIES: (continued)
Q. | GERD IP Inc. |
GERD IP Inc. (“GERD IP”) was incorporated under the laws of the State of Delaware on January 13, 2020. GERD IP is in the business of holding and licensing patents that serves as the foundation of a device used to perform a minimally invasive, trans-oral fundoplication surgical procedure for the treatment of patients suffering from gastroesophageal reflux disease.
On May 11, 2021, GERD IP signed a Confidential Settlement Agreement to resolve a lawsuit, concerning alleged infringement of its intellectual property, filed by GERD IP in July 2020 with the United States District Court for the District of Delaware against a US medical device company.
The claim for alleged intellectual property infringement referred to two patents issued by the United States Patent and Trademark Office, owned by GERD IP.
During 2021 GERD IP received USD 1 million compensation related to this settlement agreement, and after reduction of legal cost the net amount received summed up to USD 494 thousand.
During 2022 GERD IP received USD 300 thousand compensation related to this settlement agreement, and after reduction of legal cost the net amount received summed up to USD 137 thousand.
NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT:
Financial risk management:
1) | Financial risk factors |
The Group is exposed to a variety of financial risks such as: market risks, credit risks and liquidity risks. The Group’s overall risk management plan focuses on the unpredictability of financial markets and seeks to minimize the potential adverse effects on the Group’s financial performance.
Risk management is performed by the finance department according to the policy authorized by the board of directors.
a) | Market risk - Currency risk |
Currency risk is the risk that the value of financial instruments will fluctuate due to changes in foreign exchange rates.
The Group operates internationally and is exposed to foreign exchange risks due to exposure to Foreign Currencies, primarily the NIS. Foreign exchange risk arises from future commercial transactions, assets or liabilities denominated in foreign currency.
The Group’s policy to reduce the exposure to changes in exchange rates is based on maintaining, where possible, the balances of current monetary assets, according to the currency of the current liabilities.
As of December 31, 2022, and 2021, if the Group’s functional (USD) had weakened/strengthened by 10% against the NIS, with all other variables held constant, the loss for the year would decrease/increase by USD 600 thousand and USD 379 thousand, accordingly.
b) | Credit risk |
Credit risk arises when a failure by counterparties to discharge their obligations could reduce the amount of future cash inflows from financial assets on hand at the end of the reporting year.
F-73
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: (continued)
Financial risk management: (continued)
1) | Financial risk factors (continued) |
b) | Credit risk (continued) |
Credit risks are treated at the Group level. Credit risks arise typically from cash and cash equivalents, bank deposits and from credit exposures in connection with outstanding receivables and committed transactions.
No credit limits were exceeded during the reported periods and Group’s management does not expect any losses from non-performance of these parties.
c) | Liquidity risk |
Liquidity risk exists where the Group might encounter difficulties in meeting its financial obligations as they become due. The Group monitors its liquidity in order to ensure that sufficient liquid resources are available to allow it to meet its obligations.
Cash flow forecasting is performed by the Group’s finance department of each of the companies in the Group. The finance department monitors rolling forecasts of the Group’s liquidity requirements to ensure that it has sufficient cash to meet operational needs, while maintaining sufficient headroom on its undrawn committed borrowing facilities, so that the Group does not breach any of its credit facilities.
Liquidity risk arises from financial liabilities due to payable balances as of December 31, 2022, and 2021 sum up to USD 35,904 thousand and USD 7,238 thousand, accordingly.
2) | Estimates of fair value |
Below is an analysis of the financial instruments carried at fair value, by valuation method. The different levels have been defined as follows:
● | Quoted prices (unadjusted) in active markets for identical assets or liabilities (level 1). |
● | Inputs other than quoted prices included within level 1 that are observable for the asset or liability, either directly (that is, as prices) or indirectly (that is, derived from prices) (level 3). |
Financial assets
The Company has several financial assets measured at fair value through profit or loss, which meet the level 1 and level 3 criteria as of December 31, 2022, and 2021 as follow:
During 2021 the Company sold shares of Automax and since March 2021 the investment is measured at fair value through profit or loss and meets level 1 criteria.
During 2022 the Company invested another amount of USD 213 thousand in Automax to purchase 2,000,000 shares and, following these purchases, holds 15,446,111 shares and holds 6.46% of Automax’s issued and outstanding share capital (see note 4G).
During 2021 the Company invested in Safee and holds 2.35% of Safee’s issued and outstanding share capital. The investment meets level 3 criteria.
During 2021 the Company invested in Tondo and holds 0.67% of Tondo’s issued and outstanding share capital. The investment meets level 1 criteria.
During 2020 The Company invested in Safo an amount of USD 100 thousand in respect of 91,743 warrants and shares (represent holding of 0.47% Safo’s issued and outstanding share capital). The investment in share meets level 1 criteria. The investment in warrants meets level 3 criteria.
During 2021 the Company invested in SciSparc and holds 3.09% of SciSparc’s issued and outstanding share capital. The investment meets level 1 criteria (see note 4K).
During 2021 the Company invested in Maris-Tech an amount of USD 240 thousand to purchase 78,370 shares and warrants and held 2.09% of Maris-Tech’s issued and outstanding share capital as of December 31, 2021. The investment and warrants were measured according to fair value through profit or loss and meet level 3 criteria. On February 2, 2022, Maris completed an IPO. The Company participated in this IPO and invested an additional amount of USD 100 thousand in Maris-Tech to purchase additional 23,810 shares and warrants. Following this IPO and as of December 31, 2022, the Company holds 1.28% of Maris’s issued and outstanding share capital and the investment was transferred from level 3 criteria to level 1 criteria.
F-74
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: (continued)
Financial risk management: (continued)
2) | Estimates of fair value (continued) |
Financial assets (continued)
During 2022 the Company invested in Bubbles an amount of USD 306 thousand to purchase 1,236,000 shares and holds 1.49% of Bubbles’ issued and outstanding share capital as of December 31, 2022. The investment was measured according to fair value through profit or loss and meets level 1 criteria.
In April 2022 the Company invested in ClearMind an amount of USD 1,250 thousand to purchase 66,245 shares and warrants. In November 2022, the Company invested an additional amount of USD 500 thousand to purchase additional 76,800 shares and holds 5.77% of ClearMind’s issued and outstanding share capital as of December 31, 2022. The investment was measured according to fair value through profit or loss and meets level 1 criteria.
During 2022 the Company invested in Colugo an amount of USD 400 thousand to purchase 24,920 shares and holds 0.97% of Colugo’s issued and outstanding share capital as of December 31, 2022. The investment was measured according to fair value through profit or loss and meets level 3 criteria.
During 2022 the Company invested in Automax bonds an amount of USD 68 thousand to purchase 220,000 bonds. During April and May 2022, the Company sold 190,000 bonds. The Automax bonds were accounted for as asset through profit or loss measured at fair value and meets level 1 criteria.
Polyrizon Options- the Original Option (as defined in note 4H) was measured at fair value through profit or loss and was calculated using the Black & Scholes option pricing model. The Original Option and the Alternative Option (as defined in note 4H) was calculated based on management’s expectations for the IPO scenario.
IPO scenario: share price: USD 1 of expected IPO share price, expected volatility of 81.99%, risk-free interest of 4.22%, expected term of 3.55 years following the grant date.
The following table presents the level 1 and level 3 fair value financial assets as of December 31, 2022, and 2021
December 31, 2022 |
December 31, 2021 |
|||||||||||||||||||||||
Level 1 | Level 3 | Total | Level 1 | Level 3 | Total | |||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||
Gix Internet anti-dilution protection (note 4F) | 469 | 469 | ||||||||||||||||||||||
Laminera shares (note 4N) | 126 | 126 | ||||||||||||||||||||||
Safo shares | 10 | 10 | 53 | 53 | ||||||||||||||||||||
Safo warrants | 34 | 34 | ||||||||||||||||||||||
Maris shares | 84 | 84 | 246 | 246 | ||||||||||||||||||||
Maris warrants | 13 | 13 | 57 | 57 | ||||||||||||||||||||
Tondo shares | 97 | 97 | 429 | 429 | ||||||||||||||||||||
Safee shares (note 4P) | 400 | 400 | 400 | 400 | ||||||||||||||||||||
SciSparc shares (note 4K) | 659 | 659 | 911 | 911 | ||||||||||||||||||||
Polyrizon warrants (note 4H) | 399 | 399 | 516 | 516 | ||||||||||||||||||||
Polyrizon - SAFE (note 4H) | 302 | 302 | ||||||||||||||||||||||
Elbit Imaging shares (note 4J) | 613 | 613 | ||||||||||||||||||||||
ClearMind warrants (note 4O) | 4 | 4 | ||||||||||||||||||||||
ClearMind shares (note 4O) | 594 | 594 | ||||||||||||||||||||||
ClearMind anti-dilution protection (note 4O) | - | - | ||||||||||||||||||||||
Colugo shares | 400 | 400 | ||||||||||||||||||||||
Parazero - SAFE (note 4M) | 520 | 520 | ||||||||||||||||||||||
Bubbles shares | 151 | 151 | ||||||||||||||||||||||
Automax bonds (note 4G) | 9 | 9 | ||||||||||||||||||||||
Automax shares (note 4G) | 1,114 | 1,114 | 1,676 | 1,676 | ||||||||||||||||||||
Total | 3,331 | 2,038 | 5,369 | 3,069 | 1,848 | 4,917 |
F-75
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: (continued)
Financial risk management: (continued)
2) | Estimates of fair value (continued) |
Financial assets (continued)
The following table presents the Level 1 financial assets roll-forward during 2022:
ClearMind | ||||||||||||||||||||||||||||||||||||||||||||
Safo | A.I Systems | Tondo | Bubbles | SciSparc | Maris | Automax bonds | Investment | Elbit | Automax shares | Total | ||||||||||||||||||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2022 | 53 | 429 | 911 | 1,676 | 3,069 | |||||||||||||||||||||||||||||||||||||||
Purchase of securities | 75 | 306 | 32 | 75 | 69 | 1,512 | 214 | 2,283 | ||||||||||||||||||||||||||||||||||||
Net changes at fair value recognized through profit or loss | (43 | ) | (26 | ) | (148 | ) | (15 | ) | (238 | ) | (1,207 | ) | (217 | ) | (578 | ) | (2,472 | ) | ||||||||||||||||||||||||||
Sale of securities | (103 | ) | (344 | ) | (46 | ) | (60 | ) | (553 | ) | ||||||||||||||||||||||||||||||||||
Realized gain (loss) | 28 | 67 | (223 | ) | 1 | (127 | ) | |||||||||||||||||||||||||||||||||||||
Exchange differences | (29 | ) | (7 | ) | (1 | ) | (2 | ) | (198 | ) | (237 | ) | ||||||||||||||||||||||||||||||||
transfer from level 3 to level 1 | 247 | 291 | 538 | |||||||||||||||||||||||||||||||||||||||||
Transfer from equity method to level 1 | 830 | 830 | ||||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2022 | 10 | 97 | 151 | 659 | 84 | 9 | 594 | 613 | 1,114 | 3,331 |
F-76
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: (continued)
Financial risk management: (continued)
2) | Estimates of fair value (continued) |
Financial assets (continued)
The following table presents the Level 3 financial assets roll-forward during 2022:
Maris | Polyrizon warrants | Laminera | Gix Internet Anti-dilution | SAFO Warrants | ClearMind warrants | ClearMind anti-dilution | Safee | Parazero -SAFE | Polyrizon -SAFE | Colugo | Total | |||||||||||||||||||||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2022 | 303 | 516 | 126 | 469 | 34 | - | - | 400 | - | - | - | 1,848 | ||||||||||||||||||||||||||||||||||||
Initial recognition of financial asset | 25 | 197 | 40 | 520 | 314 | 400 | 1,496 | |||||||||||||||||||||||||||||||||||||||||
Exchange differences | (42 | ) | (1 | ) | (20 | ) | (63 | ) | ||||||||||||||||||||||||||||||||||||||||
Net change at fair value recognized through profit or loss | (68 | ) | (117 | ) | 507 | (427 | ) | (34 | ) | (200 | ) | 279 | (12 | ) | (72 | ) | ||||||||||||||||||||||||||||||||
transfer to equity investment treatment | (633 | ) | (633 | ) | ||||||||||||||||||||||||||||||||||||||||||||
transfer from level 3 to level 1 | (247 | ) | 8 | (299 | ) | (538 | ) | |||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2022 | 13 | 399 | - | - | - | 4 | - | 400 | 520 | 302 | 400 | 2,038 |
The following table presents the Level 1 financial assets roll-forward during 2021:
Investment in SAFO | Tondo | SciSparc ltd | Automax | Total | ||||||||||||||||
USD in thousands | ||||||||||||||||||||
Balance as of January 1, 2021 | 113 | - | - | - | 113 | |||||||||||||||
Initial recognition at fair value upon dilution of equity investment | 1,553 | 1,553 | ||||||||||||||||||
Purchase of securities | 472 | 825 | 279 | 1,576 | ||||||||||||||||
Sale of securities | (42 | ) | (42 | ) | ||||||||||||||||
Net change in fair value of financial assets at fair value recognized through profit or loss | (60 | ) | (1 | ) | 86 | (156 | ) | (131 | ) | |||||||||||
Balance as of December 31, 2021 | 53 | 429 | 911 | 1,676 | 3,069 |
F-77
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: (continued)
Financial risk management: (continued)
2) | Estimates of fair value (continued) |
Financial assets (continued)
The following table presents the Level 3 financial assets roll-forward during 2021:
Gix Media’s shares | Gix Warrants | ScoutCam warrants | Maris investment and warrants | Conversion Right | Polyrizon warrants | Laminera | Gix Internet Anti-dilution | SAFO Warrants | Safee | Total | ||||||||||||||||||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||||||||||||||||||||||
Balance as of January 1, 2021 | 2,438 | 14 | 1,393 | 473 | 98 | - | 4,416 | |||||||||||||||||||||||||||||||||||||
Initial recognition at fair value of ScoutCam warrants upon deconsolidation (note 4C) | 97 | 97 | ||||||||||||||||||||||||||||||||||||||||||
Exercise of warrants (note 4C) | (51 | ) | (51 | ) | ||||||||||||||||||||||||||||||||||||||||
Purchase of securities | - | - | - | - | - | - | - | - | - | 400 | 400 | |||||||||||||||||||||||||||||||||
Initial recognition of financial asset | 240 | 126 | 366 | |||||||||||||||||||||||||||||||||||||||||
Net changes at fair value recognized through profit or loss | 373 | (14 | ) | (46 | ) | 63 | 213 | 516 | (4 | ) | (64 | ) | - | 1,037 | ||||||||||||||||||||||||||||||
Exercise of Conversion Right (note 4F) | (2,811 | ) | (1,606 | ) | (4,417 | ) | ||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2021 | 303 | 516 | 126 | 469 | 34 | 400 | 1,848 |
Financial liabilities
Level 1 financial instruments:
As of December 31, 2022, and 2021, the Group has a financial liability measured at level 1 – Warrants C (see note 14b).
The fair value of financial instruments traded in active markets is based on quoted market prices at the statement of financial position date. A market is regarded as active if quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service, or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm’s length basis.
Level 3 financial instruments:
As of December 31, 2022, and 2021, the Group has financial liabilities measured at level 3 – commitment to issue warrants to lenders of Jeffs’ Brands upon IPO and derivative liabilities of Jeffs’ Brands (see note 4E).
F-78
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: (continued)
Financial risk management: (continued)
2) | Estimates of fair value (continued) |
Financial liabilities (continued)
The following table presents the financial liabilities that were measured at fair value through profit or loss:
December 31, | December 31, | |||||||||||||||||||||||
2022 | 2021 | |||||||||||||||||||||||
Level 1 | Level 3 | Total | Level 1 | Level 3 | Total | |||||||||||||||||||
USD in thousands | USD in thousands | |||||||||||||||||||||||
Fair value of warrants | 396 | 4,159 | 4,555 | 555 | 137 | 692 |
The following table presents the Level 3 financial liabilities roll-forward during 2022:
Warrants | ||||
USD in thousands | ||||
Opening balance as of January 1, 2022 | 137 | |||
Issuance of warrants in connection with the IPO of Jeffs’ Brands (note 4E) | 7,640 | |||
Changes in fair value of warrants in connection with the IPO of Jeffs; Brands | (3,490 | ) | ||
Changes in fair value of warrants issued to lenders of Jeffs’ Brands upon IPO | (128 | ) | ||
Closing balance as of December 31, 2022 | 4,159 |
The following table presents the Level 3 financial liabilities roll-forward during 2021:
Warrants | ||||
USD in thousands | ||||
Opening balance as of January 1, 2021 | 36 | |||
Changes in fair value of warrants issued to investors | (36 | ) | ||
Fair value of warrants to be issued to lenders of Jeffs’ Brands upon IPO | 62 | |||
Changes in fair value of warrants to be issued to lenders of Jeffs’ Brands upon IPO | 75 | |||
Closing balance as of December 31, 2021 | 137 |
The following table presents the Level 1 financial liabilities roll-forward during 2022:
Warrants | ||||
USD in thousands | ||||
Opening balance as of January 1, 2022 | 555 | |||
Changes in fair value of warrants | (159 | ) | ||
Closing balance as of December 31, 2022 | 396 |
The following table presents the Level 1 financial liabilities roll-forward during 2021:
Warrants | ||||
USD in thousands | ||||
Opening balance as of January 1, 2021 | 1,039 | |||
Changes in fair value of warrants | (484 | ) | ||
Closing balance as of December 31, 2021 | 555 |
F-79
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: (continued)
Financial risk management: (continued)
Valuation processes of the Group:
Set forth below are details regarding the valuation processes of the Group as of December 31,2022:
1) | Warrants issued on November 1, 2017: as part of a public offering - the Company used the Black-Scholes model, using the following principal assumptions: expected volatility of 67.06%, risk-free interest of 4.76%, expected term of 5.5 years following the grant date. The liability amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. For details, see note 14b.
Warrants issued on July 18, 2018: as part of a direct offering - the Company used the Black-Scholes model, using the following principal assumptions: expected volatility of 67.06%, risk-free interest of 4.76%, expected term of 5 years following the grant date. The liability amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. For details, see note 14b.
Series C warrants - financial instruments measured at fair value through profit or loss. For details, see note 14b. |
2) | Jeffs’ Brands warrants - On August 30, 2022, Jeffs’ Brands completed its initial public offering (“IPO”), In connection with the IPO, Jeffs’ Brands sold 3,717,473 units at a public offering price of USD 4.16 per unit, with each unit consisting of one ordinary share, no par value per share (“Ordinary Share”), and one warrant (“IPO Warrant”), to purchase one Ordinary Share, at an exercise price of USD 4.04 per Ordinary Share. Additionally, Jeffs’ Brands issued warrants to the underwriter to purchase up to 185,873 ordinary shares at an exercise price of USD 5.20 per Ordinary Share (“Underwriter’s Warrants”). The underwriter partially exercised its right to purchase an additional 425,912 warrants for total consideration of USD 4 thousand. Jeffs’ Brands received total net proceeds of USD 13.4 million after deducting issuance costs of USD 2.1 million.
On September 7, 2022, Jeffs’ Brands’ volume weighted average stock price was less than the exercise floor of USD 4.04 for the IPO Warrants. Accordingly, and based on the contractual terms of the IPO Warrants, effective after the closing of trading on November 28, 2022 (the 90th calendar day immediately following the issuance date of the IPO Warrants), the IPO Warrants were adjusted (“As-Adjusted IPO Warrants”) pursuant to their terms, including, but not limited to, the reduction of the exercise price of the IPO Warrants to USD 2.02.
Additionally, Additional Warrants were issued to each qualified buyer who continued to hold at least 120,192 IPO Warrants as of November 28, 2022. Accordingly, Jeffs’ Brands issued Additional Warrants to purchase 2,824,525 Ordinary Shares. Each Additional Warrant has substantially the same terms as the As-Adjusted IPO Warrant; provided, however, that the term of each Additional Warrant will be five (5) years from the issuance date and such Additional Warrant will not be listed on any securities exchange. In addition, as long as the Additional Warrants are outstanding, each holder of at least 120,192 IPO Warrants will receive semi-annual payments based on the Jeffs’ Brands consolidated revenues, dependent on the amount of the Additional Warrants outstanding. As of December 31, 2022, the payment will be equal to approximately 2.3% of Jeffs’ Brands consolidated revenues for the period ended December 31,2022. |
The following table lists the significant unobservable inputs used for calculation of fair value of the IPO Warrants and Additional Warrants during the year:
Expected volatility | 77.57% - 78.89% | |||
Exercise price (in USD) | 2.02 - 4.04 | |||
Share price (in USD) | 1.53 - 1.865 | |||
Risk-free interest rate | 3.27% - 4.04% | |||
Dividend yield | - | |||
Expected life | 3 - 4.74 | |||
WACC | 21.5% - 23.3% |
3) | Investments in SAFO, Tondo, SciSparc, Maris, Automax shares and bonds, ClearMind, Elbit and Bubbles - financial instruments measured at fair value through profit or loss. and meet level 1 criteria. |
4) | Safee shares - on October 12, 2021, the Company invested in Safee. Since Safee is a small private company, which does not raise funds on a regular basis and does not have significant activity that indicates a change in fair value, the Company assumes that there is no reason to believe that there is a material change in value and that the investment value adequately represents the fair value at the reporting date. This assumption is reviewed at each cut-off date. |
5) | Maris warrants - the Company used the Black-Scholes model, using the following principal assumptions: share price: USD 0.83, expected volatility of 83.57%, risk-free interest of 4.22%, expected term of 3 years following the grant date. The asset amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. |
F-80
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: (continued)
Financial risk management: (continued)
Valuation processes of the Group: (continued)
6) | Colugo shares - the Company assumes that there is no reason to believe that there is a material change in value and that the investment value adequately represents the fair value at the reporting date. This assumption is reviewed at each cut-off date. |
7) | SAFO warrants - the Company used the Black-Scholes model, using the following principal assumptions: share price: USD 0.75, expected volatility of 78.86%, risk-free interest of 4.73%, expected term of 3 years following the grant date. The asset amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. |
8) | Polyrizon Options - the Original Option (as defined in note 4H) was measured at fair value through profit or loss and was calculated using the Black-Scholes option price model. The Original Option (as defined in note 3H) was calculated based on management’s expectations for the IPO scenario.
Non-IPO scenario: share price: USD 0.0544, expected volatility of 78.19%, risk-free interest of 4.69%, expected term of 2.77 years following the grant date.
IPO scenario: share price: 125% of expected IPO share price, expected volatility of 81.99%, risk-free interest of 4.2%, expected term of 3years following the grant date. |
9) | Polyrizon SAFE - on January 27, 2022, the Company invested USD 111 thousand and on May 8, 2022, the Company invested USD 204 thousand. The Company used the binomial pricing model, using the following principal assumptions:
Risk-free interest of 4.76%, expected term of 0.58 years as of December 31, 2022.
The asset amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. |
10) | Options to employees and advisors. For details, see note 14c. |
Set forth below are details regarding the valuation processes of the Group as of December 31,2021:
1) | Warrants issued on December 6, 2016: as part of a registered direct offering - the Company used the Black-Scholes model, using the following principal assumptions: expected volatility of 63.32%, risk-free interest of 0.19%, expected term of 5.5 years following the grant date. The liability amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. see note 14b.
Warrants issued on March 29, 2017: as part of a public offering - the Company used the Black-Scholes model, using the following principal assumptions: expected volatility of 63.2%, risk-free interest of 0.19%, expected term of 5 years following the grant date. The liability amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. For details, see note 14b.
Warrants issued on November 28, 2017: as part of a direct offering - the Company used the Black-Scholes model, using the following principal assumptions: expected volatility of 63.2%, risk-free interest of 0.19%, expected term of 5.5 years following the grant date. The liability amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. For details, see note 14b.
Series C warrants - financial instruments measured at fair value through profit or loss. For details, see note 14b. |
2) | Gix Internet Anti-dilution feature - the Company used the Black-Scholes model, using the following principal assumptions: share price: NIS 1.45, 25% probability for the occurrence of an anti-dilution event, expected volatility of 46.85%, risk-free interest of 0.67%, expected term of 3 years following the issuance date. |
F-81
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 5 – FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT: (continued)
Financial risk management: (continued)
Valuation processes of the Group: (continued)
3) | ScoutCam warrants - the Company used the Black-Scholes model, using the following principal assumptions: share price of USD 6.3, expected volatility of 49.5%, risk-free interest of 0.65%, expected term of 3 years following the grant date. The asset amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. |
4) | Gix Warrants - the Company used the Black-Scholes model, using the following principal assumptions: share price of NIS 1.45, expected volatility of 46.85%, risk-free interest of 0.67%, expected term of 3 years following the grant date. The asset amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. |
5) | Investments in SAFO, Tondo, SciSparc and Automax - financial instruments measured at fair value through profit or loss and meet level 1 criteria. |
6) | Safee shares - on October 12, 2021, the Company invested in Safee. Since Safee is a small private company, which does not raise funds on a regular basis and does not have significant activity that indicates a change in fair value, the Company assumes that there is no reason to believe that there is a material change in value and that the investment value adequately represents the fair value at the reporting date. This assumption is reviewed at each cut-off date. |
7) | Maris investment - on March 24, 2021 the Company invested in Maris. On February 01, 2022, Maris completed initial public offering of units consisting of warrants and shares for USD 4.2 per unit and started to trade on Nasdaq at USD 3.15 per share. The Company assumed the share price as of the first trading date of Maris shares represents the fair value of Maris shares as of December 31, 2021. The fair value of the warrants was calculated using the Black & Scholes option price model, based on the following assumptions:
Non-IPO scenario: share price: USD 3.15, expected volatility of 63.2%, risk-free interest of 0.24%, expected term of 2.5 years following the grant date.
IPO scenario: share price: USD 3.15, expected volatility of 55.81%, risk-free interest of 0.81%, expected term of 5 years following the grant date. |
8) | SAFO warrants - the Company used the Black-Scholes model, using the following principal assumptions: share price: USD 7.56, expected volatility of 78.86%, risk-free interest of 0.97%, expected term of 3 years following the grant date. The asset amount is adjusted at each statement of financial position date based on the then relevant assumptions, until the earlier of full exercise or expiration. |
9) | Polyrizon Options - the Original Option (as defined in note 4H) was measured at fair value through profit or loss and was calculated using the Black & Scholes option price model. The Original Option and the Alternative Option (as defined in note 4H) was calculated based on management’s expectations for the IPO scenario.
Non-IPO scenario: share price: USD 0.0544, expected volatility of 87.86%, risk-free interest of 0.85%, expected term of 2.77 years following the grant date.
IPO scenario: share price: 120% of expected IPO share price, expected volatility of 93.76%, risk-free interest of 0.97%, expected term of 3.55 years following the grant date. |
10) | Options to employees and advisors. For details, see note 14c. |
F-82
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 6 – CASH AND CASH EQUIVALENTS, SHORT TERM DEPOSIT AND RESTRICTED CASH:
December 31 | ||||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
Cash and cash equivalents – held in bank accounts | 20,065 | 24,025 | ||||||
Short term deposits – held in bank accounts | 859 | |||||||
Restricted cash – held in bank accounts (*) | 185 | |||||||
21,109 | 24,025 |
(*) | Gix Media has pledged deposits in an aggregated amount of approximately NIS 523 thousand (USD 149 thousand) as guarantees for credit cards, banks and for the owner of the rented property. Cortex has a pledged deposit in the amount of NIS 107 thousand (USD 36 thousand) as a guarantee for the leased offices. |
The currencies in which the cash and cash equivalents, short term deposit and restricted cash are denominated or to which they are linked are as follows:
December 31 | ||||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
USD | 14,680 | 22,151 | ||||||
NIS | 6,428 | 1,874 | ||||||
Other currencies | 1 | |||||||
21,109 | 24,025 |
The carrying amount of cash and cash equivalents, short term deposit and pledged deposit approximates their fair value.
NOTE 7 – OTHER RECEIVABLES, PREPAID EXPENSES AND LOANS TO OTHERS:
a. | Other receivables and prepaid expenses |
December 31 | ||||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
Government institutions | 924 | 79 | ||||||
Prepaid expenses | 469 | 126 | ||||||
Advances to suppliers | 417 | 18 | ||||||
Other | 118 | 192 | ||||||
1,928 | 415 |
F-83
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 7 – OTHER RECEIVABLES, PREPAID EXPENSES AND LOANS TO OTHERS: (continued)
b. | Loans to others |
December 31 | ||||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
Loan to Safee (see note 4D) | 71 | |||||||
Loan to A.I Systems Ltd. * | 940 | |||||||
1,011 |
* | On August 23, 2022, the Company signed a convertible loan agreement with A.I Artificial Intelligence Research and Development Ltd. (A.I R&D Ltd.) for the assignment of a loan it has given to A.I Systems Ltd, a public company traded in Tel Aviv. The original loan amount was NIS 6,000 thousand. According to the agreement, the Company purchased from A.I R&D Ltd., 50% from the original loan in exchange for USD 914 thousand (NIS 3,000 thousand) in the same terms of the original loan given to A.I Systems Ltd.
According to the agreement, the loan will bear an interest of 1% per month. Additionally, A.I Systems Ltd. has the right to choose to repay the loan and interest in cash or to convert it into shares of A.I Systems Ltd. on March 13, 2023. The number of shares will be equal to the amount of the loan (NIS 3,000 thousand) plus NIS 1,750 thousand divided by the average quoted price per share of A.I System Ltd. during a period of 30 trading days preceding the conversion date.
The loan was accounted for as financial assets measured at fair value through profit or loss. As of December 31, 2022, the fair value of the loan was USD 940 thousand (NIS 3,307 thousand). On March 12, 2023, the Company entered into an amendment to the conversion loan agreement. According to the amendment, the repayment will be postponed by 3 months, to June 13, 2023. |
NOTE 8 – INVENTORY:
Composed as follows:
December 31 | ||||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
Goods in transit | 8 | 161 | ||||||
Finished goods | 1,783 | 1,066 | ||||||
1,791 | 1,227 |
As of December 31, 2022 and 2021, the inventory is derived from Jeffs’ Brands.
F-84
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 9 - PROPERTY AND EQUIPMENT:
a. | Composition of property and equipment and accumulated depreciation thereon, grouped by major classifications and changes therein, and their movements during 2022: |
Machinery and equipment | Leasehold improvements and furniture | Computer programs | Total | |||||||||||||
USD in thousands | ||||||||||||||||
Cost: | ||||||||||||||||
Balance as of January 01, 2022 | 735 | 135 | 537 | 1,407 | ||||||||||||
Additions | 42 | 32 | 74 | |||||||||||||
Consolidation of Gix Internet (note 4F) | 425 | 542 | 967 | |||||||||||||
Currency translation | (10 | ) | (15 | ) | (25 | ) | ||||||||||
Balance as of December 31, 2022 | 735 | 592 | 1,096 | 2,423 | ||||||||||||
Accumulated Depreciation: | ||||||||||||||||
Balance as of January 01, 2022 | 692 | 126 | 512 | 1,330 | ||||||||||||
Consolidation of Gix Internet (note 4F) | - | 205 | 401 | 606 | ||||||||||||
Additions | 10 | 48 | 41 | 99 | ||||||||||||
Currency translation | (13 | ) | (7 | ) | - | (20 | ) | |||||||||
Balance as of December 31, 2022 | 689 | 372 | 954 | 2,015 | ||||||||||||
Property and Equipment, net, as of December 31, 2022 | 46 | 220 | 142 | 408 |
b. | Composition of property and equipment and accumulated depreciation thereon, grouped by major classifications and changes therein, and their movements during 2021: |
Machinery and equipment | Leasehold improvements and furniture | Computer programs | Total | |||||||||||||
USD in thousands | ||||||||||||||||
Cost: | ||||||||||||||||
Balance as of January 01, 2021 | 947 | 172 | 605 | 1,724 | ||||||||||||
Additions | 99 | 1 | 39 | 139 | ||||||||||||
Removal upon deconsolidation | (311 | ) | (38 | ) | (107 | ) | (456 | ) | ||||||||
Balance as of December 31, 2021 | 735 | 135 | 537 | 1,407 | ||||||||||||
Accumulated Depreciation: | ||||||||||||||||
Balance as of January 01, 2021 | 703 | 149 | 527 | 1,379 | ||||||||||||
Additions | 19 | 3 | 16 | 38 | ||||||||||||
Removal upon deconsolidation | (30 | ) | (26 | ) | (31 | ) | (87 | ) | ||||||||
Balance as of December 31, 2021 | 692 | 126 | 512 | 1,330 | ||||||||||||
Property and Equipment, net, as of December 31, 2021 | 43 | 9 | 25 | 77 |
F-85
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10 – GOODWILL AND INATANGIBLE ASSETS:
A. | Composition and movements: |
Technology | Software license | Patent | Brand name | Customer relationship | Goodwill | Total | ||||||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||||||
Cost: | ||||||||||||||||||||||||||||
Balance as of January 01, 2022 | 478 | 1,506 | 75 | 6,039 | 926 | 9,024 | ||||||||||||||||||||||
Additions | 35 | 35 | ||||||||||||||||||||||||||
Currency translation | (42 | ) | (175 | ) | (23 | ) | (240 | ) | ||||||||||||||||||||
Consolidation of Gix Internet (note 4F) | 12,485 | 6,234 | 8,164 | 26,883 | ||||||||||||||||||||||||
Balance as of December 31, 2022 | 12,921 | 1,366 | 75 | 6,039 | 6,234 | 9,068 | 35,703 | |||||||||||||||||||||
Accumulated Amortization: | ||||||||||||||||||||||||||||
Balance as of January 01, 2022 | (69) | (634 | ) | (703 | ) | |||||||||||||||||||||||
Additions | (1,712 | ) | (596 | ) | (742 | ) | (3,050 | ) | ||||||||||||||||||||
Currency translation | (74 | ) | (74 | ) | ||||||||||||||||||||||||
Consolidation of Gix Internet (note 4F) | (1,014 | ) | (1,014 | ) | ||||||||||||||||||||||||
Balance as of December 31, 2022 | (2,869 | ) | (1,230 | ) | (742 | ) | (4,841 | ) | ||||||||||||||||||||
Intangible assets, net, as of December 31, 2022 | 10,052 | 1,366 | 75 | 4,809 | 5,492 | 9,068 | 30,862 |
Technology | Software license | Patent | Brand name | Goodwill | Total | |||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||
Cost: | ||||||||||||||||||||||||
Balance as of January 01, 2021 | 199 | 296 | 495 | |||||||||||||||||||||
Additions | 279 | 1,460 | 75 | 4,728 | 55 | 6,597 | ||||||||||||||||||
Currency translation | 46 | 11 | 57 | |||||||||||||||||||||
Acquisition of subsidiary | 1,311 | 564 | 1,875 | |||||||||||||||||||||
Balance as of December 31, 2021 | 478 | 1,506 | 75 | 6,039 | 926 | 9,024 | ||||||||||||||||||
Accumulated Amortization: | ||||||||||||||||||||||||
Balance as of January 01, 2021 | ||||||||||||||||||||||||
Additions | (69 | ) | (69 | ) | ||||||||||||||||||||
Impairment | (89 | ) | (89 | ) | ||||||||||||||||||||
Acquisition of subsidiary | (545 | ) | (545 | ) | ||||||||||||||||||||
Balance as of December 31, 2021 | (69 | ) | (634 | ) | (703 | ) | ||||||||||||||||||
Intangible assets, net, as of December 31, 2021 | 409 | 1,506 | 75 | 5,405 | 926 | 8,321 |
B. | Additions during the year: |
Through the period from February 14, 2022, up to February 28, 2022, the Company’s interest in Gix Internet increased to 38.03%, which resulted in gain of control in Gix Internet. Accordingly, Gix Internet was consolidated as of such date and the investment. As of the consolidation date the Company recorded intangible assets in the amount of USD 17,705 thousand and goodwill in the amount of USD 6,602 thousand. For additional information see note 4F.
On January 4, 2021, the Company closed a common stock purchase agreement with Pro, Purex and their respective stockholders (the “Pro and Purex SPA”). As of the acquisition date the Company recorded intangible assets in the amount of USD 1,311 thousand and goodwill in the amount of USD 688 thousand. For additional information about the stock exchange with Jeffs’ Brands, see note 4E.
F-86
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 10 – GOODWILL AND INATANGIBLE ASSETS: (continued)
B. | Additions during the year: (continued) |
On January 7, 2021, Charging Robotics purchased a provisional patent filed with the United States Patent and Trademark Office and know-how relating to wireless vehicle battery charging technology in consideration for USD 75 thousand. For additional information see note 4I.
On February 2, 2021, Pro entered into purchase agreement of a virtual store “Whoobli” from a third party (hereafter - the “Whoobli Seller”). As part of the agreement, Pro purchased a seller account which operates on the Amazon.com website under the name “Whoobli”, which markets a private label of basketball shooting baskets, children’s punching bags and decoration for children’s birthday parties, including the intellectual property attributed to it and including trademarks attributed to products sold on the account’s sales page, for a total of USD 4,000 thousand. In addition, in accordance with the agreement, Pro purchased from Whoobli seller the remaining inventory for a total amount of approximately USD 350 thousand, which is the cost of the inventory purchased by Whoobli seller. On the date of the acquisition, Pro fully recognized all the amount of the acquisition as an intangible asset, and in the Company’s management opinion, the useful life of the intangible asset recognized is 10 years.
On February 2, 2021, Pro entered into a purchase agreement of a virtual store “Wellted” from a third party (hereafter - the “Wellted Seller”). As part of the agreement, Pro purchased a seller account which operates on the Amazon.com website under the name “Wellted”, which markets a private label of brushes used for removing and cleaning animal body hair from fabrics, including the intellectual property attributed to it and including trademarks attributed to products sold on the account’s sales page, for a total amount of USD 250 thousand. In addition, in accordance with the agreement, Pro purchased from Wellted seller the inventory that remained in his possession for a total of approximately USD 55 thousand, which is the cost of the inventory purchased by Wellted seller. On the date of the acquisition, Pro fully recognized all the amount of the acquisition as an intangible asset, and in the Company’s management opinion, the useful life of the intangible asset recognized is 10 years.
On February 3, 2021, Pro entered into purchase agreement of a virtual store “Pet-evo” from a third party (hereafter - the “Pet-evo Seller”). As part of the agreement, Pro purchased a seller account which operates on the Amazon.com website under the name “Pet-evo”, which markets a private label of used car door protectors from damage caused by animals, including the intellectual property attributed to it and including trademarks attributed to products sold on the account’s sales page, for a total of USD 450 thousand. In addition, in accordance with the agreement, Pro purchased from Pet-evo seller the inventory that remained in his possession for a total of approximately USD 35 thousand, which is the cost of the inventory purchased by Pet-evo seller. On the date of the acquisition, Pro fully recognized all the amount of the acquisition as an intangible asset, and in the Company’s management opinion, the useful life of the intangible asset recognized is 10 years.
On February 4, 2021, Eventer signed an addendum to the agreement with Screenz Cross Media Ltd. (a company owned and managed by Eli Uzan who serves as the Company’s President). The agreement was signed during November 2020 for the purpose of collaborating in the field of virtual conferences. According to the provisions of the addendum to the agreement, Eventer will receive an exclusive license for using the broadcasting system of Screenz with respect to the field of virtual conferences and development services, and in exchange will pay Screenz an amount of USD 1,500 thousand (approximately NIS 4,280 thousand) over a period of 8 months, as well as 8% from the revenues earned from using the broadcasting system in the field of virtual conferences.
In March 2021, Purex received an update from Amazon.com (Hereafter – “Amazon”) regarding a new Environmental Protection Agency (EPA) regulation. Following the new EPA regulation, Amazon categorized the Purex’ product as a pesticide product. Amazon requires that pesticide products be filed with evidence of an EPA registration number and/or EPA Establishment number or certification that the product is exempt from EPA regulation, otherwise the existing listing (of the product) may be subject to removal. Purex examined the related costs following that requirement to comply with such regulations and decided to write off the intangible asset balance. Therefore, the Group eliminated the intangible asset related sum to the amount of USD 87 thousand.
F-87
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 11 – LEASES:
On May 21, 2022, the Company has entered into a short-term lease agreement for its offices. According to the agreement, the Company will pay NIS 17 thousand plus VAT per month. On December 30, 2022, the Company terminated the agreement and paid the lessor a one-time compensation of NIS 11 thousand.
Jeffs’ Brands leases office space with a remaining useful life of less than 3 years and uses its incremental borrowing rate as the discount rate for its leases, as the implicit rate in the lease is not readily determinable. As of December 31, 2022, Jeffs’ leases had a weighted average remaining lease term of 3 years and a weighted average borrowing rate of 10%.
On February 25, 2021, Gix Media entered into a lease agreement for a new corporate office of 479 square meters in Ramat Gan, Israel, at a monthly rent fee of USD 10 thousand. The lease period is for 36 months (the “initial lease period”) with an option by the Gix Media to extend the lease period for two additional terms of 24 months each. In accordance with the lease agreement, Gix Media made leasehold improvements in exchange for a rent fee discount of USD 67 thousand which will be spread over the initial lease period.
The Company includes renewal options that it is reasonably certain to exercise in the measurement of the lease liability.
Right-of-use assets
Buildings | ||||
USD in thousands | ||||
Cost: | ||||
At December 31, 2021 | ||||
Acquisition of subsidiary | 619 | |||
Additions | 152 | |||
At December 31, 2022 | 771 | |||
Accumulated Depreciation: | ||||
At December 31, 2021 | ||||
Acquisition of subsidiary | (92 | ) | ||
Charge for the year | (88 | ) | ||
At December 31, 2022 | (180 | ) | ||
Carrying amount | ||||
At 31 December 2022 | 591 |
December 31 | ||||
2022 | ||||
USD in thousands | ||||
Amounts recognized in profit and loss | ||||
Depreciation expense on right-of-use assets | 88 | |||
Interest expense on lease liabilities | 82 | |||
Expense relating to short-term leases | 71 |
F-88
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 11 – LEASES: (continued)
Lease liabilities
Maturities of lease liabilities as of December 31, 2022, are as follows:
2022 | ||||
USD in thousands | ||||
Year 1 | 148 | |||
Year 2 | 148 | |||
Year 3 | 133 | |||
Year 4 | 114 | |||
Year 5 | 118 | |||
Onwards | 19 | |||
Less: unearned interest | (37 | ) | ||
643 | ||||
Analyzed as: | ||||
Non-current | 512 | |||
Current | 131 | |||
643 |
NOTE 12 - TAXES ON INCOME:
a. | Tax rates applicable to the Company and subsidiaries: |
For the Company and all subsidiaries based in Israel, Eventer, Jeffs’ Brands and its subsidiary Top Rank and Viewbix Ltd. are taxed according to Israeli tax law, where the corporate tax rate is 23% for the years 2022, 2021 and 2020.
Gix Internet and its subsidiaries Gix Media and Cortex Media Group are recognized as a “Preferred-Technology Enterprise” in accordance with Section 51 of the Encouragement of Capital Investments Law, 1959 and are taxed at a reduced corporate tax rate of 12%.
For all subsidiaries of the Company based in the US, Viewbix Inc. and Jeffs’ Brands subsidiaries – Smart Pro and Purex are taxed according to US tax rates, which is 21%.
b. | Final tax assessments: |
As of December 31, 2022, the Company has a final tax assessment for all tax year up to the year ended December 31, 2017.
As of December 31, 2022, Gix Media has a final tax assessment for all tax year up to the year ended December 31, 2020. Cortex has a final tax assessment for all tax year up to the year ended December 31, 2018.Viewbix Israel has a final tax assessment for all tax year up to the year ended December 31, 2018.
As of December 31, 2022, Eventer has a final tax assessment for all tax year up to the year ended December 31, 2018.
F-89
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 12 – TAXES ON INCOME: (continued)
c. | Deferred taxes are comprised of the following components: |
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.
Deferred taxes are comprised of the following components:
As of December 31 | As of December 31 | |||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
Deferred tax assets | ||||||||
Deferred research and development expenses | 261 | |||||||
Intangible assets | 110 | 55 | ||||||
Employee compensation and benefits | 13 | |||||||
Other | 40 | |||||||
Accrued severance pay | 13 | |||||||
Total deferred tax assets | 397 | 95 | ||||||
Deferred tax liabilities: | ||||||||
Differences between tax basis and carrying values of loans | 111 | |||||||
Intangible assets associated with business combinations | 1,817 | 220 | ||||||
Total deferred tax liabilities | 1,817 | 331 | ||||||
Net deferred tax liabilities | 1,420 | 236 |
Income tax expenses are comprised as follows:
Year ended December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
USD in thousands | ||||||||||||
Current tax expenses | 813 | 94 | 9 | |||||||||
Tax benefit in respect of prior years | (82 | ) | ||||||||||
Deferred tax expenses (income) | (620 | ) | 11 | |||||||||
Taxes on expenses | 111 | 105 | 9 |
d. | Carry forward tax losses |
December 31, 2022 | December 31, 2021 | |||||||
USD in thousands | ||||||||
Medigus* | 60,000 | 62,000 | ||||||
Eventer* | 3,300 | 2,700 | ||||||
Charging Robotics* | 574 | 360 | ||||||
GERD IP* | 786 | 857 | ||||||
Jeffs’ Brands* | 1,217 | 747 | ||||||
Jeffs’ Brands subsidiaries | 49 | |||||||
Gix Internet | 18,471 |
* | There is no record deferred taxes asset in respect of these losses, as the utilization thereof is not expected to occur in the foreseeable future. |
F-90
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 12 – TAXES ON INCOME: (continued)
f. | Taxes on income included in the Statements of Loss and Other Comprehensive Loss for the periods presented: |
The following is reconciliation between the “theoretical” tax, which would apply to the Group if all of its income were taxed at the regular rate applicable to the Company in Israel and the amount of tax reflected in the consolidated statements of loss and other comprehensive loss for the reported year:
2022 | 2021 | 2020 | ||||||||||
USD in thousands | ||||||||||||
Income (Loss) before taxes on income | (10,097 | ) | 4,151 | (6,841 | ) | |||||||
Theoretical tax rate | 23 | % | 23 | % | 23 | % | ||||||
Theoretical tax expense (benefit) | (2,322 | ) | 955 | (1,575 | ) | |||||||
Disallowed deductions (tax exempt income): | ||||||||||||
Change in fair value of assets and liabilities measured at fair value through profit or loss | (38 | ) | (275 | ) | 86 | |||||||
Share-based compensation | 183 | 539 | 298 | |||||||||
Amortization of excess purchase price of an associate | 60 | 126 | ||||||||||
Profit recognized upon deconsolidation | (2,678 | ) | ||||||||||
Profit recognized upon first time consolidation | (529 | ) | ||||||||||
Non-deductible expenses | 723 | |||||||||||
Different tax rates applicable to subsidiaries | (360 | ) | (85 | ) | ||||||||
Tax benefits in respect of prior years | (84 | ) | ||||||||||
Other | 17 | 2 | ||||||||||
Tax losses and timing differences incurred in the reporting year for which deferred taxes were not created | 2,521 | 1,589 | 1,072 | |||||||||
Taxes on income | 111 | 105 | 9 |
NOTE 13 – ACCOUNTS PAYABLES, ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
a. | Accounts payables are denominated in the following currencies: |
December 31, | ||||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
NIS unlinked | 2,713 | 461 | ||||||
USD | 17,708 | 241 | ||||||
20,421 | 702 |
b. | Accrued expenses and other current liabilities: |
December 31, | ||||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
Employees and related institutions | 949 | 185 | ||||||
Government authorities | 798 | 128 | ||||||
Accrued expenses | 961 | 1,080 | ||||||
Other | 443 | 139 | ||||||
3,151 | 1,532 |
F-91
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 14 – EQUITY:
a. | Share capital: |
1) | Composed as follows: |
Number of shares | Amount | |||||||||||||||||||||||||
Authorized | Issued and paid | Authorized | Issued and paid | |||||||||||||||||||||||
December 31, | December 31, | December 31, | December 31, | |||||||||||||||||||||||
2022 | 2021 | 2022 | 2021 | 2022 | 2021 | 2022 | 2021 | |||||||||||||||||||
In thousands | NIS in thousands | USD in thousands | ||||||||||||||||||||||||
Ordinary shares of NIS 1.00 par value as of December 31, 2021, and no-par value as of December 31, 2022 | 200,000 | 50,000 | 24,661 | 23,850 |
2) | The ordinary shares confer upon their holders voting rights and the right to participate in shareholders’ meetings, the right to receive dividends and the right to participate in surplus assets in the event of liquidation of the Company. |
3) | On February 12, 2021, following the approval of an extraordinary general meeting of the Company shareholders held on February 12, 2021, the Company amended its articles of association to eliminate the par value of its ordinary shares, such that the authorized share capital of the Company following the amendment consists of 1,000,000,000 ordinary shares of no-par value. | |
4) | On January 11, 2021, the Company entered into an underwriting agreement with Aegis Capital Corp. (“Aegis”), pursuant to which the Company agreed to sell to Aegis, in a firm commitment public offering 3,659,735 ADSs, representing a total of 73,194,700 ordinary shares of no-par value for a public offering price of USD 2.30 per ADS. In addition, the Underwriter was granted an option to purchase additional 15 percent of the ADSs sold in the Offering solely to cover over-allotments, exercisable until the earlier of 30-days or the last day of trading of the Company’s ordinary shares on the Tel-Aviv Stock Exchange. Aegis exercised its over-allotment option in full to purchase an additional 548,960 ADSs, the closing of which occurred on January 19, 2021. The total gross proceeds of the offering to approximately USD 9.68 million. |
5) | On February 25, 2021, the Company entered into an underwriting agreement with Aegis pursuant to which the Company agreed to sell to Aegis, in a firm commitment public offering 3,258,438 ADSs for a public offering price of USD 2.60 per ADS. In addition, Aegis was granted an option to purchase additional 15 percent of the ADSs sold in the offering solely to cover over-allotments. Aegis exercised its over-allotment option in full to purchase an additional 488,765 thousand ADSs. The total gross proceeds of the offering to approximately USD 9.7 million. |
6) | On June 17, 2022, the Company’s shareholders approved to increase the authorized number of shares from 50 million to 200 million. |
7) | On July 7, 2022, the Company effected a reverse split of the Company’s authorized and outstanding ordinary shares at a ratio of 20:1 (the “Reverse Split”) and increased the authorized number of shares. Those changes were approved by the Company’s shareholders on June 17, 2022. On July 8, 2022, following the Reverse Split, the Company effected a change in the American Depositary Share (“ADS”) ratios for its American Depositary Receipt program such that each ADS represents one ordinary share of no-par value of the Company (the “Ordinary Share”), instead of twenty (20) pre-Reverse Split Ordinary Shares. The change in the ADS ratio is a technical change made in order to align the ratio so that one ADS equals to one Ordinary Share. |
8) | On November 14, 2022, the Company effected a change in the ratio of ordinary shares to each of the Company’s American Depositary Shares (“ADSs”), such that after the Reverse Split is implemented each ADS will represent 15 post-Split Ordinary Shares. The effect of such consolidation was applied retrospectively for all the number of shares, warrants, related par value and others presented in this note and elsewhere in the consolidated financial statements. |
F-92
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 14 – EQUITY: (continued)
b. | Share offering to the public and existing shareholders: |
The following table summarizes warrants outstanding as of December 31,
2022 | ||||||||||||
Series | Date of grant | Number of warrants conversion to equivalent ADSs(***) | exercise price per warrant in USD(***) | Expiration date | ||||||||
Series L(*) | November 2017 | 6,750 | 135 | May 27, 2023 | ||||||||
Warrants C(*) | July 2018 | 176,045 | 52.5 | July 18, 2023 | ||||||||
Warrants C(**) | July 2018 | 28,377 | 52.5 | July 18, 2023 | ||||||||
HCW warrants(*) | July 2018 | 13,242 | 65.63 | July 18, 2023 | ||||||||
Total | 224,414 |
2021 | ||||||||||||
Series | Date of grant | Number of warrants conversion to equivalent ADSs (***) | exercise price per warrant in USD (***) | Expiration date | ||||||||
Series I(*) | December 2016 | 665 | 540 | June 06, 2022 | ||||||||
Series J(**) | December 2016 | 33 | 540 | June 06, 2022 | ||||||||
Warrants A(*) | March 2017 | 35,715 | 210 | March 29, 2022 | ||||||||
Placement 03/2017(**) | March 2017 | 2,500 | 262.5 | March 29, 2022 | ||||||||
Series L(*) | November 2017 | 6,750 | 135 | May 27, 2023 | ||||||||
Series M(**) | November 2017 | 945 | 150 | November 24, 2022 | ||||||||
Warrants C(*) | July 2018 | 176,045 | 52.5 | July 18, 2023 | ||||||||
Warrants C(**) | July 2018 | 28,377 | 52.5 | July 18, 2023 | ||||||||
HCW warrants(*) | July 2018 | 13,242 | 65.63 | July 18, 2023 | ||||||||
Algomizer (Note 3)(**) | September 2019 | 22,222 | 60 | September 3, 2022 | ||||||||
Total | 286,494 |
* | These warrants, under certain circumstances, can be exercised via cashless exercise mechanism as defined in the warrant agreement. Therefore, the warrants were classified as financial liabilities measured at fair value through profit or loss at each reporting period (see note 5). |
** | Recorded in equity. |
*** | Adjusted to reflect the 1:15 ratio change of the Company’s American Depositary Receipt, or ADR, program. As a result, the number of ordinary shares of the Company represented by each American Depositary Share, or ADS, will be changed from one (1) ordinary share to fifteen (15) ordinary shares. The effective date for the ratio change was November 14, 2022 |
F-93
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 14 – EQUITY: (continued)
c. | Share based payments: |
1) | In August 2013, the Company board of directors approved and adopted the Company 2013 Share Option and Incentive Plan, or the 2013 Plan, which expires in August 2023. The 2013 Plan provides for the issuance of shares and the granting of options, restricted shares, restricted share units and other share-based awards to employees, directors, officers, consultants, advisors, and service providers of us and the Company U.S. Subsidiary. The Plan provides for awards to be issued at the determination of The Company board of directors in accordance with applicable law. |
2) | The following are the grants of options to employees and other service providers: |
Date of grant | Number of options granted (**) | exercise price per option to ordinary shares (**) | Currency exercise | Fair value on grant date in thousands | Number of options outstanding- December 31, 2022 | Number of options exercisable at 31, December 2022 | Expiration date | |||||||||||||||
October 2017 | 38,150 | 32.4 | NIS | 942 NIS | 13,850 | 13,850 | October 17, 2023 | |||||||||||||||
January 2019(*) | 150,000 | 11.8 | NIS | 947 NIS | 112,500 | 112,500 | January 9, 2025 | |||||||||||||||
July 2019(*) | 62,500 | 11.8 | NIS | 325 NIS | 62,500 | 54,688 | July 25, 2025 | |||||||||||||||
June 2020 | 62,500 | 11.8 | NIS | 283 NIS | 62,500 | 52,083 | May 31, 2026 | |||||||||||||||
July 2020(*) | 37,500 | 8.96 | NIS | 123 NIS | 37,500 | 28,125 | July 8, 2026 | |||||||||||||||
October 2020 | 15,000 | 11.8 | NIS | 70 NIS | 15,000 | 10,000 | October 21, 2026 | |||||||||||||||
June 2021(*) | 900,000 | 1.783 | USD | 1,221 USD | 900,000 | 525,000 | June 29, 2027 | |||||||||||||||
June 2021 | 280,000 | 1.783 | USD | 380 USD | 280,000 | 163,333 | June 29, 2027 | |||||||||||||||
June 2021 | 100,000 | 1.783 | USD | 136 USD | 100,000 | 50,000 | June 1, 2027 | |||||||||||||||
October 2021 | 90,000 | 1.783 | USD | 91 USD | 90,000 | 30,000 | October 12, 2027 | |||||||||||||||
Total | 1,735,650 | 1,673,850 | 1,039,579 |
(*) | Granted to related parties. |
(**) | Adjusted to reflect the Reverse Split of the Company’s authorized and outstanding ordinary shares at a ratio of 20:1 effected on July 7, 2022. |
F-94
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 14 – EQUITY: (continued)
c. | Share based payments: (continued) |
The fair value of all of the options was calculated using the Black and Scholes options pricing model, and based on the following assumptions:
Date of grant | Fair value on grant date- in thousands | Share price on date of grant (*) | Expected dividend | Expected volatility | Risk free interest | Vesting conditions | Expected term | |||||||||||
October 2017 | 1,109 NIS | 32.4 NIS | None | 64 | % | 1.16 | % | four equal batches, following one, two, three and four years from their grant date | 6 years | |||||||||
January 2019 | 947 NIS | 10.12 NIS | None | 74 | % | 1.45 | % | will vest in 12 equals quarterly instalments over a three-year period commencing October 1, 2018 | 6 years | |||||||||
July 2019 | 325 NIS | 8.72 NIS | None | 75 | % | 1.12 | % | 25% will vest on the first anniversary of the grant date and 75% will vest on a quarterly basis over a period of three years thereafter | 6 years | |||||||||
June 2020 | 282 NIS | 7.94 NIS | None | 74 | % | 0.53 | % | will vest in 12 equals quarterly instalments over a three-year period commencing June 1, 2020 | 6 years | |||||||||
July 2020 | 124 NIS | 5.8 NIS | None | 74 | % | 0.37 | % | will vest in 12 equals quarterly instalments over a three-year period commencing July 9, 2020 | 6 years | |||||||||
October 2020 | 70 NIS | 8 NIS | None | 76 | % | 0.42 | % | will vest in 12 equals quarterly instalments over a three-year period commencing October 22, 2020 | 6 years | |||||||||
June 2021 | 1,737 USD | 1.8 USD | None | 87 | % | 0.69 | % | Will vest over a period of 3 years commencing on April 1, 2021(except for 2,000,000 options commencing on June 1, 2021), with 1/12 of such options vesting at the end of each subsequent three-month period following the grant | 6 years | |||||||||
October 2021 | 91 USD | 1.4 USD | None | 85 | % | 0.47 | % | Will vest over a period of 3 years commencing on October 12, 2021, with 1/12 of such options vesting at the end of each subsequent three-month period following the grant | 6 years |
(*) | Adjusted to reflect the Reverse Split of the Company’s authorized and outstanding ordinary shares at a ratio of 20:1 effected on July 7, 2022. |
F-95
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 14 – EQUITY: (continued)
c. | Share based payments: (continued) |
3) | The changes in the number of share options and the weighted averages of their exercise prices are as follows: |
For the year ended December 31, | ||||||||||||||||||||||||
2022 | 2021 | 2020 | ||||||||||||||||||||||
Number of options | Weighted average of exercise price
per 1 ordinary share-(NIS) | Number of options | Weighted average of exercise price
per 1 ordinary share-(NIS) | Number of options | Weighted average of exercise price
per 1 ordinary share-(NIS) | |||||||||||||||||||
Outstanding at the beginning of year | 1,674,950 | 7.02 | 348,182 | 13.6 | 213,820 | 17.6 | ||||||||||||||||||
Granted | 1,370,000 | 5.81 | 152,500 | 11.1 | ||||||||||||||||||||
Forfeited | (1,100 | ) | 32.4 | (42,778 | ) | 17.23 | (17,723 | ) | 17.25 | |||||||||||||||
Expired | (454 | ) | 410 | (415 | ) | 1074 | ||||||||||||||||||
Outstanding at year end | 1,673,850 | 7.00 | 1,674,950 | 7.02 | 348,182 | 13.6 | ||||||||||||||||||
Exercisable at year end | 1,039,579 | 7.57 | 530,054 | 8.78 | 143,311 | 16.05 |
4) | The amounts of expenses that were recorded for options to employees and other service providers are USD 624 thousand, USD 1,049 thousand and USD 191 thousand for the years ended December 31, 2022, 2021 and 2020, respectively (these amounts do not include expenses of USD 79 and USD 1,107 thousand recorded in ScoutCam in Q1 2021 and 2020, respectively. The expenses recorded in Eventer in the consolidate period of 2020 are immaterial). |
5) | The plans are intended to be governed by the terms stipulated by Section 102 to the Israeli Income Tax Ordinance (except for the options to controlling shareholders and directors). |
In accordance with these general rules and the track chosen by the Company pursuant to the terms thereof, in respect of options granted to employees under the option allotment plan, the Company is not allowed to claim as an expense for tax purposes the amounts credited to employees as a benefit, including amounts recorded as salary benefits in the Company’s books, with the exception of the salary-benefit component, if exists, determined on the grant date.
d. | Dividends: |
In December 2022, the Company distributed dividends in an aggregated amount of USD 1,582 thousand.
NOTE 15 – EXPENSES BY NATURE
Year ended December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
USD in thousands | ||||||||||||
Payroll and related expenses | 7,647 | 2,656 | 2,420 | |||||||||
Professional fees | 7,421 | 5,990 | 2,963 | |||||||||
Traffic-acquisition, materials used and subcontracted work | 75,455 | 3,248 | 1,128 | |||||||||
Preparation of patents | 153 | 471 | 289 | |||||||||
Rent and office maintenance | 139 | 158 | 215 | |||||||||
Depreciation and amortization | 3,188 | 342 | 116 | |||||||||
Advertising and participation in exhibitions | 1,616 | 1,712 | 133 | |||||||||
Other | 2,262 | 1,312 | 732 | |||||||||
Amazon Fees | 2,558 | 2,426 | ||||||||||
Amortization of excess purchase price of an associate | 263 | 546 | ||||||||||
TOTAL COST OF REVENUES, INVENTORY IMPAIRMENT, RESEARCH AND DEVELOPMENT, SELLING AND MARKETING AND GENERAL AND ADMINISTRATIVE EXPENSES | 100,439 | 18,578 | 8,542 |
F-96
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 16 – EARNING (LOSS) PER SHARE:
Basic net earnings (loss) per share is computed by dividing net earnings (loss) attributable to ordinary shareholders of Medigus Ltd. by the weighted average number of ordinary shares outstanding for the reporting periods.
Diluted net earnings (loss) per share is computed by dividing the basic net loss per share including adjustment of the dilutive effect of the Company’s revaluation of warrants, by the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period. Diluted shares outstanding include the dilutive effect of in-the-money options using the treasury stock method. For the year ended December 31, 2022, and December 31, 2020, the Company reported a net loss, therefore does not have dilutive securities. For the year ended on December 31, 2021, the Company reported net earnings. Nevertheless, all the warrants and options that might be exercised by others into Medigus shares are out of the money, therefore did not have a dilutive effect.
The following table presents the numerator and denominator of the basic and diluted net loss per share computations:
Year ended December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
Numerator (USD in thousands): | ||||||||||||
Net earnings (loss) attributable to Medigus Ltd. | (9,815 | ) | 6,794 | (4,325 | ) | |||||||
Denominator (in thousands): | ||||||||||||
Weighted average number of ordinary shares used for basic and diluted earnings (loss) per share calculation* | 24,385 | 23,036 | 6,672 | |||||||||
Net earnings (loss) per share attributable to Medigus Ltd. (USD): * | ||||||||||||
Basic | (0.40 | ) | 0.2 | (0.6 | ) | |||||||
Diluted | (0.40 | ) | 0.2 | (0.6 | ) |
* | Adjusted to reflect the Reverse Split at ratio of 20:1 occurred effected on July 7, 2022 – see also note 14 |
F-97
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 17 – TRANSACTIONS AND BALANCES WITH RELATED PARTIES:
“Related Parties” – As defined in IAS 24 – ‘Related Party Disclosures” (hereinafter- “IAS 24”)
Key management personnel of the Company - included together with other entities, in the said definition of “Related Parties” mentioned in IAS 24.
a. | Transactions with related parties: | |
1): |
Year ended on December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
USD in thousands | ||||||||||||
Benefits to related parties: | ||||||||||||
Payroll and related expenses to related parties employed by the Company* | 1,784 | 1,241 | 629 | |||||||||
Compensation to directors ** | 837 | 733 | 1,115 | |||||||||
Directors’ and Officers’ insurance | 846 | 788 | 405 | |||||||||
Consultant services *** | 218 | 208 | ||||||||||
Interest and discount amortizations of loans from Jeffs’ Brands related parties **** | 42 | 172 | ||||||||||
Finance expense on Screenz payable balance (see note 4D) | 212 | 169 | ||||||||||
Compensation to member of senior management of Gix Internet ***** | 34 | |||||||||||
Eventer sales and marketing expenses to Keshet (see note 4D) | 165 | 279 | ||||||||||
Eventer revenues from related parties | 23 | |||||||||||
Eventer general and administrative expenses to Screenz | 41 | 13 |
* | Includes granted options benefit in the aggregated amount of USD 263 thousand, USD 583 thousand and USD 189 thousand for the years ended December 31, 2022, 2021 and 2020, respectively. As for the method used to determine the said value and the assumptions used in calculation thereof, see note 14c. |
** | Includes granted options benefit in the aggregated amount of USD 81 thousand, USD 195 thousand and USD 734 thousand for the years ended December 31, 2022, 2021 and 2020, respectively and provision and payments of bonus of approximately USD 77 thousand and USD 86 thousand, for each of the years ended December 31, 2022, and 2021, respectively. As for the method used to determine the said value and the assumptions used in calculation thereof, see note 14c. |
*** | Kfir Zilbrman is a related party of Jeff Brands . |
**** | Julia Gerasimova, and Victor Hakmon are related parties of Jeffs’ Brands, see note 4E. |
***** | Cortex CTO is a related party of Gix Internet. |
2) | a. Compensation to key management personnel |
The compensation to key management personnel for employment services they provide to the Company is as follows:
Year ended on December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
USD in thousands | ||||||||||||
For employment services: | ||||||||||||
Payroll and other short-term benefits | 1,521 | (*) | 657 | (**) | 440 | (***) | ||||||
Share based payments | 263 | 584 | 189 | |||||||||
1,784 | 1,241 | 629 |
* | Including provision for bonus of approximately USD 349 thousand. |
** | Including provision for bonus of approximately USD 118 thousand. |
*** | Including provision for bonus of approximately USD 53 thousand. |
F-98
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 17 – TRANSACTIONS AND BALANCES WITH RELATED PARTIES: (continued)
a. | Transactions with related parties: (continued) |
3) | Indemnification, exemption and insurance for directors and officers of the Company |
a. | The Company provides its directors and officers with an obligation for indemnification and exemption. |
b. | The Company has a liability for insurance of directors and officers’ covering all of the Company’s directors and officers. The Company currently has directors’ and officers’ liability insurance providing total coverage of USD 4 million for the benefit of all of the Company directors and officers, in respect of which the Company are charged a twelve-month premium of USD 195, and which includes a deductible of up to USD 1 million per claim, other than securities related claims filed in the United States or Canada, for which the deductible will not exceed USD 2.5 million and USD 5 million in respect of claim with respect to Mergers and Acquisitions. |
4) | Transactions |
a. | On May 30, 2019, the Company entered into an intercompany services agreement, or the Intercompany Agreement, with ScoutCam, for provision of services by the Company to ScoutCam. On April 19, 2020, the Intercompany Agreement was amended such that ScoutCam shall provide the Company with services to the Company, including usage of ScoutCam offic space in consideration for a fee determined based on the actual usage by the Company. During 2021 no services have been provided under the Intercompany Agreement. On March 22, 2022, the Company received from ScoutCam Ltd. a prior written notice of termination of the Intercompany Agreement effective May 21, 2022. |
b. | On February 12, 2020, ScoutCam’s Inc. Board of Directors authorized the grant of options to purchase 2,235,691 shares of Common Stock to Professor Benad Goldwasser, ScoutCam’s Inc. Chairman of the Board, and options to purchase 1,865,346 shares of Common Stock to certain officers of ScoutCam Inc. Each option is convertible into one share of common stock of ScoutCam Inc. of USD 0.001 par value at an exercise price of USD 0.29. | |
c. | On May 1, 2019, the Company entered into a consulting agreement, or the Consulting Agreement, with L.I.A Pure Capital Ltd. or Pure Capital, a company owned by Kfir Zilberman for the provision of business development and strategic consulting services, including ongoing consulting to the Company, its management and its chief executive officer in the fields of M&A and investment activities. In consideration for its services, Pure Capital is entitled to a monthly fee of NIS 40 thousand (approximately USD 11 thousand), a finder’s fee of 5% of any investment of equity or debt introduced by him to the Company and reimbursement of expenses of up to USD 1 thousand per month. As part of Gix Internet investment, Pure Capital received a finder fee in the amount of USD 125 thousand. On January 10, 2021, the Company and Pure Capital entered into amendment no. 2 of the Consulting Agreement. Under amendment no. 2, Pure Capital shall be entitled to a special bonus upon consummation of an offering of the Company’s securities. The special bonus will depend on the gross proceeds of such an offering. The transaction also includes granted options benefit aggregated to USD 189 thousand in 2020. | |
d. | On October 15, 2020, the Company signed a share purchase agreement and a revolving loan agreement with Eventer. As part of the share purchase agreement and the revolving loan agreement, the Company invested USD 750 thousand. For additional information see note 3D. On April 8, 2021, Eventer consummated a share purchase agreement for an aggregate amount of USD 2.25 million out of which the Company invested USD 300 thousand. As a result, the Company currently holds approximately 47.69% of Eventer’s share capital. During November 2021, the Company and Eventer agreed that the Initial Advance loan will be repaid the earlier of (i) six months following the Maturity Date of the Initial Advance; or (ii) immediately following an initial public offering of Eventer. On November 11, 2021, the Company loaned additional amount of USD 250 thousand to Eventer be repaid 6 months starting the loan received by eventer. The loan will bear 4% interest per year. |
F-99
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 17 – TRANSACTIONS AND BALANCES WITH RELATED PARTIES: (continued)
a. | Transactions with related parties: (continued) |
4) | Transactions (continued) |
e. | On April 19, 2020, the Company entered into an Asset Transfer Agreement, effective January 20, 2020, with our majority owned subsidiary GERD IP. Pursuant to the Asset Transfer Agreement, the Company transferred certain of our patents in consideration for seven capital notes issued to us by GERD IP, of USD 2 million each. | |
f. | In February 2021, the Company entered into two loans and pledges agreements with Jeffs’ Brands and its other stockholder, to finance Smart Repair Pro’s additional purchases of three new brands on the Amazon online marketplace. Pursuant to the agreements, the Company extended a USD 4 million loans, with an annual interest of 4%, to be repaid on the fifth anniversary of the effective date. Following the closing of an IPO of Jeffs’ Brands, the loans were converted to shares. | |
g. | On October 26, 2022, Jeffs’ Brands and Pure Capital entered into a consulting agreement, pursuant to which Pure Capital will provide consulting services to Jeffs’ Brands for a monthly fee of NIS 57.5 thousand (approximately USD 16.5 thousand). Jeffs’ Brands paid Pure Capital a one-time signing bonus in the amount of NIS 425 thousand (approximately USD 121 thousand) for their services to Jeffs’ Brands from the day of Jeffs’ Brands inception until the closing of the IPO. As part of the consulting agreement, Pure Capital is also entitled to the following payment: (i) an amount equal to 7% of the gross proceeds paid to Jeffs’ Brands in connection with any exercise of warrants, whether or not currently outstanding; and (ii) 8% of the total consideration paid in connection with any purchase of a new brand, businesses, or similar events initiated or assisted by Pure Capital and approved by the Chief Executive Officer and Chairman of the Board based on agreement with Pure Capital. The consulting agreement is for an undefined period of time and may be terminated after 3 years from October 26, 2022, by either party upon 30 days advance notice.
Additionally, on October 26, 2022, Jeffs’ Brands and Pure NJ Logistics LLC, owned by Pure Capital and a director of Jeffs’ Brands, entered into a warehouse lease agreement for a warehouse located in the USA. As of December 31, 2022, the advances to suppliers comprised of USD 228 thousand that were paid to Pure NJ Logistics LLC. | |
h. | On October 30, 2022, the Company signed an amendment to the revolving loan with Eventer. According to the amendment, the maturity date of the loan will be May 30, 2024. In addition, in certain event of securities issuance by Eventer (in an amount of at least USD 2 million), prior the maturity date, the loan will be automatically converted into Eventer's shares with 20% discount. The loan will bear interest of 6% annually. |
b. | Balances with related parties: |
(1) | Current assets under related parties section: |
December 31, | December 31, | |||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
Related party prepaid expense (a related party of Eventer) (note 4D) | 981 | |||||||
Advances to Pure Logistics (related party of Jeffs’ Brands) (note 4E) | 228 | |||||||
Other receivables (a related party of Gix Internet) (note 4F) | 60 | |||||||
Other receivables (a related party of Eventer) (note 4D) | 10 | 18 | ||||||
298 | 999 |
(2) | Current assets under loans to others section: |
* | Gix Internet is consolidated commencing February 28, 2022. |
F-100
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 17 – TRANSACTIONS AND BALANCES WITH RELATED PARTIES: (continued)
b. | Balances with related parties: (continued) |
(3) | Current Liabilities: |
December 31, | December 31, | |||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
Compensation to key management personnel(*) | 649 | 270 | ||||||
Other payable dividend to related parties of Gix Internet | 284 | |||||||
Current liabilities of Jeffs’ Brands to related parties | 177 | |||||||
Other accrued expenses to related parties of Eventer | 122 | 169 | ||||||
1,055 | 616 |
* | Compensation to key management: |
December 31, | ||||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
Directors’ fee | 496 | 183 | ||||||
Payroll, provision for bonus and for termination of employment | 153 | 87 | ||||||
649 | 270 |
(4) | Loans: |
December 31, | December 31, | |||||||
2022 | 2021 | |||||||
USD in thousands | ||||||||
Current portion of long-term payable - Screenz cross media Ltd (a related party of Eventer) (see note 4D) | 506 | |||||||
Long-term payable - Screenz cross media Ltd (a related party of Eventer) (see note 4D) | 711 | |||||||
Short term loans of Jeffs’ Brands from related parties (*) | 111 | |||||||
Long term loans of Jeffs’ Brands from related parties (**) | 689 |
* | Kfir Zilberman is a related party of Jeffs’ Brands. |
** | Julia Gerasimova, Kfir Zilberman and Victor Hakmon are related parties of Jeffs’ Brands. |
c. | As to options granted to related parties, see note 14c. |
F-101
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 18 – REVENUES:
a. | Disaggregation of Revenues: |
The following table present the Group’s revenues disaggregated by revenue type:
Year ended on December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
USD in thousands | ||||||||||||
Miniature camera and related equipment (from ScoutCam) | 24 | 491 | ||||||||||
Revenues from commissions (from Eventer) | 2,465 | 1,185 | 40 | |||||||||
Products (from Jeffs’ Brands) | 5,861 | 6,509 | ||||||||||
Revenues from internet services (from Gix Internet) * | 83,532 | |||||||||||
MUSE and related equipment (from Medigus). | 2,400 | |||||||||||
91,858 | 10,118 | 531 |
* | The revenues from Gix Internet are presented for the period from March 01 ,2022 to December 31, 2022. |
b. | Contract fulfilment assets: |
The Company’s contract fulfilment assets:
c. | Contract liabilities: |
The changes in the Company’s contract liabilities were as follows:
December 31, 2022 | December 31, 2021 | |||||||
USD in thousands | ||||||||
Balance at beginning of year | 108 | 2,649 | ||||||
Deferred revenue relating to new sales | 49 | 1,370 | ||||||
De recognition upon deconsolidation of ScoutCam (note 4C) | (1,511 | ) | ||||||
Revenue recognition during the period | (108 | ) | (2,400 | ) | ||||
Balance at end of year | 49 | 108 |
F-102
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 19 – SEGMENTS:
The Group identified nine operating segments as follows: medical, e-commerce, online advertising and internet traffic routing, online event management, safety systems for commercial drones, visualization and AI based solutions, energy efficiency technology, electric vehicles and corporate (see note 1a). The Company concluded that the medical, electric vehicles, safety systems for commercial drones, visualization and AI based solutions and energy efficiency technology segments are not “reportable segments” as defined in IFRS 8, Operating Segments. As such, these segments were combined and disclosed under “Others”.
The CODM measures and evaluates the operating performance of the Group’s segments based on operating loss (income), assets and liabilities.
The table set forth other information of the Group:
* | Includes an investment accounted for using the equity method of USD 9,375 thousand in relation to ScoutCam and an investment accounted for using the equity method of USD 976 thousand in relation to Paraziro. For additional information in relation to assets and liabilities of ScoutCam and Paraziro refer to note 4C and 4M. |
The table set forth the operating results of the Group:
Year ended December 31, 2022 | ||||||||||||||||||||||||||||
Corporate | E-commerce | Online | Online Event Management | Others | Adjustments and eliminations | Total | ||||||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||||||
External revenue | 5,859 | 83,534 | 2,465 | 91,858 | ||||||||||||||||||||||||
Segment results – operating income (loss) | (7,301 | ) | (4,510 | ) | 2,341 | * | (748 | ) | (2,829 | )** | (736 | ) | (13,783 | ) | ||||||||||||||
Non-operating income (loss) | (167 | ) | 3,619 | (731 | ) | (30 | ) | 137 | 3,166 | 5,994 | ||||||||||||||||||
Finance income (loss) | (224 | ) | (520 | ) | (1,100 | ) | (539 | ) | (8 | ) | 82 | (2,309 | ) | |||||||||||||||
Profit (Loss) before taxes on income | (7,692 | ) | (1,410 | ) | 510 | (1,317 | ) | (2,700 | ) | 2,512 | (10,097 | ) | ||||||||||||||||
Tax benefit (expense) on income | (5 | ) | 5 | (310 | ) | 10 | 189 | (111 | ) | |||||||||||||||||||
Segment results – profit (loss) | (7,697 | ) | (1,405 | ) | 200 | (1,317 | ) | (2,690 | ) | 2,701 | (10,208 | ) |
* | Includes equity loss of USD 215 thousand in relation to Gix Internet for the two months period until February 28, 2022. For the operating results of Gix Internet, refer to note 4F. |
** | Includes equity loss of USD 1,360 thousand in relation to ScoutCam and equity loss of USD 615 thousand in relation to Paraziro. For the operating results of Scoutcam and Paraziro, refer to note 4C and 4M. |
F-103
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 19 – SEGMENTS: (continued)
The table set forth other information of the Group: (continued)
December 31, 2021 | ||||||||||||||||||||||||
Corporate | E-commerce | Online Event Management | Others | Adjustments and eliminations | Total | |||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||
Total segments’ assets | 33,695 | 7,412 | 9,357 | * | 11,692 | ** | (2,926 | ) | 59,730 | |||||||||||||||
Total segments’ liabilities | (1,571 | ) | (6,159 | ) | (4,282 | ) | (399 | ) | 4,114 | (8,297 | ) |
* | Includes an investment accounted for using the equity method of USD 4,867 thousand in relation to Gix Internet. For additional information in relation to assets and liabilities of Gix Internet refer to note 4F. |
** | Includes an investment accounted for using the equity method of USD 10,735 thousand in relation to ScoutCam. For additional information in relation to assets and liabilities of ScoutCam refer to note 4C. |
The table set forth the operating results of the Group:
Year ended December 31, 2021 | ||||||||||||||||||||||||
Corporate | E-commerce | Online Event Management | Others | Adjustments and eliminations | Total | |||||||||||||||||||
USD in thousands | ||||||||||||||||||||||||
External revenue | 2,400 | 6,509 | 1,185 | 24 | 10,118 | |||||||||||||||||||
Segment results – operating income (loss) | (2,271 | ) | (932 | ) | (3,229 | )* | (3,531 | )** | 68 | (9,895 | ) | |||||||||||||
Non-operating income | 2,509 | 494 | 11,390 | *** | 14,393 | |||||||||||||||||||
Finance income (loss) | 555 | (629 | ) | (206 | ) | (15 | ) | (52 | ) | (347 | ) | |||||||||||||
Profit (Loss) before taxes on income | 793 | (1,561 | ) | (3,435 | ) | (3,052 | ) | 11,406 | 4,151 | |||||||||||||||
Tax benefit (expense) on income | 21 | (126 | ) | (105 | ) | |||||||||||||||||||
Segment results – profit (loss) | 793 | (1,540 | ) | (3,435 | ) | (3,052 | ) | 11,280 | 4,046 |
* | Includes equity loss of USD 823 thousand in relation to Gix Internet. For the operating results of Gix Internet, refer to note 4F. |
** | Includes equity loss of USD 1,402 thousand in relation to ScoutCam. For the operating results of Scoutcam, refer to note 4C. |
*** | Includes gain of USD 11,465 thousand upon loss of control in ScoutCam, refer to note 4C. |
F-104
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 20 – ENTITY LEVEL DISCLOSURES:
a. | Revenues by geographical area (based on the location of customers): |
Year ended on December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
USD in thousands | ||||||||||||
USA | 52,129 | 6,307 | 418 | |||||||||
Europe | 21,897 | 127 | 41 | |||||||||
Israel | 15,266 | 1,183 | 45 | |||||||||
Asia | 2,108 | 2,400 | 24 | |||||||||
Other | 458 | 101 | 3 | |||||||||
91,858 | 10,118 | 531 |
b. | All of the Group’s long-lived assets are located in Israel. |
c. | Major customers |
Set forth below is a breakdown of Company’s revenue by major customers (major customer –revenues from these customers constitute at least 10% of total revenues in a certain year):
Year ended on December 31, | ||||||||||||
2022 | 2021 | 2020 | ||||||||||
USD in thousands | ||||||||||||
Customer A | 383 | |||||||||||
Customer B | - | 2,400 | 24 | |||||||||
Customer C | 16,919 | |||||||||||
Customer D | 16,468 |
F-105
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 21 – EVENT SUBSEQUENT TO DECEMBER 31, 2022:
1. | In February 2023 the Company and other lenders, signed a convertible loan agreement with Polyrizon Ltd.in the amount of USD 180 thousand, of which the company loan amounted to USD 80 thousand. The loan bears 4% annual interest rate. The loan will be automatically converted to shares in a case of issuance securities of a financing round of at least USD 500 thousand, in a discount of 20%. |
2. | On February 16, 2023, the Company made an investment in A.I Technologies of USD 81 thousand and holds 4.99% as of the filing date of these financial statements. |
3. | On January 26, 2023, Gix Internet acquired an additional 10% of Cortex, increasing its holdings to 80% of the share capital of Cortex on a fully diluted. The subsequent purchase was completed at a valuation of Cortex of approximately USD 27 million in exchange for consideration consisting of USD 2.6 million in cash. The subsequent purchase was financed by Gix Media’s existing cash balances and by a long-term bank loan received on January 17, 2023, in the amount of USD 1,500 thousand which will be repaid in 42 monthly payments at an annual interest rate of SOFR + 5.37%. |
4. | On March 21, 2023, ScoutCam Inc. completed a private placement to existing stockholders, of 3,294,117 units, at a purchase price of USD 4.25 per unit, with each unit consisting of one share of Scoutcam’s common stock and one three-year warrant to purchase one share of Scoutcam’s common stock at an exercise price of USD 5.50 per share. The private placement was led by existing investors Mori Arkin, the Phoenix Insurance Company Ltd and Shotfut Menayot Israel – Phoenix Amitim. Following the private placement, the company held 18.45% in ScoutCam. |
5. | On February 23, 2023, Jeffs’ Brands Ltd. and Jeffs’ Brands Holdings Inc., entered into a stock purchase agreement (the “Wellution Agreement”), with SciSparc Ltd. (“SciSparc”), pursuant which, on March 22, 2022, Jeffs’ Brands Holdings acquired from SciSparc 57 shares of common stock of SciSparc Nutraceuticals Inc. (“SciSparc Nutraceuticals”), a wholly-owned subsidiary of SciSparc that owns and operates Wellution , a top-selling Amazon food supplements and cosmetics brand, representing approximately 49% of the issued and outstanding common stock of SciSparc Nutraceuticals, for approximately USD 2.5 million in cash (the “Wellution Transaction”). On March 22, 2023, Jeffs’ Brands Ltd., Jeffs’ Brands Holdings and SciSparc entered into Addendum No. 1 to the Wellution Agreement, or the Addendum, to provide for an additional amount of USD 489 thousand, representing adjustments related to inventory and working capital, to be paid to SciSparc in five equal installments of USD 98 thousand on the tenth day of each consecutive calendar month, beginning in May 2023. Also pursuant to the SciSparc SPA, in connection with the closing of the SciSparc Nutraceuticals Joint Venture, on March 22, 2023, Jeffs’ Brands entered into a consulting agreement with SciSparc Nutraceuticals (the “SciSparc Consulting Agreement”), pursuant to which Jeffs’ Brands will provide management services to SciSparc Nutraceuticals for the WellutionTM brand for a monthly fee of USD 20 thousand and Jeffs; Brands received a one-time signing bonus in the amount of USD 51 thousand. The SciSparc Consulting Agreement is for an undefined period of time and may be terminated by either party with 30 days advance notice. |
Also pursuant to the Wellution Agreement, in connection with the closing of the Wellution Transaction, on March 22, 2023, Jeffs’ Brands issued 247,415 of its Ordinary Shares to SciSparc and SciSparc issued 360,297 of its Ordinary Shares to Jeffs’ Brands in a share exchange (collectively, the “Exchange Shares”), representing 2.97% and 4.99%, respectively, of Jeffs’ Brands’ and SciSparc’s issued and outstanding ordinary shares. The number of Exchange Shares acquired by each company was calculated by dividing USD 288,238 by the average closing price of the relevant company’s shares on the Nasdaq Capital Market for the 30 consecutive trading days ending on the third trading day immediately prior to the closing.
F-106
MEDIGUS LTD.
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS
NOTE 21 – EVENT SUBSEQUENT TO DECEMBER 31, 2022: (continued)
6. | On March 2, 2023, Jeffs’ Brands entered into a share purchase agreement (the “Fort SPA”), with the holders (the “Sellers”), of all of the issued and outstanding share capital of Fort, a company incorporated under the laws of England and Wales and engaged in the sale of pest control products primarily through Amazon.uk, pursuant to which on March 9, 2023, Jeffs’ Brands acquired all of the issued and outstanding share capital of Fort, for approximately £2,000 thousand (approximately USD 2,400 thousand) in cash (the “Fort Acquisition”). The Fort SPA provides that for a period of three years from closing, the Sellers will not compete with Fort’s business. |
Also, in connection with the Fort Acquisition, on March 9th, 2023, Jeffs’ Brands and Fort entered into settlement agreements with all of Fort’s employees, including the Sellers, by which such employees’ employment with Fort will terminate three months following March 9, 2023 and certain other customary conditions. During this three-month period, Jeffs’ Brands intends to carry out operational changes in Fort’s business that will allow Fort to wind down the activities conducted in its leased warehouse and to move all such operations to warehouses operated by Amazon. In connection with the closing of the acquisition, on March 9th, 2023, Jeffs’ Brands and the Sellers entered into a consulting agreement, pursuant to which the Sellers will provide Jeffs’ Brands with consultancy services for a period of three months, in consideration for a monthly fee of £2,500 (approximately USD 3 thousand).
7. | On March 16, 2023, the Company signed an amendment to the option sale agreement by and between the Company and Buffalo Investment Ltd. (“Buffalo”) dated as of December 7, 2021 (the “Amendment” and the “Buffalo Agreement”), according to which Buffalo and Pure Capital Ltd. shall transfer to the Company shares of Hydreight Technologies Inc., Viewbix Inc., SciSparc Ltd. (“SciSparc”), ClearMind Medicine Inc. and Colugo Systems Ltd., instead of a transfer of 135,000 shares of SciSparc worth USD 817 thousand which was originally agreed under the Buffalo Agreement. The aggregated value of the shares transferred under the Amendment is USD 937 thousand reflecting USD 817 thousand plus compensation worth of USD 130 thousand. |
8. | On March 28, 2023, the company signed a security exchange agreement with Fuel Doctor to sell all its shares in its wholly owned subsidiary, Charging Robotics to Fuel Doctor. As part of the exchange agreement, Fuel Doctor will acquire all of the issued and outstanding shares of Charging Robotics, on a fully diluted basis and as a result Charging Robotics will become a wholly owned subsidiary of Fuel Doctor. In exchange for all of its shares in Charging Robotics, the company received such number of newly issues shares of Fuel Doctor’s common stock equal to 60% of the total number of shares of Fuel Doctor’s common stock issued and outstanding as of the closing on a fully diluted basis. Subject to several pre-determined milestones, the company might increase its holding in Fuel Doctor up to 71%. |
9 | On April 13, 2022, the Company acquired 19.9% of Metagramm Software Ltd. (“Metagramm”), an innovative AI, machine learning (ML) communication and grammar assistant software. In return, The Company paid Metagramm USD 250 thousand in Company’s common shares. In addition, the Company will extend Metagramm a loan in the amount of USD 250 thousand in three instalments, the first instalment of which will be granted at closing. The loan will be repaid from Metagramm’s existing and future profits and is secured by the shares of all other current Metagramm shareholders. |
10 | During February and March 2023, Cortex distributed dividends in an aggregated amount of approximately USD 1,039 thousand (approximately NIS 3.03 million) to non-controlling interest. In addition, Gix Media distributed a dividend in an aggregated amount of approximately USD 130 thousand (approximately NIS 432 thousand). |
F-107
Exhibit 1.1
THE COMPANIES LAW, 1999
A LIMITED LIABILITY COMPANY
----------------
AMENDED AND RESTATED
ARTICLES OF ASSOCIATION
OF
MEDIGUS LTD.
As Adopted on June 17, 2022
Preliminary
1. Definitions; Interpretation.
(a) | In these Articles, the following terms (whether or not capitalized) shall bear the meanings set forth opposite them, respectively, unless the subject or context requires otherwise. |
“Office Holder” or “Officer” | shall have the meaning provided for such term in the Companies Law. |
(b) | Unless the context shall otherwise require: words in the singular shall also include the plural, and vice versa; any pronoun shall include the corresponding masculine, feminine and neuter forms; the words “include”, “includes” and “including” shall be deemed to be followed by the phrase “without limitation”; the words “herein”, “hereof” and “hereunder” and words of similar import refer to these Articles in their entirety and not to any part hereof; all references herein to Articles or clauses shall be deemed references to Articles or clauses of these Articles; any references to any agreement or other instrument or law, statute or regulation are to it as amended, supplemented or restated, from time to time (and, in the case of any law, to any successor provisions or re-enactment or modification thereof being in force at the time); any reference to “law” shall include any law (‘din’) as defined in the Interpretation Law, 5741-1981 and any applicable supranational, national, federal, state, local, or foreign statute or law and shall be deemed also to refer to all rules and regulations promulgated thereunder; any reference to a “day” or a number of “days” (without any explicit reference otherwise, such as to business days) shall be interpreted as a reference to a calendar day or number of calendar days; any reference to a business day shall mean each calendar day other than any calendar day on which commercial banks in New York, New York or Tel-Aviv, Israel are authorized or required by applicable law to close; reference to a month or year means according to the Gregorian calendar; any reference to a “person” shall mean any individual, partnership, corporation, limited liability company, association, estate, any political, governmental, regulatory or similar agency or body, or other legal entity; and reference to “written” or “in writing” shall include written, printed, photocopied, typed, any electronic communication (including email, facsimile, signed electronically (in Adobe PDF, DocuSign or any other format)) or produced by any visible substitute for writing, or partly one and partly another, and signed shall be construed accordingly. |
(c) | The captions in these Articles are for convenience only and shall not be deemed a part hereof or affect the construction or interpretation of any provision hereof. |
(d) | The specific provisions of these Articles shall supersede the provisions of the Companies Law to the extent permitted thereunder. |
Limited Liability
2. | The Company is a limited liability company and each Shareholder’s liability for the Company’s debt is therefore limited (in addition to any liabilities under any contract) to the payment of the full amount (par value (if any) and premium) such Shareholder was required to pay the Company for such Shareholder’s Shares (as defined below) and which amount has not yet been paid by such Shareholder. |
Company’s Objectives
3. Objectives.
The Company’s objectives are to carry on any business, and do any act, which is not prohibited by law. |
4. Donations.
The Company may donate a reasonable amount of money (in cash or in kind, including the Company’s securities) to worthy purposes such as the Board of Directors may determine in its discretion, even if such donations are not made on the basis or within the scope of business considerations of the Company. |
2
Share Capital
5. Authorized Share Capital.
(a) | The authorized share capital of the Company shall consist of 200,000,000 Ordinary Shares without par value (the “Shares”). |
(b) | The Shares shall rank pari passu in all respects. The Shares may be redeemable to the extent set forth in Article 18. |
6. Increase of Authorized Share Capital.
(a) | The Company may, from time to time, by a Shareholders’ resolution, whether or not all of the Shares then authorized have been issued, and whether or not all of the Shares theretofore issued have been called up for payment, increase its authorized share capital by increasing the number of Shares it is authorized to issue by such amount, and such additional Shares shall confer such rights and preferences, and shall be subject to such restrictions, as such resolution shall provide. |
(b) | Except to the extent otherwise provided in such resolution, any new Shares included in the authorized share capital increase as aforesaid shall be subject to all of the provisions of these Articles that are applicable to Shares that are included in the existing share capital. |
7. Special or Class Rights; Modification of Rights.
(a) | The Company may, from time to time, by a Shareholders’ resolution, provide for shares with such preferred or deferred rights or other special rights and/or such restrictions, whether in regard to dividends, voting, repayment of share capital or otherwise, as may be stipulated in such resolution. |
(b) | If at any time the share capital of the Company is divided into different classes of shares, the rights attached to any class, unless otherwise provided by these Articles, may be modified or cancelled by the Company by a resolution of the General Meeting of the holders of all shares as one class, without any required separate resolution of any class of shares. |
(c) | The provisions of these Articles relating to General Meetings shall apply, mutatis mutandis, to any separate General Meeting of the holders of the shares of a particular class, it being clarified that the requisite quorum at any such separate General Meeting shall be Shareholders present in person or by proxy and holding not less than thirty-three and one-third percent (33⅓%) of the issued shares of such class, provided, however, that if (i) such separate General Meeting of the holders of the particular class was initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii) at the time of such meeting the Company is qualified to use the forms of a “foreign private issuer” under US securities laws, then the requisite quorum at any such separate General Meeting shall be Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present in person or by proxy and holding not less than ten percent (10%) of the issued shares of such class. |
(d) | Unless otherwise provided by these Articles, an increase in the authorized share capital, the creation of a new class of shares, an increase in the authorized share capital of a class of shares, or the issuance of additional shares thereof out of the authorized and unissued share capital, shall not be deemed, for purposes of this Article 7, to modify or derogate or cancel the rights attached to previously issued shares of such class or of any other class. |
8. Consolidation, Division, Cancellation and Reduction of Share Capital.
(a) | The Company may, from time to time, by or pursuant to an authorization of a Shareholders’ resolution, and subject to applicable law: |
(i) | consolidate all or any part of its issued or unissued authorized share capital; |
3
(ii) | divide or sub-divide its Shares (issued or unissued) or any of them and the resolution whereby any Share is divided may determine that, as among the holders of the Shares resulting from such subdivision, one or more of the Shares may, in contrast to others, have any such preferred or deferred rights or rights of redemption or other special rights, or be subject to any such restrictions, as the Company may attach to unissued or new shares; | |
(iii) | cancel any authorized Shares which, at the date of the adoption of such resolution, have not been issued to any person nor has the Company made any commitment, including a conditional commitment, to issue such Shares, and reduce the amount of its share capital by the amount of the Shares so canceled; or | |
(iv) | reduce its share capital in any manner. |
(b) | With respect to any consolidation of issued Shares and with respect to any other action which may result in fractional Shares, the Board of Directors may settle any difficulty which may arise with regard thereto, as it deems fit, and, in connection with any such consolidation or other action which could result in fractional shares, may, without limiting its aforesaid power: |
(i) | determine, as to the holder of Shares so consolidated, which issued Shares shall be consolidated; | |
(ii) | issue, in contemplation of or subsequent to such consolidation or other action, Shares sufficient to preclude or remove fractional share holdings; | |
(iii) | redeem such Shares or fractional shares sufficient to preclude or remove fractional Share holdings; | |
(iv) | round up, round down or round to the nearest whole number, any fractional Shares resulting from the consolidation or from any other action which may result in fractional Shares; or | |
(v) | cause the transfer of fractional Shares by certain Shareholders of the Company to other Shareholders thereof so as to most expediently preclude or remove any fractional Share holdings, and cause the transferees of such fractional Shares to pay the transferors thereof the fair value thereof, and the Board of Directors is hereby authorized to act in connection with such transfer, as agent for the transferors and transferees of any such fractional Shares, with full power of substitution, for the purposes of implementing the provisions of this sub-Article 8(b)(v). |
9. Issuance of Share Certificates, Replacement of Lost Certificates.
(a) | To the extent that the Board of Directors determines that all Shares shall be certificated or, if the Board of Directors does not so determine, to the extent that any Shareholder requests a share certificate or the Company’s transfer agent so requires, share certificates shall be issued under the corporate seal of the Company or its written, typed or stamped name and shall bear the signature of one Director, the Company’s Chief Executive Officer, or any person or persons authorized therefor by the Board of Directors. Signatures may be affixed in any mechanical or electronic form, as the Board of Directors may prescribe. |
(b) | Subject to the provisions of Article 9(a), each Shareholder shall be entitled to one numbered certificate for all of the Shares of any class registered in his or her name. Each certificate shall specify the serial numbers of the Shares represented thereby and may also specify the amount paid up thereon. The Company (as determined by an officer of the Company to be designated by the Chief Executive Officer) shall not refuse a request by a Shareholder to obtain several certificates in place of one certificate, unless such request is, in the opinion of such officer, unreasonable. Where a Shareholder has sold or transferred a portion of such Shareholder’s Shares, such Shareholder shall be entitled to receive a certificate in respect of such Shareholder’s remaining Shares, provided that the previous certificate is delivered to the Company before the issuance of a new certificate. |
(c) | A share certificate registered in the names of two or more persons shall be delivered to the person first named in the Register of Shareholders in respect of such co-ownership. |
(d) | A share certificate which has been defaced, lost or destroyed, may be replaced, and the Company shall issue a new certificate to replace such defaced, lost or destroyed certificate upon payment of such fee, and upon the furnishing of such evidence of ownership and such indemnity, as the Board of Directors in its discretion deems fit. |
4
10. Registered Holder.
Except as otherwise provided in these Articles or the Companies Law, the Company shall be entitled to treat the registered holder of each Share as the absolute owner thereof, and accordingly, shall not, except as ordered by a court of competent jurisdiction, or as required by the Companies Law, be obligated to recognize any equitable or other claim to, or interest in, such Share on the part of any other person.
11. Issuance and Repurchase of Shares.
(a) | The unissued Shares from time to time shall be under the control of the Board of Directors (and, to the extent permitted by applicable law, any Committee thereof), which shall have the power to issue or otherwise dispose of Shares and of securities convertible or exercisable into or other rights to acquire from the Company to such persons, on such terms and conditions (including, inter alia, price, with or without premium, discount or commission, and terms relating to calls set forth in Article 13(f) hereof), and at such times, as the Board of Directors (or the Committee, as the case may be) deems fit, and the power to give to any person the option to acquire from the Company any Shares or securities convertible or exercisable into or other rights to acquire from the Company on such terms and conditions (including, inter alia, price, with or without premium, discount or commission), during such time as the Board of Directors (or the Committee, as the case may be) deems fit. |
(b) | The Company may at any time and from time to time, subject to applicable law, repurchase or finance the purchase of any Shares or other securities issued by the Company, in such manner and under such terms as the Board of Directors shall determine, whether from any one or more Shareholders. Such purchase shall not be deemed as payment of dividends and as such, no Shareholder will have the right to require the Company to purchase his or her Shares or offer to purchase shares from any other Shareholders. |
12. Payment in Installment.
If pursuant to the terms of issuance of any Share, all or any portion of the price thereof shall be payable in installments, every such installment shall be paid to the Company on the due date thereof by the then registered holder(s) of the Share or the person(s) then entitled thereto.
13. Calls on Shares.
(a) | The Board of Directors may, from time to time, as it, in its discretion, deems fit, make calls for payment upon Shareholders in respect of any sum (including premium) which has not been paid up in respect of Shares held by such Shareholders and which is not, pursuant to the terms of issuance of such Shares or otherwise, payable at a fixed time, and each Shareholder shall pay the amount of every call so made upon him or her (and of each installment thereof if the same is payable in installments), to the person(s) and at the time(s) and place(s) designated by the Board of Directors, as any such times may be thereafter extended and/or such person(s) or place(s) changed. Unless otherwise stipulated in the resolution of the Board of Directors (and in the notice hereafter referred to), each payment in response to a call shall be deemed to constitute a pro rata payment on account of all the Shares in respect of which such call was made. |
(b) | Notice of any call for payment by a Shareholder shall be given in writing to such Shareholder not less than fourteen (14) days prior to the time of payment fixed in such notice, and shall specify the time and place of payment, and the person to whom such payment is to be made. Prior to the time for any such payment fixed in a notice of a call given to a Shareholder, the Board of Directors may in its absolute discretion, by notice in writing to such Shareholder, revoke such call in whole or in part, extend the time fixed for payment thereof, or designate a different place of payment or person to whom payment is to be made. In the event of a call payable in installments, only one notice thereof need be given. |
5
(c) | If pursuant to the terms of issuance of a share or otherwise, an amount is made payable at a fixed time, such amount shall be payable at such time as if it were payable by virtue of a call made by the Board of Directors and for which notice was given in accordance with paragraphs (a) and (b) of this Article 13, and the provision of these Articles with regard to calls (and the non-payment thereof) shall be applicable to such amount or such installment (and the non-payment thereof). |
(d) | Joint holders of a Share shall be jointly and severally liable to pay all calls for payment in respect of such Share and all interest payable thereon. |
(e) | Any amount called for payment which is not paid when due shall bear interest from the date fixed for payment until actual payment thereof, at such rate (not exceeding the then prevailing debitory rate charged by leading commercial banks in Israel), and payable at such time(s) as the Board of Directors may prescribe. |
(f) | Upon the issuance of Shares, the Board of Directors may provide for differences among the holders of such Shares as to the amounts and times for payment of calls for payment in respect of such Shares. |
14. Prepayment.
With the approval of the Board of Directors, any Shareholder may pay to the Company any amount not yet payable in respect of his or her Shares, and the Board of Directors may approve the payment by the Company of interest on any such amount until the same would be payable if it had not been paid in advance, at such rate and time(s) as may be approved by the Board of Directors. The Board of Directors may at any time cause the Company to repay all or any part of the money so advanced, without premium or penalty. Nothing in this Article 14 shall derogate from the right of the Board of Directors to make any call for payment before or after receipt by the Company of any such advance.
15. Forfeiture and Surrender.
(a) | If any Shareholder fails to pay an amount payable by virtue of a call, installment or interest thereon as provided for in accordance herewith, on or before the day fixed for payment of the same, the Board of Directors may at any time after the day fixed for such payment, so long as such amount (or any portion thereof) or interest thereon (or any portion thereof) remains unpaid, forfeit all or any of the Shares in respect of which such payment was called for. All expenses incurred by the Company in attempting to collect any such amount or interest thereon, including, without limitation, attorneys’ fees and costs of legal proceedings, shall be added to, and shall, for all purposes (including the accrual of interest thereon) constitute a part of, the amount payable to the Company in respect of such call. |
(b) | Upon the adoption of a resolution as to the forfeiture of a Shareholder’s Share, the Board of Directors shall cause notice thereof to be given to such Shareholder, which notice shall state that, in the event of the failure to pay the entire amount so payable by a date specified in the notice (which date shall be not less than fourteen (14) days after the date such notice is given and which may be extended by the Board of Directors), such Shares shall be ipso facto forfeited, provided, however, that, prior to such date, the Board of Directors may cancel such resolution of forfeiture, but no such cancellation shall stop the Board of Directors from adopting a further resolution of forfeiture in respect of the non-payment of the same amount. |
(c) | Without derogating from Articles 51 and 55 hereof, whenever Shares are forfeited as herein provided, all dividends, if any, theretofore declared in respect thereof and not actually paid shall be deemed to have been forfeited at the same time. |
(d) | The Company, by resolution of the Board of Directors, may accept the voluntary surrender of any Share. |
(e) | Any Share forfeited or surrendered as provided herein, shall become the property of the Company as a dormant Share, and the same, subject to the provisions of these Articles, may be sold, re-issued or otherwise disposed of as the Board of Directors deems fit. |
6
(f) | Any person whose Shares have been forfeited or surrendered shall cease to be a Shareholder in respect of the forfeited or surrendered Shares, but shall, notwithstanding, be liable to pay, and shall forthwith pay, to the Company, all calls, interest and expenses owing upon or in respect of such Shares at the time of forfeiture or surrender, together with interest thereon from the time of forfeiture or surrender until actual payment, at the rate prescribed in Article 13(e) above, and the Board of Directors, in its discretion, may, but shall not be obligated to, enforce or collect the payment of such amounts, or any part thereof, as it shall deem fit. In the event of such forfeiture or surrender, the Company, by resolution of the Board of Directors, may accelerate the date(s) of payment of any or all amounts then owing to the Company by the person in question (but not yet due) in respect of all Shares owned by such Shareholder, solely or jointly with another. |
(g) | The Board of Directors may at any time, before any Share so forfeited or surrendered shall have been sold, re-issued or otherwise disposed of, nullify the forfeiture or surrender on such conditions as it deems fit, but no such nullification shall stop the Board of Directors from re-exercising its powers of forfeiture pursuant to this Article 15. |
16. Lien.
(a) | Except to the extent the same may be waived or subordinated in writing, the Company shall have a first and paramount lien upon all the Shares registered in the name of each Shareholder (without regard to any equitable or other claim or interest in such Shares on the part of any other person), and upon the proceeds of the sale thereof, for his or her debts, liabilities and engagements to the Company arising from any amount payable by such Shareholder in respect of any unpaid or partly paid Share, whether or not such debt, liability or engagement has matured. Such lien shall extend to all dividends from time to time declared or paid in respect of such Share. Unless otherwise provided, the registration by the Company of a transfer of Shares shall be deemed to be a waiver on the part of the Company of the lien (if any) existing on such Shares immediately prior to such transfer. |
(b) | The Board of Directors may cause the Company to sell a Share subject to such a lien when the debt, liability or engagement giving rise to such lien has matured, in such manner as the Board of Directors deems fit, but no such sale shall be made unless such debt, liability or engagement has not been satisfied within fourteen (14) days after written notice of the intention to sell shall have been served on such Shareholder, his or her executors or administrators. |
(c) | The net proceeds of any such sale, after payment of the costs and expenses thereof or ancillary thereto, shall be applied in or toward satisfaction of the debts, liabilities or engagements of such Shareholder in respect of such Share (whether or not the same have matured), and the remaining proceeds (if any) shall be paid to the Shareholder, his or her executors, administrators or assigns. |
17. Sale After Forfeiture or Surrender or For Enforcement of Lien.
Upon any sale of a share after forfeiture or surrender or for enforcing a lien, the Board of Directors may appoint any person to execute an instrument of transfer of the Share so sold and cause the purchaser’s name to be entered in the Register of Shareholders in respect of such Share. The purchaser shall be registered as the Shareholder and shall not be bound to see to the regularity of the sale proceedings, or to the application of the proceeds of such sale, and after his or her name has been entered in the Register of Shareholders in respect of such Share, the validity of the sale shall not be impeached by any person, and the remedy of any person aggrieved by the sale shall be in damages only and against the Company exclusively.
18. Redeemable Shares.
The Company may, subject to applicable law, issue redeemable shares or other securities and redeem the same upon terms and conditions to be set forth in a written agreement between the Company and the holder of such shares or in their terms of issuance.
7
Transfer of Shares
19. Registration of Transfer.
No transfer of Shares shall be registered unless a proper writing or instrument of transfer (in any customary form or any other form satisfactory to the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer) has been submitted to the Company (or its transfer agent), together with any share certificate(s) and such other evidence of title as the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer may require. Notwithstanding anything to the contrary herein, Shares registered in the name of The Depository Trust Company or its nominee shall be transferrable in accordance with the policies and procedures of The Depository Trust Company. Until the transferee has been registered in the Register of Shareholders in respect of the Shares so transferred, the Company may continue to regard the transferor as the owner thereof. The Board of Directors, may, from time to time, prescribe a fee for the registration of a transfer, and may approve other methods of recognizing the transfer of Shares in order to facilitate the trading of the Company’s shares on the Stock Exchange.
20. Suspension of Registration.
The Board of Directors may, in its discretion to the extent it deems necessary, close the Register of Shareholders of registration of transfers of Shares for a period determined by the Board of Directors, and no registrations of transfers of Shares shall be made by the Company during any such period during which the Register of Shareholders is so closed.
Transmission of Shares
21. Decedents’ Shares.
Upon the death of a Shareholder, the Company shall recognize the custodian or administrator of the estate or executor of the will, and in the absence of such, the lawful heirs of the Shareholder, as the only holders of the right for the Shares of the deceased Shareholder, after receipt of evidence to the entitlement thereto, as determined by the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer.
22. Receivers and Liquidators.
(a) | The Company may recognize any receiver, liquidator or similar official appointed to wind-up, dissolve or otherwise liquidate a corporate Shareholder, and a trustee, manager, receiver, liquidator or similar official appointed in bankruptcy or in connection with the reorganization of, or similar proceeding with respect to a Shareholder or its properties, as being entitled to the Shares registered in the name of such Shareholder. |
(b) | Such receiver, liquidator or similar official appointed to wind-up, dissolve or otherwise liquidate a corporate Shareholder and such trustee, manager, receiver, liquidator or similar official appointed in bankruptcy or in connection with the reorganization of, or similar proceedings with respect to a Shareholder or its properties, upon producing such evidence as the Board of Directors (or an officer of the Company to be designated by the Chief Executive Officer) may deem sufficient as to his or her authority to act in such capacity or under this Article, shall with the consent of the Board of Directors or an officer of the Company to be designated by the Chief Executive Officer (which the Board of Directors or such officer may grant or refuse in its absolute discretion), be registered as a Shareholder in respect of such Shares, or may, subject to the regulations as to transfer herein contained, transfer such Shares. |
8
General Meetings
23. General Meetings.
(a) | An annual General Meeting (“Annual General Meeting”) shall be held at such time and at such place, either within or outside of the State of Israel, as may be determined by the Board of Directors. |
(b) | All General Meetings other than Annual General Meetings shall be called “Special General Meetings”. The Board of Directors may, at its discretion, convene a Special General Meeting at such time and place, within or outside of the State of Israel, as may be determined by the Board of Directors. |
(c) | If so determined by the Board of Directors, an Annual General Meeting or a Special General Meeting may be held through the use of any means of communication approved by the Board of Directors, provided all of the participating Shareholders can hear each other simultaneously. A resolution approved by use of means of communications as aforesaid, shall be deemed to be a resolution lawfully adopted at such general meeting and a Shareholder shall be deemed present in person at such general meeting if attending such meeting through the means of communication used at such meeting. |
24. Record Date for General Meeting.
Notwithstanding any provision of these Articles to the contrary, and to allow the Company to determine the Shareholders entitled to notice of or to vote at any General Meeting or any adjournment thereof, or entitled to receive payment of any dividend or other distribution or grant of any rights, or entitled to exercise any rights in respect of or to take or be the subject of any other action, the Board of Directors may fix a record date for the General Meeting, which shall not be more than the maximum period and not less than the minimum period permitted by law. A determination of Shareholders of record entitled to notice of or to vote at a General Meeting shall apply to any adjournment of the meeting; provided, however, that the Board of Directors may fix a new record date for the adjourned meeting.
25. Shareholder Proposal Request.
(a) | Any Shareholder or Shareholders of the Company holding at least the required percentage under the Companies Law of the voting rights of the Company which entitles such Shareholder(s) to require the Company to include a matter on the agenda of a General Meeting (the “Proposing Shareholder(s)”) may request, subject to the Companies Law, that the Board of Directors include a matter on the agenda of a General Meeting to be held in the future, provided that the Board of Directors determines that the matter is appropriate to be considered at a General Meeting (a “Proposal Request”). In order for the Board of Directors to consider a Proposal Request and whether to include the matter stated therein in the agenda of a General Meeting, notice of the Proposal Request must be timely delivered in accordance with applicable law, and the Proposal Request must comply with the requirements of these Articles (including this Article 25) and any applicable law and stock exchange rules and regulations. The Proposal Request must be in writing, signed by all of the Proposing Shareholder(s) making such request, delivered, either in person or by registered mail, postage prepaid, and received by the Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company). To be considered timely, a Proposal Request must be received within the time periods prescribed by applicable law. The announcement of an adjournment or postponement of a General Meeting shall not commence a new time period (or extend any time period) for the delivery of a Proposal Request as described above. In addition to any information required to be included in accordance with applicable law, a Proposal Request must include the following: (i) the name, address, telephone number, fax number and email address of the Proposing Shareholder (or each Proposing Shareholder, as the case may be) and, if an entity, the name(s) of the person(s) that controls or manages such entity; (ii) the number of Shares held by the Proposing Shareholder(s), directly or indirectly (and, if any of such Shares are held indirectly, an explanation of how they are held and by whom), which shall be in such number no less than as is required to qualify as a Proposing Shareholder, accompanied by evidence satisfactory to the Company of the record holding of such Shares by the Proposing Shareholder(s) as of the date of the Proposal Request; (iii) the matter requested to be included on the agenda of a General Meeting, all information related to such matter, the reason that such matter is proposed to be brought before the General Meeting, the complete text of the resolution that the Proposing Shareholder proposes to be voted upon at the General Meeting, and a representation that the Proposing Shareholder(s) intend to appear in person or by proxy at the meeting; (iv) a description of all arrangements or understandings between the Proposing Shareholders and any other person(s) (naming such person or persons) in connection with the matter that is requested to be included on the agenda and a declaration signed by all Proposing Shareholder(s) of whether any of them has a personal interest in the matter and, if so, a description in reasonable detail of such personal interest; (v) a description of all Derivative Transactions (as defined below) by each Proposing Shareholder(s) during the previous twelve (12) month period, including the date of the transactions and the class, series and number of securities involved in, and the material economic terms of, such Derivative Transactions; and (vi) a declaration that all of the information that is required under the Companies Law and any other applicable law and stock exchange rules and regulations to be provided to the Company in connection with such matter, if any, has been provided to the Company. The Board of Directors, may, in its discretion, to the extent it deems necessary, request that the Proposing Shareholder(s) provide additional information necessary so as to include a matter in the agenda of a General Meeting, as the Board of Directors may reasonably require. |
9
A “Derivative Transaction” means any agreement, arrangement, interest or understanding entered into by, or on behalf or for the benefit of, any Proposing Shareholder or any of its Affiliates or associates, whether of record or beneficial: (1) the value of which is derived in whole or in part from the value of any class or series of shares or other securities of the Company, (2) which otherwise provides any direct or indirect opportunity to gain or share in any gain derived from a change in the value of securities of the Company, (3) the effect or intent of which is to mitigate loss, manage risk or benefit of security value or price changes, or (4) which provides the right to vote or increase or decrease the voting power of, such Proposing Shareholder, or any of its Affiliates or associates, with respect to any Shares or other securities of the Company, which agreement, arrangement, interest or understanding may include, without limitation, any option, warrant, debt position, note, bond, convertible security, swap, stock appreciation right, short position, profit interest, hedge, right to dividends, voting agreement, performance-related fee or arrangement to borrow or lend Shares (whether or not subject to payment, settlement, exercise or conversion in any such class or series), and any proportionate interest of such Proposing Shareholder in the securities of the Company held by any general or limited partnership, or any limited liability company, of which such Proposing Shareholder is, directly or indirectly, a general partner or managing member.
(b) | The information required pursuant to this Article shall be updated as of (i) the record date of the General Meeting, (ii) five business days before the General Meeting, and (iii) as of the General Meeting, and any adjournment or postponement thereof. |
(c) | The provisions of Articles 25(a) and 25(b) shall apply, mutatis mutandis, to any matter to be included on the agenda of a Special General Meeting which is convened pursuant to a request of a Shareholder duly delivered to the Company in accordance with the Companies Law. |
26. Notice of General Meetings; Omission to Give Notice.
(a) | The Company is not required to give notice of a General Meeting, subject to any mandatory provision of the Companies Law. |
(b) | The accidental omission to give notice of a General Meeting to any Shareholder, or the non-receipt of notice sent to such Shareholder, shall not invalidate the proceedings at such meeting or any resolution adopted thereat. |
(c) | No Shareholder present, in person or by proxy, at any time during a General Meeting shall be entitled to seek the cancellation or invalidation of any proceedings or resolutions adopted at such General Meeting on account of any defect in the notice of such meeting relating to the time or the place thereof, or any item acted upon at such meeting. |
(d) | In addition to any places at which the Company may make available for review by Shareholders the full text of the proposed resolutions to be adopted at a General Meeting, as required by the Companies Law, the Company may add additional places for Shareholders to review such proposed resolutions, including an internet site. |
10
Proceedings at General Meetings
27. Quorum.
(a) | No business shall be transacted at a General Meeting, or at any adjournment thereof, unless the quorum required under these Articles for such General Meeting or such adjourned meeting, as the case may be, is present when the meeting proceeds to business. |
(b) | In the absence of contrary provisions in these Articles, the requisite quorum for any General Meeting shall be Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present in person or by proxy and holding shares conferring in the aggregate at least thirty-three and one-third percent (33⅓%) of the voting power of the Company, provided, however, that if (i) such General Meeting was initiated by and convened pursuant to a resolution adopted by the Board of Directors and (ii) at the time of such General Meeting the Company is qualified to use the forms of a “foreign private issuer” under US securities laws, then the requisite quorum shall be Shareholders (not in default in payment of any sum referred to in Article 13 hereof) present in person or by proxy and holding Shares conferring in the aggregate at least ten percent (10%) of the voting power of the Company. |
(c) | If within half an hour from the time appointed for the meeting a quorum is not present, then without any further notice the meeting shall be adjourned either (i) to the same day in the next week, at the same time and place, (ii) to such day and at such time and place as indicated in the notice of such meeting, or (iii) to such day and at such time and place as the Chairperson of the General Meeting shall determine (which may be earlier or later than the date pursuant to clause (i) above). No business shall be transacted at any adjourned meeting except business which might lawfully have been transacted at the meeting as originally called. At such adjourned meeting, if the original meeting was convened by a Shareholder pursuant to a request under Section 63 of the Companies Law, such Shareholder in addition to at least one or more Shareholder, present in person or by proxy, and holding the higher of ten percent (10%) of the voting power of the Company or the number of Shares required for making such request, shall constitute a quorum, but in any other case any Shareholder (not in default as aforesaid) present in person or by proxy, shall constitute a quorum. |
28. Chairperson of General Meeting.
The Chairperson of the Board of Directors shall preside as Chairperson of every General Meeting of the Company. If at any meeting the Chairperson is not present within fifteen (15) minutes after the time fixed for holding the meeting or is unwilling or unable to act as Chairperson, any of the following may preside as Chairperson of the meeting (and in the following order): a Director designated by the Board of Directors, the Chief Executive Officer, the Chief Financial Officer, the General Counsel, the Secretary or any person designated by any of the foregoing. If at any such meeting none of the foregoing persons is present or all are unwilling or unable to act as Chairperson, the Shareholders present (in person or by proxy) shall choose a Shareholder or its proxy present at the meeting to be Chairperson. The office of Chairperson shall not, by itself, entitle the holder thereof to vote at any General Meeting nor shall it entitle such holder to a second or casting vote (without derogating, however, from the rights of such Chairperson to vote as a Shareholder or proxy of a Shareholder if, in fact, the Chairperson is also a Shareholder or such proxy).
29. Adoption of Resolutions at General Meetings.
(a) | Except as required by the Companies Law or these Articles, including, without limitation, Article 39 below, a resolution of the Shareholders shall be adopted if approved by the holders of a simple majority of the voting power represented at the General Meeting in person or by proxy and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting. Without limiting the generality of the foregoing, a resolution with respect to a matter or action for which the Companies Law prescribes a higher majority or pursuant to which a provision requiring a higher majority would have been deemed to have been incorporated into these Articles, but for which the Companies Law allows these Articles to provide otherwise (including, Sections 327 and 24 of the Companies Law), shall be adopted by a simple majority of the voting power represented at the General Meeting in person or by proxy and voting thereon, as one class, and disregarding abstentions from the count of the voting power present and voting. |
11
(b) | Every question submitted to a General Meeting shall be decided by a show of hands, but the Chairperson of the General Meeting may determine that a resolution shall be decided by a written ballot. A written ballot may be implemented before the proposed resolution is voted upon or immediately after the declaration by the Chairperson of the results of the vote by a show of hands. If a vote by written ballot is taken after such declaration, the results of the vote by a show of hands shall be of no effect, and the proposed resolution shall be decided by such written ballot. |
(c) | A defect in convening or conducting a General Meeting, including a defect resulting from the non-fulfillment of any provision or condition set forth in the Companies Law or these Articles, including with regard to the manner of convening or conducting the General Meeting, shall not disqualify any resolution passed at the General Meeting and shall not affect the discussions or decisions which took place thereat. |
(d) | A declaration by the Chairperson of the General Meeting that a resolution has been carried unanimously, or carried by a particular majority, or rejected, and an entry to that effect in the minute book of the Company, shall be prima facie evidence of the fact without proof of the number or proportion of the votes recorded in favor of or against such resolution. |
30. | Power to Adjourn. |
A General Meeting, the consideration of any matter on its agenda, or the resolution on any matter on its agenda, may be postponed or adjourned, from time to time and from place to place: (i) by the Chairperson of a General Meeting at which a quorum is present (and he shall do so if directed by the General Meeting, with the consent of the holders of a majority of the voting power represented in person or by proxy and voting on the question of adjournment), but no business shall be transacted at any such adjourned meeting except business which might lawfully have been transacted at the meeting as originally called, or a matter on its agenda with respect to which no resolution was adopted at the meeting originally called; or (ii) by the Board of Directors (whether prior to or at a General Meeting).
31. Voting Power.
Subject to the provisions of Article 32(a) and to any provision hereof conferring special rights as to voting, or restricting the right to vote, every Shareholder shall have one vote for each Share held by the Shareholder of record, on every resolution, without regard to whether the vote thereon is conducted by a show of hands, by written ballot, or by any other means.
32. Voting Rights.
(a) | No Shareholder shall be entitled to vote at any General Meeting (or be counted as a part of the quorum thereat), unless all calls then payable by him or her in respect of his or her Shares in the Company have been paid. |
(b) | A company or other corporate body being a Shareholder of the Company may duly authorize any person to be its representative at any meeting of the Company or to execute or deliver a proxy on its behalf. Any person so authorized shall be entitled to exercise on behalf of such Shareholder all the power, which the Shareholder could have exercised if it were an individual. Upon the request of the Chairperson of the General Meeting, written evidence of such authorization (in form acceptable to the Chairperson) shall be delivered to him or her. |
(c) | Any Shareholder entitled to vote may vote either in person or by proxy (who need not be a Shareholder of the Company), or, if the Shareholder is a company or other corporate body, by representative authorized pursuant to Article (b) above. |
(d) | If two or more persons are registered as joint holders of any Share, the vote of the senior who tenders a vote, in person or by proxy, shall be accepted to the exclusion of the vote(s) of the other joint holder(s). For the purpose of this Article 32(d), seniority shall be determined by the order of registration of the joint holders in the Register of Shareholders. |
(e) | If a Shareholder is a minor, under protection, bankrupt or legally incompetent, or in the case of a corporation, is in receivership or liquidation, it may, subject to all other provisions of these Articles and any documents or records required to be provided under these Articles, vote through his, her or its trustees, receiver, liquidator, natural guardian or another legal guardian, as the case may be, and the persons listed above may vote in person or by proxy. |
12
Proxies
33. Instrument of Appointment.
(a) An instrument appointing a proxy shall be in writing and shall be substantially in the following form:
“I | of | ||
(Name of Shareholder) | (Address of Shareholder) | ||
Being a shareholder of Medigus Ltd. hereby appoints | |||
of | |||
(Name of Proxy) | (Address of Proxy) | ||
as my proxy to vote for me and on my behalf at the General Meeting of the Company to be held on the ___ day of _______, _______ and at any adjournment(s) thereof. | |||
Signed this ____ day of ___________, ______. | |||
(Signature of Appointor)” |
or in any usual or common form or in such other form as may be approved by the Board of Directors. Such proxy shall be duly signed by the appointor of such person's duly authorized attorney, or, if such appointor is company or other corporate body, in the manner in which it signs documents which binds it together with a certificate of an attorney with regard to the authority of the signatories.
(b) | Subject to the Companies Law, the original instrument appointing a proxy or a copy thereof certified by an attorney (and the power of attorney or other authority, if any, under which such instrument has been signed) shall be delivered to the Company (at its Office, at its principal place of business, or at the offices of its registrar or transfer agent, or at such place as notice of the meeting may specify) not less than forty eight (48) hours (or such shorter period as the notice shall specify) before the time fixed for such meeting. Notwithstanding the above, the Chairperson shall have the right to waive the time requirement provided above with respect to all instruments of proxies and to accept instruments of proxy until the beginning of a General Meeting. A document appointing a proxy shall be valid for every adjourned meeting of the General Meeting to which the document relates. |
13
34. Effect of Death of Appointer of Transfer of Share and or Revocation of Appointment.
(a) | A vote cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the prior death or bankruptcy of the appointing Shareholder (or of his or her attorney-in-fact, if any, who signed such instrument), or the transfer of the Share in respect of which the vote is cast, unless written notice of such matters shall have been received by the Company or by the Chairperson of such meeting prior to such vote being cast. |
(b) | Subject to the Companies Law, an instrument appointing a proxy shall be deemed revoked (i) upon receipt by the Company or the Chairperson, subsequent to receipt by the Company of such instrument, of written notice signed by the person signing such instrument or by the Shareholder appointing such proxy canceling the appointment thereunder (or the authority pursuant to which such instrument was signed) or of an instrument appointing a different proxy (and such other documents, if any, required under Article 33(b) for such new appointment), provided such notice of cancellation or instrument appointing a different proxy were so received at the place and within the time for delivery of the instrument revoked thereby as referred to in Article 33(b) hereof, or (ii) if the appointing Shareholder is present in person at the meeting for which such instrument of proxy was delivered, upon receipt by the Chairperson of such meeting of written notice from such Shareholder of the revocation of such appointment, or if and when such Shareholder votes at such meeting. A vote cast in accordance with an instrument appointing a proxy shall be valid notwithstanding the revocation or purported cancellation of the appointment, or the presence in person or vote of the appointing Shareholder at a meeting for which it was rendered, unless such instrument of appointment was deemed revoked in accordance with the foregoing provisions of this Article 34(b) at or prior to the time such vote was cast. |
Board of Directors
35. Powers of the Board of Directors.
(a) | The Board of Directors may exercise all such powers and do all such acts and things as the Board of Directors is authorized by law or as the Company is authorized to exercise and do and are not hereby or by law required to be exercised or done by the General Meeting. The authority conferred on the Board of Directors by this Article 35 shall be subject to the provisions of the Companies Law, these Articles and any regulation or resolution consistent with these Articles adopted from time to time at a General Meeting, provided, however, that no such regulation or resolution shall invalidate any prior act done by or pursuant to a decision of the Board of Directors which would have been valid if such regulation or resolution had not been adopted. |
(b) | Without limiting the generality of the foregoing, the Board of Directors may, from time to time, set aside any amount(s) out of the profits of the Company as a reserve or reserves for any purpose(s) which the Board of Directors, in its absolute discretion, shall deem fit, including without limitation, capitalization and distribution of bonus Shares, and may invest any sum so set aside in any manner and from time to time deal with and vary such investments and dispose of all or any part thereof, and employ any such reserve or any part thereof in the business of the Company without being bound to keep the same separate from other assets of the Company, and may subdivide or re-designate any reserve or cancel the same or apply the funds therein for another purpose, all as the Board of Directors may from time to time think fit. |
36. Exercise of Powers of the Board of Directors.
(a) | A meeting of the Board of Directors at which a quorum is present in accordance with Article 45 shall be competent to exercise all the authorities, powers and discretion vested in or exercisable by the Board of Directors. |
(b) | A resolution proposed at any meeting of the Board of Directors shall be deemed adopted if approved by a majority of the Directors present, entitled to vote and voting thereon when such resolution is put to a vote. |
14
(c) | The Board of Directors may adopt resolutions, without convening a meeting of the Board of Directors, in writing or in any other manner permitted by the Companies Law. |
(d) | Notwithstanding anything to the contrary herein, including under Articles 36(a) and 36(b), and without derogating from any other approvals required pursuant to these Articles or applicable law, the following actions shall require the affirmative consent of at least three-quarters (3/4) of the Directors then in office and entitled to vote thereon: |
(i) | Any resolution to enter into a merger, consolidation, acquisition, amalgamation, business combination, issue equity securities or debt securities convertible into equity or other similar transaction (collectively, a “Transaction”), in each case that would reasonably be expected to result (A) in any person (together with its Affiliates) becoming, as a result of such Transaction, a beneficial owner (as determined in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended) of fifteen percent (15%) or more of the Ordinary Shares issued and outstanding immediately following the consummation of such Transaction or (B) in the increase in the beneficial ownership of Ordinary Shares of any person (together with its Affiliates) who immediately prior to the consummation of such Transaction holds fifteen percent (15%) or more of the then issued and outstanding Ordinary Shares; |
(ii) | Any resolution to directly or indirectly sell, assign, convey, transfer, lease or otherwise dispose, in one or series of related transactions, of all or substantially all of the assets of the Company and its subsidiaries, taken as a whole, to any person; |
(iii) | Any resolution to effect any material change to the principal business of the Company, enter into new lines of business that are materially different from the Company’s then current line of business, or exit the then current line of business of the Company, or otherwise materially change the Company’s strategy and/or policies with respect to its main lines of business; or |
(iv) | Any resolution to transfer the headquarters of the Company outside of Israel. |
37. Delegation of Powers.
(a) | The Board of Directors may, subject to the provisions of the Companies Law, delegate any or all of its powers to committees (in these Articles referred to as a “Committee of the Board of Directors”, or “Committee”), each consisting of one or more persons (who may or may not be Directors), and it may from time to time revoke such delegation or alter the composition of any such Committee. Any Committee so formed shall, in the exercise of the powers so delegated, conform to any regulations imposed on it by the Board of Directors, subject to applicable law. No regulation imposed by the Board of Directors on any Committee and no resolution of the Board of Directors shall invalidate any prior act done or pursuant to a resolution by the Committee which would have been valid if such regulation or resolution of the Board of Directors had not been adopted. The meetings and proceedings of any such Committee of the Board of Directors shall, mutatis mutandis, be governed by the provisions herein contained for regulating the meetings of the Board of Directors, to the extent not superseded by any regulations adopted by the Board of Directors. Unless otherwise expressly prohibited by the Board of Directors, in delegating powers to a Committee of the Board of Directors, such Committee shall be empowered to further delegate such powers. |
(b) | The Board of Directors may from time to time appoint a Secretary to the Company, as well as Officers, agents, employees and independent contractors, as the Board of Directors deems fit, and may terminate the service of any such person. The Board of Directors may, subject to the provisions of the Companies Law, determine the powers and duties, as well as the salaries and compensation, of all such persons. |
(c) | The Board of Directors may from time to time, by power of attorney or otherwise, appoint any person, company, firm or body of persons to be the attorney or attorneys of the Company at law or in fact for such purposes(s) and with such powers, authorities and discretions, and for such period and subject to such conditions, as it deems fit, and any such power of attorney or other appointment may contain such provisions for the protection and convenience of persons dealing with any such attorney as the Board of Directors deems fit, and may also authorize any such attorney to delegate all or any of the powers, authorities and discretions vested in him or her. |
15
38. Number of Directors.
(a) | The Board of Directors shall consist of such number of Directors (not less than three (3) nor more than six (6), including the External Directors, if any were elected) as may be fixed from time to time by resolution of the Board of Directors. |
39. Election and Removal of Directors.
(a) | The Directors (excluding the External Directors if any were elected), shall be classified, with respect to the term for which they each severally hold office, into three classes, as nearly equal in number as practicable, hereby designated as Class I, Class II and Class III (each, a “Class”). The Board of Directors may assign members of the Board of Directors already in office to such classes at the time such classification becomes effective. |
(i) | The term of office of the initial Class I directors shall expire at the Annual General Meeting to be held in 2023 and when their successors are elected and qualified, |
(ii) | The term of office of the initial Class II directors shall expire at the first Annual General Meeting following the Annual General Meeting referred to in clause (i) above and when their successors are elected and qualified, and |
(iii) | The term of office of the initial Class III directors shall expire at the first Annual General Meeting following the Annual General Meeting referred to in clause (ii) above and when their successors are elected and qualified. |
(b) | At each Annual General Meeting, commencing with the Annual General Meeting to be held in 2023, each Nominee or Alternate Nominee (each as defined below) elected at such Annual General Meeting to serve as a Director in a Class whose term shall have expired at such Annual General Meeting shall be elected to hold office until the third Annual General Meeting next succeeding his or her election and until his or her respective successor shall have been elected and qualified. Notwithstanding anything to the contrary, each Director shall serve until his or her successor is elected and qualified or until such earlier time as such Director’s office is vacated. |
(c) | If the number of Directors (excluding External Directors, if any were elected) that comprises the Board of Directors is hereafter changed by the Board of Directors, any newly created directorships or decrease in directorships shall be so apportioned by the Board of Directors among the classes as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors constituting the Board of Directors shall shorten the term of any incumbent Director. |
(d) | Prior to every General Meeting of the Company at which Directors are to be elected, and subject to clauses (a) and (h) of this Article, the Board of Directors (or a Committee thereof) shall select, by a resolution adopted by a majority of the Board of Directors (or such Committee), a number of persons to be proposed to the Shareholders for election as Directors at such General Meeting (the “Nominees”). |
16
(e) | Any Proposing Shareholder requesting to include on the agenda of a General Meeting a nomination of a person to be proposed to the Shareholders for election as Director (such person, an “Alternate Nominee”), may so request provided that it complies with this Article 39(e), Article 25 and applicable law. Unless otherwise determined by the Board of Directors, a Proposal Request relating to an Alternate Nominee is deemed to be a matter that is appropriate to be considered only at an Annual General Meeting. In addition to any information required to be included in accordance with applicable law, such a Proposal Request shall include information required pursuant to Article 25, and shall also set forth: (i) the name, address, telephone number, fax number and email address of the Alternate Nominee and all citizenships and residencies of the Alternate Nominee; (ii) a description of all arrangements, relations or understandings during the past three (3) years, and any other material relationships, between the Proposing Shareholder(s) or any of its Affiliates and each Alternate Nominee; (iii) a declaration signed by the Alternate Nominee that he or she consents to be named in the Company’s notices and proxy materials and on the Company’s proxy card relating to the General Meeting, if provided or published, and that he or she, if elected, consents to serve on the Board of Directors and to be named in the Company’s disclosures and filings; (iv) a declaration signed by each Alternate Nominee as required under the Companies Law and any other applicable law and stock exchange rules and regulations for the appointment of such an Alternate Nominee and an undertaking that all of the information that is required under law and stock exchange rules and regulations to be provided to the Company in connection with such an appointment has been provided (including, information in respect of the Alternate Nominee as would be provided in response to the applicable disclosure requirements under Form 20-F (or Form 10-K, if applicable) or any other applicable form prescribed by the U.S. Securities and Exchange Commission (the “SEC”)); (v) a declaration made by the Alternate Nominee of whether he or she meets the criteria for an independent director and, if applicable, External Director of the Company under the Companies Law and/or under any applicable law, regulation or stock exchange rules, and if not, then an explanation of why not; and (vi) any other information required at the time of submission of the Proposal Request by applicable law, regulations or stock exchange rules. In addition, the Proposing Shareholder(s) and each Alternate Nominee shall promptly provide any other information reasonably requested by the Company, including a duly completed director and officer questionnaire, in such form as may be provided by the Company, with respect to each Alternate Nominee. The Board of Directors may refuse to acknowledge the nomination of any person not made in compliance with the foregoing. The Company shall be entitled to publish any information provided by a Proposing Shareholder or Alternate Nominee pursuant to this Article 39(e) and Article 25, and the Proposing Shareholder and Alternate Nominee shall be responsible for the accuracy and completeness thereof. |
(f) | The Nominees or Alternate Nominees shall be elected by a resolution adopted at the General Meeting at which they are subject to election. Notwithstanding Articles 25(a) and 25(c), in the event of a Contested Election, the method of calculation of the votes and the manner in which the resolutions will be presented to the General Meeting shall be determined by the Board of Directors in its discretion. In the event that the Board of Directors does not or is unable to make a determination on such matter, then the method described in clause (ii) below shall apply. The Board of Directors may consider, among other things, the following methods: (i) election of competing slates of Director nominees (determined in a manner approved by the Board of Directors) by a majority of the voting power represented at the General Meeting in person or by proxy and voting on such competing slates, (ii) election of individual Directors by a plurality of the voting power represented at the General Meeting in person or by proxy and voting on the election of Directors (which shall mean that the nominees receiving the largest number of “for” votes will be elected in such Contested Election), (iii) election of each nominee by a majority of the voting power represented at the General Meeting in person or by proxy and voting on the election of Directors, provided that if the number of such nominees exceeds the number of Directors to be elected, then as among such nominees the election shall be by plurality of the voting power as described above, and (iv) such other method of voting as the Board of Directors deems appropriate, including use of a “universal proxy card” listing all Nominees and Alternate Nominees by the Company. For the purposes of these Articles, election of Directors at a General Meeting shall be considered a “Contested Election” if the aggregate number of Nominees and Alternate Nominees at such meeting exceeds the total number of Directors to be elected at such meeting, with the determination thereof being made by the Secretary (or, in the absence thereof, by the Chief Executive Officer of the Company) as of the close of the applicable notice of nomination period under Article 25 or under applicable law, based on whether one or more notice(s) of nomination were timely filed in accordance with Article 25, this Article 39 and applicable law; provided, however, that the determination that an election is a Contested Election shall not be determinative as to the validity of any such notice of nomination; and provided, further, that, if, prior to the time the Company mails its initial proxy statement in connection with such election of Directors, one or more notices of nomination of an Alternate Nominee are withdrawn such that the number of candidates for election as Director no longer exceeds the number of Directors to be elected, the election shall not be considered a Contested Election. Shareholders shall not be entitled to cumulative voting in the election of Directors, except to the extent specifically set forth in this clause (f). |
(g) | Notwithstanding anything to the contrary in these Articles, the election, qualification, removal or dismissal of External Directors, if so elected, shall be only in accordance with the applicable provisions set forth in the Companies Law. |
17
40. Commencement of Directorship.
Without derogating from Article 39, the term of office of a Director shall commence as of the date of his or her appointment or election, or on a later date if so specified in his or her appointment or election.
41. Continuing Directors in the Event of Vacancies.
The Board of Directors (and, if so determined by the Board of Directors, the General Meeting) may at any time and from time to time appoint any person as a Director to fill a vacancy (whether such vacancy is due to a Director no longer serving or due to the number of Directors serving being less than the maximum number stated in Article 38 hereof). In the event of one or more such vacancies in the Board of Directors, the continuing Directors may continue to act in every matter, provided, however, that if the number of Directors serving is less than the minimum number provided for pursuant to Article 38 hereof, they may only act in an emergency or to fill the office of a Director which has become vacant up to a number equal to the minimum number provided for pursuant to Article 38 hereof, or in order to call a General Meeting of the Company for the purpose of electing Directors to fill any or all vacancies. The office of a Director that was appointed by the Board of Directors to fill any vacancy shall only be for the remaining period of time during which the Director whose service has ended was filled would have held office, or in case of a vacancy due to the number of Directors serving being less than the maximum number stated in Article 38 hereof the Board of Directors shall determine at the time of appointment the class pursuant to Article 39 to which the additional Director shall be assigned.
42. Vacation of Office.
The office of a Director shall be vacated and he shall be dismissed or removed:
(a) | ipso facto, upon his or her death; |
(b) | if he or she is prevented by applicable law from serving as a Director; |
(c) | if the Board of Directors determines that due to his or her mental or physical state he or she is unable to serve as a director; |
(d) | if his or her directorship expires pursuant to these Articles and/or applicable law; |
(e) | by a resolution adopted at an Annual General Meeting by a majority of at least 65% of the total voting power of the Shares (with such removal becoming effective on the date fixed in such resolution); |
(f) | by his or her written resignation, such resignation becoming effective on the date fixed therein, or upon the delivery thereof to the Company, whichever is later; or |
(g) | with respect to an External Director, if so elected, and notwithstanding anything to the contrary herein, only pursuant to applicable law. |
43. Conflict of Interests; Approval of Related Party Transactions.
(a) | Subject to the provisions of applicable law and these Articles, no Director shall be disqualified by virtue of his or her office from holding any office or place of profit in the Company or in any company in which the Company shall be a Shareholder or otherwise interested, or from contracting with the Company as vendor, purchaser or otherwise, nor shall any such contract, or any contract or arrangement entered into by or on behalf of the Company in which any Director shall be in any way interested, be avoided, nor, other than as required under the Companies Law, shall any Director be liable to account to the Company for any profit arising from any such office or place of profit or realized by any such contract or arrangement by reason only of such Director’s holding that office or of the fiduciary relations thereby established, but the nature of his or her interest, as well as any material fact or document, must be disclosed by him or her at the meeting of the Board of Directors at which the contract or arrangement is first considered, if his or her interest then exists, or, in any other case, at no later than the first meeting of the Board of Directors after the acquisition of his or her interest. |
18
(b) | Subject to the Companies Law and these Articles, a transaction between the Company and an Office Holder, and a transaction between the Company and another entity in which an Office Holder of the Company has a personal interest, in each case, which is not an Extraordinary Transaction (as defined by the Companies Law), shall require only approval by the Board of Directors or a Committee of the Board of Directors. Such authorization, as well as the actual approval, may be for a particular transaction or more generally for specific type of transactions. |
(c) | Notwithstanding anything to the contrary in these Articles, the Company shall not engage in any Business Combination (as defined below) with any Shareholder and/or any of its Affiliates and/or investors for a period of three years following (i) with respect to any Shareholder holding as of the Effective Time fifteen percent (15%) or more of the voting power of the Shares, the Effective Time and (ii) with respect to all Shareholders, each time as such Shareholder and/or any of its Affiliates and/or investors become(s) (other than due to a buyback, redemption or cancellation of shares by the Company) the holder(s) (beneficially or of record) of fifteen percent (15%) or more of the issued and outstanding voting power of the Shares (the “Threshold” and such shareholder, an “Interested Shareholder”), except if the Board of Directors approves either the Business Combination or the transaction which resulted in such Shareholder and/or any of its Affiliates and/or investors becoming an Interested Shareholder prior to consummation of a Business Combination. As used in this Article 43 only, “Business Combination” means (i) a merger or consolidation of the Company in which the holders of a majority of the Ordinary Shares issued and outstanding immediately prior to the consummation of such transaction hold immediately following the consummation of such transaction less than 50% of the issued and outstanding share capital of the surviving, acquiring or resulting company (or if the surviving, acquiring or resulting company is a wholly owned subsidiary of another company immediately following the consummation of such transaction, the parent company of such surviving, acquiring or resulting company) or (ii) a disposition of assets of the Company with an aggregate market value equal to 10% or more of the Company’s assets or of its outstanding shares. |
Proceedings of the Board of Directors
44. Meetings.
(a) | The Board of Directors may meet and adjourn its meetings and otherwise regulate such meetings and proceedings as the Board of Directors thinks fit. |
(b) | A meeting of the Board of Directors shall be convened by the Secretary upon instruction of the Chairperson or upon a request of at least two (2) Directors which is submitted to the Chairperson or in any event that such meeting is required by the provisions of the Companies Law. In the event that the Chairperson does not instruct the Secretary to convene a meeting upon a request of at least two (2) Directors within seven (7) days of such request, then such two (2) Directors may convene a meeting of the Board of Directors. Any meeting of the Board of Directors shall be convened upon not less than two (2) days' notice, unless such notice is waived in writing by all of the Directors as to a particular meeting or by their attendance at such meeting or unless the matters to be discussed at such meeting are of such urgency and importance that notice is reasonably determined by the Chairperson as ought to be waived or shortened under the circumstances. |
(c) | Notice of any such meeting shall be given orally, by telephone, in writing or by mail, facsimile, email or such other means of delivery of notices as the Company may apply, from time to time. |
(d) | Notwithstanding anything to the contrary herein, failure to deliver notice to a Director of any such meeting in the manner required hereby may be waived by such Director, and a meeting shall be deemed to have been duly convened notwithstanding such defective notice if such failure or defect is waived prior to action being taken at such meeting, by all Directors entitled to participate at such meeting to whom notice was not duly given as aforesaid. Without derogating from the foregoing, no Director present at any time during a meeting of the Board of Directors shall be entitled to seek the cancellation or invalidation of any proceedings or resolutions adopted at such meeting on account of any defect in the notice of such meeting relating to the date, time or the place thereof or the convening of the meeting. |
45. Quorum.
Until otherwise unanimously decided by the Board of Directors, a quorum at a meeting of the Board of Directors shall be constituted by the presence in person or by any means of communication of a majority of the Directors then in office who are lawfully entitled to participate and vote in the meeting. No business shall be transacted at a meeting of the Board of Directors unless the requisite quorum is present (in person or by any means of communication on the condition that all participating Directors can hear each other simultaneously) when the meeting proceeds to business. If within thirty (30) minutes from the time appointed for a meeting of the Board of Directors a quorum is not present, the meeting shall stand adjourned at the same place and time forty-eight (48) hours thereafter unless the Chairperson has determined that there is such urgency and importance that a shorter period is required under the circumstances. If an adjourned meeting is convened in accordance with the foregoing and a quorum is not present within thirty (30) minutes of the announced time, the requisite quorum at such adjourned meeting shall be, any two (2) Directors, if the number of Directors then serving is up to five (5), and any three (3) Directors, if the number of Directors then serving is more than five (5), in each case who are lawfully entitled to participate in the meeting and who are present at such adjourned meeting. At an adjourned meeting of the Board of Directors the only matters to be considered shall be those matters which might have been lawfully considered at the meeting of the Board of Directors originally called if a requisite quorum had been present, and the only resolutions to be adopted are such types of resolutions which could have been adopted at the meeting of the Board of Directors originally called.
19
46. Chairperson of the Board of Directors.
The Board of Directors shall, from time to time, elect one of its members to be the Chairperson of the Board of Directors, remove such Chairperson from office and appoint in his or her place. The Chairperson of the Board of Directors shall preside at every meeting of the Board of Directors, but if there is no such Chairperson, or if at any meeting he is not present within fifteen (15) minutes of the time fixed for the meeting or if he is unwilling to take the chair, the Directors present shall choose one of the Directors present at the meeting to be the Chairperson of such meeting. The office of Chairperson of the Board of Directors shall not, by itself, entitle the holder to a second or casting vote.
47. Validity of Acts Despite Defects.
All acts done or transacted at any meeting of the Board of Directors, or of a Committee of the Board of Directors, or by any person(s) acting as Director(s), shall, notwithstanding that it may afterwards be discovered that there was some defect in the appointment of the participants in such meeting or any of them or any person(s) acting as aforesaid, or that they or any of them were disqualified, be as valid as if there were no such defect or disqualification.
Chief Executive Officer
48. Chief Executive Officer.
The Board of Directors shall from time to time appoint one or more persons, whether or not Directors, as Chief Executive Officer of the Company who shall have the powers and authorities set forth in the Companies Law, and may confer upon such person(s), and from time to time modify or revoke, such titles and such duties and authorities of the Board of Directors as the Board of Directors may deem fit, subject to such limitations and restrictions as the Board of Directors may from time to time prescribe. Such appointment(s) may be either for a fixed term or without any limitation of time, and the Board of Directors may from time to time (subject to any additional approvals required under, and the provisions of, the Companies Law and of any contract between any such person and the Company) fix their salaries and compensation, remove or dismiss them from office and appoint another or others in his, her or their place or places.
Minutes
49. Minutes.
Any minutes of the General Meeting or the Board of Directors or any Committee thereof, if purporting to be signed by the Chairperson of the General Meeting, the Board of Directors or a Committee thereof, as the case may be, or by the Chairperson of the next succeeding General Meeting, meeting of the Board of Directors or meeting of a Committee, as the case may be, shall constitute prima facie evidence of the matters recorded therein.
Dividends
50. Declaration of Dividends.
The Board of Directors may, from time to time, declare, and cause the Company to pay dividends as permitted by the Companies Law. The Board of Directors shall determine the time for payment of such dividends and the record date for determining the shareholders entitled thereto.
20
51. Amount Payable by Way of Dividends.
Subject to the provisions of these Articles and subject to the rights or conditions attached at that time to any Share in the capital of the Company granting preferential, special or deferred rights or not granting any rights with respect to dividends, any dividend paid by the Company shall be allocated among the Shareholders (not in default in payment of any sum referred to in Article 13 hereof) entitled thereto on a pari passu basis in proportion to their respective holdings of the issued and outstanding Shares in respect of which such dividends are being paid.
52. Interest.
No dividend shall carry interest as against the Company.
53. Payment in Specie.
If so declared by the Board of Directors, a dividend declared in accordance with Article 50 may be paid, in whole or in part, by the distribution of specific assets of the Company or by distribution of paid up Shares, debentures or other securities of the Company or of any other companies, or in any combination thereof, in each case, the fair value of which shall be determined by the Board of Directors in good faith.
54. Implementation of Powers.
The Board of Directors may settle, as it deems fit, any difficulty arising with regard to the distribution of dividends, bonus shares or otherwise, and in particular, to issue certificates for fractions of shares and sell such fractions of shares in order to pay their consideration to those entitled thereto, or to set the value for the distribution of certain assets and to determine that cash payments shall be paid to the Shareholders on the basis of such value, or that fractions whose value is less than NIS 0.01 shall not be taken into account. The Board of Directors may instruct to pay cash or convey these certain assets to a trustee in favor of those people who are entitled to a dividend, as the Board of Directors shall deem appropriate.
55. Deductions from Dividends.
The Board of Directors may deduct from any dividend or other moneys payable to any Shareholder in respect of a Share any and all sums of money then payable by him or her to the Company on account of calls or otherwise in respect of Shares of the Company and/or on account of any other matter of transaction whatsoever.
56. Retention of Dividends.
(a) | The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a Share on which the Company has a lien, and may apply the same in or toward satisfaction of the debts, liabilities, or engagements in respect of which the lien exists. |
(b) | The Board of Directors may retain any dividend or other moneys payable or property distributable in respect of a Share in respect of which any person is, under Articles 21 or 22, entitled to become a Shareholder, or which any person is, under said Articles, entitled to transfer, until such person shall become a Shareholder in respect of such Share or shall transfer the same. |
21
57. Unclaimed Dividends.
All unclaimed dividends or other moneys payable in respect of a Share may be invested or otherwise made use of by the Board of Directors for the benefit of the Company until claimed. The payment of any unclaimed dividend or such other moneys into a separate account shall not constitute the Company a trustee in respect thereof, and any dividend unclaimed after a period of one (1) year (or such other period determined by the Board of Directors) from the date of declaration of such dividend, and any such other moneys unclaimed after a like period from the date the same were payable, shall be forfeited and shall revert to the Company, provided, however, that the Board of Directors may, at its discretion, cause the Company to pay any such dividend or such other moneys, or any part thereof, to a person who would have been entitled thereto had the same not reverted to the Company. The principal (and only the principal) of any unclaimed dividend of such other moneys shall be if claimed, paid to a person entitled thereto.
58. Mechanics of Payment.
Any dividend or other moneys payable in cash in respect of a Share, less the tax required to be withheld pursuant to applicable law, may, as determined by the Board of Directors in its sole discretion, be paid by check or warrant sent through the post to, or left at, the registered address of the person entitled thereto or by transfer to a bank account specified by such person (or, if two (2) or more persons are registered as joint holders of such Share or are entitled jointly thereto in consequence of the death or bankruptcy of the holder or otherwise, to any one of such persons or his or her bank account or the person who the Company may then recognize as the owner thereof or entitled thereto under Article 21 or 22 hereof, as applicable, or such person’s bank account), or to such person and at such other address as the person entitled thereto may by writing direct, or in any other manner the Board of Directors deems appropriate. Every such check or warrant or other method of payment shall be made payable to the order of the person to whom it is sent, or to such person as the person entitled thereto as aforesaid may direct, and payment of the check or warrant by the banker upon whom it is drawn shall be a good discharge to the Company. Every such check shall be sent at the risk of the person entitled to the money represented thereby.
Accounts
59. Books of Account.
The Company's books of account shall be kept at the Office of the Company, or at such other place or places as the Board of Directors may think fit, and they shall always be open to inspection by all Directors. No shareholder, not being a Director, shall have any right to inspect any account or book or other similar document of the Company, except as explicitly conferred by law or authorized by the Board of Directors. The Company shall make copies of its annual financial statements available for inspection by the Shareholders at the principal offices of the Company. The Company shall not be required to send copies of its annual financial statements to the Shareholders.
60. Auditors.
The appointment, authorities, rights and duties of the auditor(s) of the Company, shall be regulated by applicable law, provided, however, that in exercising its authority to fix the remuneration of the auditor(s), the Shareholders in General Meeting may act (and in the absence of any action in connection therewith shall be deemed to have so acted) to authorize the Board of Directors (with right of delegation to a Committee thereof or to management) to fix such remuneration subject to such criteria or standards, and if no such criteria or standards are so provided, such remuneration shall be fixed in an amount commensurate with the volume and nature of the services rendered by such auditor(s). The General Meeting may, if so recommended by the Board of Directors, appoint the auditors for a period that may extend until the third Annual General Meeting after the Annual General Meeting in which the auditors were appointed.
22
61. Fiscal Year.
The fiscal year of the Company shall be the 12 months period ending on December 31 of each calendar year.
Supplementary Registers
62. Supplementary Registers.
Subject to and in accordance with the provisions of Sections 138 and 139 of the Companies Law, the Company may cause supplementary registers to be kept in any place outside Israel as the Board of Directors may think fit, and, subject to all applicable requirements of law, the Board of Directors may from time to time adopt such rules and procedures as it may think fit in connection with the keeping of such branch registers.
Exemption, Indemnity and Insurance
63. Insurance.
Subject to the provisions of the Companies Law with regard to such matters, the Company may enter into a contract for the insurance of the liability, in whole or in part, of any of its Office Holders imposed on such Office Holder due to an act performed by or an omission of the Office Holder in the Office Holder’s capacity as an Office Holder of the Company arising from any matter permitted by law, including the following:
(a) | a breach of duty of care to the Company or to any other person; |
(b) | a breach of his or her duty of loyalty to the Company, provided that the Office Holder acted in good faith and had reasonable grounds to assume that act that resulted in such breach would not prejudice the interests of the Company; |
(c) | a financial liability imposed on such Office Holder in favor of any other person; and |
(d) | any other event, occurrence, matters or circumstances under any law with respect to which the Company may, or will be able to, insure an Office Holder, and to the extent such law requires the inclusion of a provision permitting such insurance in these Articles, then such provision is deemed to be included and incorporated herein by reference (including, without limitation, in accordance with Section 56h(b)(1) of the Securities Law, if and to the extent applicable, and Section 50P of the Economic Competition Law). |
64. Indemnity.
(a) | Subject to the provisions of the Companies Law, the Company may retroactively indemnify an Office Holder of the Company to the maximum extent permitted under applicable law, including with respect to the following liabilities and expenses, provided that such liabilities or expenses were imposed on such Office Holder or incurred by such Office Holder due to an act performed by or an omission of the Office Holder in such Office Holder’s capacity as an Office Holder of the Company: |
(i) | a financial liability imposed on an Office Holder in favor of another person by any court judgment, including a judgment given as a result of a settlement or an arbitrator’s award which has been confirmed by a court; |
(ii) | reasonable litigation expenses, including legal fees, expended by the Office Holder (A) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such investigation or proceeding, provided that (1) no indictment (as defined in the Companies Law) was filed against such Office Holder as a result of such investigation or proceeding; and (2) no financial liability in lieu of a criminal proceeding (as defined in the Companies Law) was imposed upon him or her as a result of such investigation or proceeding or if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent or (B) in connection with a financial sanction; |
(iii) | reasonable litigation costs, including legal fees, expended by an Office Holder or which were imposed on an Office Holder by a court in proceedings filed against the Office Holder by the Company or in its name or by any other person or in a criminal charge in respect of which the Office Holder was acquitted or in a criminal charge in respect of which the Office Holder was convicted for an offence which did not require proof of criminal intent; and |
23
(iv) | any other event, occurrence, matter or circumstance under any law with respect to which the Company may, or will be able to, indemnify an Office Holder, and to the extent such law requires the inclusion of a provision permitting such indemnity in these Articles, then such provision is deemed to be included and incorporated herein by reference (including, without limitation, in accordance with Section 56h(b)(1) of the Israeli Securities Law, if and to the extent applicable, and Section 50P(b)(2) of the RTP Law). |
(b) | Subject to the provisions of the Companies Law, the Company may undertake to indemnify an Office Holder, in advance, with respect to those liabilities and expenses described in the following Articles: |
(i) | Sub-Article 64(a)(i)(a)(ii) to 64(a)(iv); and |
(ii) | Sub-Article 64(a)(i), provided that: |
(1) | the undertaking to indemnify is limited to such events which the Directors shall deem to be foreseeable in light of the operations of the Company at the time that the undertaking to indemnify is made and for such amounts or criterion which the Directors may, at the time of the giving of such undertaking to indemnify, deem to be reasonable under the circumstances; and |
(2) | the undertaking to indemnify shall set forth such events which the Directors shall deem to be foreseeable in light of the operations of the Company at the time that the undertaking to indemnify is made, and the amounts and/or criterion which the Directors may, at the time of the giving of such undertaking to indemnify, deem to be reasonable under the circumstances. |
65. Exemption.
Subject to the provisions of the Companies Law, the Company may, to the maximum extent permitted by law, exempt and release, in advance, any Office Holder from any liability for damages arising out of a breach of a duty of care.
66. General.
(a) | Any amendment to the Companies Law or any other applicable law adversely affecting the right of any Office Holder to be indemnified, insured or exempt pursuant to Articles 63 to 65 and any amendments to Articles 63 to 65 shall be prospective in effect, and shall not affect the Company’s obligation or ability to indemnify, insure or exempt an Office Holder for any act or omission occurring prior to such amendment, unless otherwise provided by applicable law. |
(b) | The provisions of Articles 63 to 65 (i) shall apply to the maximum extent permitted by law (including, the Companies Law, the Securities Law and the Economic Competition Law); and (ii) are not intended, and shall not be interpreted so as to restrict the Company, in any manner, in respect of the procurement of insurance and/or in respect of indemnification (whether in advance or retroactively) and/or exemption, in favor of any person who is not an Office Holder, including, without limitation, any employee, agent, consultant or contractor of the Company who is not an Office Holder; and/or any Office Holder to the extent that such insurance and/or indemnification is not specifically prohibited under law. |
Winding Up
67. Winding Up.
If the Company is wound up, then, subject to applicable law and to the rights of the holders of Shares with special rights upon winding up, the assets of the Company available for distribution among the Shareholders shall be distributed to them in proportion to the number of issued and outstanding Shares held by each Shareholder.
24
Notices
68. Notices.
(a) | Any written notice or other document may be served by the Company upon any Shareholder either personally, by facsimile, email or other electronic transmission, or by sending it by prepaid mail (airmail if sent internationally) addressed to such Shareholder at his or her address as described in the Register of Shareholders or such other address as the Shareholder may have designated in writing for the receipt of notices and other documents. |
(b) | Any written notice or other document may be served by any Shareholder upon the Company by tendering the same in person to the Secretary or the Chief Executive Officer of the Company at the principal office of the Company, by facsimile transmission, email or other electronic submission, or by sending it by prepaid registered mail (airmail if posted outside Israel) to the Company at its Office. |
(c) | Any such notice or other document shall be deemed to have been served: |
(i) | in the case of mailing, forty-eight (48) hours after it has been posted, or when actually received by the addressee if sooner than forty-eight hours after it has been posted, or |
(ii) | in the case of overnight air courier, on the next business day following the day sent, with receipt confirmed by the courier, or when actually received by the addressee if sooner than three business days after it has been sent; |
(iii) | in the case of personal delivery, when actually tendered in person, to such addressee; |
(iv) | in the case of facsimile, email or other electronic transmission, on the first business day (during normal business hours in place of addressee) on which the sender receives automatic electronic confirmation by the addressee’s facsimile machine that such notice was received by the addressee or delivery confirmation from the addressee’s email or other communication server. |
(d) | If a notice is, in fact, received by the addressee, it shall be deemed to have been duly served, when received, notwithstanding that it was defectively addressed or failed, in some other respect, to comply with the provisions of this Article 68. |
(e) | All notices to be given to the Shareholders shall, with respect to any Share to which persons are jointly entitled, be given to whichever of such persons is named first in the Register of Shareholders, and any notice so given shall be sufficient notice to the holders of such Share. |
(f) | Any Shareholder whose address is not described in the Register of Shareholders, and who shall not have designated in writing an address for the receipt of notices, shall not be entitled to receive any notice from the Company. |
(g) | Notwithstanding anything to the contrary contained herein, notice by the Company of a General Meeting, containing the information required by applicable law and these Articles to be set forth therein, which is published, within the time otherwise required for giving notice of such meeting, in either or several of the following manners (as applicable) shall be deemed to be notice of such meeting duly given, for the purposes of these Articles, to any Shareholder whose address as registered in the Register of Shareholders (or as designated in writing for the receipt of notices and other documents) is located either inside or outside the State of Israel: |
(i) | if the Company’s Shares are then listed for trading on a national securities exchange in the United States or quoted in an over-the-counter market in the United States, publication of notice of a General Meeting pursuant to a report or a schedule filed with, or furnished to, the SEC pursuant to the Securities Exchange Act of 1934, as amended; and/or |
(ii) | on the Company’s internet site. |
25
(h) | The mailing or publication date and the record date and/or date of the meeting (as applicable) shall be counted among the days comprising any notice period under the Companies Law and the regulations thereunder. |
Amendment
69. Amendment.
Any amendment of these Articles shall require, in addition and prior to the approval of the General Meeting of Shareholders in accordance with these Articles, also the approval of the Board of Directors with the affirmative vote of at least three-quarters (3/4) of the Directors then in office and entitled to vote thereon.
Forum for Adjudication of Disputes
70. Forum for Adjudication of Disputes.
(a) | Unless the Company consents in writing to the selection of an alternative forum, the federal district courts of the United States of America, shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the U.S. Securities Act of 1933, as amended, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by the Company, its officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional or entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering. The foregoing provisions of this Article 70 shall not apply to causes of action arising under the U.S. Securities Exchange Act of 1934, as amended. |
(b) | Unless the Company consents in writing to the selection of an alternative forum, the competent courts in Tel Aviv, Israel shall be the exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company’s shareholders, or (iii) any action asserting a claim arising pursuant to any provision of the Companies Law or the Securities Law. |
(c) | Any person or entity purchasing or otherwise acquiring or holding any interest in shares of the Company shall be deemed to have notice of and consented to the provisions of this Article 70. |
* * *
26
Exhibit 2.3
Description of Securities
The following description of Medigus Ltd.’s (the “Company”) share capital, provisions of its amended and restated articles of association as may be amended and restated from time to time, and Israeli law are summaries and do not purport to be complete, and is qualified in its entirety by reference to, the provisions of our amended and restated articles of association (the “Articles”) as well as the Israeli law and any other documents referenced in the summary and from which the summary is derived. For a description of the American Depositary Shares (“ADSs”), see “Item 12. Description of Securities Other Than Equity Securities – D. American Depositary Shares.”
Name of exchange on which registered
Our ordinary shares traded on the Tel Aviv Stock Exchange Ltd. (“TASE”) under the symbol “MDGS” since February 2006 and until January 25, 2021 when we voluntarily delisted our ordinary shares from TASE.
Our ADSs are listed on Nasdaq Capital Market (“Nasdaq”) under the symbol “MDGS” with one ADS representing 15 ordinary shares. Our ADSs commenced trading on Nasdaq under the symbol “MDGS” on August 2015. Each ADS represents 15 ordinary shares.
Our Series C Warrants have been trading on Nasdaq under the symbol “MDGSW” since July 2018. Each Series C Warrant is exercisable into one/fifteen (1/15) ADS at an exercise price of $52.50 , and will expire five years from the date of issuance.
Registration number and purposes of the Company
Our registration number with the Israeli Registrar of Companies is 51-286697-1. Our purpose as set forth in our Articles is to carry on any business, and do any act, which is not prohibited by law
Transfer of shares
Our fully paid ordinary shares are issued in registered form and may be freely transferred under our Articles, unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our Articles or the laws of the State of Israel, except for ownership by nationals of certain countries that are, or have been, in a state of war with Israel.
Liability to further capital calls
Our board of directors may make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by such shareholders which is not payable at a fixed time. Such shareholder has to pay the amount of every call so made upon him or her.
Election of directors
Under our Articles, our board of directors must consist of at least three and not more than six directors, including two external directors appointed as required under the Companies Law. According to our Articles, which were approved at our annual meeting on June 17, 2022, our board is divided into three classes with staggered three-year terms. At each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the term of office of the directors of that class of directors shall be for a term of office that expires on the third annual general meeting following such election or re-election, Directors holds office until the annual general meeting of our shareholders for the year in which his or her term expires and until his or her successor is duly appointed, unless the tenure of such director expires earlier pursuant to the Companies Law upon the occurrence of certain events or unless removed from office by a vote of the holders of at least 65% of the total voting power of our shareholders at a general meeting of our shareholders in accordance with our Articles.
In addition, the board of directors (and, if so determined by the board of directors, the general meeting) may at any time and from time to time appoint any person as a director to fill a vacancy (whether such vacancy is due to a director no longer serving or due to the number of directors serving being less than the maximum number of six directors. In the event of one or more such vacancies in the board of directors, the continuing directors may continue to act in every matter, provided, however, that if the number of directors serving is less than three, than our board of directors may only act in an emergency or to fill the office of a director which has become vacant up to three directors, or for the purpose of convening a general meeting of the Company’s shareholders for the purpose of electing directors to fill any or all vacancies. The office of a director that was appointed by the board of directors to fill any vacancy shall only be for the remaining period of time during which the director whose service has ended was filled would have held office, or in case of a vacancy due to the number of directors serving being less than six, the board of directors shall determine at the time of appointment the class to which the additional director shall be assigned. For further information on the election and removal of directors see “Item 6. Directors, Senior Management and Employees—C. Board Practices” in our Annual Report on Form 20-F for the year ended December 31, 2022.
Dividend and liquidation rights
We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company’s Articles provide otherwise. Our Articles do not require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors.
Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according to our then last reviewed or audited consolidated financial statements, provided that the date of the financial statements is not more than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors and the court, if applicable, determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due.
In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future.
Exchange controls
There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of certain countries that are, or have been, in a state of war with Israel.
Shareholder meetings
Under the Companies Law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred to in our Articles as special general meetings. Our board of directors may call special general meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors is required to convene a special general meeting upon the written request of (i) any two of our directors or one-quarter of the members of our board of directors or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b) 5% or more of our outstanding voting power.
Under the Companies Law, one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include a matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the general meeting.
Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and 40 days prior to the date of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at a general meeting of our shareholders:
● | amendments to our Articles; |
● | appointment or termination of our auditors; |
● | Appointment and dismissal of external directors (if applicable); |
● | approval of certain related party transactions; |
● | director compensation and compensation of the principal executive officer (subject to certain exceptions); |
● | increases or reductions of our authorized share capital; |
● | mergers; and |
● | the exercise of our board of directors’ powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management. |
The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, or as otherwise required under applicable law, notice must be provided at least 35 days prior to the meeting.
Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by the board of directors.
2
Voting rights
Voting rights
All our ordinary shares have identical voting and other rights in all respects.
Quorum requirements
Pursuant to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general meeting. The quorum required for our general meetings of shareholders consists of at least two shareholders, present in person or by proxy, holding at least thirty-three and one-third percent (331/3%) of the voting rights of the Company, within half an hour from the appointed time, provided, however, that if (i) such general meeting was initiated by and convened pursuant to a resolution adopted by the board of directors and (ii) at the time of such General Meeting the Company is qualified to use the forms of a “foreign private issuer” under US securities laws, then the requisite quorum shall be shareholders present in person or by proxy and holding Shares conferring in the aggregate at least ten percent (10%) of the voting power of the Company. A meeting adjourned for lack of a quorum will be adjourned to the same day of the following week at the same time and place, or to such other day, time or place (i) if such is stated in the notice of the meeting or (ii) as the chairperson of the general meeting shall determine. At the reconvened meeting, if a quorum is not present within a half an hour, any number of shareholders present in person or by proxy will constitute a lawful quorum.
Vote requirements
Our Articles provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our amended and restated articles of association. Under the Companies Law, each of (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of employment or other engagement of the controlling shareholder of the company or such controlling shareholder’s relative (even if not extraordinary) requires the approval described under “Item 6. Directors, Senior Management and Employees—C. Board Practices—Fiduciary duties and approval of specified related party transactions and compensation under Israeli law—Disclosure of personal interests of a controlling shareholder and approval of transactions” in our Annual Report on Form 20-F. Certain transactions with respect to remuneration of our office holders and directors require further approvals described under “Item 6. Directors, Senior Management and Employees—C. Board Practices—Fiduciary duties and approval of specified related party transactions and compensation under Israeli law—Approval of compensation of directors and executive officers” in our Annual Report on Form 20-F. Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, which requires the approval of the majority of the shareholders voting their shares, other than abstainees, holding at least 75% of the voting rights represented at the meeting, in person, by proxy or by voting deed and voting on the resolution. Under our amended and restated articles of association, the removal of an acting director by a vote of the Company’s shareholders requires at least 65% of the voting power of the Company. In addition, certain provisions of our amended and restated articles may be amended by a majority resolution adopted by the general meeting of the Company’s shareholders, provided that such amendment was approved prior to the general meeting by at least 75% of the Company’s board of directors then in office and entitled to vote thereon.
Access to corporate records
Under the Companies Law, shareholders are provided access to minutes of our general meetings, our shareholders register and principal shareholders register, our Articles, our financial statements and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be provided with any document related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny these requests if we believe they have not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent.
Modification of class rights
Under the Companies Law and our Articles, the rights attached to any class of shares, such as voting, liquidation and dividend rights, may be modified or cancelled by the Company by a resolution of the general meeting of the holders of all shares as one class, without any required separate resolution of any class of shares.
Acquisitions under Israeli law
Full tender offer
A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company’s issued and outstanding share capital is required by the Companies Law to make a tender offer to all of the company’s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares.
3
Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above.
If a tender offer is not accepted in accordance with the requirements set forth above, the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company’s issued and outstanding share capital or of the applicable class from shareholders who accepted the tender offer.
Special tender offer
The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of at least 25% of the voting rights in the company. Alternatively, such an acquisition may be approved pursuant to a private placement approved by the company’s shareholders with the purpose of approving the acquisition of 25% or more, or 45% or more of the company’s voting rights. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions.
In the event that a special tender offer is made, a company’s board of directors is required to express its opinion on the advisability of the offer, or shall abstain from expressing any opinion if it is unable to do so, provided that it gives the reasons for its abstention. In addition, the board of directors must disclose any personal interest each member of the board of directors has in the offer or stems therefrom.
A special tender offer must be extended to all shareholders of a company, but the offeror is not required to purchase shares representing more than 5% of the voting power attached to the company’s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated only if (i) at least 5% of the voting power attached to the company’s outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser and its controlling shareholder, holders of 25% or more of the voting rights in the company or any person having a personal interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives and entities under such person’s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer.
Merger
The Companies Law permits merger transactions if approved by each party’s board of directors and, unless certain requirements described under the Companies Law are met, by a majority vote of each party’s shares, and, in the case of the target company, a majority vote of each class of its shares voted on the proposed merger at a shareholders meeting. The board of directors of a merging company is required pursuant to the Companies Law to discuss and determine whether in its opinion there exists a reasonable concern that as a result of a proposed merger, the surviving company will not be able to satisfy its obligations towards its creditors, such determination taking into account the financial status of the merging companies. If the board of directors has determined that such a concern exists, it may not approve a proposed merger.
For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at the shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company’s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval that governs all extraordinary transactions with controlling shareholders (as described under “Item 6. Directors, Senior Management and Employees—C. Board Practices—Fiduciary duties and approval of specified related party transactions and compensation under Israeli law—Disclosure of personal interests of a controlling shareholder and approval of transactions” in our Annual Report on Form 20-F for the year ended December 31, 2022).
4
If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value to the parties to the merger and the consideration offered to the shareholders of the company.
Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors.
In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party.
Borrowing powers
Pursuant to the Companies Law and our Articles, our board of directors may exercise all powers and take all actions that are not required under law or under our Articles to be exercised or taken by a certain organ of the Company, including the power to borrow money for company purposes.
Changes in capital
Our Articles enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board of directors and an Israeli court.
Transfer agent and registrar
Our transfer agent and registrar for our ordinary shares is Computershare Trust Company, N.A.
Series C Warrants
In an underwritten public offering that closed on July 23, 2018, we issued, 2,837,674 units, at a price of $3.50 per unit. Each unit consists of (i) one ADS, and (ii) one Series C Warrant to purchase one ADS. The ADSs and the accompanying Series C warrants included in the units were purchased together in the public offering, but were issued separately and were immediately separable upon issuance. On November 14, 2022, following a ratio change of 1:15 between our ADSs and Ordinary Shares, the Series C Warrants were adjusted such that Each Series C Warrant is exercisable into one/fifteen (1/15) ADS for an exercise price of $52.50.
Warrant Agreement
Our warrants were issued in registered form pursuant to the Warrant Agent Agreement dated July 23, 2018, by and between the Company and Computershare, Inc., as warrant agent (the “Warrant Agreement”). You should review a copy of the Warrant Agreement and the form of warrant included therein, as publicly disclosed, for a complete description of the terms and conditions of the warrants and the Warrant Agreement.
Duration and Exercise Price Adjustments
The warrants will expire at 5:00 p.m., New York City time on July 23, 2023. The exercise price and number of ordinary shares or ADSs (or ADS equivalents) issuable upon exercise is subject to appropriate adjustments in the event of stock dividends, stock splits, reorganizations or other events affecting our ordinary shares or ADSs and the exercise price.
5
Exercisability
The warrants may be exercised upon surrender of the warrant certificate on or prior to the expiration date at the offices of the warrant agent, with the exercise form completed and executed as indicated, accompanied by full payment of the exercise price (or on a cashless basis, if applicable), by paying in full, in lawful money of the United States by wire transfer to the warrant agent, for the number of warrants being exercised. The warrant holders do not have the rights or privileges of a shareholder of the Company and any voting rights until they exercise their warrants and receive ADSs (or ADS equivalents).
Cashless Exercise
If, at the time a holder exercises its warrants, a registration statement registering the issuance of the ADSs underlying the warrants under the Securities Act is not then effective or available for the issuance of such ADSs, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of ADSs determined according to a formula set forth in the warrants.
Fractional Shares
No fractional shares or ADSs will be issued upon exercise of the warrants. As to any fraction of an ADS which a holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price or round up to the next whole ADS.
Transferability
Subject to applicable laws, each warrant may be transferred at the option of the holder upon surrender of the warrant to the Company or its designated agent together with a written assignment substantially in the form attached to the warrant as an exhibit.
Warrant Agent
The warrant agent for our warrants is Computershare, Inc. Its address is 250 Royall Street, Canton, MA 02021, Attention: Client Services.
Exchange Listing
Our warrants are listed on Nasdaq under the symbol “MDGSW.”
6
Exhibit 4.6
LOAN AGREEMENT
This Loan Agreement (this “Loan Agreement”) is made and entered into as of the 12 day of October 2021 (the “Effective Date”) between Medigus Ltd., a company organized under the State of Israel, with principal offices at Omer Industrial Park, No.7A, P.O. Box 3030, Omer 8496500, Israel (the “Lender”), and Gix Internet Ltd. (f/k/a Algomizer Ltd.), a company organized under the State of Israel, with principal offices at Arieh Shenkar, 12, Herzliya 4672514, Israel (the “Borrower”). Each of the Lender and the Borrower shall be referred to as “Party” and together as the “Parties”.
WHEREAS, | the Lender is a shareholder of the Borrower; and |
WHEREAS, | the Lender has agreed to extend to the Borrower a loan in a principal amount of NIS 4,000,000 and the Borrower has agreed to receive such loan from the Lender, under the terms and conditions set forth herein. |
NOW, THEREFORE, it is declared and stipulated between the parties as follows:
1. | Loan Amount; Interest; Utilization of the Loan |
1.1. | Subject to the terms and conditions set forth herein, the Lender shall extend to the Borrower a loan in a principal amount of NIS 4,000,000 (the “Principal Amount”). |
1.2. | The Principal Amount shall be transferred to the Borrower’s bank account, the details of which shall be provided in writing to the Lender by the Borrower by wire transfer of immediately available funds, upon the execution of this Loan Agreement. |
1.3. | The Principal Amount shall bear interest at a rate equivalent to the minimal interest rate recognized and attributed by the Israel Tax Authority, as such may be adjusted from time to time (the “Interest”), accruing from the date of the actual disbursement of the Principal Amount through the date of the repayment in full of the Principal Amount. |
1.4. | The Interest will be calculated on the basis of the actual number of days elapsed in a year consisting of 365 days. |
2. | Loan Repayment |
2.1. | The Borrower shall repay in full the Principal Amount, together with the accrued Interest thereon (the “Loan Amount”), in one (1) payment upon the earliest of: (i) the closing of a rights offering by the Borrower for an aggregate amount of at least NIS 12,000,000 or (ii) June 30, 2022 (the “Repayment Date”). |
2.2. | Notwithstanding anything to the contrary, the Borrower may elect to repay a part or all of the Loan Amount earlier than contemplated in Section 2.1 with no penalty, premium or other fee or payment. |
2.3. | Payment to the Lender of the Loan Amount shall be made in NIS only by wire transfer of immediately available funds to the Lender’s bank account, the details of which shall have been provided in writing to the Borrower, no later than three (3) business days in advance of such payment date. |
2.4. | Upon full repayment of the Loan Amount, all rights of the Lender with respect to this Loan Agreement shall terminate. |
2.5. | All payments due hereunder shall be made without any counterclaim, setoff or deduction whatsoever. |
3. | Events of Default . |
3.1. | Notwithstanding the aforesaid, the Lender may declare the entire Loan Amount, due and payable at any time upon the earlier of any of the following events: |
3.1.1. | the Borrower fails to pay any sum under this Agreement on the Repayment Date or fails in any material respect to comply with any provision of this Agreement; |
3.1.2. | the Borrower commences negotiations with any one or more of its creditors with a view to the general readjustment or rescheduling of its indebtedness; |
3.1.3. | the Borrower makes a general assignment for the benefit of, or a composition with, its creditors; |
3.1.4. | the Borrower passes any resolution or takes any corporate action, or a petition is presented or proceedings are commenced, or any action is taken by any person for the winding-up, dissolution, or re-organization or for the appointment of a liquidator, receiver, trustee or similar officer of the Borrower or of any or all of its revenues or assets; or |
3.1.5. | any distress, execution, attachment or other legal process is levied, or enforced on or sued against all or any material part of the property or assets of the Borrower. |
3.2. | The Borrower shall notify the Lender in writing within 48 hours from the time such event first becomes known to the Borrower. |
4. | Miscellaneous |
4.1. | Entire Agreement. This Agreement is the entire Agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and arrangements between the parties hereto with respect to the subject matter hereof. |
4.2. | Waiver. A failure by any of the parties to this Agreement to assert its rights for or upon any breach of this Agreement or any such other agreement shall not be deemed a waiver of such rights nor shall any waiver be implied from any act. No waiver in writing by a Party with respect to any right shall extend its effect to any subsequent breach either of like or different kind. |
4.3. | Severability. In the event that any part or parts of this Agreement shall be held illegal or null and void by any court or administrative body of competent jurisdiction, such determination shall not affect the remaining parts of this or such agreement and they shall remain in full force and effect as if such part or parts determined illegal or void had not been included herein; provided, however, that nothing in this Section shall relieve any Party of any liability for breach of covenant, warranty or representation. |
4.4. | Assignment. Neither this Agreement nor any rights or obligations hereunder may be assigned by any Party without the prior written consent of the other parties. |
4.5. | Books. The books and accounts of the Borrower will bind the Lender in respect of the details of this Loan Agreement and/or the Principle Amount. |
4.6. | Applicable Law and Dispute Resolution. All questions arising out of or concerning this Agreement or its validity, interpretation, performance or breach shall be governed and decided by application of the laws of the State of Israel and without reference to its conflict of law rules. The parties shall make good faith efforts to resolve amicably any disputes or claims arising out of this Agreement. Any dispute or claim arising out of or relating to this Agreement, or the breach thereof, which cannot be resolved by mutual agreement of the parties, shall be submitted to the exclusive jurisdiction of the competent courts in Tel-Aviv. |
4.7. | Headings. The headings of the paragraphs of this Agreement are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof. |
4.8. | Counterparts: This Agreement and any amendment hereto may be executed in multiple counterparts, each of which shall be deemed an original agreement and all of which shall constitute one and the same agreement. |
4.9. | Amendments. This Agreement may be amended only by the written consent of both Parties. |
4.10. | Notices. Notices to be served hereunder shall be in writing as hereinafter provided and shall be served upon the parties at the address specified in the preamble of this Loan Agreement. Notices served by registered airmail shall be deemed served on the day of actual delivery by the addressee’s receipt, or at the expiration of the 7th (seventh) day after the date of mailing, whichever is earlier. Notices served by e-mail shall be deemed to be in writing and to have been served within 12 (twelve) hours of dispatch. |
[Signature Page to Follow]
-2-
IN WITNESS WHEREOF, the Parties have hereunder executed this Loan Agreement as of the date written above.
Medigus Ltd. | Gix Internet Ltd. | |||||
By: | By: |
-3-
Exhibit 4.7
AMENDMENT TO THE LOAN AGREEMENT
This Amendment (“Amendment”) to the Loan Agreement (as defined below) is entered into as of August 25, 2022 with the effective date of July 1 2022 (“Amendment Effective Date”) by and between Medigus Ltd., having its principal offices at Omer Industrial Park, No.7A, P.O. Box 3030, Omer 8496500, Israel (the “Lender”), and Gix Internet Ltd. (f/k/a Algomizer Ltd.), a company organized under the laws of the State of Israel, with principal offices at Menachem Begin, 11, Ramat Gan 5268104, Israel (the “Borrower”). Each of the Lender and the Borrower shall be referred to herein as “party” and together as the “Parties”.
WHEREAS, the Parties have entered into a loan agreement, dated October 12, 2021 (the “Loan Agreement”), according to which the Lender has extended to the Borrower a loan with a principal amount of NIS 4,000,000, in the terms set forth in the Loan Agreement (the “Loan”); and
WHEREAS, immediately after the Borrower repays his loan to Bank Leumi in the principal amount of NIS 2,419,000, the Borrower will repay all accrued interest until the repayment date, on account of the Loan and an amount of NIS 1,000,000 on account of the principal of the Loan (the “Partial Repayment Date”), such that after such repayment, the outstanding amount of the Loan is NIS 3,000,000 (the “Remaining Loan Amount”); and
WHEREAS, the Parties have agreed on new terms that will apply to the Loan and the Remaining Loan Amount as set forth in this Amendment.
NOW THEREFORE, in consideration of the premises and the mutual covenants herein contained, the Parties hereto agree as follows:
1. | Definitions. All capitalized terms used herein, not otherwise defined, shall have the meaning set forth in the Loan Agreement. |
2. | Amendments. |
2.1. | Loan Repayment - The Repayment Date, as defined under Section 2.1 of the Loan agreement of the Remaining Loan Amount shall be June 30, 2023 (the “Amended Repayment Date”). The Lender shall have the right to convert all or part of the outstanding Amended Principal Amount into ordinary shares of the Borrower, at a price per share equal to the average price of the Borrower’s ordinary shares on the Tel-Aviv Stock Exchange during the 30 trading days prior to the Amended Repayment Date, subject to obtaining all approvals required under applicable law, including the approval of the Borrower’s general meeting, if required. |
2.2. | Interest – from the Amendment Effective Date The Loan (including the Remaining Loan Amount) and the Remaining Loan Amount shall bear annual interest at a rate equals to the Prime Rate published by the Bank of Israel + 2.92%, which will be paid in quarterly installments, not later than the 15 day of each of calendar quarter, starting on 15 of October 2022, except for the last interest payment, which shall be made on the Amended Repayment Date, for the period starting on the preceding interest payment date . |
3. | No Further Amendments. Other than as set forth herein, all terms and conditions set forth in the Loan Agreement shall remain without change, binding and of full force and effect. |
4. | Miscellaneous. This Amendment shall be governed and construed by the terms and conditions set forth in the Loan Agreement. In any event of a conflict between the terms contained in this Amendment and the Loan Agreement, the terms contained in this Amendment shall govern. |
IN WITNESS WHEREOF, the Parties have caused this Amendment to the Loan Agreement to be executed by their duly authorized representatives effective as of the Amendment Effective Date.
Medigus Ltd. | Gix Internet Ltd. | |||
By: | Liron Carmel | By: | Amihay Hadad | |
Title: | CEO | Title: | CEO | |
Date: 25.8.2022 | Date: 25.8.2022 |
Exhibit 4.8
Share Purchase Agreement
Among
ParaZero Technologies Ltd. (the “Company”)
and
Delta Drone International Ltd (ACN 618 678 701) (the “Seller”)
and
L.I.A
Pure Capital Ltd. and additional entities on its behalf as listed in Exhibit A
(each an “Acquiror” and collectively, the “acquirers”)
Dated
January 28, 2022
TABLE OF CONTENTS
ARTICLE 1 Certain Definitions | 1 | |
ARTICLE 2 The Share Purchase | 9 | |
2.1 | Purchase and Sale of Shares | 9 |
2.2 | Share Purchase Consideration. | 9 |
2.3 | Withholding; Certain Tax Matters. | 9 |
2.4 | Further Assurances | 10 |
ARTICLE 3 Representations and Warranties of each of the Company and the Seller | 11 | |
3.1 | Organization and Good Standing | 11 |
3.2 | Subsidiaries | 11 |
3.3 | Power, Authorization and Validity | 11 |
3.4 | Capitalization of the Company. | 13 |
3.5 | No Conflict. | 14 |
3.6 | Taxes. | 14 |
3.7 | Company Financial Statements. | 16 |
3.8 | Intellectual Property. | 18 |
3.9 | Employees | 23 |
3.10 | Organization; Power and Capacity. | 25 |
3.11 | Enforceability; Noncontravention. | 25 |
3.12 | Title to Shares. | 26 |
3.13 | Litigation. | 26 |
3.14 | Solvency. | 26 |
3.15 | Australian Securities Exchange Ltd. and Reports. | 26 |
3.16 | Representations Complete. | 26 |
ARTICLE 4 Representations and Warranties of Acquiror | 27 | |
4.1 | Organization and Standing. | 27 |
4.2 | Authority; Noncontravention. | 27 |
4.3 | Available Financing. | 27 |
4.4 | Disclosure of Information. | 27 |
-i-
ARTICLE 5 Company and Seller Covenants |
28 | |
5.1 | No Solicitation. | 28 |
5.2 | Non-Competition; Non-Solicitation. | 29 |
5.3 | Advice of Changes. | 30 |
5.4 | Maintenance of Business. | 30 |
5.5 | Regulatory Approvals. | 33 |
5.6 | Necessary Consents. | 33 |
5.7 | Litigation. | 33 |
5.8 | Access to Information; Confidentiality. | 33 |
5.9 | Closing Financial Certificate and Spreadsheet. | 34 |
5.10 | Tax Matters. | 34 |
5.11 | Satisfaction of Conditions Precedent. | 34 |
5.12 | Release. | 34 |
5.13 | D&O Insurance/Run-Off Policy | 35 |
ARTICLE 6 Acquiror Covenants | 35 | |
6.1 | Advice of Changes. | 35 |
6.2 | Satisfaction of Conditions Precedent. | 35 |
ARTICLE 7 Closing Matters | 35 | |
7.1 | The Closing. | 35 |
7.2 | Payment Procedures. | 35 |
7.3 | Company Net Working Capital Adjustment. | 36 |
ARTICLE 8 Conditions to Obligations of the Company | 37 | |
8.1 | Accuracy of Representations and Warranties. | 37 |
8.2 | Covenants. | 37 |
8.3 | Compliance with Law; No Legal Restraints. | 38 |
8.4 | Government Consents. | 38 |
8.5 | Escrow Agreement. | 38 |
8.6 | Supply Agreement. | 38 |
8.7 | Warrant. | 38 |
ARTICLE 9 Conditions to Obligations of Acquirers | 38 | |
9.1 | Accuracy of Representations and Warranties. | 38 |
9.2 | Covenants. | 38 |
9.3 | No Material Adverse Change. | 38 |
9.4 | Compliance with Law; No Legal Restraints; No Litigation. | 38 |
9.5 | Government Consents. | 39 |
9.6 | Employment Matters. | 39 |
9.7 | Requisite Company Shareholder Approval. | 39 |
9.8 | Shareholders’ Register. | 39 |
9.9 | Receipt of Closing Deliveries. | 39 |
-ii-
ARTICLE 10 Termination of Agreement |
40 | |
10.1 | Termination by Mutual Consent. | 40 |
10.2 | Unilateral Termination. | 40 |
10.3 | Effect of Termination. | 41 |
10.4 | For the avoidance of doubt | 41 |
ARTICLE 11 Escrow, Survival Indemnification and Remedies | 41 | |
11.1 | RESERVED | 41 |
11.2 | At the Closing | 41 |
11.3 | Subject to terms further elaborated under the Escrow Agreement | 42 |
11.4 | Survival of Representations and Warranties. | 42 |
11.5 | If the Share Purchase is consummated | 42 |
11.6 | Agreement to Indemnify. | 43 |
11.7 | Limitations. | 44 |
11.8 | Notice of Claim. | 45 |
11.9 | Defense of Third-Party Claims. | 47 |
11.10 | Resolution of Notice of Claim. | 48 |
11.11 | Treatment of Indemnification Payments. | 49 |
11.12 | Acquiror Representative. | 49 |
ARTICLE 12 Miscellaneous | 50 | |
12.1 | Governing Law; Jurisdiction. | 50 |
12.2 | Assignment; Binding Upon Successors and Assigns. | 50 |
12.3 | Severability. | 50 |
12.4 | Counterparts. | 50 |
12.5 | Other Remedies. | 50 |
12.6 | Amendments and Waivers. | 51 |
12.7 | Expenses. | 51 |
12.8 | Notices. | 51 |
12.9 | Interpretation; Rules of Construction. | 52 |
12.10 | Third Party Beneficiary Rights. | 53 |
12.11 | Public Announcement. | 53 |
12.12 | Confidentiality. | 53 |
12.13 | Legal Representation. | 53 |
12.14 | Entire Agreement. | 53 |
-iii-
Execution Copy
This Share Purchase Agreement (this “Agreement”) is made and entered into as of January 28, 2022 (the “Agreement Date”) by and among Delta Drone International Ltd. (ACN 618 678 701), an Australian corporation (“Seller”), ParaZero Technologies Ltd., a company organized under the laws of Israel (the “Company”), L.I.A Pure Capital Ltd., a company organized under the laws of Israel (“Pure and/or an “Acquiror”), and additional entities/individuals as listed in Exhibit A (each an “Acquiror” and together with Pure, the “Acquirers”).
Recitals
A. | The Seller alone holds 100% of the Company Share Capital and desires to accept an offer by Acquirers to purchase all Company Shares on the terms and subject to the conditions set forth in this Agreement. |
B. | Upon the terms and subject to the conditions set forth in this Agreement, the Acquirers desire to purchase from the Seller all Company Share Capital owned by Seller free and clear from all Encumbrances (the “Share Purchase”), and Seller desires to sell, assign, transfer and deliver to the Acquirers all Company Share Capital owned by Seller free and clear from all Encumbrances, all pursuant to and in accordance with the terms of this Agreement. |
C. | Prior to the date hereof, the Seller, Company and each of the Acquirers have entered into that certain Paying Agent Agreement, and the Acquirers have transferred to an account managed by the Paying Agent the amount equal to the Closing Consideration known to the Parties on the execution date of the Paying Agent Agreement. |
D. | Seller, Acquirers and the Company desire to make certain representations, warranties, covenants and agreements in connection with the Transactions and to prescribe various conditions to the Transactions. |
Now, Therefore, in consideration of the foregoing and the mutual promises, covenants and conditions contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:
ARTICLE
1
Certain Definitions
As used in this Agreement, the following terms shall have the meanings set forth below.
“Acquisition Proposal” means with respect to the Company, any agreement, offer, proposal or bona fide indication of interest (other than this Agreement or any other offer, proposal or indication of interest by either of the Acquirers), or any public announcement of intention to enter into any such agreement or of (or intention to make) any offer, proposal or bona fide indication of interest, relating to, or involving: (i) any acquisition or purchase from the Company, or from the Seller, by any Person, or any merger, consolidation, business combination or similar transaction involving the Company pursuant to which the Seller immediately preceding such transaction hold securities representing less than 100% of the total outstanding voting securities of the surviving or resulting entity of such transaction (or parent entity of such surviving or resulting entity), (ii) any sale, lease, mortgage, pledge, exchange, transfer, license (other than in the ordinary course of business consistent with past practices), acquisition, or disposition of any part of the consolidated assets of the Company in any single transaction or series of related transactions, (iii) any liquidation, dissolution, recapitalization or other significant corporate reorganization of the Company, or any extraordinary dividend or distribution, whether of cash or other property, or (iv) any other transaction outside of the ordinary course of the Company Business the consummation of which could reasonably be expected to impede, interfere with, prevent or materially delay the Share Purchase.
-1-
“Action” means any action, suit, litigation, arbitration, mediation, proceeding, claim, complaint, allegation, demand, charge, grievance, prosecution, investigation, inquiry, hearing, audit, examination or subpoena (whether (i) civil, criminal, administrative, judicial, investigative or appellate, (ii) formal or informal, (iii) public or private, or (iv) at law or at equity) commenced, brought, conducted or heard by or before, or otherwise involving, any court, arbitrator, mediator or other Governmental Authority or tribunal.
“Adjustment Escrow Amount” means A$100,000.
“Affiliate” means, with respect to any Person, any other Person that directly or indirectly through one or more intermediaries, controls, is controlled by or is under common control with the first Person; “control” (including the term “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of a Person, whether through the ownership of voting securities, by Contract or credit arrangement, as trustee or executor, or otherwise.
“Applicable Law” means, with respect to any Person, any applicable federal, state, foreign, local, municipal or other law, statute, constitution, legislation, principle of common law, resolution, ordinance, code, edict, decree, rule, directive, license, permit, regulation, extension order, ruling or requirement issued, enacted, adopted, promulgated, implemented or otherwise put into effect by or under the authority of any Governmental Authority and applicable to such Person and any Orders applicable to such Person or to any of its assets, properties or business.
“Board” means the Board of Directors of the Company.
“Business Day” means a day on which commercial banks are open for business in the State of Israel and/or in the Commonwealth of Australia, respectively.
“Charter Documents” means the Company’s Articles of Association, as existing on the Agreement Date.
“Closing” means the closing of the Transactions.
“Closing Balance Sheet” means the Company’s balance sheet as of January 14th, 2021.
“Closing Date” means three Business Days after the satisfaction or waiver of the conditions set forth in Article 8 and Article 9 (excluding conditions that, by their terms, are intended to be satisfied on the Closing Date, which conditions shall be capable of being satisfied on the Closing Date).
-2-
“Closing Consideration” means an amount in cash equal to (i) A$6,000,000 less (ii) all Company Debt that remains unpaid as of the Closing Date, plus (iii) the Company Cash Surplus, if any, less (iv) the Company Cash Shortfall, if any, less (v) the aggregate amount of Transaction Expenses that remain unpaid as of the Closing (whether or not incurred as of the Closing), plus (vi) the Closing Net Working Capital Surplus, if any, less (vii) the Closing Net Working Capital Shortfall, if any.
“Closing Net Working Capital Shortfall” means the amount, if any, by which the Closing Net Working Capital Target exceeds Company Net Working Capital as set forth in the Company Closing Financial Certificate.
“Closing Net Working Capital Surplus” means the amount, if any, by which the Company Net Working Capital as set forth in the Company Closing Financial Certificate exceeds the Closing Net Working Capital Target.
“Closing Net Working Capital Target” means US $360,000.
“Company Ancillary Agreements” means, collectively, each certificate to be delivered on behalf of the Company by an officer or officers of the Company at the Closing pursuant to Section 9.9 and each agreement or document (other than this Agreement) that the Company is to enter into as a party thereto pursuant to this Agreement.
“Company Business” means drone safety technology systems, as presently conducted.
“Company Cash” means the aggregate amount of the Company’s unrestricted cash and cash equivalents on hand as of the Closing Date calculated in accordance with IFRS and as set forth in the Closing Balance Sheet.
“Closing Cash Shortfall” means the amount, if any, by which the Company Cash Target exceeds Company Cash as set forth in the Company Closing Financial Certificate.
“Closing Cash Surplus” means the amount, if any, by which the Company Cash as set forth in the Company Closing Financial Certificate exceeds the Cash Target.
“Closing Cash Target” means US $0.
“Company Closing Financial Certificate” means a certificate executed by an executive officer of the Company reflecting the Company’s best estimation as of the Closing Date, dated as of the Closing Date, certifying, as of January 14, 2022, (i) the amount of Company Net Working Capital (including (A) the Closing Balance Sheet (B) an itemized list of each element of the Company’s consolidated current assets included therein and (B) an itemized list of each element of the Company’s consolidated current liabilities included therein), (ii) an itemized list of each item of Company Debt that remains unpaid as of January 14, 2022 with a description of the nature of such Company Debt and the Person to whom such Company Debt is owed, (iii) an aggregate amount of Company Cash, (iv) the amount of any Transaction Expenses that are unpaid as of the January 14, 2022 (whether or not incurred as of January 14, 2022) and (v) that the Closing Balance Sheet, which shall be attached as an exhibit, has been prepared in accordance with IFRS on a consistent basis with the Company Balance Sheet.
-3-
“Company Debt” means, without duplication, as of January 14, 2022: (i) all obligations (including the principal amount thereof or, if applicable, the accreted amount thereof and the amount of accrued and unpaid interest thereon) of the Company, whether or not represented by bonds, debentures, notes or other securities (whether or not convertible into any other security), for the repayment of money borrowed, whether owing to banks, financial institutions, on equipment leases or otherwise including towards government agencies (including, for the removal of doubt the full amount of royalty payments due to the Israeli Innovation Authority on account of sales by the Company during 2021), (ii) all deferred indebtedness of the Company for the payment of the purchase price of property or assets purchased (other than accounts payable incurred in the ordinary course of business), (iii) all outstanding reimbursement obligations of the Company with respect to letters of credit, bankers’ acceptances or similar facilities issued for the account of the Company, (iv) all obligations of the Company under any interest rate swap agreement, forward rate agreement, interest rate cap or collar agreement or other financial agreement or arrangement entered into for the purpose of limiting or managing interest rate risks, and (iv) all obligations secured by any Encumbrance existing on property owned by the Company, whether or not indebtedness secured thereby will have been assumed, (v) all premiums, penalties, fees, expenses, breakage costs and change of control payments required to be paid or offered in respect of any of the foregoing on prepayment (regardless if any of such are actually paid), as a result of the consummation of the Transactions or in connection with any lender consent, and (vi) all guaranties, endorsements, assumptions and other contingent obligations of the Company in respect of, and (vii) all employee benefit obligations, salaries, liabilities for vacation, paid time off and performance or other bonuses accrued by or for the Company’s employees, or to purchase or to otherwise acquire, any of the obligations and other matters of the kind described in any of the clauses (i) through (vii) appertaining to third parties.
“Company Net Working Capital” means (i) the Company’s consolidated total current assets as of January 14, 2022 (as defined by and determined in accordance with IFRS as applied in the Company Balance Sheet) less (ii) the Company’s consolidated total current liabilities as of January 14, 2022 (as defined by and determined in accordance with IFRS as applied in the Company Balance Sheet). For purposes of calculating Company Net Working Capital, (x) the Company’s consolidated total current assets shall (regardless of whether they would be treated as a current asset under IFRS as applied in the Company Balance Sheet) exclude (A) Company Cash, and (B) deferred Tax assets and (y) the Company’s consolidated total current liabilities shall (regardless of whether they would be treated as a current liability under IFRS as applied in the Company Balance Sheet) (A) include, without duplication, (1) all deferred revenue, (2) all Pre-Closing Taxes, and any other Liabilities of the Company for Taxes as of January 14, 2022 (including, for clarity, Taxes arising in connection with any payment required pursuant to, or arising as a result of, this Agreement or the Transactions (except any Taxes included in the definition of “Transaction Expenses”) whether or not such Liabilities for Taxes would be then due and payable), (B) exclude (1) all Company Debt and (2) all Transaction Expenses, in each case included in the calculation of Total Consideration.
“Company Shares” means the Company Ordinary Shares with a nominal value of NIS 0.01.
“Company Share Capital” means the issued and outstanding share capital of the Company.
-4-
“Contract” means any written or oral legally binding contract, agreement, instrument, commitment or undertaking of any nature (including leases, subleases, licenses, mortgages, notes, guarantees, sublicenses, subcontracts, letters of intent and purchase orders) as of the Agreement Date or as may hereafter be in effect, including all amendments, supplements, exhibits and schedules thereto.
“Encumbrance” means, with respect to any asset, any mortgage, deed of trust, lien, pledge, hypothecation, charge, security interest, title retention device, collateral assignment, adverse claim, restriction, infringement, interference, option, right of first refusal, preemptive right, community property interest or other encumbrance or restriction of any kind in respect of such asset (including any restriction on the voting of any security, any restriction on the transfer of any security or other asset, any restriction on the receipt of any income derived from any asset, any restriction on the use of any asset and any restriction on the possession, exercise or transfer of any other attribute of ownership of any asset).
“Entity” means any corporation (including any non-profit corporation), general partnership, limited partnership, limited liability partnership, joint venture, estate, trust, proprietorship, company (including any company limited by shares, limited liability company or joint stock company), firm, society, enterprise, association, organization or other entity.
“Escrow Agent” means IBI Trust Management.
“Escrow Amount” means A$900,000.
“Fully-Diluted Company Shares” means the sum, without duplication, of (i) the aggregate number of shares of Company Share Capital that are issued and outstanding immediately prior to the Closing, and (ii) the aggregate number of shares of Company Shares issuable upon the exercise or settlement of the vested Company options or other direct or indirect rights to acquire shares of Company Share Capital that are issued and outstanding immediately prior to the Closing.
“IFRS” means the International Financial Reporting Standards applied on a consistent basis.
“Governmental Authority” means any: (i) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature, (ii) federal, state, local, municipal, foreign or other government, (iii) governmental authority of any nature (including any governmental division, department, agency, commission, instrumentality, official, ministry, fund, foundation, center, organization, unit, body or Entity, and any court or other tribunal), or (iv) Entity to whom a Governmental Authority has assigned or delegated any authority or oversight responsibilities.
“Income Tax Ordinance” means the Israeli Income Tax Ordinance (New Version) 1961, as amended, and any rules and regulations promulgated thereunder.
“Intellectual Property” means Intellectual Property Rights and Technology.
-5-
“Intellectual Property Rights” means any and all industrial and intellectual property rights and all intangible rights associated therewith, throughout the world, including (i) all patents and applications therefor and all reissues, divisions, renewals, extensions, provisionals, continuations and continuations-in-part thereof, (ii) all rights in inventions (whether patentable or not), invention disclosures, improvements, trade secrets, proprietary information, know how, Technology, technical data, proprietary processes and formulae, algorithms, specifications, customer lists and supplier lists, (iii) all rights in industrial designs and any registrations and applications therefor, (iv) all rights in trade names, logos, trade dress, trademarks and service marks, trademark and service mark registrations, trademark and service mark applications, and any and all goodwill associated with and symbolized by the foregoing items, (v) all rights in Internet domain name registrations, Internet and World Wide Web URLs or addresses, (vi) all copyrights, copyright registrations and applications therefor, and all other rights corresponding thereto, (vii) all rights in mask works, mask work registrations and applications therefor, and any equivalent or similar rights in semiconductor masks, layouts, architectures or topology, (viii) all rights in computer software, including all source code, object code, firmware, development tools, files, records and data, (ix) all rights in schematics, netlists, test methodologies, test vectors, emulation and simulation tools and reports, (x) all rights in hardware development tools, prototypes, breadboards and other devices, (xi) all rights in databases and data collections, (xii) all rights in moral and economic rights of authors and inventors, however denominated, and (xiii) any similar or equivalent rights to any of the foregoing.
“Israeli Law” means Israeli Applicable Law.
“ITA” means the Israeli Tax Authority.
“knowledge” means, with respect to any fact, circumstance, event or other matter in question, the knowledge of such fact, circumstance, event or other matter (after reasonable inquiry) of the Seller.
“Liability” means any debt, obligation, duty or liability of any nature (whether direct or indirect, known or unknown, disclosed or undisclosed, matured or unmatured, accrued or unaccrued, asserted or unasserted, absolute or contingent, determined or conditional, express or implied, fixed or variable and whether vicarious, derivative, joint, several or secondary), including any such debt, obligation, duty or liability arising under any Applicable Law, Contract or Action, regardless of whether any such debt, obligation, duty or liability would be required to be disclosed on a balance sheet prepared in accordance with IFRS, including the notes thereto, or is immediately due and payable.
“Material Adverse Change” when used in connection with an Entity means any change, event, circumstance, condition or effect (regardless of whether or not such change, event, circumstance, condition or effect is inconsistent with the representations or warranties made by such Entity in this Agreement) that, individually or in the aggregate, taking into account all other changes, events, circumstances, conditions or effects, is or is reasonably likely to: (i) be materially adverse in relation to the near-term or longer-term condition (financial or otherwise), capitalization, properties, products, assets (including intangible assets), Intellectual Property, liabilities, business, operations or results of operations of such Entity and its subsidiaries, taken as a whole, or (ii) materially impede or delay such Entity’s ability to perform any obligation under or otherwise consummate the Transactions, including those contemplated by this Agreement or any Company Ancillary Agreement or Acquiror Ancillary Agreement in accordance with its terms and Applicable Laws, except, in each case, to the extent that any such change, event, condition or effect does not result from (A) changes in general economic or financial market conditions (including with respect to each Acquirer, changes in the Acquirer’s or any of its Affiliate’s stock price) (provided that such changes do not affect such Entity disproportionately as compared to such Entity’s competitors), (B) changes generally affecting the industry in which such Entity operates (provided that such changes do not affect such Entity disproportionately as compared to such Entity’s competitors), (C) any acts of terrorism, military action or war, (D) changes or developments in Applicable Law or GAAP or IFRS (provided that such changes do not affect such Entity disproportionately as compared to such Entity’s competitors), (E) the impact of the announcement, existence or pendency of the transactions contemplated by this Agreement, including but not limited to, the impact thereof on (1) any resulting actions of competitors of the Entity, (2) any resulting shortfalls or declines in revenue, margins or profitability of the Entity, and (3) the Entity’s relationship with their suppliers, customers or prospective customers attributable thereto; provided further that the impact of Coronavirus (COVID-19) shall not be taken into consideration in determining whether a Material Adverse Change has occurred.
“Order” means any written order, writ, injunction, judgment, decision, ruling, decree, award, determination or stipulation issued, promulgated or entered by, or any settlement or other agreement under the jurisdiction of, any court, arbitrator, mediator or other Governmental Authority or tribunal.
“ordinary course of business” means any action taken by a Person if such action is materially consistent with such Person’s past practices and is taken in the ordinary course of such party’s normal day to day operations.
-6-
“Paying Agent” means IBI Trust Management.
“Paying Agent Agreement” means the Paying Agent Agreement dated January 17, 2022 by the Acquirers, the Seller and the Paying Agent attached hereto as Schedule 7.2.
“Per Share Closing Consideration” means the average price per share calculated as follows: (i) the Closing Consideration divided by (ii) the Fully-Diluted Company Shares.
“Per Share Total Consideration” means average price per share calculated as follows: (i) the Total Consideration divided by (ii) the Fully-Diluted Company Shares.
“Person” means any natural person, company, corporation, limited liability company, general partnership, limited partnership, limited liability partnership, trust, estate, proprietorship, joint venture, business organization or Governmental Authority.
“Pre-Closing Taxes” means any (i) Taxes of the Company and the Company Subsidiaries for a Taxable period (or portion thereof) ending on or prior to January 14, 2022 and (ii) any Taxes of any other Person for which the Company is liable if the agreement, event or occurrence giving rise to such Liability occurred on or before January 14, 2022. For clarity, Pre-Closing Taxes includes any payroll taxes or other Taxes of the Company arising in connection with any payment required pursuant to, or arising as a result of, this Agreement or the Transactions, whether or not such Taxes are due and payable as of January 14, 2022. In the case of any Taxes of the Company that are imposed on a periodic basis and that are payable for a Taxable period that includes (but does not end on) January 14, 2022, such Taxes shall (i) in the case of property, ad valorem or other Taxes that accrue based upon the passage of time, be deemed to be Pre- Closing Taxes in an amount equal to the amount of such Taxes for the entire Taxable period multiplied by a fraction, the numerator of which is the number of days in the Taxable period through and including January 14, 2022and the denominator of which is the number of days in the entire Taxable period, and (ii) in the case of any other Taxes, be deemed to be Pre-Closing Taxes in an amount equal to the amount of Taxes that would be payable if the relevant Taxable period ended on January 14, 2022. Any credits relating to a Taxable period that includes (but does not end on) January 14, 2022 shall be taken into account as though the relevant Taxable period ended on January 14, 2022.
“Securities Act” means the Securities Act of 1933, as amended.
“Spreadsheet” means a spreadsheet in form reasonably acceptable to Acquirers Representative , which spreadsheet shall be dated as of January 14, 2022 and shall set forth, as of January 14, 2022 and immediately prior to January 14, 2022, the following factual information relating to Seller: the address, e-mail addresses and taxpayer identification numbers and, bank information (including the respective bank name and number, branch name and address, swift number, account number and other wire transfer information), (ii) the number and type of shares of Company Share Capital held by Seller and, in the case of outstanding shares, the respective certificate numbers, (iii) the calculation of the Closing Consideration, Total Consideration, Fully-Diluted Company Shares, Per Share Closing Consideration and Per Share Total Consideration, (iv) the Escrow Amount and the Adjustment Escrow Amount, (v) the calculation of aggregate cash amounts payable to Seller pursuant to Section 2.2.
“Tax” (and, with correlative meaning, “Taxes” and “Taxable”) means (i) any federal, state, local or foreign, net or gross income, gross receipts, capital gains, franchise, alternative or add-on minimum, estimated, sales, use, ad valorem, goods and services, transfer, registration, value added, excise, natural resources, severance, stamp, occupation, premium, windfall profits, environmental, customs, duties, real property, personal property, share capital, social security, national health insurance, unemployment, employment, disability, payroll, license, employee or other withholding, contributions or other tax, of any kind whatsoever, escheat assessments, duties, fees, levies or other governmental charges or assessment of any nature, whether disputed or not, including any interest, consumer price index linkage, penalties or additions to tax or additional amounts in respect of the foregoing, (ii) any liability for the payment of any amounts of the type described in clause (i) of this sentence as a result of being a member of an affiliated, consolidated, combined, unitary or aggregate group for any Taxable period, and (iii) any liability for the payment of any amounts of the type described in clause (i) or (ii) of this sentence as a result of being a transferee of or successor to any Person or as a result of any express or implied obligation to assume such Taxes or to indemnify any other Person.
-7-
“Tax Authority” means any Governmental Authority responsible for the imposition, administration, assessment, and/or collection of any Tax.
“Tax Return” means any return, declaration, statement, form, report, estimate, claim for refund, information return or other document (including any related or supporting schedule, statement or information) filed or required to be filed with a Tax Authority with respect to Taxes.
“Technology” means any or all of the following: (i) works of authorship including software programs, objects, modules, routines, algorithms, schematics, and architecture, whether in source code or executable code form, documentation (including programmers notes and annotations, technical and user documentation, specifications, manuals, instructions, designs, layouts, plans, drawings, bills of materials, net lists, and GDSII Files), (ii) inventions (whether or not patentable), discoveries and improvements, (iii) proprietary and confidential information and know how, (iv) databases, data compilations and collections and technical data, (v) logos, trade names and trade dress, (vi) domain names, web addresses and sites, (vii) technology, methods and processes, algorithms and formulae, (viii) devices, prototypes, designs, specifications and schematics, and (ix) and all embodiments, representations and manifestations of any of the foregoing or any Intellectual Property Rights.
“Total Consideration” means an amount in cash equal to the Closing Consideration.
“Transaction/s” means the transactions contemplated under this Agreement.
“Transaction Expenses” means all third-party fees, costs, expenses, payments and expenditures incurred by or on behalf of the Company directly in connection with the Transactions, whether or not billed or accrued prior to or upon January 14th 2022, in any event, which have not been previously paid, including (i) any fees, costs expenses, payments and expenditures of legal counsel and accountants, the fees costs, expenses, payments and expenditures payable to brokers, finders, financial advisors, investment bankers or similar Persons engaged by the Company or Sellers notwithstanding any earn-outs, escrows or other contingencies including all fees sue the Paying Agent and Escrow Agent in accordance with the Paying Agent Agreement and Escrow Agreement, and all fees and costs relating to the D&O/Run- Off policy, as set forth in Section 5.13 hereto, (iii) all bonuses or severance obligations (including statutorily mandated severance payments) owed by the Company to the Company’s directors, employees and/or consultants in connection with the Transactions that are unpaid as of the Closing (except in connection with any request of the Acquiror including request of the Acquiror to terminate engagements of employees and/or consultants by the Acquirer), (iv) the employer portion of any payroll taxes or other withholding obligations arising from payments described in clause (iii) of this definition, and not previously paid, and (v) any such fees, costs, expenses, payments and expenditures incurred by Sellers or Key Employees paid for or to be paid for by the Company; provided that Transaction Expenses shall be calculated to be inclusive of any VAT.
-8-
ARTICLE
2
The Share Purchase
2.1 Purchase and Sale of Shares. At the Closing, on the terms and subject to the conditions set forth in this Agreement, in consideration for the payments set forth in Section 2.2 below, the Seller, shall sell, assign, transfer and deliver to Acquirers, and Acquirers shall, on a several and not joint basis, purchase from the Seller, good and valid title to all of the Company Shares, free and clear from all Encumbrances. The allocation of the Company Shares and of the Closing Consideration between the Acquirers shall be as set forth under Annex A (the “Acquirers Allocation Table”).
2.2 Share Purchase Consideration.
(a) Company Capital Shares. On the terms and subject to the conditions set forth in this Agreement, Seller shall sell, transfer and deliver to Acquirers at the Closing, and the Acquirers shall purchase from Seller, good and valid title to all of the Company Shares owned by Seller as of immediately prior to the Closing (as set forth on the Spreadsheet) free and clear of all Encumbrances, in exchange for the Closing Consideration.
(b) Adjustments. In the event of any share split, reverse share split, share dividend (including any dividend or distribution of securities convertible into capital shares), reorganization, reclassification, combination, recapitalization or other like change with respect to the Company Shares occurring after the Agreement Date and prior to the Closing, all references in this Agreement to specified numbers of shares of any class or series affected thereby, and all calculations provided for that are based upon numbers of shares of any class or series (or trading prices therefor) affected thereby, shall be equitably adjusted to the Seller’s indemnification obligations under Article 11.
2.3 Withholding; Certain Tax Matters.
(a) The Escrow Agent and any Person acting on its behalf (each, a “Payor”) shall be entitled to deduct and withhold from any consideration payable or otherwise deliverable pursuant to this Agreement and the Escrow Agreement to, or on behalf of, Seller such amounts as the Payor reasonably determines are required to be deducted or withheld therefrom or in connection therewith under any provision of state, local or foreign Tax law or under any other Applicable Law, including, without limitation, the Income Tax Ordinance, unless the Payor is provided, prior to the applicable payment date, with a valid certificate that exempts the Seller from Tax or implies a reduced Tax rate, in which case the Payor will withhold tax according to the tax rate provided in such certificate. To the extent such amounts were so deducted or withheld, such amounts shall be (A) treated for all purposes under this Agreement as having been paid to the Person to whom such amounts would otherwise have been paid and (B) timely remitted by the Payor to the applicable Governmental Authority. In the case of any amounts withheld, the withholding party shall promptly provide to the Seller written confirmation of the amount so withheld.
-9-
(b) Notwithstanding Section 2.3(a), with respect to Israeli Tax, any amount payable to Seller (excluding amounts held in the Escrow Fund) (in this section the “Payee”) under this Agreement at the Closing shall, at the request of Payee, be retained by the Paying Agent for the benefit of Payee for a period of up to 180 days from the Closing or an earlier date required in writing by Payee or as otherwise requested by the ITA (the “Withholding Drop Date”) (during which time no amount shall be withheld from amounts paid to the Paying Agent, except as provided below or as requested in writing by the ITA) and during which time, Payee may obtain (or, if one already exists, present to the Paying Agent) a valid certificate or ruling issued by the ITA specifically in regards to this Transaction in form and substance reasonably acceptable to Acquirers Representative: (A) exempting the Payor from the duty to withhold Israeli Taxes with respect to Payee, (B) determining the applicable rate of Israeli Taxes to be withheld from the payment due to Payee or (C) providing any other instructions regarding the payment or withholding with respect to the applicable portion of the consideration due to Payee (the “Qualified Withholding Certificate”). In the event that no later than three (3) Business Days prior to the Withholding Drop Date Payee submits to the Paying Agent a Qualified Withholding Certificate, the Paying Agent shall act in accordance with the provisions of such Qualified Withholding Certificate, subject to any deduction and withholding as may be reasonably required to be deducted and withheld under any provision of state, local or foreign Tax law (other than Israeli Tax law) and the balance of the payment that is not withheld shall be paid to Payee. If Payee: (A) does not provide the Paying Agent with a Qualified Withholding Certificate no later than three Business Days prior to the Withholding Drop Date, or (B) submits a written request to the Paying Agent to release the amounts held by the Paying Agent to Payee, prior to the Withholding Drop Date and fails to submit a Qualified Withholding Certificate at or before such time, then the amount to be withheld and transferred to the ITA from the amounts payable to Payee, shall be calculated according to the applicable withholding rate (increased by interest plus linkage differences, as defined in Section 159A of the Israeli Income Tax Ordinance, for the period between the Closing and the time the relevant payment is made, and calculated in NIS based on a A$:NIS exchange rate at the Closing Date, as published by the Bank of Israel). Such amount shall be delivered or caused to be delivered to the ITA by the Paying Agent, and the Paying Agent shall release to Payee the balance of the amount due to Payee that is not so withheld, subject to any deduction and withholding as may reasonably be required to be deducted and withheld under any provision of state, local or foreign Tax law (other than Israeli Tax law). For the avoidance of doubt, in the absence of a Qualified Withholding Certificate which also applies to the Escrow Fund, the applicable amount to be withheld from any amount deposited with the Paying Agent will be deducted, and delivered to the ITA as provided above. Any currency conversion commissions will be borne by the Seller and deducted from payments to be made to Seller.
(c) Each party hereto is relying solely on the advice of his, her or its own Tax advisors with respect to the Tax consequences of the Share Purchase.
2.4 Further Assurances. If, at any time before or after the Closing, the parties reasonably believe or are advised that any further instruments, deeds, assignments or assurances are reasonably necessary or desirable to consummate the Share Purchase or to carry out the purposes and intent of this Agreement at or after the Closing, then the Company, Acquirers, Seller and their respective officers and directors shall execute and deliver all such proper deeds, assignments, instruments and assurances and do all other things reasonably necessary or desirable to consummate the Transactions and to otherwise carry out the purposes and intent of this Agreement so long as such action is not inconsistent with this Agreement.
-10-
ARTICLE
3
Representations and Warranties of each of the Company and the Seller
Subject to the exceptions set forth in a numbered or lettered section of the disclosure letter addressed to Acquirers, dated as of the Agreement Date and delivered to Acquirers concurrently with the parties’ execution of this Agreement (the “Disclosure Letter”) referencing a representation or warranty herein (each of which exceptions, in order to be effective, shall clearly indicate the section and, if applicable, the subsection of this Article 3 to which it relates (unless and to the extent the relevance to other representations and warranties is reasonably apparent from the face of the disclosed exception without reference to extrinsic documentation or independent knowledge on the part of the reader regarding the disclosed exception), and each of which exceptions shall also be deemed to be representations and warranties made by each of the Seller and the Company, severally and not jointly, under this Article 3), each of the Company and Seller, severally and not jointly, hereby represents and warrants to Acquiror as follows:
3.1 Organization and Good Standing. The Company is a company duly organized and validly existing under the laws of the State of Israel. The Company has the corporate power and authority to own, operate, and lease its properties and to carry on the Company Business. The Company is duly qualified or licensed to do business, and is in good standing, in each jurisdiction where the character of the properties owned, leased or operated by it or the nature of its activities makes such qualification or licensing necessary, except where the failure to be so qualified and in good standing, individually or in the aggregate with any such other failures, would not reasonably be expected to be material to the Company; without limiting the foregoing, the Company is so qualified or licensed and in good standing in each jurisdiction listed on Schedule 3.1 of the Disclosure Letter. The Company has delivered to Acquiror true and complete copies of the Charter Documents, each as currently in effect, and is not in violation of its Charter Documents.
3.2 Subsidiaries. Except as set forth on Schedule 3.2 of the Company Disclosure Letter, the Company does not have, and since its inception has not had, any subsidiaries or any equity or ownership interest (or any interest convertible or exchangeable or exercisable for, any equity or ownership interest), whether direct or indirect, in, or any loans to, any Entity.
3.3 Power, Authorization and Validity.
(a) Power and Authority. The Company has all requisite corporate power and authority to enter into, execute, deliver and perform its obligations under this Agreement and the Company Ancillary Agreements and to consummate the Transactions. The execution and delivery of this Agreement and the consummation of the Transactions have been duly authorized by all necessary corporate action on the part of the Company. This Agreement has been duly executed and delivered by the Company and, assuming the due execution and delivery of this Agreement by the other parties hereto, constitutes the valid and binding obligation of the Company enforceable against the Company in accordance with its terms subject only to the effect, if any, of (i) applicable bankruptcy and other similar Applicable Law affecting the rights of creditors generally and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies. The holder of 100% of the Company Share Capital have executed this Agreement and no further vote of the Company shareholders is required, including under the Charter Documents and Israeli law, as in effect at the time of such approval, in connection with the execution, delivery or performance of this Agreement by the Company or the Seller or the consummation of the Share Purchase and the other Transactions.
-11-
(b) Board Approval. The Board, by resolutions duly adopted (and not thereafter modified or rescinded) by the unanimous vote of the Board, has approved this Agreement in accordance with the provisions of Israeli Law and the Charter Documents.
(c) No Consents. Except as set forth on Schedule 3.3(c) of the Company Disclosure Letter, no consent, approval, Order or authorization, release or waiver of, or registration, declaration or filing with, or notice to, any Governmental Authority or any other Person is necessary or is required to be made or obtained by or with respect to the Company to enable the Company to lawfully execute and deliver, enter into and perform its obligations under this Agreement and each of the Company Ancillary Agreements or to consummate the Share Purchase and the other Transactions (including the consent of any Person required to be obtained in order to keep the Contract between such Person and the Company in effect following the Share Purchase or to provide that the Company is not in breach or violation of any such Contract) (including, and in reliance on the assumption that Acquiror is not considered a monopoly for the purposes of Israeli Law, any filings and notifications as may be required to be made by the Company in connection with the Share Purchase under the Israeli Restrictive Trade Practices Law, 5748-1988, antitrust laws and other Applicable Law).
(d) Enforceability. This Agreement has been, and on the Closing Date the Company Ancillary Agreements will have been, duly executed and delivered by the Company. This Agreement and each of the Company Ancillary Agreements are, or when executed by the Company shall be, valid and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, assuming the due execution and delivery by the other parties thereto and subject to the effect of (i) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect relating to rights of creditors generally and (ii) rules of law and equity governing specific performance, injunctive relief and other equitable remedies.
(e) Seller. This Agreement has been, and on the Closing Date the Escrow Agreement and Supply Agreement will have been, duly executed and delivered by the Seller. This Agreement, the Escrow Agreement are, or when executed by the Seller shall be, valid and binding obligations of the Seller, enforceable against the Seller in accordance with their respective terms, assuming the due execution and delivery by the other parties thereto and subject to the effect of (i) applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect relating to rights of creditors generally and (ii) rules of law and equity governing specific performance, injunctive relief and other equitable remedies.
-12-
3.4 Capitalization of the Company.
(a) The authorized share capital of the Company, as of immediately prior to the Closing, consists solely of 10,000,000 Company Ordinary Shares, of which 1,671,280 Company Ordinary Shares, are issued and outstanding as of the Agreement Date. The Company holds no treasury shares. As of the Agreement Date, there are no other issued and outstanding shares of Company Share Capital and no outstanding commitments or Contracts to issue any shares of Company Share Capital including not under any outstanding Company options except as set forth in Schedule 3.4(a) of the Company Disclosure Letter. As of immediately prior to the Closing, the Seller is the only owner and registered owner of 1,671,280 Company Ordinary Shares which constitute as of the Agreement Date and shall constitute as of the Closing Date 100% of the issued and outstanding Fully-Diluted Company Shares. The number of such shares owned by Seller constitutes the entire interest of Seller in the issued and outstanding Company Share Capital or voting securities of the Company and no such shares shall be issued or outstanding as of the Closing Date that are not set forth above. All issued and outstanding shares of Company Share Capital have been duly authorized, validly issued, fully paid and non-assessable and are free of any Encumbrances, outstanding subscriptions, preemptive rights, rights of first refusal or “put” or “call” rights created by statute, the Charter Documents or any Contract to which the Company is a party or by which the Company or any of its assets is bound. The Company has never declared or paid any dividends on any shares of Company Share Capital. There is no Liability for dividends accrued and unpaid by the Company. The Company is not under any obligation to register under the Securities Act, applicable Israeli securities law or the rules and regulations promulgated thereunder, any other Applicable Law or “blue sky” laws, any shares of Company Share Capital, any equity interests or any other securities of the Company, whether currently outstanding or that may subsequently be issued. All issued and outstanding shares of Company Share Capital were issued in compliance with all Applicable Law and all requirements set forth in the Charter Documents and any applicable Contracts to which the Company is a party or by which the Company or any of its assets is bound.
(b) Except as set forth in Schedule 3.4(b) of the Company Disclosure Letter, as of the Agreement Date, the Company has not reserved any Company Ordinary Shares for issuance to employees, non-employee directors and contractors whether pursuant to the Company option plan, or otherwise.
(c) No Other Rights. Except as set forth in Schedule 3.4(c) of the Company Disclosure Letter, there are no stock appreciation rights, options, warrants, calls, rights, commitments, conversion privileges or preemptive or other rights or Contracts outstanding to purchase or otherwise acquire any shares of Company Share Capital or any securities or debt convertible into or exchangeable for Company Share Capital or obligating the Company to grant, extend or enter into any such option, warrant, call, right, commitment, conversion privilege or preemptive or other right or Contract. The Charter Documents do not provide, and the Company is not a party to or otherwise bound by any Contract providing, registration rights, rights of first refusal, preemptive rights, co-sale rights or other similar rights or other restrictions applicable to any outstanding securities of the Company. The Company is not a party to any Contract regarding the voting of any outstanding securities of the Company.
-13-
3.5 No Conflict. Neither the execution and delivery of this Agreement or any of the Company Ancillary Agreements by the Company, nor the consummation of the Share Purchase or any other transaction contemplated hereby or thereby, conflicts with, or (with or without notice or lapse of time, or both) results in a termination, acceleration, cancellation, breach, impairment or violation of, constitutes a default under, or results in the creation of any Encumbrance on any of the assets properties or rights of the Company pursuant to: (a) any provision of the Charter Documents or any resolution adopted by the Company Shareholders or the Board, each as currently in effect, (b) any Applicable Law, or (c) any Contract to which the Company is a party or by which the Company or any of its assets or properties are bound. Neither the execution and delivery by the Company of this Agreement nor the consummation of the Share Purchase or the other Transactions shall give rise to, or trigger the application of, any rights of any third party or any obligations of the Company that would come into effect upon the completion of the Share Purchase and the other Transactions.
3.6 Taxes.
(a) Except as set forth in Schedule 3.6(a) of the Company Disclosure Letter, the Company has duly filed with the appropriate Tax Authorities all Tax Returns required to be filed by it prior to the Closing Date, has duly paid all Taxes required to be paid by it (whether or not shown on any Tax Return), and has no Liability for Taxes in excess of the amounts so paid. All such Tax Returns were complete and accurate and have been prepared in compliance with Applicable Law. There is no claim for Taxes that has resulted in an Encumbrance against any of the assets of the Company.
(b) The Company has delivered to Acquiror true, correct and complete copies, in all material respects, of all Tax Returns, examination reports and statements of deficiencies, adjustments and proposed deficiencies and adjustments in respect of the Company, in each case, since fiscal year 2019.
(c) The Company Balance Sheet reflects all Liabilities for unpaid Taxes of the Company for periods (or portions of periods) through the Company Balance Sheet Date. The Company does not have any Liability for unpaid Taxes accruing after the Company Balance Sheet Date except for Taxes arising in the ordinary course of business consistent with past practice following the Company Balance Sheet Date. The Company does not have any Liability for Taxes (whether outstanding, accrued for, contingent or otherwise) that are not included in the calculation of Company Net Working Capital.
(d) There is (i) no past or pending audit of, or Tax controversy associated with, any Tax Return of the Company that, to the knowledge of the Seller and Company, has been or is being conducted by a Tax Authority, and, to the knowledge of the Seller and the Company, there is no ground for any Tax controversy, (ii) no other procedure, proceeding or contest of any refund or deficiency in respect of Taxes pending or on appeal with any Governmental Authority, (iii) no extension of any statute of limitations on the assessment of any Taxes granted by the Company currently in effect and (iv) no agreement to any extension of time for filing any Tax Return that has not been filed. No claim has ever been made by any Governmental Authority in a jurisdiction where the Company does not file Tax Returns that the Company is or may be subject to taxation by that jurisdiction.
-14-
(e) The Company will not be required to include any item of income in, or exclude any item of deduction from, Taxable income for any Taxable period (or portion thereof) ending after the Closing Date as a result of any (i) change in method of accounting for a Taxable period ending on or prior to the Closing Date, (ii) installment sale or open transaction disposition made on or prior to the Closing Date, or (iii) prepaid amount received on or prior to the Closing Date.
(f) The Company has complied in all material respects with all applicable Laws relating to the payment reporting and withholding of Taxes from payments made or deemed made to any Person and have duly withheld and paid over to the appropriate Taxing Authority all amounts required to be so withheld and paid under all Applicable Laws. The Company duly filed all withholding Tax Returns, for all Tax periods through and including the Closing Date. The Company is in material compliance with, and its records contain all applicable information and documents necessary to comply with, all applicable information reporting and withholding requirements under all applicable Tax Laws.
(g) The Company is duly registered for the purposes of Israeli value added tax and has complied in all material respects with all requirements concerning value added Taxes (“VAT”). The Company has complied, in all material respects, with all Applicable Laws concerning VAT, including with respect to the making on time of accurate returns and payments and the maintenance of records. The Company (i) has not made any exempt transactions (as defined in the Israel Value Added Tax Law of 1975) and to the Company’s knowledge, there are no circumstances by reason of which there might not be an entitlement to full credit of all VAT chargeable or paid on inputs, supplies, and other transactions and imports made by it, (ii) has collected and duly remitted to the relevant Taxing Authority all output VAT which it is required to collect and remit under any Applicable Law, and (iii) has not received a refund for input VAT for which it is not entitled under any Applicable Law.
(h) Neither the Company nor Seller is subject to any restrictions or limitations pursuant to Part E2 of the Israeli Income Tax Ordinance or pursuant to any Tax ruling made with reference to the provisions of Part E2.
(i) The Company does not and has never participated or engaged in any transaction listed in Section 131(g) of the Israeli Income Tax Ordinance and the Israeli Income Tax Regulations (Reportable Tax Planning), 5767-2006 promulgated thereunder. The Company does not and has never taken a tax position that is subject to reporting under Section 131E of the Israeli Income Tax Ordinance. The Company has never obtained a legal or tax opinion that is subject to reporting under Section 131D of the Israeli Income Tax Ordinance.
(j) The Company is not and has never been a real property corporation (Igud Mekarke’in) within the meaning of this term under Section 1 of the Israeli Land Taxation Law (Appreciation and Acquisition), 5723-1963.
(k) The Company is a resident for Tax purposes of its country of incorporation, organization or formation, and, the Company is not nor has it ever been subject to Tax in any country other than its country of incorporation by virtue of having employees, a permanent establishment or any other place of business in that country or by virtue of exercising management and control in such country.
-15-
(l) The Company has provided to Acquiror all material documentation relating to any Tax holidays or incentives applicable to the Company, including pursuant to applications made by the Company under the laws of the State of Israel, the period for which such Tax incentive applies, and the nature of such Tax incentive. The Company is in material compliance with all requirements for any applicable Tax holidays or incentives. The Company states that: (a) no claim or challenge has been made by any Tax authority with respect to the Company’s entitlement to such incentives; and (b) subject to receipt of the approvals required herein, consummation of the Transaction will not adversely affect the continued qualification for the incentives or the terms or duration thereof or require any recapture of any previously claimed incentive.
(m) The Company is not a party to or bound by any Tax sharing, Tax indemnity, or Tax allocation agreement, and the Company does not have any Liability or potential Liability to another party under any such agreement.
(n) No closing agreements, private letter rulings, technical advice memoranda or similar agreements or rulings relating to Taxes have been entered into or issued by any Governmental Entity with or in respect of the Company. The Company has not requested or received any “taxation decision” (hachlatat misui) from the ITA.
(o) The Company does not own any interest in any controlled foreign corporation pursuant to Section 75B of the Israeli Income Tax Ordinance, or other entity the income of which is required to be included in the income of the Company for Israeli Tax purposes.
(p) No independent contractor was considered as an employee of the Company by an applicable Tax Authority.
(q) There is no limitation on the utilization of any Tax attributes, Tax credits or similar items of the Company under any provision of Applicable Law, other than any such limitations resulting from the transactions contemplated by this Agreement.
(r) The Company did not receive final assessments of its Tax returns (“shumot sofiot”) since its incorporation.
3.7 Company Financial Statements.
(a) The Company has delivered to Acquiror its audited financial statements for the 12- month period ended December 31, 2020 and its unaudited, consolidated financial statements for the period ended November 30, 2021 (including, in each case, balance sheets, statements of operations and statements of cash flows) (collectively, the “Financial Statements”), which are included as Schedule 3.7(a) of the Company Disclosure Letter. The Financial Statements (i) are derived from and in accordance with the books and records of the Company, (ii) complied as to form with applicable accounting requirements with respect thereto as of their respective dates, (iii) fairly and accurately present, in all material respects, the financial condition of the Company at the dates therein indicated and the consolidated results of operations and cash flows of the Company for the periods therein specified (subject, in the case of unaudited interim period financial statements, to normal recurring year-end audit adjustments, none of which individually or in the aggregate are or will be material in amount), (iv) are true, correct and complete in all material respects, (v) were prepared in accordance with IFRS, except for the absence of footnotes in the unaudited Financial Statements, applied on a consistent basis throughout the periods involved and (vi) have been kept accurately in the ordinary course of business consistent in all material respects with Israeli Law. The transactions entered in the Financial Statements represent bona fide transactions, and the revenues, expenses, assets and liabilities of the Company have been properly recorded therein in all material respects.
-16-
(b) Except as set forth in Schedule 3.7(b) of the Company Disclosure Letter, the Company has no Liabilities of any nature other than (i) those set forth or adequately provided for in the balance sheet included in the Financial Statements as of December 31, 2020 and November 30, 2021 (such date, the “Company Balance Sheet Date” and such balance sheet, the “Company Balance Sheet”), (ii) those incurred in the conduct of the Company’s business since the Company Balance Sheet Date in the ordinary course of business that are of the type that ordinarily recur and, individually or in the aggregate, are not material in nature or amount and do not result from any breach of Contract, warranty, infringement, tort or violation of Applicable Law and (iii) those incurred by the Company in connection with the execution of this Agreement. Except for Liabilities reflected in the Financial Statements, and other than as set forth in Schedule 3.7(b) of the Company Disclosure Letter, the Company has no off-balance sheet Liability of any nature to, or any financial interest in, any third parties or entities, the purpose or effect of which is to defer, postpone, reduce or otherwise avoid or adjust the recording of expenses incurred by the Company. All reserves that are set forth in or reflected in the Company Balance Sheet have been established in accordance with IFRS consistently applied and are adequate. Without limiting the generality of the foregoing, the Company has never guaranteed any debt or other obligation of any other Person.
(c) Schedule 3.7(c) of the Company Disclosure Letter sets forth a true, correct and complete list of all Company Debt including, for each item of Company Debt, the agreement governing the Company Debt and the interest rate, maturity date, any assets securing such Company Debt and any prepayment or other penalties payable in connection with the repayment of such Company Debt at the Closing. All Company Debt may be prepaid at the Closing without penalty under the terms of the Contracts governing such Company Debt.
(d) Schedule 3.7(d) of the Company Disclosure Letter sets forth the names and locations of all banks and other financial institutions at which the Company maintains accounts and the names of all Persons authorized to make withdrawals therefrom.
(e) The accounts receivable of the Company (the “Accounts Receivable”) as reflected on Schedule 3.7(e) of the Company Disclosure Letter arose in the ordinary course of business and represent bona fide claims against debtors for sales and other charges, and to the knowledge of the Company the Accounts Receivable are collectible in the book amounts thereof within 90 days following the Agreement Date, less an amount not in excess of the allowance for doubtful accounts provided for in the Company Balance Sheet or in the Company Closing Financial Certificate, as the case may be. Allowances for doubtful accounts and warranty returns have been prepared in accordance with IFRS consistently applied and in accordance with the Company’s past practice and are sufficient to provide for any losses that may be sustained on realization of the applicable Accounts Receivable. The Accounts Receivable arising after the date hereof and before the Closing Date, (i) arose or shall arise in the ordinary course of business, (ii) represented or shall represent bona fide claims against debtors for sales and other charges and (iii) have been collected or are collectible in the book amounts thereof within 60 days following the Agreement Date, less allowances for doubtful accounts and warranty returns determined in accordance with IFRS consistently applied and the Company’s past practice that are or shall be sufficient to provide for any losses that may be sustained on realization of the applicable Accounts Receivable. None of the Accounts Receivable is subject to any claim of offset, recoupment, set-off or counter-claim and, to the knowledge of the Seller and the Company, there are no facts or circumstances (whether asserted or unasserted) that could give rise to any such claim. No material amount of Accounts Receivable is contingent upon the performance by the Company of any obligation or Contract other than normal warranty repair and replacement. No Person has any Encumbrance on any Accounts Receivable, and no agreement for deduction or discount has been made with respect to any such Accounts Receivable. Schedule 3.7(e) of the Company Disclosure Letter sets forth, as of the Agreement Date, an aging of the Accounts Receivable in the aggregate and by customer, and indicates the amounts of allowances for doubtful accounts and warranty returns. Schedule 3.7(e) of the Company Disclosure Letter sets forth, as of the Agreement Date, such amounts of Accounts Receivable that are subject to asserted warranty claims by customers and reasonably detailed information regarding asserted warranty claims made within the last year, including the type and amounts of such claims.
(f) The Company has established and maintains a system of internal accounting controls sufficient to provide reasonable assurances (i) that transactions, receipts and expenditures of the Company are being executed and made only in accordance with appropriate authorizations of management and the Board, (ii) that transactions are recorded as necessary (A) to permit preparation of financial statements in conformity with IFRS and (B) to maintain accountability for assets, (iii) regarding prevention or timely detection of unauthorized acquisition, use or disposition of the assets of Company and (iv) that the amount recorded for assets on the books and records of the Company is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. None of the Company, the Company’s independent auditors and, to the knowledge of the Seller and the Company, any current or former employee, consultant or director of the Company, has identified or been made aware of any fraud, whether or not material, that involves Company’s management or other current or former employees, consultants directors of Company who have a role in the preparation of financial statements or the internal accounting controls utilized by the Company, or any claim or allegation regarding any of the foregoing. None of the Company, and, to the knowledge of the Seller and the Company, any Company Representative has received or otherwise had or obtained knowledge of any material complaint, allegation, assertion or claim, whether written or oral, in each case, regarding deficient accounting or auditing practices, procedures, methodologies or methods of the Company or its or their internal accounting controls or any material inaccuracy in the financial statements of the Company. No attorney representing the Company, whether or not employed by the Company, has reported to the Board or any committee thereof or to any director or officer of the Company evidence of a material violation of securities laws, breach of fiduciary duty or similar violation by the Company or the Company Representatives or any of its officers, directors, employees or agents. There are no significant deficiencies or material weaknesses in the design or operation of the Company’s internal controls that could adversely affect the Company’s ability to record, process, summarize and report financial data. There has been no change in the accounting policies of the Company since the Company’s inception, except as described in the Financial Statements.
-17-
3.8 Intellectual Property.
(a) The Company (i) owns or (ii) has the valid right or license to use, and, to the extent that it does any of the following, to develop, make, have made, offer for sale, sell, import, copy, modify, create derivative works of, distribute, license, and dispose of all Company IP. “Company IP” means all Company-Owned IP and all other Intellectual Property used in the conduct of the Company Business. The Company IP is sufficient for the conduct of the Company Business. As used in this Agreement, “Company- Owned IP” means Intellectual Property that the Company owns or purports to own, or is licensed to the Company.
(b) Neither the execution, delivery and performance of this Agreement or the Company Ancillary Agreements nor the consummation of the Share Purchase and the other Transactions will: (i) constitute a material breach of or default under any instrument, license or other Contract pursuant to which the Company grants to any third party any rights in, to, or under any Company IP (the “Outbound Company IP Agreements”) or pursuant to which the Company receives licenses in, to, or under any third- party Intellectual Property Rights or to use any third-party Technology (the “Inbound Company IP Agreements”), (ii) cause the forfeiture or termination of, or give rise to a right of forfeiture or termination of, any Company IP, or (iii) materially impair the right of the Company to use, develop, make, have made, offer for sale, sell, import, copy, modify, create derivative works of, distribute, license, or dispose of any Company IP or portion thereof. Except as set forth on Schedule 3.8(b)(i) of the Company’s Disclosure Letter, there are no royalties, fees or other payments payable by the Company to any third Person (other than salaries payable to employees and independent contractors not contingent on or related to use of their work product) as a result of the use, license-in, manufacture, sale, offering for sale, copying, distribution, or disposition of any Company IP by the Company and none shall become payable as a result of the consummation of the Transactions. After the Closing, all Company-Owned IP will be fully transferable, alienable or licensable by the Company and Acquiror without restriction and without payment of any kind to any third party (except (i) to the extent relating to restrictions which the Acquiror is independently subject to, or resulting specifically from the identity of the Acquirer, and (ii) any fees and/or approvals in connection to the Israel Innovation Authority (“IIA”) or the ITA). Other than pursuant to Outbound Company IP Agreements identified in Schedule 3.8(b)(ii) of the Company Disclosure Letter, the Company has not authorized or granted to any third party any rights to use or otherwise exploit any of the Company- Owned IP.
(c) Schedule 3.8(c) of the Company Disclosure Letter sets forth a list of each of the products and services currently produced, manufactured, marketed, licensed, sold, or distributed by the Company and each product and service currently under development by the Company (each, a “Company Product or Service”). Neither the operation of the Company Business nor the use, development, manufacture, marketing, licensing, sale, offering for sale, distribution, or intended use of any Company Product or Service (i) has violated or violates any Inbound Company IP Agreements, or (ii) directly or indirectly (including via contribution or inducement) has, to the Company’s knowledge, infringed or misappropriated, infringes or misappropriates or any Intellectual Property of any other party. There is no pending, or to the knowledge of the Company, threatened, claim or litigation contesting the validity, ownership or right of the Company to exercise any Company IP, nor to the knowledge of the Company, is there any legitimate basis for any such claim, nor has the Company received any notice asserting that any Company IP or the proposed use, development, manufacture, sale, offering for sale, licensing, or distribution thereof directly or indirectly (including via contribution or inducement) conflicts with or infringes or shall conflict with or infringe the rights of any other party, nor to the knowledge of the Company, is there any legitimate basis for any such assertion and the has not received any written notice or offer from any third party offering a license under any patents.
-18-
(d) Other than as set forth in Schedule 3.8(d) of the Company Disclosure Letter, none of the Company IP, the Company Products or Services, nor the Company is subject to any Action, Order, Contract or stipulation (i) restricting in any manner the use, distribution, transfer, or licensing by the Company of any Company IP or any Company Product or Service, or which may affect the validity, use or enforceability of any Company-Owned IP or (ii) restricting the conduct of the Company Business in order to accommodate Intellectual Property rights of a third party.
(e) No current or former employee, consultant or independent contractor of the Company, to the Company’s knowledge: (i) has been or is in material violation of any term or covenant of any employment contract, patent disclosure agreement, invention assignment agreement, nondisclosure agreement, noncompetition agreement or any other Contract with any other party by virtue of such employee’s, consultant’s or independent contractor’s being employed by, or performing services for, the Company or using trade secrets or proprietary information of others without permission, or (ii) has developed any Intellectual Property for the Company or during a period of time during which they were working for the Company that is subject to any Contract under which such employee, consultant or independent contractor has assigned or otherwise granted to any third party any rights (including Intellectual Property Rights) in or to such Intellectual Property. Neither the employment of any employee of the Company, nor the use by the Company of the services of any consultant or independent contractor subjects the Company to any Liability to any third party for improperly soliciting such employee, consultant or independent contractor to work for the Company, whether such Liability is based on contractual or other legal obligations of the Company to such third party.
(f) Other than as set forth in Schedule 3.8(f) of the Company Disclosure Letter, the Company has taken all commercially reasonable steps to protect, preserve and maintain the secrecy and confidentiality of the Company IP and to preserve and maintain all the Company’s interests, proprietary rights and trade secrets in the Company IP. All current and former officers, employees, consultants and independent contractors of the Company having access to proprietary information of the Company, its customers or business partners and inventions owned by the Company have executed and delivered to the Company an agreement regarding the protection of such proprietary information (in the case of proprietary information of the Company’s customers and business partners, to the extent required by such customers and business partners). The Company has secured valid written assignments from all of the Company’s current and former consultants, independent contractors, founders and employees who were involved in, or who contributed to, the creation or development of any Company-Owned IP, pursuant to which: (i) the Company has obtained unencumbered, unrestricted and exclusive ownership of all Intellectual Property Rights therein; and (ii) the assignor waived all right, title and interest in and to all Intellectual Property Rights therein, including the right to receive royalties or other consideration. No current or former employee, officer, director, consultant or independent contractor of the Company has any right, license, claim or interest whatsoever in or with respect to any Company-Owned IP.
-19-
(g) Schedule 3.8(g) of the Company Disclosure Letter sets forth a list and description of all Technology developed or otherwise owned by a third party that is incorporated into, integrated or bundled with, or used by the Company in the development, manufacture or compilation of any of the Company Products or Services and the applicable Contract therefor.
(h) Schedule 3.8(h) of the Company Disclosure Letter contains a true and complete list of all United States, international and foreign (i) patents and patent applications (including provisional applications), (ii) registered trademarks, applications to register trademarks, intent-to-use applications, or other registrations or applications related to trademarks, (iii) registered Internet domain names, registered copyrights and applications for copyright registration, and (v) any other Intellectual Property that is, including in each case of (i) through (iv), the subject of an application, certificate, filing, registration or other document issued, filed, or recorded by or with any Governmental Authority or quasi-governmental authority anywhere in the world, including Internet domain name registries, which are owned by, registered or filed in the name of, the Company, and where applicable the jurisdiction in which each of the items of the Company IP has been applied for, filed, issued or registered (collectively, the “Company Registered IP”). All Company Registered IP are subsisting and, to the knowledge of the Company, valid and enforceable, and the Company is the record owner thereof. Schedule 3.8(h) of the Company Disclosure Letter sets forth a list of (A) all actions that are required to be taken by the Company within 120 days of the Agreement Date with respect to any of the Company Registered IP in order to avoid prejudice to, impairment or abandonment of such Company Registered IP and (B) all inter parties proceedings or actions before any court or tribunal (including the United States Patent and Trademark Office) or equivalent authority anywhere else in the world) related to any of the Company IP. The Company is the exclusive owner of all trademarks and trade names used in connection with the operation or conduct of the Company Business, including the sale, licensing, distribution or provision of any Company Products or Services by the Company as listed in Schedule 3.8(h). The Company owns exclusively, and has good title to, all copyrighted works that are included or incorporated into Company Products or Services.
(i) The Company owns all right, title and interest in and to all Company-Owned IP free and clear of all Encumbrances and licenses (other than licenses and rights listed in Schedule 3.8(i) of the Company Disclosure Letter).
(j) The Company has not (i) granted any third party exclusive rights to or under any Company-Owned IP (ii) transferred ownership of any Intellectual Property that is or was owned by the Company to any third party, or (iii) knowingly permitted the Company’s rights in any Company-Owned IP to lapse or enter the public domain (other than through the expiration of registered Intellectual Property Rights at the end of its statutory term).
(k) None of the Company and any other party acting on their respective behalf has disclosed or delivered to any party, or permitted the disclosure or delivery to any escrow agent or other party of, any Company Source Code. No event has occurred, and no circumstance or condition exists, that (with or without notice or lapse of time, or both) shall, or could reasonably be expected to, result in the disclosure or delivery by the Company or any other party acting on their respective behalf to any party of any Company Source Code. Schedule 3.8(k) of the Company Disclosure Letter identifies each Contract pursuant to which the Company has deposited, or is or may be required to deposit, with an escrow agent or other party, any Company Source Code and further describes whether the execution of this Agreement or the consummation of the Share Purchase or any of the other Transactions, in and of itself, could reasonably be expected to result in the release from escrow of any Company Source Code. As used in this Section 3.8(k), “Company Source Code” means, collectively, any human readable software source code, or any material portion or aspect of the software source code, or any material proprietary information or algorithm contained in or relating to any software source code, that constitutes Company-Owned IP or any other Company Product or Service marketed by the Company.
-20-
(l) To the knowledge of the Seller and the Company, there is no unauthorized use, disclosure, infringement or misappropriation of any Company IP by any third party, including any employee or former employee of the Company.
(m) The Company has not agreed to indemnify any Person for any infringement of any Intellectual Property of any third party by any Company Product or Service that has been sold, licensed to third parties, leased to third parties, supplied, marketed, distributed or provided by the Company, except pursuant to standard customer agreements in effect as at the Agreement Date.
(n) All Company Products or Services provided by or through the Company to customers on or prior to the Closing Date conform in all material respects to applicable contractual commitments, express and implied warranties, product specifications and product documentation and to any representations provided to customers. The Company has made available to Acquiror all documentation and notes relating to the testing of the Company Products or Services and plans and specifications for Company Products or Services currently under development by the Company. The Company has a policy and procedure for tracking material bugs, errors and defects of which it becomes aware in any Company Products or Services, and maintains a database covering the foregoing. For all software used by the Company in providing Company Products or Services, or in developing or making available any of the Company Products or Services, to the Company’s knowledge, the Company has implemented any and all security patches or upgrades that are generally available for that software.
(o) Except as set forth in Schedule 3.8(o) of the Company Disclosure Letter, no government funding or other incentives, facilities or resources of a university, college, other educational institution or research center, or funding from third parties (other than funds received in consideration for Company Share Capital) was used in or received for the development of the Company Products or Services or any Company-Owned IP and the Company did not request to receive any such funding or incentives. To the Company’s knowledge, no current or former employee, consultant or independent contractor of the Company who was involved in, or who contributed to, the creation or development of any Company-Owned IP has performed services for the government, for a university, college or other educational institution or for a research center during a period of time during which such employee, consultant or independent contractor was also performing services for the Company. Without derogating from the generality of the foregoing, no Governmental Authority has any rights in any Company IP.
(p) Schedule 3.8(p) of the Company Disclosure Letter lists all Open Source Materials that have been incorporated into, combined with or distributed with any Company Products or Services. As used in this Section 3.8(p), “Open Source Materials” (i) means any software that (A) contains, or is derived in any manner (in whole or in part) from, any software that is distributed as free software, open source software (including Linux) or (B) requires as a condition of its use, modification or distribution that it, or other software incorporated, distributed with, or derived from it, be disclosed or distributed in source code form or made available at no charge and (ii) includes software licensed under the GNU’s General Public License (GPL) or Lesser/Library GPL, the Mozilla Public License, the Netscape Public License, the Sun Community Source License, the Sun Industry Standards License, the BSD License, a Microsoft Shared Source License, the Common Public License, the Apache License, and any license listed at www.opensource.org.
-21-
(q) Except as set forth in Schedule 3.8(q) of the Company Disclosure Letter, the Company has not (i) incorporated Open Source Materials into, or combined Open Source Materials with, Company-Owned IP or Company Products or Services, (ii) distributed Open Source Materials in conjunction with any Company IP or Company Products or Services, or (iii) otherwise used Open Source Materials; in each case, in such a way that creates, or purports to create obligations for the Company with respect to any Company-Owned IP or grants, or purport to grant, to any third party, any rights or immunities under any Company-Owned IP (including by using any Open Source Materials that require, as a condition of use, modification or distribution of such Open Source Materials that any Company-Owned IP incorporated into, derived from, or distributed or combined with such Open Source Materials be (A) disclosed or distributed in source code form, (B) be licensed for the purpose of making derivative works, or (C) be redistributable at no charge). The Company is in compliance with the terms and conditions of all licenses for Open Source Materials and has not received any written notice or other communication regarding any actual or possible violation or breach of or default under, or intention to cancel or modify, any licenses for Open Source Materials.
(r) Except as set forth in Schedule 3.8(r) of the Company Disclosure Letter, the Company is not nor has it ever been a member or promoter of, or a contributor to, any industry standards body or any similar organization that could reasonably be expected to require or obligate the Company to grant or offer to any other Person any license or right to any Company-Owned IP.
(s) None of the Company Products or Services contain any “back door”, “drop dead device”, “time bomb”, “Trojan horse”, “virus” or “worm” (as such terms are commonly understood in the software industry) or any other code designed or intended to have, or capable of performing or without user intent will cause, any of the following functions: (i) disrupting, disabling, harming or otherwise impeding in any manner the operation of, or providing unauthorized access to, a computer system or network or other device on which such code is stored or installed, (ii) damaging or destroying any data or file without the user’s consent, or (iii) sending information to the Company, or any third party.
(t) The Company has not experienced, and, to the Company’s knowledge, no circumstances exist that are likely or expected to give rise to, any disruption in or to the operation of the Company Business as a result of: (i) any substandard performance or defect in any part of the information and communications Technology infrastructure and systems (including software, hardware, firmware, networks and the Company’s websites) that is or has been used in the Company Business, whether caused by any viruses, bugs, worms, software bombs or otherwise, lack of capacity or otherwise or (ii) a breach of security in relation to any part of such infrastructure.
(u) None of the Company Products or Services (i) constitutes or is considered “spyware” or “trackware” as such term is commonly understood in the software industry, (ii) is installed on a user’s computer without their knowledge, (iii) records a user’s actions without their knowledge, (iv) employs a user’s Internet connection without their knowledge to gather or transmit information on the user or their behavior, or (v) will load whenever a browser starts or share the browser’s memory context. For the purposes of this paragraph, “without a user’s knowledge” includes but is not limited to (A) without explicitly informing the user and (B) without being expected by a reasonable such user even if the text of a license agreement, help file, or other user information file does explicitly inform such user.
(v) The Company does not, directly or indirectly sell, license, or provide any Company Products or Services to any governmental agencies or other government entities or under government Contracts.
(w) Except as set forth in Schedule 3.8(w), in connection with any collection, storage, transfer (including, without limitation, any transfer across national borders) (if occurs and applicable to the Company) and/or use of any personally identifiable information from any individuals, including, without limitation, any customers, prospective customers, employees and/or other third parties (if occurs and applicable to the Company) (collectively “Personal Information”), the Company is and has been in all material respects in compliance with all Applicable Laws in all relevant jurisdictions. The Company is and has been in compliance in all material respects with all Applicable Laws relating to data loss, theft and breach of security notification obligations. The Company’s privacy policies conform, and at all times have conformed, to all of the Company’s contractual commitments to their customers. The Company has been and is in material compliance with all Contracts pursuant to which the Company processes or has processed personally identifiable information and other information relating to the end users of the Company Products or Services (the “Company Privacy Commitments”). In addition, the Company has at all times provided adequate notice and obtained any necessary consents from data subjects required for the processing of personally identifiable information as conducted by or for the Company. Neither the execution, delivery and performance of this Agreement nor the taking over by Acquiror of all of the personally identifiable information and other information relating to the end users of the Company Products or Services will cause, constitute, or result in a breach or violation of any Applicable Laws or Company Privacy Commitments, or standard terms of service entered into by users of the Company Products or Services. No claims have been asserted or, to the knowledge of the Seller and the Company, are threatened against the Company by any Person or Entity alleging a violation of such Person’s or Entity’s privacy, personal or confidentiality rights under the privacy policies of the Company. With respect to all personal and user information described in this Section 3.8(w), the Company has at all times taken all steps reasonably necessary (including implementing and monitoring compliance with adequate measures with respect to technical and physical security) to ensure that the information is protected against loss and against unauthorized access, use, modification, disclosure or other misuse. To the knowledge of the Seller and the Company, there has been no unauthorized access to or other misuse of that information.
-22-
(x) Where the Company has provided services (including software development services) to any third party on a “work for hire basis” where title to the Company work product produced by or on behalf of the Company for such third party has been transferred to such third party, (i) such work product does not form part of any Company Product or Service marketed by the Company and (ii) the Company has not used such work product for other purposes, including for other customers.
3.9 Employees
(a) Schedule 3.9(a) of the Company Disclosure Letter lists, with respect to the Company, each employment, consulting, contracting, severance or other similar Contract, and any other benefit arrangement, each loan to an employee and each written plan, program, policy, Contract or other arrangement providing for insurance coverage, workers’ benefits, vacation benefits, pension arrangement and any other provident fund, termination pay, severance benefits, retention, disability benefits, sickness benefits, relocation benefits, deferred compensation, profit-sharing, bonuses, stock options, stock purchase, phantom stock, stock appreciation or other forms of incentive compensation or post-retirement insurance, compensation or benefits for employees, consultants or directors that is currently in effect, maintained or contributed to by the Company and which covers any current employee, consultant of the Company or to which the Company has or may have an obligation to contribute. Such Contracts, plans, programs, policies, practices and arrangements as are described in this Schedule 3.9(a) are hereinafter collectively referred to as “Company Benefit Arrangements.”
(b) Except as set forth in Schedule 3.9(b)(1), the Company has complied and is in compliance in all material respects with Applicable Law, Contracts, and Orders, relating to labor, employment and fair employment practices (including termination of employment), including all Applicable Laws, Contracts and Orders relating to, hiring, discharge and/or terms and conditions of employment, discrimination in employment, privacy, harassment, retaliation, terms and conditions of employment, compensation matters, use of agency workers, worker classification (including employee- independent contractor classification and the proper classification of employees as exempt employees and nonexempt employees under the Working Hours and Rest Law, 5711-1951, and similar Applicable Laws), engagement with service providers (including in the field of cleaning, catering, security and protection) wages and hours, overtime, day of rest, sick leave, annual leave, prior notice, severance payment, notice to employees, disability rights or benefits, pension arrangements, equal opportunity, plant closures and layoffs, workers’ compensation employee leave issues, labor relations, unemployment insurance, occupational safety and health and employment practices, engagement of youth or foreign employees, work visas and/or employment authorization, and is not engaged in any unfair labor practice. The Company has duly withheld all amounts required by Applicable Law or by Contract to be withheld from the wages, salaries, and other payments to employees or consultants and the Company has duly transferred all amounts required by Applicable Law or by Contract to transfer to any Company Benefit Arrangement; and is not liable for any arrears of wages, compensation, Taxes, penalties or other sums for failure to comply with any of the foregoing. Except as set forth in Schedule 3.9(b)(2) and to the Company’s knowledge, the Company has paid in full to all employees, independent contractors and consultants all wages, salaries, commissions, bonuses, benefits and other compensation due to or on behalf of such employees, independent contractors and consultants. The Company is not liable for any material payment to any trust or other fund or to any Governmental Authority, with respect to unemployment compensation benefits, social security or other benefits or obligations for employees (other than routine payments to be made in the normal course of business and consistently with past practice). There are no pending claims against the Company under any Company Benefit Arrangements, workers compensation plan or policy or for long term disability. There are no controversies pending or, to the knowledge of the Company, threatened, between the Company and any of its employees, which controversies have or could reasonably be expected to result in an Action.
-23-
(c) A complete list of all employees, officers and consultants of the Company and their current status (e.g., employee or consultant and employee’s classification as either exempt or non-exempt from the overtime requirements under any Applicable Law), title and/or job description, work location, start date, compensation, base compensation (monthly base salary or hourly wage rate, and overtime consideration as applicable), commission/bonuses and all fringe benefits, including, vacation entitlement and accrued vacation or paid time-off balance, travel pay or car maintenance or car entitlement, sick leave entitlement and accrual, recuperation pay entitlement and accrual, entitlement to pension arrangement and/or any other provident fund (including manager’s insurance and education fund), their respective contribution rates and the base salary for such contributions, whether such employee is subject to the Section 14 Arrangement under the Israeli Severance Pay Law, 5723-1963 (the “Section 14 Arrangement”) (and, to the extent such employee is subject to the Section 14 Arrangement, an indication of whether such arrangement has been applied to such person from the commencement date of their employment and on the basis of their entire salary), notice period entitlement and legal status for purposes of eligibility to work in the jurisdiction in which they perform their services is set forth on Schedule 3.9(b) of the Company Disclosure Letter.
(d) All employees of the Company are legally permitted to be employed by the Company in Israel in their current job capacities for the maximum period allowed under Applicable Law. As of the date hereof, the Company does not have, and to the knowledge of Seller and the Company, no other Person has, (i) entered into any Contract that obligates or purports to obligate the Company, or Acquiror to make an offer of employment to any present or former employee or consultant of the Company and/or (ii) promised or otherwise provided any assurances (contingent or otherwise) to any present or former employee or consultant of the Company of any terms or conditions of employment with Acquiror following the Closing.
(e) The Company is not a party to or bound by any labor agreement or collective bargaining agreement, work rules or practices, or any other labor-related agreement or arrangement with any labor union, labor organization, employee representation group or works council, and no employees, consultants or contractors are represented by a labor union, labor organization, employee representation group or works council with respect to their employment or provision of services to the Company. No labor union, labor organization, works council or other collective group of employees, consultants or contractors has made a demand for recognition or certification with respect to the Company, and , to the Company’s knowledge, there are no representation or certification proceedings or applications seeking a representation or certification proceeding pending or, to the knowledge of the Seller and the Company, threatened in writing to be brought or filed before any Governmental Authority. To the Company’s knowledge, there is, and prior to the date hereof there has been, no union organizing activities among employees, consultants or contractors. The Company is not obligated under and no employee of the Company benefits from any extension order (tzavei harchava) except for extension orders which generally apply to all employees in Israel. There is no pending, or to the knowledge of the Seller and the Company, threatened work stoppage, lockout, labor grievance, arbitration, labor dispute, slowdown or labor strike against or affecting the Company. To the knowledge of the Seller and the Company, neither the Company nor any of its representatives, agents or employees, consultants or contractors has committed any unfair labor practice and the Company has no current labor disputes. The Company has good labor relations. The Seller and the Company have no knowledge of any facts indicating that the consummation of the Share Purchase or the other Transactions shall have a material effect on such labor relations, and has no knowledge that any of its Key Employees, consultants or contractors intends to terminate their relationship with the Company. There are no pending, or threatened, efforts to certify any Person as the collective bargaining agent of all or some of the employees, consultants or contractors of the Company.
(f) Each Company Benefit Arrangement has been maintained in compliance in all material respects with its terms and with the requirements prescribed by any and all Applicable Laws. The Company has delivered to Acquiror and its legal counsel a complete and correct copy and description of each Company Benefit Arrangement (including all employee benefit plans maintained by any company previously acquired by the Company), including all plan documents, adoption agreements, and amendments and restatements thereto executed since the inception of such Company Benefit Arrangement and any resolutions executed in connection with such documents, trust documents, financial statements, insurance policies, vendor contracts, employee booklets, summary plan descriptions, and summary of material modifications and other authorizing documents, all to the extent relevant.
-24-
(g) All contributions due from the Company with respect to any of the Company Benefit Arrangements have been duly made under the terms of the applicable Company Benefit Arrangement any other Applicable Law, or there is a period of time remaining for such contributions to be duly made. Except as set forth in Schedule 3.9(g), the Company’s obligations to provide statutory severance pay to its employees pursuant to the Israeli Severance Pay Law, 5723-1963 and vacation pursuant to the Israeli Annual Leave Law, 5711-1951 and any personal employment agreement have been satisfied or have been fully funded by contributions to appropriate insurance funds or accrued on the Company’s financial statements and the Company applies the provisions of Section 14 of the Israeli Severance Pay Law, 5723- 1963 with respect to such statutory severance pay. Except as set forth in Schedule 3.9(g), no further contributions shall be due or shall have accrued thereunder as of the Closing Date (other than contributions accrued in the ordinary course of business after the Company Balance Sheet Date as a result of the operations of the Company after the Company Balance Sheet Date).
(h) Unless otherwise indicated in Schedule 3.9(h) of the Company Disclosure Letter, the Company is not a party to any: (i) Contract with any Person (A) the benefits of which are contingent, or the terms of which are materially altered, upon the occurrence of a transaction involving the Company in the nature of the Share Purchase or any of the other Transactions, (B) providing any term of employment or compensation guarantee, or (C) providing severance benefits or other benefits after the termination of employment of such employee regardless of the reason for such termination of employment (other than as required by Applicable Law); or (ii) Company Benefit Arrangement, any of the benefits of which shall be increased, or the vesting of benefits of which shall be accelerated, by the occurrence of the Share Purchase or any of the other Transactions, or any event subsequent to the Share Purchase such as the termination of employment of any person, or the value of any of the benefits of which shall be calculated on the basis of any of the Transactions. The Company has no obligation to pay any amount or provide any benefit to any former director, officer, employee, consultant other than obligations (i) for which the Company has established a reserve (or purchased an insurance policy) for such amount on the Company Balance Sheet and (ii) pursuant to Contracts entered into after the Company Balance Sheet Date and disclosed on Schedule 3.9(h) of the Company Disclosure Letter.
(i) To the Company’s knowledge, no director, officer, employee, consultant or contractor of the Company is in material violation of (i) any Contract or (ii) any restrictive covenant relating to the right of any such employee or consultant to be employed by or render services to the Company or to use trade secrets or proprietary information of others. The employment or engagement of any director, officer, employee, consultant or contractor by the Company does not subject the Company to any Liability to any third party.
(j) Schedule 3.9(j) of the Company Disclosure Letter lists as of the Agreement Date each director, officer, employee, consultant or contractor of the Company who is not fully available to perform work because of disability or other leave and also lists, with respect to each such director, officer, employee, consultant or contractor, the basis of such disability or leave and the anticipated date of return to full service.
(k) Each of Company and Seller has fully and completely settled all prior undertakings towards all Key Employees including payment of contingent bonuses and/or benefits previously promised to such employees by Seller and the Company. Up and until the Closing, any options, shares or other interests in Seller that are outstanding and held by such Key Employees shall be properly dealt with by the Seller in accordance with the terms of the relevant employee share option plans, or otherwise at the discretion of Seller, however in any event without any recourse by any of the Key Employees to Acquiror.
3.10 Organization; Power and Capacity. Seller possesses all requisite legal capacity necessary to enter into, execute, deliver and perform its obligations under this Agreement and any other document related to the Transactions to which it is a party and to carry out the Transactions that are required to be carried out by Seller.
3.11 Enforceability; Noncontravention.
(a) This Agreement has been duly executed and delivered by Seller and, assuming the due execution and delivery of this Agreement by the other parties hereto, constitutes the valid and legally binding obligation of Seller enforceable against Seller in accordance with its terms, except as may be limited by and subject only to the effect, if any, of (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies.
-25-
(b) The execution, delivery and performance by Seller of this Agreement, or its otherwise being bound by it, does not, and the consummation of the Transactions will not, conflict with, or result in any violation of or default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or loss of any benefit under, or require any consent, approval or waiver from any Person pursuant to, or result in the creation of any Encumbrance upon the Company Shares pursuant to (i) any Contract or Order to which the Seller is subject or (ii) any Applicable Law, except where such conflict, violation, default, termination, cancellation or acceleration, individually or in the aggregate, would not be material to Seller’s ability to consummate the Share Purchase or to perform its obligations under this Agreement.
(c) No consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental Authority or any other Person is required by Seller in connection with the execution and delivery of this Agreement or the consummation of the Transactions that would reasonably be expected to adversely affect the ability of Seller to consummate the Share Purchase or any of the other Transactions.
3.12 Title to Shares. Seller owns of record and beneficially the Company Shares as set forth in Section 3.4 above, and has good and valid title to such Company Shares, free and clear of all Encumbrances and, at Closing, shall deliver to Acquiror good and valid title to such Company Shares, free and clear of all Encumbrances and Taxes. Seller does not own, and does not have the right to acquire, directly or indirectly, any other Company Share Capital. Such Company Shareholder is not a party to any option, warrant, purchase right, or other Contract or commitment that could require Seller to sell, transfer, or otherwise dispose of any Company Share Capital (other than this Agreement). Seller is not a party to any voting trust, proxy, or other agreement or understanding with respect to the voting of any share capital of the Company, except as set forth on the Company Disclosure Letter.
3.13 Litigation. There are no actions, suits, arbitrations, mediations, proceedings or claims pending or, to the knowledge of Seller, threatened against Seller that seek to restrain or enjoin the consummation of the Transactions.
3.14 Solvency. Seller is not bankrupt or insolvent and has not proposed a voluntary arrangement or made or proposed any arrangement or composition with Seller’s creditors or any class of such creditors, and no petition in respect of any such arrangement or composition has been presented. The consummation of the Share Purchase and the other Transactions shall not constitute a fraudulent transfer by Seller under applicable bankruptcy and other similar laws relating to bankruptcy and insolvency of Seller.
3.15 Australian Securities Exchange Ltd. and Reports. The Company is a material asset of the Seller and Seller is under legal obligation in Australia to furnish all reports, schedules, forms, statements and other documents with respect to the Company and the Company Business, pursuant to the applicable Australian laws in this respect. Seller has duly filed or furnished all reports, schedules, forms, statements and other documents required to be filed or furnished by Seller with respect to the Company and the Company Business under any Applicable Law (including securities laws) and the Australian Securities Exchange Ltd. (the “ASX”) rules and regulations (the “Stock Exchange Rules”), for the period commencing as of the Seller’s re-listing on the ASX on December 2020 (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein, and financial statements notes and schedules thereto being collectively referred to herein as the “Public Reports”) on a timely basis or has received a valid extension of such time of filing or furnishing and has filed or furnished any such Public Reports prior to the expiration of any such extension. As of their respective dates, the Public Reports complied in all material respects with the requirements of all Applicable Laws and the Stock Exchange Rules, and none of the Public Reports, when filed or furnished, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. True and complete copies of the Public Reports are available for public access via the ASX electronic data gathering, analysis, and retrieval system.
3.16 Representations Complete. None of the representations or warranties made by the Seller and the Company herein or in any Exhibit or Schedule hereto, including the Disclosure Letter, or in any certificate delivered by the Seller and/or the Company pursuant to this Agreement, when all such documents are read together in their entirety, contains any untrue statement of a material fact, or omits to state any material fact necessary in order to make the statements contained herein or therein, in the light of the circumstances under which made, not misleading.
-26-
ARTICLE
4
Representations and Warranties of Acquiror
Each Acquiror represents and warrants to the Company and the Seller, on a several and not joint basis, as of the Agreement Date and as of the Closing Date, as follows:
4.1 Organization and Standing. To the extent an Acquiror is not a natural person, Acquiror is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of organization. Acquiror is not in violation of any of the provisions of its articles or certificate of incorporation, as applicable, or bylaws or equivalent organizational or governing documents.
4.2 Authority; Noncontravention.
(a) Acquiror has all requisite corporate power and authority to enter into this Agreement and to consummate the Transactions. The execution and delivery of this Agreement and the consummation of the Transactions have been duly authorized by all necessary corporate action on the part of Acquiror and no other corporate proceeding on the part of the Acquiror is necessary to authorize this Agreement and to consummate the Transactions. This Agreement has been duly executed and delivered by Acquiror and, assuming the due execution and delivery of this Agreement by the other parties hereto, constitutes the valid and binding obligation of Acquiror, enforceable against Acquiror in accordance with its terms, subject only to the effect, if any, of (i) applicable bankruptcy and other similar Applicable Laws affecting the rights of creditors generally and (ii) rules of law governing specific performance, injunctive relief and other equitable remedies.
(b) The execution, delivery and performance of this Agreement by Acquiror does not, and the consummation of the Transactions do not and will not, conflict with, or result in any violation of, or default under (with or without notice or lapse of time, or both), or give rise to a right of termination, cancellation or acceleration of any obligation or loss of a benefit under, or require any consent, approval or waiver from any Person pursuant to, (i) any provision of the articles or certificate of incorporation, as applicable, or bylaws or other equivalent organizational or governing documents of Acquiror, in each case as amended to date, or (ii) Applicable Law, or (iii) any Contract to which the Acquiror is a party or by which the Acquiror or any of its assets or properties are bound, except where such conflict, violation, default, termination, cancellation or acceleration, individually or in the aggregate, would not be material to Acquiror’s ability to consummate the Share Purchase or to perform their respective obligations under this Agreement.
(c) The execution, delivery and performance of this Agreement by Acquiror does not, and the consummation of the Transactions do not and will not (with or without notice or lapse of time or both) require on the part of the Acquiror any authorization, consent, approval, exemption or other action by or declaration or notice to or registration with any third Person or Government Entity.
4.3 Available Financing. As of the date hereof, the Acquiror has sufficient cash and shall have sufficient cash to satisfy all of its obligations in connection with the transactions contemplated by this Agreement, and to satisfy any other payment obligations that shall arise in connection with the transactions contemplated by this Agreement.
4.4 Disclosure of Information. Without derogating from the representations and warranties provided by the Seller and/or Company herein and without derogating the Acquiror’s right to indemnification under this Agreement, and the reliance of the Acquiror on such representations and warranties, the Acquiror approves that it has received and reviewed information about the Company as requested and has had an opportunity to discuss the Company’s business, management and financial affairs with its management. In addition to the providence of the representations and warranties by the Company and the Seller in this Agreement, the Acquiror has conducted independent due diligence examination of the information and materials with respect to the Company.
-27-
ARTICLE
5
Company and Seller Covenants
During the time period from the Agreement Date until the earlier to occur of (a) the Closing or (b) the termination of this Agreement in accordance with the provisions of Article 10, the Company and Seller covenants and agrees with Acquiror as follows:
5.1 No Solicitation.
(a) Each of the Company and the Seller will not, and will not authorize or permit any of its respective directors, officers, employees, stockholders or Affiliates or any investment banker, attorney or other advisor or representative retained by any of them (all of the foregoing collectively being the “Company/Seller Representatives”) to, directly or indirectly, (i) solicit, initiate, seek, entertain, knowingly encourage, facilitate, support or induce the making, submission or announcement of any inquiry, expression of interest, proposal or offer that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal, (ii) enter into, participate in, maintain or continue any communications (except solely to provide written notice as to the existence of these provisions) or negotiations regarding, or deliver or make available to any Person any non-public information with respect to, or take any other action regarding, any inquiry, expression of interest, proposal or offer that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal, (iii) agree to, accept, approve, endorse or recommend (or publicly propose or announce any intention or desire to agree to, accept, approve, endorse or recommend) any Acquisition Proposal, (iv) enter into any letter of intent or any other Contract contemplating or otherwise relating to any Acquisition Proposal, (v) submit any Acquisition Proposal to the Seller or (vi) enter into any other transaction or series of transactions not in the ordinary course of the Company’s business, the consummation of which could reasonably be expected to impede, interfere with, prevent or delay the Share Purchase or the other Transactions. The Company and Seller will, and will cause each of its own Company/Seller Representatives to, (A) immediately cease and cause to be terminated any and all existing activities, discussions or negotiations with any Persons conducted prior to or on the Agreement Date with respect to any Acquisition Proposal and (B) immediately revoke or withdraw access of any Person (other than Acquiror and its directors, officers, employees, stockholders or Affiliates or any investment banker, attorney or other advisor or representative retained by Acquiror (all of the foregoing collectively being the “Acquiror Representatives”)) to any data room (virtual or actual) containing any non-public information with respect to the Company in connection with an Acquisition Proposal and request from each Person (other than Acquiror and the Acquiror Representatives) the prompt return or destruction of all non-public information with respect to the Company previously provided to such Person in connection with an Acquisition Proposal. If any Company/Seller Representatives, whether in his or her or its capacity as such or in any other capacity, takes any action that the Company and Seller are obligated pursuant to this Section 51 to cause such Company/Seller Representatives not to take, then, the Company and Seller shall be deemed for all purposes of this Agreement to have breached this Section 5.1.
-28-
(b) The Company and Seller shall promptly (but in any event, within 24 hours) notify Acquiror orally and in writing after receipt by the Company (or, to the knowledge of the Seller and/or Company, by any of the Company/Seller Representatives), of (i) any Acquisition Proposal, (ii) any inquiry, expression of interest, proposal or offer that constitutes, or could reasonably be expected to lead to, an Acquisition Proposal, (iii) any other written notice that any Person is considering making an Acquisition Proposal, or (iv) any request for nonpublic information relating to the Company or for access to any of the properties, books or records of the Company by any Person or Persons other than Acquiror and the Acquiror Representatives.
5.2 Non-Competition; Non-Solicitation.
(a) Seller, shall not (and shall not permit any of its respective Affiliates to) and shall cause any of its directors and senior management team who have been in office before April 1st, 2021 and prior to signing the term sheet of September 2021 (in this Section “Seller Representatives”), directly or indirectly, from the Closing Date until 4 years from the Closing Date (the “Non-Compete Period”), without the prior written consent of the Acquiror Representative, own, manage, operate, finance, control or participate in the ownership, management, operation, financing, or control of, or otherwise be engaged in any way in any business anywhere in the world that, at any time during the Non-Compete Period competes with the Company Business. For the purpose of this Section 5.2 the term “Affiliates” shall also include any entity in which the Seller, Seller Representatives hold (directly or indirectly), alone or jointly with each other or any Affiliate thereof, at least 5% of the share capital of such entity, as well as any entity in which Seller, Seller Representatives serves as a director, officer, employee or similar capacity.
(b) The Seller acknowledges that the consideration received hereunder is paid in consideration, in part, for the non-competition obligations hereunder. In light of the nature of this transaction, the interest that the Acquirers have in the success of the Company and the critical significance of the non-competition covenant to the Company Business and the Acquiror’s willingness to enter into this Agreement and pay the Total Consideration, Seller hereby acknowledges that the foregoing non- competition covenant is reasonable and necessary for the protection of the legitimate commercial interest of the Company and Acquirers.
(c) From the Closing Date until the lapse of 4 years from the Closing Date (the “Non- Hire Period”), Seller shall not (and shall not authorize its respective Affiliates and Seller Representatives to) (i) cause, solicit, induce or encourage (other than through general publications not aimed at a Company’s employees) any employees of the Company or any Affiliate thereof, or any Persons who become employees or Contractors of any of the foregoing at any point during the Non-Hire Period to leave such employment or engagement or otherwise engage any such Person, or (ii) hire or engage any employees or any Persons who become employees or significant Contractors or consultants of the Company, Pure or an Affiliate thereof, at any point during the Non-Hire Period, whether as employees consultants or otherwise, or (iii) cause, induce or encourage any material client, customer, supplier, agent, reseller or licensor of the Company, Pure or an Affiliate thereof, or any Person who become a client, customer, supplier or licensor of any of the foregoing at any point during the Non-Hire Period or any other Person who has a business relationship with the Business, to terminate or adversely modify any such relationship with any of the foregoing.
(d) The covenants and undertakings contained in this Section 5.2 are related to matters which are of a special, unique and extraordinary character and a violation of any of the terms of this Section 5.2 may cause irreparable injury to the Acquirers and the Company, the amount of which will be impossible to estimate or determine and which cannot be adequately compensated. Therefore, the Acquiror and/or the Company will be entitled to an injunction, restraining order or other equitable relief from any court of competent jurisdiction in the event of any breach of this Section 5.2. The rights and remedies provided by this Section 5.2 are cumulative and in addition to any other rights and remedies that the Acquirors or the Company may have hereunder or at Law or in equity.
(e) The parties agree that (i) if any covenant or undertaking contained in this Section 52 is held to be void or invalid but would not have been so held if part of the wording were deleted or its extent reduced or modified, then such undertaking shall apply with such modification(s) as may be necessary to make the same valid and enforceable; and (ii) if any court of competent jurisdiction in a judgment determines that a specified time period, a specified geographical area, a specified business limitation or any other relevant feature of this Section 5.2 is unreasonable, arbitrary or against public policy, then a lesser time period, geographical area, a specified business limitation or any other relevant feature which is determined to be reasonable, not arbitrary and not against public policy may be enforced against the applicable Party.
-29-
5.3 Advice of Changes. The Seller and the Company shall promptly advise Acquiror Representative in writing of (a) any event occurring subsequent to the Agreement Date that would render any representation or warranty of the Seller and/or the Company contained in Article 3 untrue or inaccurate such that the condition set forth in Section 9.1 would not be duly satisfied, (b) any breach of any covenant or obligation of the Seller and/or the Company pursuant to this Agreement or any Company Ancillary Agreement such that the condition set forth in Section 9.2 would not be duly satisfied, (c) any Material Adverse Change in the Company or (d) any change, event, circumstance, condition or effect that could reasonably be expected to cause any of the conditions set forth in Article 9 not to be duly satisfied; provided that the delivery of any notice pursuant to this Section 5.3 shall not be deemed to amend or supplement the Disclosure Letter, affect the representations, warranties, covenants or other agreements herein, affect the satisfaction or non-satisfaction of any conditions to the obligations of the parties hereto under this Agreement or otherwise limit or affect the remedies available hereunder to Acquiror or the Company.
5.4 Maintenance of Business.
(a) The Company shall make reasonable commercial efforts to carry on and preserve the Company Business and its relationships with customers, suppliers, employees and others with whom the Company has contractual relations in substantially the same manner as it has prior to the Agreement Date consistent with its past practices. If the Company becomes aware of a material deterioration in the relationship with any key customer, key supplier or Key Employee, consultant or contractor, it shall promptly bring such information to the attention of the Acquirer Representative in writing and, if requested in writing by the Acquirer Representative, shall exert commercially reasonable efforts to promptly restore the relationship.
(b) The Company shall (i) pay all of its liabilities, debts and taxes when due, subject to good faith disputes over such debts or taxes and (ii) pay or perform its other Liabilities when due.
(c) The Company shall use its reasonable best efforts to assure that each of its Contracts entered into after the Agreement Date will not require the procurement of any consent, waiver or novation (and to promptly notify the Acquirer Representative in the event any such Contract requires the procurement of any consent, waiver, or novation) or provide for any change in the obligations of any party in connection with, or terminate as a result of the consummation of Share Purchase and the other Transactions.
(d) Conduct of Business. The Company shall continue to conduct the Company Business and maintain its business relationships in the ordinary and usual course consistent with its past practices, and the Company shall not, except as expressly contemplated or permitted by this Agreement without the Acquirer Representative’s prior written consent, which shall not be unreasonably withheld:
(i) amend its Charter Documents;
(ii) declare, set aside or pay any cash or share dividend or other distribution (whether in cash, stock or property) in respect of its capital stock, or redeem, repurchase or otherwise acquire any of its capital stock or other securities, or pay or distribute any cash or property to Seller or make any other cash payment to Seller;
(iii) issue, sell, create or authorize any shares of its capital stock of any class or series or any other of its securities, or issue, grant or create any warrants, obligations, subscriptions, options, convertible securities, or other commitments to issue shares of its capital stock or any securities that are potentially exchangeable for, or convertible into, shares of its capital stock;
(iv) subdivide, split, combine, reclassify or reverse split the outstanding shares of its capital stock of any class or series (or other securities in respect of, in lieu of or in substitution for such capital stock) or enter into any recapitalization affecting the number of outstanding shares of its capital stock of any class or series or affecting any other of its securities;
-30-
(v) modify or change the exercise or conversion rights or exercise or purchase prices of any of its capital stock, any of its stock options, warrants or other securities, or accelerate or otherwise modify (A) the right to exercise any option, warrant or other right to purchase any of its capital stock or other securities or (B) the vesting or release of any shares of its capital stock or other securities from any repurchase options or rights of refusal held by it or any other party or any other restrictions;
(vi) (A) hire, or offer to hire, any additional officers or other employees, or any consultants or independent contractors, (B) terminate the employment, change the title, office or position, or materially reduce the responsibilities of any employee of the Company, (C) enter into any Contract with a labor union or collective bargaining agreement (unless required by Applicable Law) or (D) add any new members to the Board;
(vii) (A) pay any bonus, increased salary, severance, gift or special remuneration to any director, officer, employee, consultant or contractor, (B) except in the ordinary course of business consistent with past practice, amend or enter into any employment, consulting, contracting or similar Contract with any such person, or (C) adopt any plan or arrangement to provide compensation or benefits to any current or former directors, employees, consultants or contractors, or amend or terminate any Company Benefit Arrangements (except in each case as required under Applicable Law or this Agreement);
(viii) Except in the ordinary course of business and consistent with past practice, incur any Company Debt;
(ix) place or allow the creation of any Encumbrance on any of its assets or properties;
(x) (A) lend any money, other than reasonable advances to employees for bona fide travel and business expenses that are incurred in the ordinary course of business (provided that no proceeds of any such advances are used directly or indirectly to purchase shares of Company Share Capital), (B) make any investments in or capital contributions to, any Person, (C) forgive or discharge in whole or in part any outstanding loans or advances or (D) prepay any Company Debt (except that the Company shall be permitted to use cash on hand to pay Transaction Expenses);
(xi) sell, lease, license, transfer or dispose of, or permit to lapse, any assets material to the Company Business (except for sales of Company Products or Services in the ordinary course of business under the Standard Customer Agreement);
(xii) (A) enter into any Company Material Contract (other than for sales of Company Products or Services in the ordinary course of business on standard terms under the Standard Customer Agreement) or other material Contract, (B) violate, terminate, amend or otherwise modify or waive any of the material terms of any Company Material Contract, (C) enter into, amend, modify or terminate any Contract or waive, release or assign any rights or claims thereunder, which if so entered into, modified, amended, terminated, waived, released or assigned would be reasonably like to (1) adversely affect the Company (or, following consummation of the Transactions, Acquirers or any of its Affiliates) in any material respect, (2) impair the ability of the Company or the Seller to perform their respective obligations under this Agreement or (3) prevent or materially delay or impair the consummation of the Share Purchase and the other Transactions or (D) enter into any other material transaction or take any other action not in the ordinary course of business;
(xiii) transfer or license any of its technology or Intellectual Property or provide a copy of any source code (except for licenses under the Standard Customer Agreement made in the ordinary course of business), or acquire any Intellectual Property (or any license thereto) from any third party (other than licenses in the ordinary course of business);
(xiv) (A) pay, discharge or satisfy, in an amount in excess of US $5,000 in any one case, any Liability arising otherwise than in the ordinary course of business, other than (1) the payment, discharge or satisfaction of Liabilities reflected or reserved against in the Company Balance Sheet and (2) the payment, discharge or satisfaction of Transaction Expenses, or (B) make any capital expenditures, capital additions or capital improvements in an amount in excess of US $5,000.
(xv) change the manner in which it extends warranties, discounts or credits to customers;
-31-
(xvi) accelerate or delay collection of notes or accounts receivable in advance of or beyond their regular due dates or the dates when the same would have been collected in the ordinary course of business or otherwise offer discounts, accommodations, commitments, services or other concessions, in order to accelerate or induce the collection of any receivable; (B) delay or accelerate payment of any account payable in advance of its due date or the date such liability would have been paid in the ordinary course of business; (C) make any changes to cash management policies; (D) delay or postpone the repair or maintenance of their properties; or (E) vary any inventory purchase practices in any material respect from past practices;
(xvii) terminate, waive or release any right or claim;
(xviii) (A) initiate any Action (other than for the routine collection of bills) or (B) settle or agree to settle any Action (except where the amount in controversy does not exceed US $5,000 and does not involve injunctive or other equitable relief);
(xix) change any of its accounting methods, unless required by IFRS;
(xx) merge, consolidate or reorganize with, acquire, or enter into any other business combination with, any business, corporation, partnership, limited liability company or any other Entity or any division thereof, acquire a substantial portion of the assets of any such Entity, business or division, or otherwise acquire or agree to acquire any assets that are material, individually or in the aggregate, to the Company or Company Business, or enter into any Contract with respect to a joint venture, strategic alliance or partnership, or enter into any negotiations, discussions or agreement for such purpose;
(xxi) engage, retain or enter into any Contract with any investment banker or broker related to or in connection with the Transactions;
(xxii) (A) except as required by Applicable Law, agree to any audit assessment by any Tax Authority, (B) file any Tax Return or amendment to any Tax Return unless copies of such Tax Return or amendment have first been delivered to the Acquirer Representative for its review at a reasonable time prior to filing, (C) except as required by Applicable Law, make or change any material election in respect of taxes or adopt or change any material accounting method in respect of taxes, (D) enter into any closing agreement, settle any claim or assessment in respect of taxes, or consent to any extension or waiver of the limitation period applicable to any claim or assessment in respect of taxes, or (E) take any other similar action that would knowingly have the effect of increasing the Tax liability of the Acquirers or their Affiliates for any period ending after the Closing Date or decreasing any Tax attribute of the Company existing on the Closing Date;
(xxiii) enter into any agreement for the purchase, sale or lease of any real property; or
(xxiv) (A) agree to do any of the things described in the preceding clauses (i)- (xix), (B) take or agree to take any action which could reasonably be expected to render any of the Seller and Company’s representations or warranties contained in this Agreement untrue or inaccurate such that the condition set forth in Section 9.1 would not be satisfied, or (C) take or agree to take any action which could reasonably be expected to prevent the Company from performing or cause the Company not to perform one or more covenants required hereunder to be performed by the Company such that the condition set forth in Section 9.2 would not be satisfied.
For purposes of this Section 5.4, “Company Material Contract” includes any Contract arising subsequent to the Agreement Date (including by amendment or modification) providing for payments (whether fixed, contingent or otherwise) by or to it in an aggregate amount of US $25,000 or more.
-32-
5.5 Regulatory Approvals. The Company shall promptly execute and file, or join in the execution and filing of, any application, notification or other document that may be necessary in order to obtain the authorization, approval or consent of any Governmental Authority, whether federal, state, local or foreign, which may be reasonably required, or which Acquiror may reasonably request, in connection with the consummation of the Share Purchase and the other Transactions or any Company Ancillary Agreement. The Company shall use reasonable best efforts to obtain, and to cooperate with Acquiror to promptly obtain, all such authorizations, approvals and consents and shall pay any associated filing fees payable by the Company with respect to such authorizations, approvals and consents. The Company shall promptly inform Acquiror of any material communication between the Seller and/or the Company and any Governmental Authority regarding any of the Transactions, and shall provide Acquiror reasonable advance notice of the nature and substance of any planned communication with any Governmental Authority. If the Seller and/or the Company or any Affiliate of the Seller and/or the Company receives any formal or informal request for supplemental information or documentary material from any Governmental Authority with respect to the Transactions, then the Seller and the Company shall make, or cause to be made, as soon as reasonably practicable, a response in compliance with such request. The Seller and/or the Company shall direct, in its sole discretion, the making of such response, but shall review any proposed response in advance with, and consider in good faith the views of, Acquiror. The Seller and/or the Company shall not, without the prior written consent of Acquiror, (a) permit any of the Company Representatives to participate in any meeting with any Governmental Authority relating to the Transactions unless the Company consults with Acquiror in advance and, to the extent permitted by such Governmental Authority, grants Acquiror the opportunity to attend and lead the discussions at such meeting or (b) proffer, make proposals, negotiate, execute, carry out or submit to any agreements or Orders; provided that the Company shall, if directed by Acquiror, agree to any such action that is conditioned on the consummation of the Share Purchase.
5.6 Necessary Consents. Following consultation with Acquirers Representative , the Company shall use reasonable efforts to promptly obtain prior to the Closing (to the extent required), such written consents and authorizations of other third parties, give notices to third parties and take such other actions as may be necessary or appropriate in order to effect the consummation of the Share Purchase and the other Transactions, to enable Acquirers to carry on the Company Business immediately after the Closing and to keep in effect and avoid the breach, violation of, termination of, or adverse change to any Contract to which the Company is a party or is bound or by which any of its assets is bound. The Company will (x) consult with Acquirers Representative beforehand regarding the process for seeking such consents and providing such notices, (y) provide Acquirers Representative with a reasonable opportunity to review and comment in advance on the forms of such consent requests and notices and (z) incorporate, in its sole discretion, any reasonable comments thereto made by Acquirers Representative.
5.7 Litigation. The Company shall notify Acquiror in writing promptly after learning of any Action initiated by or against it, or known by the Company to be threatened against the Company or any of its directors, officers, employees, consultants, contractors or stockholders in their capacity as such.
5.8 Access to Information; Confidentiality.
(a) The Company shall allow Acquirers Representative and its agents and advisors access at reasonable times and following prior coordination to the files, books, records, technology, Contracts, personnel and offices of the Company, including any and all information relating to the Company’s taxes, Contracts, Liabilities, financial condition (including internal financial statements) and real, personal and intangible property, subject to the terms of the Non-Disclosure Agreement between the Seller and Pure dated September 2021 (the “NDA”). The Company shall cause its accountants and other Company representative to cooperate with the Acquirers Representative in making available all financial information reasonably requested by Acquirers Representative and its agents and advisors, including the right to examine all working papers pertaining to all financial statements prepared or audited by such accountants. No information or knowledge obtained by Acquirers Representative during the pendency of the Transactions in any investigation pursuant to this Section 5.8 shall affect or be deemed to modify any representation, warranty, covenant, agreement, obligation or condition set forth herein.
(b) Seller shall, and shall use its commercially reasonable efforts to cause its Affiliates and representatives to, keep confidential and not disclose to any other Person, any Confidential Information (as defined in the NDA). Seller agrees that promptly after the Closing, it shall destroy all Company confidential information and Company Intellectual Property in Seller’s possession and control, in whatever form or medium. If the Acquirers Representative requests, Seller shall promptly provide written confirmation and certification that Seller has returned or destroyed all such materials.
-33-
5.9 Closing Financial Certificate and Spreadsheet. At least one (1) Business Days prior to the Closing Date, the Company shall deliver a draft of each of the Company Closing Financial Certificate and Spreadsheet to Acquirers Representative. The Company shall cause such documents to be derived from and be in accordance with the books and records of the Company and true, correct and complete. Without limiting the generality or effect of the provisions of Section 5.8, the Company shall provide to Acquirers Representative, promptly after Acquirers Representative request, copies of the documents evidencing the amounts set forth on any such draft or final document. The Company shall reasonably consider any comments to such draft Company Closing Financial Certificate and Spreadsheet made by Acquirers Representative to be reflected in the final versions thereof delivered at least 1 Business Day prior to the Closing (it being understood that any such comments, or lack thereof, whether or not reflected in the final versions thereof shall not diminish or otherwise affect Acquirer’s remedies hereunder if such final versions are not accurate). Without limiting the foregoing or Section 5.8, the Company shall provide to the Acquirers Representative, together with the Company Closing Financial Certificate and the Spreadsheet, such supporting documentation, information and calculations as are reasonably necessary (or reasonably requested by Acquirers Representative) for Acquirers Representative to verify and determine the calculations, amounts and other matters set forth in the Company Closing Financial Certificate, Closing Balance Sheet and the Spreadsheet.
5.10 Tax Matters. Each of the Acquirers, the Company and the Seller shall cooperate fully, as and to the extent reasonably requested by any of the others, in connection with the filing of Tax Returns and any Action with respect to Taxes. Such cooperation shall include the retention and (upon request therefor) the provision of records and information reasonably relevant to any such Action and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. Acquirers, the Company and the Seller agree to retain all books and records with respect to Tax matters pertinent to the Company relating to any taxable period beginning before the Closing Date until expiration of the statute of limitations of the respective taxable periods, and to abide by all record retention agreements entered into with any Tax Authority.
5.11 Satisfaction of Conditions Precedent. The Company shall use its reasonable best efforts to satisfy or cause to be satisfied all the conditions precedent set forth in Article 8, and the Company shall use its reasonable best efforts to cause the Share Purchase and the other Transactions to be consummated in accordance with the terms of this Agreement.
5.12 Release.
(a) Effective as of, and contingent upon, the Closing and in consideration of the mutual covenants and agreements contained herein and subject to the payment of the Closing Consideration, Seller, on Seller’s behalf and on behalf of any Seller’s assigns and successors and all Persons that might allege a claim or demand through Seller or on Seller’s behalf, hereby knowingly, fully, unconditionally and irrevocably (a) acknowledges and agrees that it has no rights or entitlements with respect to any shares of Company Share Capital or any other equity interest in the Company, (b) acknowledges and agrees that it has no current or potential right, title, license, claim or unassigned personal interest of any kind in or to any Company-Owned IP or, more generally, to any Company IP and (c) waives, releases, and forever discharges, effective as of the Closing, any and all claims, demands and causes of action that Seller has or may have against the Company or any present or former director, officer, manager, employee or agent of the Company, whether asserted or unasserted, known or unknown, suspected or unsuspected, contingent or noncontingent, past or present, arising or resulting from or relating, directly or indirectly, to any act, omission, event or occurrence prior to the Closing relating to the Company, the Company-Owned IP, the Company Share Capital and any rights or interests therein. Notwithstanding anything to the contrary in the foregoing, nothing in this Section Article 5 will be deemed to constitute release by Seller of any right of Seller under this Agreement or any Company Ancillary Agreement including, without limitation, as it relates to (1) failure to pay the of the Total Consideration pursuant to and subject to the provisions of this Agreement, and (2) failure to perform any of its obligations, undertakings or covenants set forth in this Agreement in accordance with its terms.
(b) Notwithstanding anything to the contrary in this Agreement, Seller on such Seller’s behalf and on behalf of any Seller’s assigns, successors and all Persons that might allege a claim or demand through Seller or on Seller’s behalf, hereby knowingly, fully, unconditionally and irrevocably waives any claim, demand or right of recourse it may have against the Company with respect to the Company’s representations and warranties (including any inaccuracies thereof) set forth in Article 3 and the covenants of the Company set forth in.
-34-
5.13 D&O Insurance/Run-Off Policy
Prior to the Closing Date, the Company shall purchase and maintain for a period of seven (7) years following the Closing, directors’ and officers’ liability insurance policy (on comparable terms and coverage as the Company’s policy as of the date hereof), to cover any exposure and liability of the directors and officers of the Company in respect of the period prior to the Closing Date, or alternatively, obtain a Run- Off policy to cover such liabilities and exposure for the same period. The aforementioned insurance shall not impose any liability or obligation on the Company or Acquiror, and the costs associated in obtaining such insurance shall be taken into account in the calculation the Company Debt.
ARTICLE
6
Acquiror Covenants
During the time period from the Agreement Date until the earlier to occur of (a) the Closing or (b) the termination of this Agreement in accordance with the provisions of Article 10, each Acquiror on its own behalf, covenants and agrees with the Company and Seller as follows:
6.1 Advice of Changes. Acquiror shall promptly advise the Company in writing of (a) any event occurring subsequent to the Agreement Date that would render any representation or warranty of Acquiror contained in Article 6 untrue or inaccurate such that the condition set forth in Section 8.1 would not be satisfied and (b) any breach of any covenant or obligation of Acquiror pursuant to this Agreement or any Acquiror Ancillary Agreement such that the condition set forth in Section 8.2 would not be satisfied.
6.2 Satisfaction of Conditions Precedent. Acquiror shall use its reasonable best efforts to satisfy or cause to be satisfied all of the conditions precedent that are set forth in Article 9, and Acquiror shall use its reasonable best efforts to cause the Share Purchase and the other Transactions to be consummated in accordance with the terms of this Agreement.
ARTICLE
7
Closing Matters
7.1 The Closing. Subject to termination of this Agreement as provided in Article 10, the Closing shall take place remotely by electronic means (via email, PDF and/or facsimile transmissions) or by such other means as the Parties hereto shall agree on the Closing Date.
7.2 Payment Procedures.
(a) At the Closing, the Acquirers Representative and Seller shall provide the Paying Agent with a Joint Confirmation Letter (as defined in the Paying Agent Agreement attached hereto as Schedule 7.2), instructing the Paying Agent to release to the Seller, the cash payable pursuant to Section 2.2 (which, for the avoidance of doubt, will not include any portion of the Escrow Fund) by wire transfer of same-day funds the amount of cash to which Seller is entitled pursuant to Section 2.2.
(b) At the Closing, the Paying Agent, shall retain and not distribute an amount in cash equal to (i) the Escrow Amount, and (ii) of an additional amount in cash equal to the Adjustment Escrow Amount. The Escrow Amount will be available to secure the obligations in accordance with Article 11 and shall be held and distributed in accordance with the provisions of Section 11 and the Adjustment Escrow Amount shall be available to secure the obligations in accordance with Section 7.3, for a limited period of 100 days as of the Closing Date, and shall be held and distributed in accordance with the provisions of Section 7.3.
-35-
7.3 Company Net Working Capital Adjustment.
(a) Pursuant to Section 5.11, the Company shall deliver the Company Closing Financial Certificate to the Acquirers Representative prior to or upon Closing.
(b) Within ninety (90) days after the Closing, Acquirers Representative may object to the calculation of the Closing Consideration and deliver to the Seller a statement (the “Acquiror Closing Financial Statement”) setting forth Acquirer Representative’s calculation of the Closing Consideration and each element thereof set forth in the Company Closing Financial Certificate (“Acquiror Calculations”), in each case together with supporting documentation, information and calculations and any other relevant information reasonably requested by Seller.
(c) The Seller may object to the Acquirer Representative’s Calculations by providing written notice of such objection to the Acquirers Representative within thirty (30) days after the Acquirers Representative’s delivery of the Acquiror Closing Financial Statement (the “Notice of Objection”), together with supporting documentation, information and Calculations (the “Seller Calculations”). Any matters not expressly set forth in the Notice of Objection shall be deemed to have been accepted by the Seller.
(d) If the Seller timely provides the Notice of Objection, then Acquirers Representative and the Seller shall confer in good faith for a period of up to ten (10) Business Days following Acquiror’s timely receipt of the Notice of Objection in an attempt to resolve any disputed matter set forth in the Notice of Objection, and any resolution by them shall be in writing and shall be final and binding on the parties hereto.
(e) If, after the ten (10) Business Day period set forth in Section 7.3(d), Acquirers Representative and the Seller cannot resolve any matter set forth in the Notice of Objection, then Acquirers and the Seller shall engage one of the big four accounting firms in Israel or, if such firm is not able or willing to so act, another auditing firm acceptable to both Acquirers Representative and the Seller (the “Reviewing Accountant”) to review only the matters in the Notice of Objection that are still disputed by Acquiror Representative and the Seller and the Acquiror Calculations or Seller Calculations to the extent relevant thereto. After such review and a review of the Company’s relevant books and records, the Reviewing Accountant shall promptly (and in any event within twenty (20) days following its engagement) determine the resolution of such remaining disputed matters, which determination shall be final and binding on the parties hereto, and the Reviewing Accountant shall provide Acquiror Representative and the Seller with a calculation of the Closing Consideration in accordance with such determination.
-36-
(f) If the Closing Consideration as finally determined pursuant to Section 7.3(b) Section 7.3(d) and/or Section 7.3(e), as the case may be (the “Final Consideration”) included in the Company Closing Financial Certificate exceeds the Final Consideration (the amount of such excess, the “Final Consideration Shortfall”), the Seller and Acquirers Representative shall within five (5) Business Days of the Final Consideration being finally determined jointly instruct the Escrow Agent to pay to Acquirors from the Adjustment Escrow Amount in the Escrow Fund an amount equal to:
(i) the Final Consideration Shortfall; plus
(ii) all fees, costs and expenses of the Reviewing Accountant to be paid by the Seller pursuant to Section 7.3(h)(ii) or Section 7.3(h)(iii), if any.
(g) If the Total Consideration included in the Company Closing Financial Certificate is less than the Final Consideration (the amount of such difference, the “Final Consideration Surplus”), then Acquirers shall within five (5) Business Days of the Final Consideration being finally determined pay to the Paying Agent an amount in cash equal to the Final Consideration Surplus and instruct the Paying Agent to distribute to Seller the Final Consideration Surplus.
(h) The fees, costs and expenses of the Reviewing Accountant shall be paid (i) by Acquirers in the event the difference between the Final Consideration as determined by the Reviewing Accountant pursuant to Section 7.3(f) and the Acquiror Calculations (such difference, the “Acquiror’s Difference”) is greater than the difference between the Final Consideration as determined by the Reviewing Accountant pursuant to Section 7.3(e) and the Seller Calculations (such difference, the “Seller’s Difference”), (ii) by the Seller if the Acquirer’s Difference is less than the Seller’s Difference or (iii) equally by Acquiror on the one hand, and the Seller on the other hand, if the Acquirer’s Difference is the same as the Seller’s Difference.
ARTICLE
8
Conditions to Obligations of the Company
The Company obligations to consummate the Share Purchase and take the other actions required to be taken at the Closing are subject to the fulfillment or satisfaction as of the Closing, of each of the following conditions (it being understood that any one or more of the following conditions may be waived by the Company in a writing signed on behalf of the Company):
8.1 Accuracy of Representations and Warranties. The representations and warranties of Acquirers set forth in Article 4, (a) that are qualified as to materiality shall be true and correct and (b) that are not qualified as to materiality shall be true and correct in all material respects, in each case on the Agreement Date and as of the Closing with the same force and effect as if they had been made on the Closing Date (except for any such representations or warranties that by their terms speak only as of a specific date or dates, in which case such representations and warranties that are qualified as to materiality shall be true and correct, and such representations and warranties that are not qualified as to materiality shall be true and correct in all material respects, on and as of such specified date or dates, except to the extent the failure of such representations and warranties to be so true and correct would not be material to the ability of Acquiror to complete the Share Purchase or to perform its obligations under this Agreement.
8.2 Covenants. Acquirers shall have performed and complied in all material respects with all of its covenants contained in Article 6 on or before the Closing (to the extent that such covenants require performance by Acquiror on or before the Closing).
-37-
8.3 Compliance with Law; No Legal Restraints. There shall not be issued, enacted or adopted by any Governmental Authority any statute, regulation, enactment, Order or Action (whether temporary, preliminary or permanent) that prohibits or renders illegal or imposes limitations on the Share Purchase or any other material transaction contemplated by this Agreement.
8.4 Government Consents. There shall have been obtained at or prior to the Closing Date such permits or authorizations, and there shall have been taken all such other actions by any Governmental Authority or other regulatory authority having jurisdiction over the parties and the actions herein proposed to be taken, as may be required to lawfully consummate the Share Purchase.
8.5 Escrow Agreement. The Escrow Agreement in the form attached as Schedule 8.5 shall have been executed and delivered by Acquirers and the Escrow Agent.
8.6 Supply Agreement. The Supply Agreement in the form attached as Schedule 8.6 shall have been executed and delivered by Seller and the Company.
8.7 Warrant. The Warrant in the form attached as Schedule 8.7 hereto shall have been issued by the Company to Seller.
ARTICLE
9
Conditions to Obligations of Acquirers
Acquiror’s obligations to consummate the Share Purchase and take the other actions required to be taken by them at the Closing are subject to the fulfillment or satisfaction, as of the Closing, of each of the following conditions (it being understood that any one or more of the following conditions may be waived by the Acquirer Representative):
9.1 Accuracy of Representations and Warranties. The representations and warranties of the Company and the Seller herein, (a) that are qualified as to materiality shall be true and correct and (b) that are not qualified as to materiality shall be true and correct in all material respects, in each case on and as of the Closing with the same force and effect as if they had been made on the Closing Date (except for any such representations or warranties that by their terms speak only as of a specific date or dates, in which case such representations and warranties that are qualified as to materiality shall be true and correct, and such representations and warranties that are not qualified as to materiality shall be true and correct in all material respects, on and as of such specified date or dates).
9.2 Covenants. The Company and the Seller shall have performed and complied in all material respects with all of its covenants contained in this Agreement at or before the Closing (to the extent that such covenants require performance by the Company at or before the Closing).
9.3 No Material Adverse Change. Since the date hereof, there shall not have been any Material Adverse Change with respect to the Company.
9.4 Compliance with Law; No Legal Restraints; No Litigation. No Governmental Authority or other Person shall have commenced or threatened in writing to commence any Action challenging or seeking the recovery of a material amount of damages in connection with the Share Purchase or the other Transactions or seeking to prohibit or limit the exercise by Acquiror of any material right pertaining to ownership of equity interests of the Company. No Order issued by any court of competent jurisdiction or other legal or regulatory restraint or prohibition limiting or restricting Acquiror’s ownership, conduct or operation of the Company Business following the Closing shall be in effect, and no Action seeking any of the foregoing, or any other injunction, restraint or material damages in connection with the Share Purchase or the other Transactions shall be pending or threatened.
-38-
9.5 Government Consents. There shall have been obtained at or prior to the Closing Date such permits or authorizations, and there shall have been taken all such other actions by any Governmental Authority or other regulatory authority having jurisdiction over the parties and the actions herein proposed to be taken, as may be required to consummate the Share Purchase and the other Transactions.
9.6 Employment Matters. Each of the Key Employees listed under Schedule 9.6(a) (“Key Employees”), shall have executed the retention letter attached hereto as Schedule 9.6(b).
9.7 Requisite Company Shareholder Approval. This Agreement shall have been executed by Seller (representing 100% of all of the issued and outstanding shares of Company Share Capital as of immediately prior to the Closing).
9.8 Shareholders’ Register. The Company shall have delivered (i) a copy of the Company’s updated shareholders’ register evidencing the holdings in the Company immediately following the Closing certified by the Company’s secretary or other officer in charge of the Company’s shareholders’ register and attached hereto as Exhibit B and (ii) share certificates registered in the name of the Acquirers, representing ownership of 100% of the Company Share Capital attached hereto as Exhibit C.
9.9 Receipt of Closing Deliveries. Acquirers shall have received each of the following agreements, instruments, certificates and other documents:
(a) share transfer form for the Company Shares, in the form attached hereto as Schedule 9.9(a)(1), duly executed by Seller in favor of each respective Acquiror (or as it shall otherwise direct in writing) accompanied by their respective share certificates or affidavit evidencing that such certificate was lost or never issued, such affidavit in the form attached hereto as Schedule 9.9(a)(2).
(b) a certificate, dated as of the Closing Date on behalf of the Company by its Chief Executive Officer and member of the board of directors of the Company, certifying: (A) that each of the conditions set forth in Article 9 has been satisfied; with respect to the condition under Section 9.1, such certificate may include exception for changes in the ordinary course of business which do not have a Material Adverse Effect and shall be deemed for all purposes and intents as a representation and warranty of the Company and/or Seller, as the case may be, provided that the Fundamental Representations (as defined below) shall not include changes, and (B) that (i) the Charter Documents as in effect as of the Closing and (ii) board and shareholders resolutions approving this Agreement, the Company Ancillary Agreements, the Share Purchase and the other Transactions, in accordance with the terms of this Agreement and other matters, in the forms attached hereto as Exhibit D (the “Board Resolutions”) and Exhibit E (the “Shareholder Resolutions”), and (C) that the Spreadsheet is true, correct and complete;
(c) evidence reasonably satisfactory to the Acquirers Representative of the resignation of each director of the Company in office immediately prior to the Closing as directors of the Company, effective as of, and contingent upon, the Closing. Such resignation to include a standard waiver of claims each director of the Company may have against the Company;
(d) the Spreadsheet in a form reasonably satisfactory to the Acquirers Representative and a certificate executed by a member of the Board of the Company, dated as of the Closing Date, effective as of January 14th, 2022;
-39-
(e) the Company Closing Financial Certificate;
(f) evidence reasonably satisfactory to the Acquirers Representative of the Company’s receipt of all consents, waivers and approvals described in Section 5.6;
Receipt by the Acquirers Representative of any of the agreements, instruments, certificates or documents delivered pursuant to this Section 9.9 shall not be deemed to be an agreement by an Acquiror that the information or statements contained therein are true, correct or complete, and shall not diminish Acquiror’s remedies hereunder if any of the foregoing agreements, instruments, certificates or documents are not true, correct or complete.
ARTICLE
10
Termination of Agreement
10.1 Termination by Mutual Consent. This Agreement may be terminated at any time prior to the Closing by the mutual written consent of Acquirers Representative, Seller and the Company.
10.2 Unilateral Termination.
(a) Either Acquirers Representative or the Seller or Company, by giving written notice to the other, may terminate this Agreement if a court of competent jurisdiction or other Governmental Authority shall have issued a non-appealable final order, decree or ruling or taken any other action, in each case having the effect of permanently restraining, enjoining or otherwise prohibiting the Share Purchase or any other material transaction contemplated by this Agreement.
(b) Either Acquirers Representative or the Seller or the Company, by giving written notice to the other, may terminate this Agreement if the Closing shall not have occurred by midnight Israel Time on January 23, 2022; provided that the right to terminate this Agreement pursuant to this Section 10.2(b) shall not be available to any party whose breach of a representation or warranty or covenant made under this Agreement by such party results in the failure of any condition set forth in Article 8 or Article 9 to be fulfilled or satisfied on or before such date.
-40-
(c) Either Acquirors, through the Acquirers Representative or the Seller or Company may terminate this Agreement at any time prior to the Closing if (i) the other has committed a breach of (i) any of its representations and warranties under Article 3 or Article 4, as applicable, or (ii) any of its covenants under Article 5 or Article 6, as applicable, and has not cured such breach within twenty (20) Business Days after the party seeking to terminate this Agreement has given the other party written notice of the material breach and its intention to terminate this Agreement pursuant to this Section 10.2 (provided that no such cure period shall be available or applicable to any such breach which by its nature cannot be cured) and (iii) such breach, if not cured on or prior to the Closing Date, would result in the failure of any of the conditions set forth in Article 8 or Article 9, as applicable, to be fulfilled or satisfied; provided that the right to terminate this Agreement under this Section 10.2 shall not be available to a party if the party is at that time in material breach of this Agreement.
10.3 Effect of Termination. In the event of termination of this Agreement as provided in Section 10.2, this Agreement shall forthwith become void and there shall be no liability or obligation on the part of Acquirers, unless provided otherwise herein and the entire amount previously transferred to the Paying Agent until such time shall be immediately returned to the Acquirers on a pro-rated basis in accordance with the terms of the Paying Agent Agreement. Provided that (a) the provisions of this Section 10.3 (Effect of Termination) and Article 12 (Miscellaneous) shall remain in full force and effect and survive any termination of this Agreement and (b) nothing herein shall relieve any party hereto from liability in connection with any intentional misrepresentation made by, or a breach of, any of such party’s representations, warranties or covenants contained herein.
10.4 For the avoidance of doubt, following the consummation of the Closing hereunder, this Section 10 shall expire and shall have no further force and effect.
ARTICLE
11
Escrow, Survival Indemnification and Remedies
11.1 RESERVED
11.2 At the Closing, Paying Agent shall withhold the Escrow Amount and Adjustment Escrow Amount from the Closing Consideration payable pursuant to Section 2.2 and as previously transferred to the Paying Agent, and shall deposit the Escrow Amount and the Adjustment Escrow Amount with the Escrow Agent (the aggregate amount of cash so held by the Escrow Agent from time to time, the “Escrow Fund”), which Escrow Fund shall be governed by this Agreement and the Escrow Agreement. The Escrow Amount in the Escrow Fund shall constitute security for the benefit of the Acquirers (on behalf of itself or any other Acquiror Indemnified Person) with respect to any Damages pursuant to the indemnification obligations of the Seller under this Article 11. Subject to the provisions of this Article 11, the Escrow Agent shall hold the Escrow Amount until 11:59 p.m. local time on the date (the “Escrow Release Date”) that is 12 months after the Closing and the Adjustment Escrow Amount until 11:59 p.m. local time on the date (the “Adjustment Escrow Release Date”) that is one hundred (100) days after the Closing. Neither the Escrow Fund (including any portion thereof) nor any beneficial interest therein may be pledged, subjected to any Encumbrance, sold, assigned or transferred by Seller or be taken or reached by any legal or equitable process in satisfaction of any debt or other Liability of Seller, in each case prior to the distribution of the Escrow Fund to Seller in accordance with Section 11.1 except that Seller shall be entitled to assign its rights to the Escrow Fund by will, by the laws of intestacy or by other operation of law.
-41-
11.3 Subject to terms further elaborated under the Escrow Agreement: within 24 hours following the Escrow Release Date, the Escrow Agent will distribute to Seller the Escrow Amount less that portion of the Escrow Amount that is subject to any unsatisfied or disputed claims for indemnification specified in any Notice of Claim delivered to the Seller on or prior to the Escrow Release Date in accordance with this Article 11. Any portion of the Escrow Amount held by the Escrow Agent following the Escrow Release Date shall be distributed thereafter pursuant to and in accordance with the terms of the Escrow Agreement.
11.4 Survival of Representations and Warranties. If the Share Purchase is consummated, the representations and warranties of the Company and Seller contained in this Agreement and the other agreements, certificates and documents contemplated hereby shall survive the Closing and remain in full force and effect, regardless of any investigation made, disclosure received, or knowledge obtained, by or on behalf of any of the parties to this Agreement, for a period of 24 months following the Closing Date, except for the representation and warranties set forth in Section 3.8 (Intellectual Property) which shall survive the Closing for a period of 36 months following the Closing Date, and except for the representation and warranties set forth in Section 3.1 (Organization and Good Standing), Section 3.2 (Subsidiaries), Section 3.3 (Power, Authorization and Validity), Section 3.4 (Capitalization of the Company), Section 3.5 (No Conflict), Section 3.6 (Taxes), Section 3.10 (Organization; Power and Capacity), Section 3.11 (Enforceability; Noncontravention), Section 3.12 (Title to Shares), Section 3.13 (Litigation), and Section 3.14 (Solvency) (“Fundamental Representation(s)”), which shall survive the Closing and continue in full force and effect until the end of the statute of limitations under Israeli Law following the Closing Date. The parties hereby agree that this Article shall constitute a separate agreement for the requirements of Section 19 of the Israeli Statue of Limitation, 1958;
Notwithstanding the foregoing, such expiration shall not affect the rights of any Acquiror Indemnified Person under Article 11 or otherwise to seek recovery of Damages arising out of any fraud, intentional misrepresentation or willful misconduct by or on behalf of the Seller and/or the Company. Any claims under this Agreement with respect to a breach of a representation and warranty must be asserted by written notice within the applicable survival period contemplated by this Section 11.4, and if such a notice is given, the survival period for such representation and warranty shall continue until the claim is fully resolved provided however, that in the event such written notice is not followed by a legal suit, within a period of 45 days following the end of the applicable survival period, then the applicable representation or warranty in respect of which indemnity is sought under this Article 11, and the indemnity with respect thereto, shall expire in accordance with the applicable survival period set forth under this Section 11.4.
11.5 If the Share Purchase is consummated, upon Closing the representations and warranties of Acquirors contained in this Agreement and the other agreements, certificates and documents contemplated hereby shall expire and be of no further force or effect as of the Closing (other than those which by nature or context should survive the Closing). If the Share Purchase is consummated, all covenants of the parties (including the covenants set forth in Article 5 and Article 6) shall expire and be of no further force or effect as of the Closing, except to the extent such covenants provide that they are to be performed after the Closing (such as and without limitations, covenants with respect to the Supply Agreement and Warrant which shall remain in effect pursuant to their terms); provided that no right to indemnification pursuant to Article 11 in respect of any claim based upon any breach of a covenant that is set forth in a Notice of Claim delivered prior to the expiration of the Claims Period with respect to such covenant shall be affected by the expiration of such covenant.
-42-
11.6 Agreement to Indemnify. Subject to the terms and conditions of this Article 11, Seller shall indemnify and hold harmless each Acquiror and its respective directors, employees, agents, representatives, stockholders and subsidiaries, and each Person, if any, who controls or may control Acquiror or any of its subsidiaries (each hereinafter referred to individually as an “Acquiror Indemnified Person” and collectively as “Acquiror Indemnified Persons”) from and against any and all direct damages, losses, reductions or diminutions in value, costs, penalties, Liabilities and expenses (including reasonable attorneys’ fees, other professionals’ and experts’ fees, costs of investigation and court costs (including such fees and costs incurred in connection with enforcing the provisions of this Article 11, but excluding indirect or consequential damages, or loss of profits)) (hereinafter collectively referred to as “Damages”), arising from claims, assertions of liability, assessments, taxes, or actual or threatened Actions directly arising out of, resulting from or in connection with the following:
(a) any breach of any representation or warranty made by the Company or Seller in this Agreement, the Disclosure Letter, the certificate issued pursuant to Section 9.9(b), any Company Ancillary Agreement or any exhibit or schedule to this Agreement to be true and correct as of the Agreement Date and as of the Closing Date (as though such representation or warranty were made as of the Closing Date, except in the case of representations and warranties which by their terms speak only as of a specific date or dates, in which case such representations and warranties shall be true and correct on and as of such specified date or dates.
(b) any failure of any certification, representation or warranty made by the Company or Seller in any certificate delivered to Acquiror pursuant to any provision of this Agreement to be true and correct as of the date such certificate is delivered to Acquiror, and disregarding any disclosure in the Disclosure Letter, any liability with respect to violation of Dassault Systems Solidworks Corporation’s copyrights;
(c) any breach of or default in connection with any of the covenants or agreements made by the Company or the Seller in this Agreement, the Disclosure Letter, any Company Ancillary Agreement or any exhibit or schedule to this Agreement;
(d) the unpaid Transaction Expenses, (B) any Closing Net Working Capital Shortfall and (C) any Company Debt as of the Closing Date; in each case if and to the extent not included in the Company Net Working Capital.
(e) any inaccuracy in the Spreadsheet or the Company Closing Financial Certificate not settled according to Section 7.3 to this Agreement.
-43-
(f) any fraud, intentional misrepresentation or willful misconduct or breach by or on behalf of the Company or the Seller (“Fraud”);
(g) disregarding any disclosure in the Disclosure Letter, (A) any Taxes with respect to any pre-Closing Tax period, (B) any failure of any representation or warranty made by Company and/or Seller in Section 3.6 (Taxes) to be true and correct as of the date of this Agreement and as of the Closing Date as though such representation or warranty were made as of the Closing Date, (C) any Tax liability in connection with any payment or deemed payment made by Company in connection with the transactions contemplated by this Agreement;
(h) any claims by (i) any then-current or former holder or alleged then-current or former holder of any equity interests of the Company (including any predecessors), arising out of, resulting from or in connection with (A) the Transactions or this Agreement, including the allocation of the Total Consideration or any portion thereof, or (B) such Person’s status or alleged status as a holder of equity interests of the Company (including any predecessors) at any time at or prior to the Closing, whether for breach of fiduciary duty or otherwise, (ii) any Person to the effect that such Person is entitled to any equity interest of Acquiror or the Company or any payment in connection with the Transactions other than as specifically set forth on the Spreadsheet or (iii) any Person with respect to any plan, policy or Contract providing for compensation to any Person in the form of equity interests.
11.7 Limitations.
Notwithstanding anything to the contrary contained herein or under any applicable law:
(a) No Acquiror Indemnified Person may recover any amounts in respect of any claim for indemnification that is made pursuant to this Agreement and does not involve: (i) a Fundamental Representation or (ii) Fraud, (iii) Pre-Closing Taxes, (iv) any matter for which specific indemnification is available to an Acquiror Indemnified Person, unless and until the aggregate amount of Damages that may be claimed exceeds US $50,000 (the “Threshold”), and once the Threshold has been reached, the Acquiror Indemnified Person may make claims for indemnification and may receive amounts for all Damages (including the amount of the Threshold) pursuant to the terms herein.
(b) The total and aggregate indemnification under this Agreement and applicable law shall be limited to (A) the aggregate amount of cash the Seller actually received pursuant to Section 2.2 hereof with respect to (i) breaches of the Fundamental Representations; (ii) breaches of the Company’s and/or Seller’s covenants under this Agreement, and (B) an aggregate amount of A$1,500,000 for breach of the representation and warranties set forth in Section 3.8 (Intellectual Property), otherwise the total and aggregate indemnification under this Agreement and/or applicable law shall be limited to the aggregate amount A $900,000. In the case of Fraud, such Liability for Damages shall be unlimited with respect to Seller. Nothing shall prevent or restrict the Acquiror Indemnified Person from seeking (A) injunctive or other equitable relief to enjoin the breach, or threatened breach, of any provision of this Agreement or any Transaction Document, (B) specific performance of the provisions of this Agreement or any Transaction Document, and (C) declaratory relief with respect to this Agreement or any Transaction Document. In any event and notwithstanding anything to the contrary herein or under any applicable law or agreement, will the aggregate liability of the Seller under this Agreement exceed the aggregate amount of cash the Seller actually received pursuant to Section 2.2 hereof.
-44-
(c) Damages shall be calculated net of actual recoveries under existing insurance policies (net of any applicable collection costs and reserves, deductibles, premium adjustments and retrospectively rated premiums), it being understood that Acquiror Indemnified Person shall be obligated to take reasonable actions to reduce damages seek recovery under any insurance policies with respect to any particular Damages and the failure of an Acquiror Indemnified Person to seek recovery under any insurance policies shall not in any way affect or modify such Acquiror Indemnified Person’s rights under this Article 11.
(d) In determining the existence or amount of any Damages in respect of the failure of any representation or warranty to be true and correct as of any particular date or the breach of or default in connection with any covenant or agreement, any knowledge materiality or Material Adverse Change standard or qualification, or standard or qualification that a matter be or not be “reasonably expected” or “reasonably likely” to occur, contained in or otherwise applicable to such representation, warrant, covenant or agreement shall be disregarded; provided that such standard or qualification shall not be disregarded for the purposes of the initial determination of whether there was a failure of such representation or warranty to be true and correct, or a breach of or default in connection with any covenant or agreement, as aforesaid.
(e) Notwithstanding anything to the contrary herein, (i) Seller will not have any right of indemnification, contribution or right of advancement from Acquiror, the Company or any other Acquiror Indemnified Person with respect to any Damages claimed by any Acquiror Indemnified Person, the rights and remedies of the Acquiror Indemnified Persons after the Closing shall not be limited by any investigation made, disclosure received, or knowledge obtained, by or on behalf of any Acquiror Indemnified Person prior to the Closing regarding any failure, breach or other event or circumstance or (B) any waiver of any condition to the Closing related thereto and (iii) if an Acquiror Indemnified Person’s claim under this Article 11 may be properly characterized in multiple ways in accordance with this Article 11 such that such claim may or may not be subject to different caps and other limitations depending on such characterization, then such Acquiror Indemnified Person shall have the right to characterize such indemnifiable matter in a manner that maximizes the recovery permitted in accordance with this Article 11.
11.8 Notice of Claim.
(a) As used herein, the term “Claim” means a claim for indemnification of Acquiror or any other Acquiror Indemnified Person for Damages under this Article 11. Acquirer Representative may give notice of a Claim under this Agreement, whether for its own Damages or for Damages incurred by any other Acquiror Indemnified Person, and Acquirer Representative shall give written notice of a Claim executed by an officer of Acquiror (a “Notice of Claim”) to the Seller (with a copy to the Escrow Agent) promptly after Acquirer Representative becomes aware of the existence of any actual claim by an Acquiror Indemnified Person for indemnification from Seller under this Article 11, arising from or relating to (i) any matter listed in the foregoing clauses (a)-(g) of Section 11.6 or (ii) the assertion, whether orally or in writing, against Acquiror or any other Acquiror Indemnified Person of a tax, claim, demand or Action brought by a third party against Acquiror or such other Acquiror Indemnified Person (in each such case, a “Third-Party Claim”) that is based on, arises out of or relates to any matter listed in the foregoing clauses (a)-(g) of Section 11.6.
-45-
(b) The period during which claims may be initiated (the “Claims Period”) for indemnification from the Escrow Fund shall commence at the Closing and terminate at 11:59 p.m. Israel Time on the 12-month anniversary of the Closing Date (the “Escrow Period”). The Claims Period for indemnification from and against Damages arising out of, resulting from or in connection with representation and warranties shall commence at the Closing and terminate at 11:59 p.m. Israel Time on the date that is 24 months following the Closing Date, provided, however, that in connection with (i) representation and warranties set forth in Section 3.8 (Intellectual Property), shall commence at the Closing and terminate at 11:59 p.m. Israel Time on the date that is 36 months following the Closing Date and in connection with (ii) Fundamental Representation(s), shall commence at the Closing and terminate at 11:59 p.m. Israel Time on the date that is the end of the statute of limitations under Israeli Law following the Closing Date and (ii) Fraud shall be unlimited.
(c) Each Notice of Claim by Acquirer Representative shall contain the following information:
(i) that Acquiror or another Acquiror Indemnified Person has directly incurred, paid, sustained, reserved or accrued, or in good faith believes that it may directly incur, pay, sustain, reserve or accrue, Damages (or that with respect to any Tax matters, that any Tax Authority may raise such matter in audit of Acquiror, which could give rise to Indemnifiable Damages);
(ii) to the extent reasonably practicable, a non-binding, preliminary estimate of the amount of such Damages (which amount may be the amount of damages claimed by a third party in an action brought against any Acquiror Indemnified Person based on alleged facts, which if true, would give rise to liability for Damages to such Acquiror Indemnified Person under this Article 11); and
(iii) a brief description, in reasonable detail (based on the information then possessed by Acquiror), of the facts, circumstances or events giving rise to such Damages based on Acquiror’s good faith belief thereof, including (x) the basis for such anticipated liability and the nature of the breach to which such Damages are related and (y) the identity of any third-party claimant (to the extent reasonably available to Acquiror) and (z) all the documents reasonably required relating to or supporting the claim;
provided that the Notice of Claim (i) need only specify such information to the knowledge of such officer of Acquiror and the Acquirer Representative as of the date thereof, (ii) shall not limit any of the rights or remedies of any Acquiror Indemnified Person with respect to the underlying facts and circumstances specifically set forth in such Notice of Claim, and (iii) may be updated and amended from time to time by Acquirer Representative by delivering an updated or amended Notice of Claim, so long as the delivery of the original Notice of Claim is made within the applicable Claims Period and such update or amendment relates to the underlying facts and circumstances specifically set forth in such original Notice of Claim; provided, further, that all Claims for Damages properly set forth in the original Notice of Claim or any update or amendment thereto shall remain outstanding until such Claims for Damages have been resolved or satisfied, notwithstanding the expiration of such Claims Period provided however, that in the event such Notice of Claim is not followed by a legal suit, within a period of 45 days following the end of the applicable survival period, then the applicable representation or warranty in respect of which indemnity is sought under this Article 11, and the indemnity with respect thereto, shall expire and be of no further force and effect.
-46-
(d) No delay on the part of Acquirer Representative in giving the Seller a Notice of Claim (or any update or amendment thereto after conducting discovery regarding the underlying facts and circumstances set forth therein) shall relieve the Seller from any of their respective obligations under this Article 11 unless (and then only to the extent that) the Seller is materially prejudiced thereby in terms of the amount of Damages the Seller is obligated to indemnify the Acquiror Indemnified Persons for.
(e) As soon as reasonably practicable following the expiration of the Escrow Period, but in no event later than five (5) Business Days thereafter, Acquirors Representative shall instruct the Escrow Agent to release the Escrow Fund and send to the Seller the Escrow Fund less that portion of the Escrow Fund that is necessary to satisfy all unsatisfied, pending or unresolved claims for indemnification specified in any Notice of Claim and any amount previously paid to, or requested in writing to be held by, the Seller in satisfaction of reimbursable costs and expenses incurred by, or expected to be incurred by in connection with unsatisfied, pending and unresolved Claims, the Seller. Any portion of the Escrow Fund held as a result of unsatisfied, pending or unresolved claims shall be released to the Seller or forfeited to Acquiror, as appropriate, as soon as reasonably practicable following resolution of all such unsatisfied, pending or unresolved Claims in accordance with the terms of this Article 11.
(f) No portion of the Escrow Fund or any beneficial interest therein may be pledged, encumbered, sold, assigned or transferred (including any transfer by operation of law), by Acquiror or Seller or be taken or reached by any legal or equitable process in satisfaction of any debt or other liability of Acquiror or Seller, prior to the delivery of such portion of the Escrow Fund, respectively, to Acquiror or Seller in accordance with this Agreement, except that Seller shall be entitled to assign its rights to such portion of the Escrow Fund by will or the laws of intestacy.
11.9 Defense of Third-Party Claims.
(a) Acquirer Representative shall determine and conduct the investigation, defense and the settlement, adjustment or compromise of any Third-Party Claim, provided, however, that if the Acquirer Representative settles, adjusts, compromises or consents to any Third-Party Claim without the prior written consent of the Seller (which shall not be unreasonably withheld or delayed), then such settlement, adjustment or compromise shall not be conclusive evidence of the amount of Damages incurred by the Acquiror Indemnified Person in connection with such claim or proceeding (it being understood that if the Acquirer Representative requests that the Seller consents to a settlement, adjustment or compromise, the Seller shall not unreasonably withhold or delay such consent) and (ii) any amount of such settlement in excess of amounts consented to by the Seller shall be deemed a contested amount, and thereafter any such contested amounts shall constitute Damages subject to indemnification hereunder solely to the extent it is ultimately determined that such contested amounts arose out of, resulted from or was in connection with a matter listed in Section 11.6 and shall be included in the Damages for which Acquiror may seek indemnification pursuant to a Claim made by any Acquiror Indemnified Person hereunder and such costs and expenses shall constitute Damages subject to indemnification under Section 11.6 provided it is ultimately determined by a competent court that the Third-Party Claim itself is indemnifiable under Section 11.6.
-47-
(b) The Seller shall have the right to receive copies of all pleadings, notices and communications with respect to the Third-Party Claim (subject to execution by the Seller of Acquirer Representative’s standard non-disclosure agreement to the extent that such materials contain confidential or proprietary information) and in its sole discretion and cost to participate in the defense of the Third-Party Claim.
(c) No settlement, adjustment or compromise of any such Third-Party Claim with any third party claimant shall be determinative of the amount of Damages relating to such matter, except with the consent of the Seller, which consent shall not be unreasonably withheld, conditioned or delayed and which shall be deemed to have been given if (i) the Seller unreasonably withholds its consent or (ii) the Seller has not objected within fifteen (15) days after a written request for such consent by the Acquirer Representative.
11.10 Resolution of Notice of Claim. Each Notice of Claim given by Acquirer Representative shall be resolved as follows:
(a) Uncontested Claims. If, within thirty (30) days after a Notice of Claim is received by the Seller, the Seller does not contest such Notice of Claim in writing to Acquirer Representative as provided in Section 11.9(b), the Seller shall be conclusively deemed to have consented, to the recovery by the Acquiror Indemnified Person of the full amount of Damages specified in the Notice of Claim in accordance with this Article 11, including the forfeiture of Escrow Fund, and, without further notice, to have stipulated to the entry of a final judgment for damages against the Seller for such amount in any court having jurisdiction over the matter where venue is proper.
(b) Contested Claims. If the Seller gives Acquirer Representative written notice contesting all or any portion of a Notice of Claim (a “Contested Claim”) (with a copy to the Escrow Agent) within the twenty (20) day period specified in Section 11.9(a), then such Contested Claim shall be resolved by either (i) a written settlement agreement executed by Acquirer Representative and the Seller (a copy of which shall be furnished to the Escrow Agent and applicable Acquiror) or (ii) in the absence of such a written settlement agreement within sixty (60) days following receipt by Acquirer Representative of the written notice from the Seller, by binding litigation between Acquirer Representative and the Seller in accordance with the terms and provisions of Section 11.9(c).
(c) Litigation of Contested Claims. Either Acquirer Representative or the Seller may resolve the Contested Claim in accordance with Section 12.1 of this Agreement. The Escrow Agent shall be entitled to act in accordance with such decision and make or withhold payments out of the Escrow Fund in accordance therewith. The non-prevailing party shall pay its own fees and expenses and the fees and expenses of the prevailing party, including attorneys’ fees and costs, reasonably incurred in connection with such suit.
-48-
11.11 Treatment of Indemnification Payments. The Seller and Acquiror agree to treat (and cause their Affiliates to treat) any payment received pursuant to this Article 11 as adjustments to the Total Consideration for all tax purposes, to the maximum extent permitted by Applicable Law.
11.12 Acquiror Representative. The Company and the Seller shall be deemed to have consented to the appointment of Pure as the Acquirer’s Representative (the “Acquirer’s Representative”), as the attorney-in-fact for and on behalf of each such party, and the taking by the Acquirer’s Representative of any and all actions and the making of any decisions required or permitted to be taken by the Acquirer’s Representative under this Agreement, including the exercise of the power to take all actions necessary in the sole and absolute judgment of the Acquirer’s Representative for the accomplishment of all of the other terms, conditions and limitations of this Agreement. Accordingly, the Acquirer’s Representative has authority and power to act on behalf of each such party with respect to this Agreement, the Paying Agent Agreement, the Escrow Agreement, and the disposition, settlement or other handling of all Indemnification Claims, rights or obligations arising from and taken pursuant to this Agreement, the Paying Agent Agreement, the Escrow Agreement. Each Acquiror will be bound by all actions taken by the Acquirer’s Representative in connection with this Agreement, the Paying Agent Agreement, the Escrow Agreement. The Acquirer’s Representative will incur no Liability with respect to any action taken or suffered by the Acquirer’s Representative in reliance upon any notice, direction, instruction, consent, statement or other document believed by the Acquirer’s Representative to be genuine and to have been signed by the proper Person (and shall have no responsibility to determine the authenticity thereof), nor for any other action or inaction, except in the event of any liability directly resulting from the Acquirer’s Representative own willful misconduct, gross negligence or bad faith. The appointment of the Acquirer’s Representative shall be deemed coupled with an interest and shall be irrevocable, and any other person may conclusively and absolutely rely, without inquiry, upon any action of the Acquirer’s Representative as the act of any Acquiror in all matters referred to herein. Each Acquiror, as applicable, hereby ratifies and confirms any action that the Acquirer’s Representative shall do or cause to be done by virtue of such Acquirer’s Representative’s appointment as a representative of such Acquiror. The Acquirer’s Representative shall act for each Acquiror on all matters set forth herein in the manner the Acquirer’s Representative believes to be in the best interest of such Acquirer, but the Acquirer’s Representative shall not be responsible to any Acquiror for any loss or damage any Acquiror may suffer in connection with the Acquirer’s Representative services pursuant to this Agreement, the Escrow Agreement, or the Paying Agent Agreement, other than loss, liability or damage resulting from the Acquirer’s Representative willful misconduct, gross negligence or bad faith.
-49-
ARTICLE
12
Miscellaneous
12.1 Governing Law; Jurisdiction. The Agreement shall be governed by and construed in accordance with the laws of the State of Israel, without giving effect to the principles thereof relating to conflict of laws. The competent courts of the District of Tel Aviv, Israel shall have exclusive jurisdiction to hear all disputes arising in connection with this Agreement and no other courts shall have any jurisdiction whatsoever in respect of such disputes.
12.2 Assignment; Binding Upon Successors and Assigns. This Agreement shall inure to the benefit of the successors and assigns of Acquiror, including any successor to, or assignee of, all or substantially all of the business and assets of Acquiror provided that such assignment shall not relieve the Acquiror of any of its obligations hereunder. Except as set forth in the preceding sentence, no party hereto may assign any of its rights or obligations hereunder without the prior written consent of the other parties hereto. This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns. Any assignment in violation of this provision shall be void.
12.3 Severability. If any provision of this Agreement, or the application thereof, shall for any reason and to any extent be invalid or unenforceable, then the remainder of this Agreement and the application of such provision to other Persons or circumstances shall be interpreted so as reasonably to effect the intent of the parties hereto. The parties further agree to replace such void or unenforceable provision of this Agreement with a valid and enforceable provision that shall achieve, to the extent possible, the economic, business and other purposes of the void or unenforceable provision.
12.4 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original as regards any party whose signature appears thereon and all of which together shall constitute one and the same instrument. This Agreement shall become binding when one or more counterparts hereof, individually or taken together, shall bear the signatures of all parties reflected hereon as signatories.
12.5 Other Remedies. Except as otherwise expressly provided herein, any and all remedies herein expressly conferred upon a party hereunder shall be deemed cumulative with and not exclusive of any other remedy conferred hereby or by law on such party, and the exercise of any one remedy shall not preclude the exercise of any other. The parties hereto agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed that the parties shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions hereof in any court having jurisdiction.
-50-
12.6 Amendments and Waivers. Any term or provision of this Agreement may be amended, and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only in writing signed by Acquirers Representative and the Seller. The waiver by a party of any breach hereof or default in the performance hereof shall not be deemed to constitute a waiver of any other default or any succeeding breach or default. This Agreement may be amended by the parties hereto as provided in this Section 12.6 at any time before or after adoption of this Agreement by the Seller, but, after such adoption, no amendment shall be made which by Applicable Law requires the further approval of the Seller without obtaining such further approval. At any time prior to the Closing, each of Seller, Company and Acquirer Representative, may, to the extent legally allowed, (a) extend the time for the performance of any of the obligations or other acts of the other, (b) waive any inaccuracies in the representations and warranties made to it contained herein or in any document delivered pursuant hereto, and (c) waive compliance with any of the agreements or conditions for its benefit contained herein. No such waiver or extension shall be effective unless signed in writing by the party against whom such waiver or extension is asserted. The failure of any party to enforce any of the provisions hereof shall not be construed to be a waiver of the right of such party thereafter to enforce such provisions.
12.7 Expenses. Except as otherwise provided herein, whether or not the Share Purchase is successfully consummated, each party shall bear its respective legal, auditors’, investment bankers’ and financial advisors’ fees and other expenses incurred with respect to this Agreement, the Share Purchase and the other Transactions.
12.8 Notices. All notices and other communications required or permitted under this Agreement shall be in writing and shall be either hand delivered in person, sent by facsimile, e-mail or sent by nationally recognized overnight courier service. Such notices and other communications shall be effective upon receipt, (or in case of delivery by email, upon transmission, unless sent during a day which is not a business day, in which case, it shall be deemed to have been duly given upon the first Business Day following transmission), if hand delivered or sent by facsimile, and one Business Day after dispatch if sent by overnight courier, to the following addresses, or such other addresses as any party may notify the other parties in accordance with this Section 12.8:
If to Acquirors:
to Acquirers Representative:
L.I.A Pure Capital Ltd.
Attention: Orly Aaronson
e-mail: Orly@shreminvest.com
with a copy (which shall not constitute notice) to:
Shibolet & Co., Law Offices
4 Berkowitz St.
Tel Aviv, Israel
e-mail: a.dozetas@shibolet.com
Attention: Adam Dozetas, Adv.
If to the Company:
ParaZero Technologies Ltd.
30 Dov Hoz St.
Kiryat Ono, Israel
e-mail: contact@parazero.com
Attention: Boaz Shetzer
-51-
with a copy (which shall not constitute notice) to:
Shibolet & Co., Law Offices
4 Berkowitz St.
Tel Aviv, Israel
Email: o.manor@shibolet.com
Attention: Ofer Manor, Adv.
If to the Seller:
Delta Drone International Ltd.
Level 27, 101 Collins Street,
Melbourne VIC 3000
e-mail: stephen.buckley@dlti.com.au
Attention: Stephen Buckley
with a copy (which shall not constitute notice) to:
Shibolet & Co., Law Offices
4 Berkowitz St.
Tel Aviv, Israel
Email: o.manor@shibolet.com
Attention: Ofer Manor, Adv.
12.9 Interpretation; Rules of Construction. When a reference is made in this Agreement to Exhibits, such reference shall be to an Exhibit to this Agreement unless otherwise indicated. When a reference is made in this Agreement to Sections, such reference shall be to a Section of this Agreement unless otherwise indicated. When a reference is made in this Agreement to Articles, such reference shall be to an Article of this Agreement unless otherwise indicated. The words “include,” “include” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation” and corresponding syntactical variant expressions. The phrases “delivered,” “provided,” “made available” and phrases of similar import mean, with respect to any statement in Article 3 of this Agreement to the effect that any information, document or other material has been “delivered,” “provided” or “made available” to Acquiror, its legal counsel or its other representatives, that such information, document or material was: (a) sent in electronic or physical format until no later than 5:00 p.m. Israel Time on the date three (3) Business Days prior to the Agreement Date. The headings contained in this Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Agreement. Reference to the subsidiaries of an Entity shall be deemed to include all direct and indirect subsidiaries of such Entity. The parties hereto agree that they have been represented by legal counsel during the negotiation and execution of this Agreement and, therefore, waive the application of any law, regulation, holding or rule of construction providing that ambiguities in an agreement or other document shall be construed against the party drafting such agreement or document.
-52-
12.10 Third Party Beneficiary Rights. No provisions of this Agreement are intended, nor shall be interpreted, to provide or create any third party beneficiary rights or any other rights of any kind in any client, customer, employee, consultant, contractor, Affiliate, shareholder or partner of any party hereto or any other Person unless specifically provided otherwise herein and, except as so provided, all provisions hereof shall be personal solely between the parties to this Agreement; except that Article 11 is intended to benefit the Acquiror Indemnified Persons.
12.11 Public Announcement. Upon execution of this Agreement, Acquirer Representative, Company and Seller may mutually decide to issue a press release announcing the proposed Share Purchase. The parties will coordinate the wording of such press release, it being understood that the ultimate content of such press release will be determined mutually. Prior to the publication of such initial press release, no party to this Agreement shall make any public announcement relating to this Agreement or the Transactions (except as may be required by law, including with respect to the Seller under the ASX Rules and with respect to any Acquiror under the NASDAQ rules and/or as required under the rules or provisions of any listing agreement with any national securities exchange or stock market, provided that any such publications or announcements by the Parties shall be coordinated and preapproved in writing by the Seller and Acquirer’s Representative, which shall not be unreasonably withheld and taking into consideration legal filing reports of the each Party).
12.12 Confidentiality. The Company and each Acquiror confirms that they have entered into the NDA and to the extent they have not signed the NDA, they are each bound by, and shall abide by, the provisions of such NDA; provided that Acquiror shall not be bound by such NDA after the Closing. If this Agreement is terminated, the NDA shall remain in full force and effect, and all copies of documents containing confidential information of a disclosing party shall be returned by the receiving party to the disclosing party or be destroyed, as provided in the NDA. The existence and terms of this Agreement, the Company Ancillary Agreements and the documents and instruments contemplated hereby and thereby, and the Transactions, shall constitute “Confidential Information” under such NDA.
12.13 Legal Representation. The parties hereby consent to Shibolet & Co (“Shibolet”) drafting this Agreement and the ancillary documents hereto on their behalf as trusted legal counsel with respect to the transaction contemplated hereby and on other matters. Each Party recognizes the inherent conflict of interest in such dual representation and hereby waive any claim against the other Party or against Shibolet based upon such dual representation.
12.14 Entire Agreement. This Agreement, the exhibits and schedules hereto, the Company Ancillary Agreements constitute the entire understanding and agreement of the parties hereto with respect to the subject matter hereof and supersede all prior and contemporaneous agreements or understandings, inducements or conditions, express or implied, written or oral, between the parties with respect hereto other than the NDA. The express terms hereof control and supersede any course of performance or usage of the trade inconsistent with any of the terms hereof.
[Signature Pages Follow.]
-53-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
L.I.A. Pure Capital Ltd | ||
By: | /s/ Kfir Silberman | |
Name: | Kfir Silberman | |
Title: | CEO |
-54-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
Buffalo Investments Ltd. | ||
By: | /s/ Nir Reinhold | |
Name: | Nir Reinhold | |
Title: | CEO |
-55-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
TOMER SINGER | ||
By: | /s/ Tomer Singer | |
Name: | Tomer Singer | |
Title: |
-56-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
MONI SAAT | ||
By: | /s/ Moni Saat | |
Name: | Moni Saat | |
Title: |
-57-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
LIRON CARMEL | ||
By: | /s/ Liron Carmel | |
Name: | Liron Carmel | |
Title: |
-58-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
ARIEL DOR A.D. INVESTMENTS LTD. | ||
By: | /s/ Ariel Dor | |
Name: | Ariel Dor | |
Title: | CEO |
-59-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
DROR ATZMON | ||
By: | /s/ Dror Atzmon | |
Name: | ||
Title: |
-60-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
Capitalink Ltd. | ||
By: | /s/ Lavi Krasney | |
Name: | Lavi Krasney | |
Title: | CEO |
-61-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
AMIR UZIEL ECONOMIC CONSULTANT LTD. | ||
By: | /s/ Amir Uziel | |
Name: | Amir Uziel | |
Title: | CEO |
-62-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
YORAM BAUMAN | ||
By: | /s/ Yoram Bauman | |
Name: | Yoram Bauman | |
Title: | Mr. |
-63-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
WEISS AMITAY | ||
By: | /s/ Amitay Weiss | |
Name: | ||
Title: |
-64-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
LAGZIEL HAI COMPANY | ||
By: | /s/ Hai Lagziel | |
Name: | ||
Title: | Director |
-65-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
ZEEV ZIMBLER | ||
By: | /s/ Zeev Zimbler | |
Name: | Zeev Zimbler | |
Title: | Mr. |
-66-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
OMER SELINGER | ||
By: | /s/ Omer Selinger | |
Name: | Omer Selinger | |
Title: | Mr. |
-67-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
YARON DAVID | ||
By: | /s/ Yaron David | |
Name: | Yaron David | |
Title: | Mr |
-68-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
SHIRAN SHMUEL KAUFMAN | ||
By: | /s/ Shiran Shmuel Kaufman | |
Name: | Shiran Shmuel Kaufman | |
Title: | Mr. |
-69-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
Roy Borochov | ||
By: | /s/ Roy Borochov | |
Name: | Roy Borochov | |
Title: |
-70-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
BOAZ SHETZER | ||
By: | /s/ Boaz Shetzer | |
Name: | Boaz Shetzer | |
Title: | ID 036392355 |
-71-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
SHOMRONI JOSSEPH | ||
By: | /s/ Somroni Josseph | |
Name: | Somroni Josseph | |
Title: |
-72-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
Yoresh Capital Ltd. | ||
By: | /s/ Eli Yoresh | |
Name: | Eli Yoresh | |
Title: | Director |
-73-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
Attribute ltd. | ||
By: | /s/ Itschak Shrem | |
Name: | Itschak Shrem | |
Title: | CEO |
-74-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
RON YAIR PELED | ||
By: | /s/ Ron Yair Peled | |
Name: | ||
Title: |
-75-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
ELYAHU CHAIM ZAMIR | ||
By: | /s/ Elyahu Chaim Zamir | |
Name: | ||
Title: |
-76-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
RONI MENASHE | ||
By: | /s/ Roni Menashe | |
Name: | ||
Title: |
-77-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
Tamarid Ltd. | ||
By: | /s/ Sagie Mali | |
Name: | Sagie Mali | |
Title: | Director |
-78-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
RACHEL MENASHE | ||
By: | /s/ Rachel Menashe | |
Name: | ||
Title: |
-79-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
Avdinco Ltd. | ||
By: | /s/ Sagie Mali | |
Name: | Sagie Mali | |
Title: | CEO |
-80-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
Medigus Ltd. | ||
By: | /s/ Liron Carmel | |
Name: | Liron Carmel | |
Title: | CEO |
-81-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
Company | ||
By: | /s/ Eden Attias | |
Name: | Eden Attias | |
Title: | Director |
-82-
IN WITNESS WHEREOF, Acquiror, Company and the Seller have caused this Share Purchase Agreement to be executed and delivered by their respective officers thereunto duly authorized, all as of the date first written above.
Seller | ||
EXECUTED by Delta Drone International Ltd | ) | |
(ACN 618 678 701) in accordance with section | ) | |
127(1) of the Corporations Act 2001 | ) | |
) | ||
/s/ Eden Attias | /s/ Christopher Clark | |
Signature of Director | Signature of Director | |
Eden Attias | Christopher Clark | |
Name of Director | Name of Director |
-83-
Exhibit A
List of Acquirers; Acquirers Allocation Table
- 84 -
Exhibit 4.9
SECURITIES EXCHANGE AGREEMENT
THIS SECURITIES EXCHANGE AGREEMENT (the “Agreement”) is entered into as of March 28, 2023 (the “Effective Date”), by and between Medigus Ltd., an Israeli Corporation (“Medigus”), the additional shareholders of Charging Robotics Ltd. listed on Schedule 1 attached hereto (together with Medigus, the “CR Shareholders”), and Fuel Doctor Holdings, Inc., a publicly-traded Delaware corporation (the “FDOC”). Medigus, each of the CR Shareholders, and FDOC, each a “Party” and collectively, the “Parties”.
WHEREAS, the CR Shareholders own 100% of the share capital of Charging Robotics Ltd., an Israeli corporation (the “Company”) on a fully diluted basis (the “Exchange Shares”);
WHEREAS, The CR Shareholders believe that it is in their best interests to exchange all of the Exchange Shares for shares of common stock of FDOC, par value US$0.0001 per share (the “Common Stock”), and FDOC believes that it is in its best interests to issue the CR Shareholders shares of Common Stock of FDOC in consideration for the Exchange Shares, (the “Exchange”), all upon the terms and subject to the conditions set forth in this Agreement; and
NOW THEREFORE, on the stated premises and for and in consideration of the mutual covenants and agreements hereinafter set forth and the mutual benefits to the Parties to be derived herefrom, and intending to be legally bound hereby, the Parties hereby agree as follows:
ARTICLE I
SECURITIES EXCHANGE
1.1 The Exchange.
1.1.1 On the terms and subject to the conditions set forth in this Agreement, each of the CR Shareholders shall sell, assign, transfer, and deliver, free and clear of all liens, all of the Exchange Shares to FDOC, in exchange for the issuance to the CR Shareholders, on a pro rata basis, of a total of 6,145,000 shares of Common Stock of FDOC, representing 72.88% of FDOC’s issued and outstanding stock, on a fully diluted basis (the “FDOC Stock”), after taking into account (i) FDOC’s planned 1-for-150 reverse split of its common stock (the “Reverse Stock Split”) such that at the closing of the Exchange (the “Closing”), the Company shall be a wholly-owned subsidiary of FDOC, (ii) the issuance of an additional 2,000,000 shares of Common Stok of FDOC in respect of financings to be completed by FDOC as detailed in Schedule 3, (iii) the issuance of 6,150,000 Milestone Warrants, as defined in section 1.1.1, and (iv) the issuance of Post Closing FDOC Options as described in section 1.3 (a)(ii).
1.1.2 The number of Exchange Shares to be transferred by each of the CR Shareholders at the Closing is set forth in Schedule 1 and the corresponding number of shares of FDOC Stock to be issued to each of the CR Shareholders at the Closing, on a post-Reverse Stock Split basis, is set forth in Schedule 1.
1.1.3 The CR Shareholders shall be entitled to receive, on a pro rata basis, up to a total of 6,150,000 additional shares of FDOC Stock, on a post-Reverse Stock Split basis (“Milestone Warrants”), in three equal tranches of 2,050,000 shares of FDOC Stock, on a post-Reverse Stock Split basis, upon the Company acheiving each of the three (3) performance milestones (the “Earn Out Milestones”) as is set forth in Schedule 2. All remaining Earn Out Milestones will immediately accelerate upon FDOC listing to Nasdaq.
1.2 Closing.
The Closing of this Agreement shall take place on such date that all conditions precedent and obligations of the Parties, including as set forth in Section 1.4 below, are satisfied or waived by the respective Party, (the “Closing Date”), at such location to be determined by the Parties. Either Party may terminate this Agreement in the event that the Closing Date shall not have occurred on or before April 10, 2023; provided, however, that the right to terminate this Agreement pursuant to this Section shall not be available to any party hereto (i) whose actions or omissions have been a principal cause of, or primarily resulted in, the failure of the Closing to occur on or before such date and such action or failure to act constitutes a breach of this Agreement or (ii) that is in material breach of this Agreement.
1.3 Conditions to Closing.
The respective obligations of each of the Parties to effect the Closing shall be subject to the satisfaction at or prior to the Closing of each of the following conditions:
(a) Exercise or Waiver of Options. (i) Ariel Dor or anyone on his behalf shall have exercised or deemed to have waived the options to purchase shares of the Company set forth in the Collaboration Agreement dated January 7, 2021 by and between Medigus and Ariel Dor. (ii) All other entities with options to purchase shares in the Company as set forth in Schedule 1 shall consent to receive options to purchase Common Stock in FDOC equal to their fully diluted holding in the Company immediately prior to the Closing multiplied by 60% (“Post Closing FDOC Options”).
(b) ITA Tax Ruling. Medigus shall have received a satisfactory preliminary tax ruling of the ITA with respect to the Exchange, or any other satisfactory preliminary confirmation by the ITA Confirming that the exchange of shares is not taxable in Israel. All parties to this agreement agree to meet all the conditions that will appear in the preliminary approval of the ITA and to act in accordance with it, including not selling the CR shares for two years.
(c) Board Composition. At the Closing, Eli Yoresh, Tali Dinar, Yaki Baranes and Amitai Weiss, shall be appointed to fill vacancies on the Board of Directors of FDOC. In addition, at the Closing, the current directors of FDOC shall deliver their resignations effective the day following the Closing Date and current officers of FDOC shall deliver their resignations effective as of the Closing.
(d) SEC Reports. FDOC shall have filed all reports and other documents required to be filed by it under the U.S. federal securities laws through the Closing Date.
(e) OTC Pink Sheets Quotation. FDOC shall have maintained its status as a company whose Common Stock is quoted on the OTC Pink Sheets and no reason shall exist as to why such status shall not continue immediately following the Closing.
(f) No Suspensions of Trading in FDOC Stock. Trading in FDOC’s Common Stock shall not have been suspended by federal regulators or any trading market at any time since the date of execution of this Agreement.
(g) Good Standing Certificate. FDOC shall have delivered to Medigus a certificate of good standing of FDOC dated within two (2) business days of Closing issued by the Secretary of State of Delaware.
(h) Financial Statements of the Company. Medigus shall have delivered to FDOC, the audited financial statements of the Company, in compliance with the applicable rules of the Securities and Exchange Commission (the “SEC”) and the Public Company Accounting Oversight Board, as required for FDOC’s reporting under Items 2.01 and 9.01 of Form 8-K.
(i) No Injunctions. No statute, rule, regulation, order, decree, ruling or injunction shall have been enacted, entered, promulgated, endorsed or threatened or is pending by or before any governmental authority of competent jurisdiction which in any material respect restricts, prohibits or threatens to restrict or prohibit the consummation of any of the transactions contemplated herein.
(j) FDOC Cash Balance. FDOC shall have at least US$425,000 in cash on hand (the “Available Cash”) in a secure bank account in FDOC’s name, which shall be readily available upon the Closing Date, and which shall exclude any expenses incurred in connection with the execution of the Agreement or any other transactions contemplated hereby.
(k) Company Cash Balance. The Company shall have at least US$500,000 in cash on hand (the “Company Cash”) in a secure bank account in the Company’s name, which shall be readily available upon the Closing Date; provided, however, that the following liabilities of the Company may be deducted from the Company Cash: (a) all transaction expenses incurred in connection with the execution of the Agreement and the Exchange, (b) all loans made by Medigus to the Company during 2022 until the Closing and (c) investments or loans made by the Company to its affiliate, Revoltz.
(l) Representations and Warranties. The representations and warranties made by each of the Parties herein shall be true and correct in all material respects as of the date hereof and as of the Closing with the same effect as if the representations and warranties were made as of the date hereof and as of the Closing.
(m) Covenants. All covenants, agreements and conditions contained in this Agreement to be performed by either Party on or prior to the Closing shall have been performed or complied with in all material respects.
(n) Medigus board approval. Medigus board of directors to approve the execution of this agreement prior to Closing.
2
1.4 Officers’ Certificate. With respect to the closing conditions listed in Section 1.3(m) and 1.3(n) above, the Parties shall deliver at the Closing an executed officer’s certificate to such effect.
1.5 Taxes. Any tax consequences arising from the sale, assignment and transfer or any other event or act hereunder, shall be borne solely by Medigus.
ARTICLE II
REPRESENTATIONS AND WARRANTIES OF MEDIGUS
The CR Shareholders represent and warrant to FDOC that, as of the date hereof and as of the Closing, except for those representations and warranties that speak of a different date:
2.1 Good Title. The CR Shareholders are the record and beneficial owners, and have good title to, the Exchange Shares, with the full right and authority to sell and deliver such Exchange Shares, free and clear of any and all liens, encumbrances, pledges, security interests, claims, charges, options, rights of first refusal, proxies, voting trusts, or agreements, transfer restrictions under any equity holder or similar agreement or any other restriction or limitation whatsoever, including any contract granting any of the foregoing (collectively, the “Title Liens”), to FDOC pursuant to the Exchange. FDOC, as the new owner of the Exchange Shares, shall receive good title to the Exchange Shares, free and clear of all Title Liens. The Exchange Shares represent 100% of the issued and outstanding share capital of the Company on a fully diluted basis and there are no other issued and outstanding share capital of the Company and no outstanding commitments or contracts to issue any share capital of the Company.
2.2 Organization, Standing and Corporate Power of the Company. The Company is duly incorporated, validly existing and in good standing under the laws of the State of Israel and has the requisite corporate power and authority to carry on its business as now being conducted. The Company is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership or leasing of its properties makes such qualification or licensing necessary, other than in such jurisdictions where the failure to be so qualified or licensed (individually or in the aggregate) would not have a Material Adverse Effect with respect to the Company. As used herein the term “Material Adverse Effect” or “Material Adverse Change” shall mean any change or effect that either individually or in the aggregate with all other such changes or effects is materially adverse to the business, assets, properties, condition (financial or otherwise) or results of operations of the Parties or the Company taken as a whole.
2.3 Authority; Non-Contravention. The CR Shareholders have all requisite authority to enter into this Agreement and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement by the CR Shareholders and the consummation by the CR Shareholders of the transactions contemplated by this Agreement have been (or at Closing will have been) duly authorized by all necessary corporate action on the part of Medigus and the Company. This Agreement has been duly executed and delivered by and constitutes a valid and binding obligation of the CR Shareholders , enforceable in accordance with its terms. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated by this Agreement and compliance with the provisions of this Agreement will not, conflict with, or result in any breach or violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of or “put” right with respect to any obligation or to loss of a material benefit under, or result in the creation of any lien upon any of the properties or assets of the Company under, (i) the articles of association of the Company, (ii) any loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, permit, concession, franchise or license applicable to the Company or their respective properties or assets, or (iii) subject to the governmental filings and other matters referred to in the following sentence, any judgment, order, decree, statute, law, ordinance, rule, regulation or arbitration award applicable to the Company or their respective properties or assets, other than, in the case of clauses (ii) and (iii), any such conflicts, breaches, violations, defaults, rights, losses or liens that individually or in the aggregate could not have a Material Adverse Effect with respect to the Company or could not prevent, hinder or materially delay the ability of the CR Shareholders to consummate the transactions contemplated by this Agreement. No consent, approval, order or authorization of, or registration, declaration or filing with, or notice to, any governmental entity is required by or with respect to the CR Shareholders or the Company in connection with the execution and delivery of this Agreement by the CR Shareholders or the consummation by the CR Shareholders , as the case may be, of any of the transactions contemplated by this Agreement.
3
2.4 Acquisition of FDOC Stock for Investment.
2.4.1 Purchase Entirely for Own Account. The FDOC Stock to be acquired by the CR Shareholders hereunder is being for investment purposes and for the CR Shareholders’ own accounts and not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and the CR Shareholders have no present intention of selling, granting any participation in or otherwise distributing the FDOC Stock. The CR Shareholders further represent that they do not have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant participation to such Person with respect to the FDOC Stock. For purposes of this Agreement, “Person” means any individual, partnership, corporation, association, joint stock company, trust, joint venture, unincorporated organization or governmental entity (or any department, agency or political subdivision thereof) or other entity.
2.4.2 The CR Shareholders (i) can bear the economic risk of its investment and (ii) possesses such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of its investment in FDOC and its securities.
2.4.3 The CR Shareholders understand that the FDOC Stock being acquired in the Exchange is not registered under the Securities Act and that the issuance hereof to the CR Shareholders is intended to be exempt from registration under the Securities Act pursuant to Regulation S and/or Regulation D promulgated thereunder. Each CR Shareholder is an “accredited investor,” as such term is defined in Rule 501 of Regulation D or, if not an accredited investor, otherwise meets the suitability requirements of Regulation D and Section 4(a)(2) of the Securities Act. The certificates representing the FDOC Stock issued to the CR Shareholders shall be endorsed with the following legends, in addition to any other legend required to be placed thereon by applicable securities laws:
“THIS SECURITY HAS BEEN ACQUIRED FOR INVESTMENT PURPOSES AND HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (“SECURITIES ACT”), OR APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS.”
“TRANSFER OF THESE SECURITIES IS PROHIBITED UNLESS A REGISTRATION STATEMENT UNDER THE SECURITIES ACT WITH RESPECT TO SUCH SECURITY SHALL THEN BE IN EFFECT AND SUCH TRANSFER HAS BEEN QUALIFIED UNDER ALL APPLICABLE STATE SECURITIES OR “BLUE SKY” LAWS, OR AN EXEMPTION THEREFROM SHALL BE AVAILABLE UNDER THE ACT AND SUCH LAWS.”
2.4.4 The CR Shareholders acknowledge that neither the SEC, nor the securities regulatory body of any state or other jurisdiction, has received, considered or passed upon the accuracy or adequacy of the information and representations made in this Agreement.
2.4.5 The CR Shareholders acknowledge that they have carefully reviewed such information as they have deemed necessary to evaluate an investment in FDOC and its securities. To the full satisfaction of the CR Shareholders, they have been furnished all materials that they have requested relating to FDOC and the issuance of the FDOC Stock hereunder.
2.4.6 The CR Shareholders understand that the FDOC Stock may not be sold, transferred, or otherwise disposed of without registration under the Securities Act or an exemption therefrom, and that in the absence of an effective registration statement covering the FDOC Stock or any available exemption from registration under the Securities Act, the FDOC Stock may have to be held indefinitely and the CR Shareholders further acknowledge that the FDOC Stock may not be sold pursuant to Rule 144 promulgated under the Securities Act unless all of the conditions of Rule 144 are satisfied, including, without limitation, FDOC’s compliance with the reporting requirements under the Exchange Act.
4
2.5 Additional Legend; Consent. Additionally, the FDOC Stock will bear any legend required by the “blue sky” laws of any state to the extent such laws are applicable to the securities represented by the certificate so legended and the CR Shareholders consent to FDOC making a notation on its records or giving instructions to any transfer agent of the FDOC Stock in order to implement the restrictions on transfer of the FDOC Stock.
2.6 Capital Structure. The authorized capital stock of the Company consists of 2,990,000,000 shares of Common Stock, of which 449,406,030 shares shall be issued and outstanding immediately prior to the Closing. As of immediately prior to the Closing, there will be no outstanding bonds, debentures, notes or other indebtedness or other securities of the Company having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which shareholders of the Company. As of immediately prior to the Closing, there will be no outstanding securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind to which the Company is a party or by which it is bound obligating the Company to issue, deliver or sell, or cause to be issued, delivered or sold, additional common stock of the Company or other equity or voting securities of the Company or obligating the Company to issue, grant, extend or enter into any such security, option, warrant, call, right, commitment, agreement, arrangement or undertaking. As of immediately prior to the Closing, there will be no outstanding contractual obligations, commitments, understandings or arrangements of the Company to repurchase, redeem or otherwise acquire or make any payment in respect of any common stock of the Company or any other securities of the Company.
ARTICLE III
REPRESENTATIONS AND WARRANTIES OF FDOC
FDOC represents and warrants to the CR Shareholders that, as of the date hereof and as of the Closing, except for those representations and warranties that speak of a different date, and subject to the FDOC Reports (as defined below) and the schedule of exceptions attached hereto:
3.1 Organization, Standing and Corporate Power of FDOC. FDOC is duly incorporated, validly existing and in good standing under the laws of the State of Delaware and has the requisite corporate power and authority to carry on its business as now being conducted. FDOC is duly qualified or licensed to do business and is in good standing in each jurisdiction in which the nature of its business or the ownership or leasing of its properties makes such qualification or licensing necessary, other than in such jurisdictions where the failure to be so qualified or licensed (individually or in the aggregate) would not have a Material Adverse Effect with respect to FDOC.
3.2 Capital Structure. The authorized capital stock o f FDOC consists of 10,000,000 shares of Preferred Stock, of which Nil are issued and 2,990,000,000 shares of Common Stock, of which 449,406,030 shares shall be issued and outstanding immediately prior to the Closing. Except as disclosed in FDOC’s public securities filings, as of immediately prior to the Closing, there will be no outstanding bonds, debentures, notes or other indebtedness or other securities of FDOC having the right to vote (or convertible into, or exchangeable for, securities having the right to vote) on any matters on which shareholders of FDOC. Except as disclosed in the FDOC’s public securities filings, as of immediately prior to the Closing, there will be no outstanding securities, options, warrants, calls, rights, commitments, agreements, arrangements or undertakings of any kind to which FDOC is a party or by which it is bound obligating FDOC to issue, deliver or sell, or cause to be issued, delivered or sold, additional common stock of FDOC or other equity or voting securities of FDOC or obligating FDOC to issue, grant, extend or enter into any such security, option, warrant, call, right, commitment, agreement, arrangement or undertaking. As of immediately prior to the Closing, there will be no outstanding contractual obligations, commitments, understandings or arrangements of FDOC to repurchase, redeem or otherwise acquire or make any payment in respect of any common stock of FDOC or any other securities of FDOC. As of immediately prior to the Closing, there will be no agreements or arrangements pursuant to which FDOC is or could be required to register the FDOC’s common stock or other securities under the Securities Act or other agreements or arrangements with or among any holders of FDOC Stock or with respect to any securities of FDOC. The issuance of the FDOC Stock will not trigger any anti-dilution rights of any existing securities of FDOC. Except as disclosed in the FDOC’s public securities filings, as of the Closing, there will be no rights, subscriptions, warrants, options, conversion rights, or agreements of any kind outstanding to purchase from FDOC, or otherwise require the FDOC to issue, any shares of capital stock of FDOC or securities or obligations of any kind convertible into or exchangeable for any shares of capital stock of FDOC.
5
3.3 Authority; Non-Contravention. FDOC has all requisite authority to enter into this Agreement and to consummate the transactions contemplated by this Agreement. Following the approval of the stockholders of FDOC, the execution and delivery of this Agreement by FDOC and the consummation by FDOC of the transactions contemplated by this Agreement have been (or at Closing will have been) duly authorized by all necessary corporate action on the part of FDOC. This Agreement has been duly executed and delivered by and constitutes a valid and binding obligation of FDOC, enforceable in accordance with its terms. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated by this Agreement and compliance with the provisions of this Agreement will not, conflict with, or result in any breach or violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of or “put” right with respect to any obligation or to loss of a material benefit under, or result in the creation of any lien upon any of the properties or assets of FDOC under, (i) the certificate of incorporation or bylaws of FDOC, (ii) any loan or credit agreement, note, bond, mortgage, indenture, lease or other agreement, instrument, permit, concession, franchise or license applicable to FDOC or their respective properties or assets, or (iii) subject to the governmental filings and other matters referred to in the following sentence, any judgment, order, decree, statute, law, ordinance, rule, regulation or arbitration award applicable to FDOC or their respective properties or assets, other than, in the case of clauses (ii) and (iii), any such conflicts, breaches, violations, defaults, rights, losses or liens that individually or in the aggregate could not have a Material Adverse Effect with respect to FDOC or could not prevent, hinder or materially delay the ability of FDOC to consummate the transactions contemplated by this Agreement. No consent, approval, order or authorization of, or registration, declaration or filing with, or notice to, any governmental entity is required by or with respect to FDOC in connection with the execution and delivery of this Agreement by FDOC or the consummation by FDOC, as the case may be, of any of the transactions contemplated by this Agreement, except, as required, such other consents, approvals, orders, authorizations, registrations, declarations, filings or notices as may be required under the “blue sky” laws of various states.
3.4 FDOC Reports. Since March 8. 2021, FDOC has filed all forms, reports and documents with the SEC that have been required to be filed by it under applicable laws prior to the date hereof (all such forms, reports and documents, together with all documents filed or furnished on a voluntary basis and all exhibits and schedules thereto, the “FDOC Reports”). As of its filing date (or, if amended or superseded by a filing prior to the date of this Agreement, on the date of such amended or superseded filing), (i) each FDOC Report complied as to form in all material respects with the applicable requirements of the Securities Act, the Exchange Act, and/or the Sarbanes-Oxley Act, as the case may be, each as in effect on the date such FDOC Report was filed, and (ii) each FDOC Report did not contain any ratement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the circumstances under which they were made, not misleading. To the Knowledge of FDOC, none of the FDOC Reports is the subject of ongoing SEC review or investigation. The financial statements included in Reports comply in all material respects with the applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. The financial statements included in the FDOC Reports have been prepared in accordance with generally accepted accounting principles in the United States applied on a consistent basis (“GAAP”), and fairly represent the financial position of FDOC and as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, year-end audit adjustments and the omission of certain footnotes. Except as set forth in the FDOC Reports, FDOC has no liabilities or obligations of any nature (whether accrued, absolute, contingent or otherwise) required by GAAP to be set forth on a balance sheet of the FDOC or in the notes thereto. As of the Closing, all liabilities of the FDOC shall have been paid off and shall in no event remain liabilities of the FDOC following the Closing, other than immaterial liabilities that will be scheduled prior to the Closing Date.
3.5 No Material Change. Since March 8, 2021, and except as disclosed in its FDOC Reports, (i) FDOC has not incurred any liabilities or obligations, indirect, or contingent, or entered into any oral or written agreement or other transaction which exceeds US$10,000; (ii) FDOC has not paid or declared any dividends or other distributions with respect to its capital stock, or redeemed or purchased or otherwise acquired any of its stock and FDOC is not in default in the payment of principal or interest on any outstanding debt obligations, except as set forth herein; (iii) FDOC has not initiated any compensation arrangement or agreement with any employee or executive officer; (iv) FDOC has not entered into any contract; (v) there has not been any change in the capital stock of FDOC; and (vi) there has not been any other event which has caused, or is likely to cause, a material adverse effect on FDOC.
6
3.6 Litigation. There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending against or, to the knowledge of FDOC, threatened against FDOC. FDOC is not subject to any order, writ, judgment, injunction, decree or award of any court or any governmental authority.
3.7 Compliance. FDOC has not been advised, nor does FDOC have reason to believe, that it is not conducting its business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting its business.
3.8 Material Agreements. All material agreements to which FDOC is a party are included as part of or specifically identified in the FDOC Reports to the extent required by the rules and regulations of the SEC as in effect at the time of filing (“Material Agreements”). Except for the Material Agreements, FDOC has no contracts. Neither FDOC nor, to FDOC’s knowledge, any other party to the Material Agreements, is in breach of or default under any of such contracts.
3.9 Taxes. Except as disclosed in the FDOC Reports, FDOC has filed all necessary federal, state and foreign income and franchise tax returns and has paid or accrued all taxes shown as due thereon, and FDOC has no knowledge of a tax deficiency which has been or might be asserted or threatened against it.
3.10 Conformity of Descriptions. The FDOC Stock, when issued, will conform in all material respects to the descriptions of the FDOC’s Common Stock contained in the FDOC Reports and other filings with the SEC.
3.11 Investment Company. FDOC is not, and is not an affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940, as amended.
3.13 Disclosure. All disclosure provided to the CR Stockholders regarding FDOC, its business and the transactions contemplated hereby, including the exhibits to this Agreement, furnished by FDOC with respect to the representations and warranties made herein are true and correct with respect to such representations and warranties and do not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading. FDOC acknowledges and agrees that the CR Shareholders makes or has made no representations or warranties with respect to the transaction contemplated hereby other than those specifically set forth in Section 9 hereof.
ARTICLE IV
COVENANTS
4.1 Securities Law Compliance. Each of FDOC and the CR Shareholders understand and agree that the consummation of this Agreement, including the issuance of the Exchange Shares upon Closing as contemplated hereby, constitutes the offer and sale of securities under the Securities Act and applicable state statutes. Each of FDOC and the CR Shareholders agree that such transactions shall be consummated in reliance on exemptions from the registration requirements of such statutes, which depend, among other items, on the circumstances under which such securities are acquired. Furthermore, in connection with the transactions contemplated by this Agreement, FDOC and the CR Shareholders shall each file, with the assistance of the other and their respective legal counsel, such notices, applications, reports or other instruments as may be deemed by them to be necessary or appropriate in an effort to document reliance on such exemptions, all to the extent and in the manner as may be deemed by the Parties to be appropriate.
4.2 Access to Information; Confidentiality.
4.2.1 The Parties hereto shall, and shall cause its officers, employees, counsel, financial advisors and other representatives to, afford to any other party and its representatives reasonable access during normal business hours during the period prior to the Closing Date of the Agreement to its properties, books, contracts, commitments, personnel and records and, during such period, the parties shall, and shall cause each of its officers, employees and representatives to, furnish promptly to any other party all information concerning its business, properties, financial condition, operations and personnel as such other party may from time to time reasonably request. For the purposes of determining the accuracy of the representations and warranties of each Party set forth herein and compliance by each Party of its obligations hereunder, during the period prior to the Closing Date of the Exchange, each party shall provide each other party and its representatives with reasonable access during normal business hours to its properties, books, contracts, commitments, personnel and records as may be necessary to enable each party to confirm the accuracy of the representations and warranties of each other party set forth herein and compliance by each party of their obligations hereunder, and, during such period, cause its, officers, employees and representatives to, furnish promptly to each party upon its request (i) a copy of each report, schedule, registration statement and other document filed by it during such period pursuant to the requirements of federal or state securities laws and (ii) all other information concerning its business, properties, financial condition, operations and personnel as such other party may from time to time reasonably request.
7
4.2.2 Except as required by law, each party will hold, and will cause its respective directors, officers, employees, accountants, counsel, financial advisors and other representatives to hold, any nonpublic information concerning another party in strict confidence.
4.2.3 No investigation pursuant to this Section shall affect any representations or warranties of the parties herein or the conditions to the obligations of the parties hereto.
4.3 Commercially Reasonable Best Efforts. Upon the terms and subject to the conditions set forth in this Agreement, each of the parties agrees to use its commercially reasonable best efforts to take, or cause to be taken, all actions, and to do, or cause to be done, and to assist and cooperate with the other parties in doing, all things necessary, proper or advisable to consummate and make effective, in the most expeditious manner practicable, the Exchange and the other transactions contemplated by this Agreement. The Parties hereto will use their commercially reasonable best efforts and cooperate with one another (i) in promptly determining whether any filings are required to be made or consents, approvals, waivers, permits or authorizations are required to be obtained (or, which if not obtained, would result in an event of default, termination or acceleration of any agreement or any put right under any agreement) under any applicable law or regulation or from any governmental authorities or third parties in connection with the transactions contemplated by this Agreement, and (ii) in promptly making any such filings, in furnishing information required in connection therewith and in timely seeking to obtain any such consents, approvals, permits or authorizations. The Parties hereto shall mutually cooperate in order to facilitate the achievement of the benefits reasonably anticipated from the Exchange.
4.4 Further Assurances. Subject to the terms and conditions herein provided, each Party shall use its reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under applicable laws and regulations to consummate and make effective this Agreement and the transactions contemplated herein.
4.5 Post-Closing Funding. Immediately following the Closing, FDCO shall conduct a private placement of 1,100,000 shares of FDOC Stock, on a post-Reverse Stock Split basis, at a price of $0.55 per share.
ARTICLE V
MISCELLANEOUS
5.1 Brokers. Each Party agrees that there were no finders or brokers involved in bringing the Parties together or who were instrumental in the negotiation, execution or consummation of this Agreement. Each Party agrees to indemnify the other against any claim by any third Person for any commission, brokerage or finder’s fee arising from the transactions contemplated hereby based on any alleged agreement or understanding between the indemnifying party and such third Person, whether express or implied, from the actions of the indemnifying party.
5.2 Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions other than the State of New York. Each Party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the State of New York, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each Party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such Party at the address for such notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner permitted by law.
8
5.3 Notices. All notices or other communications required or permitted by this Agreement shall be in writing and addressed as follows:
or such other addresses as shall be furnished in writing by any Party in the manner for giving notices hereunder.
Notice shall be deemed to have been duly received: (a) if given email, when transmitted and the appropriate confirmation received, as applicable, if transmitted on a business day and during normal business hours of the recipient, and otherwise on the next business day following transmission; (b) if given by certified or registered mail, return receipt requested, postage prepaid, three business days after being deposited in the U.S. mail; and (c) if given by courier, messenger or other means, when received or personally delivered and, in any such case, addressed as indicated herein, or to such other addresses as may be specified by any Party to the other Parties pursuant to notice given by such Party in accordance with the provisions of this Section 5.3.
5.4 Attorneys Fees. In the event that any Party institutes any action or suit to enforce this Agreement or to secure relief from any default hereunder or breach hereof, the prevailing Party shall be reimbursed by the losing Party for all costs, including, without limitation, reasonable attorneys’ fees, incurred in connection therewith and in enforcing or collecting any judgment rendered therein.
5.5 Third Party Beneficiaries. This contract is strictly between FDOC and CR Shareholders and, except as specifically provided, no other Person shall be deemed to be a third party beneficiary of this Agreement.
5.6 Expenses. Whether or not the Closing shall occur, except as provided herein, FDOC shall bear the expenses, including legal, accounting and professional fees, incurred in connection with this Agreement and any other agreements in connection therewith, the Exchange or any of the other transactions contemplated hereby.
5.7 Entire Agreement. This Agreement and the related documents referenced herein represent the entire agreement between the Parties relating to the subject matter hereof, and supersedes all prior agreements, understandings and negotiations, written or oral, with respect to such subject matter.
5.8 Survival; Termination. The representations, warranties and covenants of the respective Parties shall survive the consummation of the transactions herein contemplated for a period of two years.
5.9 Counterparts. This Agreement may be executed in multiple counterparts, each of which shall be deemed an original, and all of which taken together shall be but a single instrument. Signatures delivered by email shall be deemed original signatures.
5.10 Amendment or Waiver. Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, at law or in equity, and may be enforced concurrently therewith, and no waiver by any Party of the performance of any obligation by the other shall be construed as a waiver of the same or any other default then, theretofore or thereafter occurring or existing. This Agreement may by amended by a writing signed by all Parties, with respect to any of the terms contained herein, and any term or condition of this Agreement may be waived or the time for performance may only be extended by a writing signed by the Party or Parties for whose benefit the provision is intended.
[Signature pages follow]
9
IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the date first written above.
Fuel Doctor Holdings, Inc. | ||
By: | ||
Name: | ||
Title: |
CR Shareholders: | ||
Medigus, Ltd. | ||
By: | ||
Name: | ||
Title: | ||
Name: Ariel Dor |
[Signature page to Securities Exchange Agreement]
10
SCHEDULE 1
CR SHAREHOLDERS
CR Shareholder | Address | Number of Company Shares Held | Number of Company options Held | Shares of FDOC Stock to be Allocated |
Medigus | Hanechoshet 10, Tel Aviv | 100 | ||
Ariel Dor | 18 | |||
Por. Kuperman | 2 | |||
Ben Gurion University | 2 | |||
Automax | 6 | |||
Total: | 100 | 28 |
11
SCHEDULE 2
Earn Out Milestones
1. Inhouse demonstration for automatic robotic charging of an electric vehicle – until 31.12.2025
2. Conditional PO for 1st system for automatic car parks – until 31.12.2025
3. Commercial agreement for pilot with an organization which was approved by the board – until 31.12.2025
12
SCHEDULE 3
FDOC - POST CLOSING CAP TABLE
13
Exhibit 8.1
Subsidiaries of the Registrant
Legal Name of Subsidiary | Jurisdiction of Organization | |
Jeffs’ Brands Ltd. | Israel | |
Eventer Technologies Ltd. | Israel | |
Gix Internet Ltd. | Israel | |
Charging Robotics Ltd. | Israel |
Exhibit 12.1
CERTIFICATION
I, Liron Carmel, certify that:
1. | I have reviewed this annual report on Form 20-F of Medigus Ltd.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; |
4. | The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and |
5. | The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting. |
Date: May 3, 2023 | /s/ Liron Carmel |
Liron Carmel | |
Chief Executive Officer |
Exhibit 12.2
CERTIFICATION
I, Tali Dinar, certify that:
1. | I have reviewed this annual report on Form 20-F of Medigus Ltd.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report; |
4. | The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and |
5. | The company’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting. |
Date: May 3, 2023 | /s/ Tali Dinar |
Tali Dinar | |
Chief Financial Officer |
Exhibit 13.1
CERTIFICATION
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002
(SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE)
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Medigus Ltd., a company organized under the laws of the State of Israel (the “Company”), does hereby certify that, to his knowledge:
1. | This Annual Report on Form 20-F for the year ended December 31, 2022 (the “Form 20-F”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 3, 2023 | /s/ Liron Carmel |
Liron Carmel | |
Chief Executive Officer |
This certification accompanies this annual report on Form 20-F pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
Exhibit 13.2
CERTIFICATION
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
OF 2002
(SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE)
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), the undersigned officer of Medigus Ltd., a company organized under the laws of the State of Israel (the “Company”), does hereby certify that, to his knowledge:
1. | This Annual Report on Form 20-F for the year ended December 31, 2022 (the “Form 20-F”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Form 20-F fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 3, 2023 | /s/ Tali Dinar |
Tali Dinar | |
Chief Financial Officer |
This certification accompanies this annual report on Form 20-F pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
Exhibit 15.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (Nos. 333-238162 and 333-237774) and Form S-8 (Nos. 333-206803, 333-258624, 333-229429 and 333-221019) of Medigus Ltd. of our report dated May 3, 2023, relating to the financial statements, which appears in this Form 20-F.
/s/ Brightman Almagor Zohar & Co.
Certified Public Accountants
A Firm in the Deloitte Global Network
Tel Aviv, Israel
May 3, 2023